<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>100-BRADYCARIA-INDUCING-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BRADYCARIA INDUCING DRUGS" code="C0N0S0" /></DRUG1>
<DRUG2>
<CLASS name="OTHER BRADYCARIA INDUCING DRUGS" code="C0N0S0" /></DRUG2>
<DESCRIPTION>Risk of excessive bradycardia (addition of the effects)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>100-BRADYCARIA-INDUCING-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BRADYCARIA INDUCING DRUGS" code="C0N0S0" /></DRUG1>
<DRUG2>
<DRUG name="FINGOLIMOD" rxcui="1012892">
<ATC code="L04AA27" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the bradycardia inducing effects which can have fatal consequences. The beta-blocking agents are even more at risk since they inhibit the adrenergic compensation mechanisms</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Clinical monitoring and sustained EKG during the 24 hours following the first dose.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>100-BRADYCARIA-INDUCING-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BRADYCARIA INDUCING DRUGS" code="C0N0S0" /></DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>101-BRENTUXIMAB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BRENTUXIMAB " rxcui="1147320">
<ATC code="L01XC12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BLEOMYCIN " rxcui="1622">
<ATC code="L01DC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of pulmonary toxicity</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>101-BRENTUXIMAB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BRENTUXIMAB " rxcui="1147320">
<ATC code="L01XC12" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the concentrations of the active metabolite of the brentuximab, with risk of neutropenia</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>102-BUPRENORPHINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUPRENORPHINE" rxcui="1819">
<ATC code="N02AE01" />
<ATC code="N07BC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase or decrease of the effects of the buprenorphine, due to simultaneous inhibition and acceleration of its metabolism by the protease inhibitor </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>102-BUPRENORPHINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUPRENORPHINE" rxcui="1819">
<ATC code="N02AE01" />
<ATC code="N07BC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BENZODIAZEPINES AND RELATED" code="N05-001" /></DRUG2>
<DESCRIPTION>With the buprenorphine used in opioid replacement therapy: increased risk of respiratory depression which could be fatal.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>Evaluate carefully the risk/benefits relationship of administering these substances together. Inform the patient of the necessity of adhering to the prescribed dosages.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>102-BUPRENORPHINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUPRENORPHINE" rxcui="1819">
<ATC code="N02AE01" />
<ATC code="N07BC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FOSAMPRENAVIR" rxcui="358262">
<ATC code="J05AE07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase or of decrease of the effects of the A to take into account buprenorphine [sic], simultaneously by inhibition and acceleration of its metabolism by the protease inhibitor. </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>102-BUPRENORPHINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUPRENORPHINE" rxcui="1819">
<ATC code="N02AE01" />
<ATC code="N07BC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>102-BUPRENORPHINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUPRENORPHINE" rxcui="1819">
<ATC code="N02AE01" />
<ATC code="N07BC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>102-BUPRENORPHINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUPRENORPHINE" rxcui="1819">
<ATC code="N02AE01" />
<ATC code="N07BC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>103-BUPROPION.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLOMIPRAMINE" rxcui="2597">
<ATC code="N06AA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the cloripramine due to decrease of its hepatic metabolism by the bupropion</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the clomipramine during the treatment with the bupropion.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>103-BUPROPION.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DESIPRAMINE" rxcui="3247">
<ATC code="N06AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the desipramine due to decrease of its hepatic metabolism by the bupropion</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the desipramine during the treatment with the bupropion.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>103-BUPROPION.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the flecainide due to decrease of its hepatic metabolism by the bupropion</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the bupropion.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>103-BUPROPION.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="MAOI-B " code="N04BD0-001" /></DRUG2>
<DESCRIPTION>Risk of hypertensive crises</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>103-BUPROPION.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MEQUITAZINE" rxcui="29528">
<ATC code="R06AD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>103-BUPROPION.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the metoprolol used for heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the bupropion</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the bupropion</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>103-BUPROPION.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NORTRIPTYLINE" rxcui="7531">
<ATC code="N06AA10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the nortriptyline due to decrease of its hepatic metabolism by the bupropion</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the nortriptyline during the treatment with the bupropion.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>103-BUPROPION.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the propafenone due to decrease of its hepatic metabolism by the bupropion</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the bupropion.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>103-BUPROPION.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TAMOXIFEN" rxcui="10324">
<ATC code="L02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine [sic]</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>103-BUPROPION.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TRAMADOL" rxcui="10689">
<ATC code="N02AX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the tramadol due to decrease of its hepatic metabolism by the bupropion. In addition, risk of convulsions due to addition of the effects of the two medications</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>103-BUPROPION.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VEMURAFENIB" rxcui="1147220">
<ATC code="L01XE15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the bupropion, with increase of its active metabolite and increased toxicity</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>104-BUSPIRONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUSPIRONE" rxcui="1827">
<ATC code="N05BE01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIAZEPAM" rxcui="3322">
<ATC code="N05BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the buspirone</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>104-BUSPIRONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUSPIRONE" rxcui="1827">
<ATC code="N05BE01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the diltiazem, with increase of its undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the buspirone if necessary.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>104-BUSPIRONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUSPIRONE" rxcui="1827">
<ATC code="N05BE01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="D10AF52" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>104-BUSPIRONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUSPIRONE" rxcui="1827">
<ATC code="N05BE01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>104-BUSPIRONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUSPIRONE" rxcui="1827">
<ATC code="N05BE01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT (JUICE AND FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Rick of increase of the undesirable effects of the buspirone due to decrease of its metabolism by the grapefruit</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>104-BUSPIRONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUSPIRONE" rxcui="1827">
<ATC code="N05BE01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the buspirone due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the buspirone during the treatment with rifampicin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>104-BUSPIRONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUSPIRONE" rxcui="1827">
<ATC code="N05BE01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the verapamil, with increase of its undesirable effects.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the buspirone if necessary.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>105-BUSULFAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUSULFAN" rxcui="1828">
<ATC code="L01AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the busulfan due to decrease of its clearance by the deferasirox</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>105-BUSULFAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUSULFAN" rxcui="1828">
<ATC code="L01AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the busulfan in large doses: doubling of the concentrations of busulfan by the itraconazole</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>105-BUSULFAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BUSULFAN" rxcui="1828">
<ATC code="L01AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METRONIDAZOLE" rxcui="6922">
<ATC code="A02BD08" />
<ATC code="A02BD03" />
<ATC code="A02BD02" />
<ATC code="A01AB17" />
<ATC code="D06BX01" />
<ATC code="G01AF01" />
<ATC code="J01XD01" />
<ATC code="P01AB01" />
<ATC code="A02BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>106-CABAZITAXEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CABAZITAXEL" rxcui="996051">
<ATC code="L01CD04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the concentrations of the cytotoxic by increase of its metabolism by the inducer, with risk of lower effectiveness</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>106-CABAZITAXEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CABAZITAXEL" rxcui="996051">
<ATC code="L01CD04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable dose dependent effects of the cabazitaxel due to inhibition of its metabolism by the enzymatic inducer</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the cabazitaxel during the treatment with the enzymatic inhibitor.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>107-CAFFEINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="N06BC01" />
<ATC code="V04CG30" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIPROFLOXACIN" rxcui="2551">
<ATC code="J01MA02" />
<ATC code="S01AE03" />
<ATC code="S02AA15" />
<ATC code="S03AA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>107-CAFFEINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="N06BC01" />
<ATC code="V04CG30" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIPYRIDAMOLE" rxcui="3521">
<ATC code="B01AC07" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the caffeine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Interrupt a caffeine based treatment at least 5 days before myocardial perfusion imaging with the dipyridamole and avoid consumption of coffee, tea, chocolate, or cola during the 24 hours that precede the test.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>107-CAFFEINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="N06BC01" />
<ATC code="V04CG30" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ENOXACIN" rxcui="3925">
<ATC code="J01MA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of caffeine, which can lead to agitation and hallucinations, due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>107-CAFFEINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="N06BC01" />
<ATC code="V04CG30" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>In case of sudden discontinuation of consumption of coffee or of medications containing caffeine, risk of increase of the plasma concentrations of lithium</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>107-CAFFEINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="N06BC01" />
<ATC code="V04CG30" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MEXILETINE" rxcui="6926">
<ATC code="C01BB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of caffeine, due to inhibition of its hepatic metabolism by the mexiletine</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>107-CAFFEINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="N06BC01" />
<ATC code="V04CG30" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NORFLOXACINE" rxcui="7517">
<ATC code="J01MA06" />
<ATC code="S01AE02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of caffeine, due to decrease of the hepatic metabolism of the caffeine</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>107-CAFFEINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="N06BC01" />
<ATC code="V04CG30" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Possible increase of the plasma concentrations of the caffeine, with risk of overdose, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of caffeine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>108-CALCITONIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CALCITONIN" rxcui="36118">
<ATC code="H05BA" />
<ATC code="H05BA03" />
<ATC code="H05BA02" />
<ATC code="H05BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the calcitonin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>109-CALCIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CALCIUM" rxcui="1895">
<ATC code="A12AA" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BISPHOSPHONATES" code="M05B-001" /></DRUG2>
<DESCRIPTION>For the calcium salts administered via oral route: decrease of the digestive absorption of the bisphosphonates</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take calcium salts and antacids at a different time from the bisphosphonates (from 30 minutes minimum to more than 2 hours apart, if possible, depending on the bisphosphonate). </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>109-CALCIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CALCIUM" rxcui="1895">
<ATC code="A12AA" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="TETRACYCLINE ANTIBIOTICS" code="J01AA" /></DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the tetracycline antibiotics</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the calcium salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>109-CALCIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CALCIUM" rxcui="1895">
<ATC code="A12AA" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of serious arrhythmias, even lethal ones, with the calcium salts administered by IV route. </DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>-with the calcium salts via IV, except for parenteral supplementation</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>109-CALCIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CALCIUM" rxcui="1895">
<ATC code="A12AA" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THIAZIDE DIURETICS AND RELATED" code="C03-003" /></DRUG2>
<DESCRIPTION>Risk of hypercalcemia due to decrease of the urinary elimination of the calcium. </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>109-CALCIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CALCIUM" rxcui="1895">
<ATC code="A12AA" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ESTRAMUSTINE" rxcui="4089">
<ATC code="L01XX11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the estramustine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the calcium salts at a different time from the estramustine (more than 2 hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>109-CALCIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CALCIUM" rxcui="1895">
<ATC code="A12AA" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the iron salts by oral route: decrease of the digestive absorption of the iron salts</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the iron salts at a different time from meals and in the absence of calcium.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>109-CALCIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CALCIUM" rxcui="1895">
<ATC code="A12AA" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG2>
<DESCRIPTION>Decrease of the absorption of the thyroid hormones</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the calcium salts at a different time from the thyroid hormones (more than 2 hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>109-CALCIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CALCIUM" rxcui="1895">
<ATC code="A12AA" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STRONTIUM" rxcui="81638">
<ATC code="M05BX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the calcium salts administered by oral route: decrease of the digestive absorption of the strontium</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the strontium at a different time from the calcium salts (more than two hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>109-CALCIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CALCIUM" rxcui="1895">
<ATC code="A12AA" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZINC" rxcui="11416">
<ATC code="A12CB" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the zinc by the calcium </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the calcium salts at a different time from the zinc (more than 2 hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>10-FUSIDIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FUSIDIC ACID" rxcui="4608">
<ATC code="D06AX01" />
<ATC code="D09AA02" />
<ATC code="J01XC01" />
<ATC code="S01AA13" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS)" code="C10AA" /></DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Stop the treatment with the HMG-COA Reductase Inhibitor before starting a treatment with fusidic acid or use another antibiotic.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>10-FUSIDIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FUSIDIC ACID" rxcui="4608">
<ATC code="D06AX01" />
<ATC code="D09AA02" />
<ATC code="J01XC01" />
<ATC code="S01AA13" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPEVIR" code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the fusidic acid due to decrease of its hepatic metabolism by the therapy with ombitasvir+paritaprevir</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>110-CANAKINUMAB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CANAKINUMAB" rxcui="853491">
<ATC code="L04AC08" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTI-TNF ALPHA" code="4ABO" /></DRUG2>
<DESCRIPTION>Risk of increase of serious infections</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ACETAZOLAMIDE" rxcui="167">
<ATC code="S01EC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and, if needed, testing of the plasma concentrations of carbamazepine and possible reduction of its dosage</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: at the beginning of treatment, increase of the plasma concentrations of carbamazepine due to inhibition of its hepatic metabolism by the cimetidine </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the carbamazepine, especially during the first days of treatment with the cimetidine </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the carbamazepine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLONAZEPAM" rxcui="2598">
<ATC code="N03AE01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the active metabolite of the carbamazepine. In addition, decrease of the plasma concentrations of the clonazepam due to increase of its hepatic metabolism by the carbamazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinincal monitoring, plasma dosages, and possible adjustment of the dosages of the two anticonvulsants</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLOZAPINE" rxcui="2626">
<ATC code="N05AH02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the serious hematological effects </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DANAZOL" rxcui="3102">
<ATC code="G03XA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine, with signs of overdose</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the carbamazepine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine and decrease of the digoxinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Exercise caution in the interpretation of the plasma concentrations.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="POTASSIUM LOWERING DIURETICS" code="C03" /></DRUG2>
<DESCRIPTION>Risk of symptomatic hyponatremia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring. If possible, use another class of diuretics.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ETHOSUXIMIDE" rxcui="4135">
<ATC code="N03AD51" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of ethosuximide</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, plasma dosage of the ethosuximide and possible increase of its dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FELBAMATE" rxcui="24812">
<ATC code="N03AX10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the active metabolite of the carbamazepine. In addition, decrease of the plasma concentrations of felbamate due to increase of its hepatic metabolism by the carbamazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, plasma dosages, and possible adjustment of the dosages of the two anticonvulsants.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>For doses of fluconazole &gt;=200 mg per day: possible increase of the undesirable effects of the carbamazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Adjust the dosage of carbamazepine, during the antifungal treatmentand after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, testing of the plasma concentrations of carbamazepine, and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, testing of the plasma concentrations of carbamazepine, and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose, due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and. if needed, plasma dosage and possible reduction of the dosage of the carbamazepine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LAMOTRIGINE" rxcui="28439">
<ATC code="N03AX09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the neurological effects (vertigo, ataxia, diplopia) of the carbamazepine when the lamotrigine is introduced</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the carbamazepine. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of neurotoxicity manifesting as disorders of the cerebellum, confusion, drowsiness, ataxia. These disorders are reversible when the treatment with the lithium is stopped.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHN'S WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations and of the effectiveness of the carbamazepine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="L01XE31" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of nintedanib due to decrease of its absorption by the carbamazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="OLANZAPINE" rxcui="61381">
<ATC code="N05AH03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the olanzapine and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the carbamazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and if needed, adjustment of the dosage of the olanzapine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT (JUICE AND FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine, with risk of overdose, due to inhibition of its metabolism by the grapefruit</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, testing of the plasma concentrations of carbamazepine and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG2>
<DESCRIPTION>Progressive decrease of the plasma concentrations of carbamazepine and of its active metabolite without apparent modification of its anticonvulsive effectiveness</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>Use prudence with respect to the interpretation of the plasma concentrations.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Reciprocal reduction of the plasma concentrations (increase of the metabolism without apparent modification of the anticonvulsive effectiveness)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>Use prudence in the interpretation of the plasma concentrations. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the carbamazepine due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, testing of the plasma concentrations, and adjustment of the dosage of the carbamazepine during the treatment with the refampicin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RISPERIDONE" rxcui="35636">
<ATC code="N05AX08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the active fraction of the risperidone and of its therapeutic effectiveness due to increase of its hepatic metabolism by the carbamazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and, if needed, adjustment of the dosage of the risperidone.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of simvastatin, due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TOPIRAMATE" rxcui="38404">
<ATC code="N03AX11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the carbamazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and if needed, adjustment of the dosage of the topiramate during the treatment with the carbamazepine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>111-CARBAMAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the active metabolite of the carbamazepine with signs of overdose. In addition, decrease of the plasma concentrations of valproic acid due to increase of its hepatic metabolism by the carbamazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, plasma dosages, and adjustment of the dosage of the two anticonvulsants.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>112-CARMUSTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARMUSTINE" rxcui="2105">
<ATC code="L01AD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the carmustine) </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>113-CARVEDILOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARVEDILOL" rxcui="20352">
<ATC code="C07AG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the carvedilol, which can be dangerous in the case of treatment for heart failure due to decrease of its hepatic metabolism by the cimetidine</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Use another gastric H2 receptor antagonist.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>113-CARVEDILOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CARVEDILOL" rxcui="20352">
<ATC code="C07AG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of the carvedilol, due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring and adjustment of the dosage of the carvedilol during the treatment with the rifampicin. When the rifampicin is stopped, risk of large increase of the plasma concentrations of carvedilol imposing a reduction of the dosage and strict clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>114-CALCIUM-POLYSTYRENE-SULFONATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CALCIUM POLYSTYRENE SULFONATE" rxcui="47630">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SORBITOL" rxcui="9945">
<ATC code="A06AD18" />
<ATC code="A06AG07" />
<ATC code="B05CX02" />
<ATC code="V04CC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the resin administered by oral and rectal routes: risk of colonic necrosis, possibly fatal</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>115-SODIUM-POLYSTYRENE-SULFONATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SODIUM POLYSTYRENE SULFONATE" rxcui="56512">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SORBITOL" rxcui="9945">
<ATC code="A06AD18" />
<ATC code="A06AG07" />
<ATC code="B05CX02" />
<ATC code="V04CC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the resin administered by oral and rectal routes: risk of colonic necrosis, possibly fatal</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>116-CEFALOTIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CEFALOTIN" rxcui="2236">
<ATC code="J01DB03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="AMINOGLYCOSIDES" code="J01GB-001" /></DRUG2>
<DESCRIPTION>Increase of the nephrotoxicity of the aminoglycosides by the cefalotin is under discussion</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of renal function.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>117-CEFAMANDOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CEFAMANDOLE" rxcui="2178">
<ATC code="J01DC03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>118-CEFOPERAZONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CEFOPERAZONE" rxcui="2184">
<ATC code="J01DD12" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>119-CEFOTETAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CEFOTETAN" rxcui="2187">
<ATC code="J01DC05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>11-NICOTINIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NICOTINIC ACID" rxcui="446722">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ALCOHOL (DRINK OR INGREDIENT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of rash, redness, and heat linked to an increase of the vasodilator effect </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>120-CEFTRIAXONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CEFTRIAXONE" rxcui="2193">
<ATC code="J01DD04" />
<ATC code="J01DD54" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>121-CHLORDIAZEPOXIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CHLORDIAZEPOXIDE" rxcui="2356">
<ATC code="N05BA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Warn patients of the increase of risk when driving an automobile or using machinery.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>122-CHLOROQUINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CHLOROQUINE" rxcui="2393">
<ATC code="P01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the blood concentrations of ciclosporin and of the creatinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after the chloroquine is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>122-CHLOROQUINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CHLOROQUINE" rxcui="2393">
<ATC code="P01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
<ATC code="A02BA51" />
</DRUG>
</DRUG2>
<DESCRIPTION>Slowing of the elimination of the chloroquine and risk of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>122-CHLOROQUINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CHLOROQUINE" rxcui="2393">
<ATC code="P01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG2>
<DESCRIPTION>Risk of clinical hypothyroidism in patients taking thyroid hormones in substitution therapy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormone during the treatment with the antimalarial and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>123-CHLORPROMAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CHLORPROMAZINE" rxcui="2403">
<ATC code="N05AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="INSULIN" rxcui="631657">
<ATC code="5856" />
</DRUG>
</DRUG2>
<DESCRIPTION>With strong doses (100 mg per day of chlorpromazine): elevation of glycemia (decrease of the freeing of insulin)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient and reinforce self monitoring of blood glucose. Possible adjustment of the dosage of the insulin during the treatment with the neuroleptic and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>123-CHLORPROMAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CHLORPROMAZINE" rxcui="2403">
<ATC code="N05AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG2>
<DESCRIPTION>With strong doses (100 mg per day of chlorpromazine): elevation of glycemia (decrease of the freeing of insulin)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient and reinforce self monitoring of blood glucose. Possible adjustment of the dosage of the neuroleptic during the treatment and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="URSODEOXYCHOLIC ACID" rxcui="11065">
<ATC code="A05AA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of variation of the blood concentrations of ciclosporin </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of afatinib due to increase of its absorption by the ciclosporin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommended that the ciclosporin be administered as far from the afatinib as possible, preferably at an interval of 6 to 12 hours away from the administration of the dose of afatinib. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09XA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase by nearly 5 times of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMBRISENTAN" rxcui="358274">
<ATC code="C02KX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Doubling of the concentrations of ambrisentan, with increase of the vasodilator effect (severe headaches )</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="AMINOGLYCOSIDES" code="J01GB-001" /></DRUG2>
<DESCRIPTION>Larger increase of the creatinemia than with ciclosporin alone, with increase of the nephrotoxic risk </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of ciclosporin, due to decrease of its hepatic metabolism, with risk of nephrotoxic effects

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Blood concentration dosage of ciclosporin, testing of the renal function, and adjustment of the dosage of the ciclosporin during the treatment with the amiodarone</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMPHOTERICIN B " rxcui="732">
<ATC code="A01AB04" />
<ATC code="A07AA07" />
<ATC code="G01AA03" />
<ATC code="J02AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the amphotericin B administered by IV route: greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SOMATOSTATIN ANALOGS" code="H01CB0-001" /></DRUG2>
<DESCRIPTION>With the ciclosporin administered orally:

reduction of the blood concentrations of ciclosporin (decrease of its intestinal absorption).

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increase of the doses of ciclosporin according to testing of the plasma concentrations and reduction of the dosage after the treatment with the somatostatin analog is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Risk of addition of the nephrotoxic effects, especially with older patients.

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitor renal function at the beginning of the treatment with the NSAI.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the intestinal absorption of the cholesterol lowering medication)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Do not exceed the dosage of 10mg/day of atorvastatin. If the therapeutic objective is not reached at that dosage, use another statin not affected by this type of interaction.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AZITHROMYCIN " rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the blood concentrations of ciclosporin and of the creatinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the two substances together and after the macrolide is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the blood concentrations of the ciclosporin and increase of the plasma concentrations of bosentan</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CHLOROQUINE" rxcui="2393">
<ATC code="P01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the blood concentrations of ciclosporin and of the creatinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after the chloroquine is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the blood concentrations of ciclosporin</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLINDAMYCIN" rxcui="2582">
<ATC code="D10AF01" />
<ATC code="G01AA10" />
<ATC code="J01FF01" />
<ATC code="D10AF51" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforce testing of the blood dosages of ciclosporin and possible increase of its dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of addition of the undesirable neuromuscular effects and increase of the toxicity of the colchicine with risk of overdose due to inhibition of its elimination by the ciclosporin, especially in cases of pre-existing renal insufficiency</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase by more than double of the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DANAZOL" rxcui="3102">
<ATC code="G03XA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of ciclosporin due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)" code="C0E-004" /></DRUG2>
<DESCRIPTION>Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="POTASSIUM LOWERING DIURETICS" code="C03" /></DRUG2>
<DESCRIPTION>Risk of increase of the creatinemia without modification of the blood concentrations of ciclosporin, even in the absence of fluid depletion. Also risk of hyperuricemia and of complications such as gout</DESCRIPTION>
<SEVERITY>Tale into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERIBULINE" rxcui="1045453">
<ATC code="L01XX41" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of eribuline by the ciclosporin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EVEROLIMUS" rxcui="141704">
<ATC code="L04AA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the everolimus by the ciclosporin. The nephrotoxicity of the ciclosprorin is also increased when the two medications are administered together </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the everolimus, possibly adjustment of the dosage, and testing of the renal function during the administration of the two together and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EZETIMIBE" rxcui="341248">
<ATC code="C10BA05" />
<ATC code="C10AX09" />
<ATC code="C10BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>For one thing, increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to increase of the concentrations of ezetimibe; for another thing, possible increase of the concentrations of ciclosporin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FENOFIBRATE" rxcui="8703">
<ATC code="C10AB05" />
<ATC code="C10BA03" />
<ATC code="C10BA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the nephrotoxicity of the ciclosporin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring of the renal function during and after the administration of the two medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FIDAXOMICIN" rxcui="1111103">
<ATC code="A07AA12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the fidaxomicin. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the blood concentrations of ciclosporin and of the creatinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of these medications together and after the macrolide is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LERCANIDIPINE" rxcui="135056">
<ATC code="C09BB02" />
<ATC code="C08CA13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Moderate increase of the blood concentrations of the immunosuppressant and larger increase of the concentrations of the lercanidipine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Separate the administration of the two medications. Blood concentration dosage of the immunosuppressant, and adjustment if necessary of its dosage during the administration of the medications together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the toxicity of the methotrexate and of the ciclosporin with increase of the creatinemia: reciprocal decrease of the clearances of the two medications</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of ciclosporin and of methotrexate. Adjustment of the dosage if necessary during the administration of the two together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHYLPREDNISOLONE" rxcui="6902">
<ATC code="D07AA01" />
<ATC code="D10AA02" />
<ATC code="H02AB04" />
<ATC code="D07CA02" />
<ATC code="S01CA08" />
<ATC code="H02BX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia. Mecanism proposed: decrease of the hepatic elimination of the ciclosporin</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MIDECAMYCIN" rxcui="30005">
<ATC code="J01FA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the blood concentrations of ciclosporin and of the creatinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after the macrolide is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MODAFINIL" rxcui="30125">
<ATC code="N06BA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the blood concentrations and of the effectiveness of the immunosuppressant</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NIFEDIPINE" rxcui="7417">
<ATC code="C08CA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of addition of undesirable effects of the gum disorders type.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Use another dihydropyridine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="L01XE31" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the nintedanib due to increase of its absorption by the ciclosporin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of there substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the blood concentrations of ciclosporin due to decrease of its intestinal absorption, with risk of loss of the immunosuppressive activity</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Take the orlistat at a different time form the ciclosporin (at least 3 hours apart). Reinforce testing of blood dosages of the ciclosporin, especially at the beginning of the administration of the medications together, and at the time of a possible increase in the dosage of the orlistat.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PITAVASTATIN" rxcui="861634">
<ATC code="C10AA08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the pitavastatin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="POTASSIUM" rxcui="8588">
<ATC code="A12BA" />
</DRUG>
</DRUG2>
<DESCRIPTION>Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Avoid the administration of these two substances together unless there is pre-existing hypokalemia.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PREDNISOLONE" rxcui="8638">
<ATC code="A07EA01" />
<ATC code="C05AA04" />
<ATC code="D07AA03" />
<ATC code="D07XA02" />
<ATC code="H02AB06" />
<ATC code="R01AD02" />
<ATC code="S01BA04" />
<ATC code="S01CB02" />
<ATC code="S02BA03" />
<ATC code="S03BA02" />
<ATC code="D07CA03" />
<ATC code="S01CA02" />
<ATC code="S02CA01" />
<ATC code="S03CA02" />
<ATC code="D07BA01" />
<ATC code="S01BB02" />
<ATC code="V03AB05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of more than double of the concentrations of the repaglinide due to increase of its absorption</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ROSUVASTATIN" rxcui="301542">
<ATC code="C10AA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the rosuvastatin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ROXITHROMYCIN" rxcui="9478">
<ATC code="J01FA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the blood concentrations of ciclosporin and of the creatinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration with the macrolide and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolosis type due to decrease of the metabolism of the simvastatin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIROLIMUS" rxcui="35302">
<ATC code="L04AA10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of sirolimus by the ciclosporin. The nephrotoxicity of the ciclosporin is also increased when the two medications are administered together</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommended that the sirolimus be administered 4 hours after the cyclosporine. Testing of the renal function, during the administration of the two medications together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SULFINPYRAZONE" rxcui="10205">
<ATC code="M04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the blood concentrations of ciclosporin due to increase of its metabolism by the sulfinpyrazone</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Testing of blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with sulfinpyrazone and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TENEFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In case of administration with the ciclosporin, the dose of tenofovir alafenamide must be limited to 10 mg per day. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TERBINAFINE" rxcui="37801">
<ATC code="D01BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the blood concentrations of ciclosporin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Testing of blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with terbinafine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TICLOPIDINE" rxcui="10594">
<ATC code="B01AC05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the blood concentrations of ciclosporin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increase of the dosage of the ciclosporin according to testing of the blood concentrations. Reduction of the dosage when the ticlodipine is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TRIMETHOPRIM" rxcui="10829">
<ATC code="J01EA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporin

With the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>124-CICLOSPORIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the ciclosporin (decrease of its hepatic metabolism), and increase of the risk of gum disorders</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>125-CIMETIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ALFENTANIL" rxcui="480">
<ATC code="N01AH02" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800mg/day: increase of the opioid analgesic&#39;s effect of respiratory depression due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Adjust the dosage of the alfentanil when administered with the cimetidine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>125-CIMETIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cimetidine and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>125-CIMETIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: at the beginning of treatment, increase of the plasma concentrations of carbamazepine due to inhibition of its hepatic metabolism by the cimetidine </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the carbamazepine, especially during the first days of treatment with the cimetidine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>125-CIMETIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARMUSTINE" rxcui="2105">
<ATC code="L01AD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the carmustine)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>125-CIMETIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARVEDILOL" rxcui="20352">
<ATC code="C07AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the carvedilol, which can be dangerous in the case of treatment for heart failure due to decrease of its hepatic metabolism by the cimetidine</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Use another H2 receptor antagonist.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>125-CIMETIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CHLORDIAZEPOXIDE" rxcui="2356">
<ATC code="N05BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cemitidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Warn patients of the increase of risk when driving an automobile or using machinery.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>125-CIMETIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CHLOROQUINE" rxcui="2393">
<ATC code="P01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Slowing of the elimination of the chloroquine and risk of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>125-CIMETIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the blood concentrations of ciclosporin</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>125-CIMETIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIAZEPAM" rxcui="3322">
<ATC code="N05BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increased risk of drowsiness</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Warn the patient of the increase of risk when driving an automobile or using machinery. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>125-CIMETIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LIDOCAINE" rxcui="6387">
<ATC code="C01BB01" />
<ATC code="C05AD01" />
<ATC code="D04AB01" />
<ATC code="N01BB02" />
<ATC code="R02AD02" />
<ATC code="S01HA07" />
<ATC code="S02DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>125-CIMETIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LOMUSTINE" rxcui="6466">
<ATC code="L01AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the lomustine)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>125-CIMETIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N07BC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strengthen clinical and electrocardiographic monitoring; if needed, adjustment of the dosage of the methadone during the treatment with the cimetidine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>125-CIMETIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the metoprolol used for heart failure, and the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the cimetidine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>125-CIMETIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MOCLOBEMIDE" rxcui="30121">
<ATC code="N06AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the moclobemide, due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring with possible adjustment of the dosage of moclobemide</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>125-CIMETIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NIFEDIPINE" rxcui="7417">
<ATC code="C08CA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the hypotensive effect of the nifedipine due to inhibition of its hepatic metabolism by the cimetidine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring: adjust the dosage of the nifedipine during the treatment with the cimetidine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>125-CIMETIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of phenytoin with possibility of appearance of the usual signs of overdose</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering the substances together cannot be avoided, strict clinical monitoring, plasma concentration dosages of the phenytoin, and possible adjustment of its dosage during the treatment with the cimetidine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>125-CIMETIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia. If there is reason for it, adjustment of the theophylline during the treatment with the cimetidine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>126-CINACALCET.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CINACALCET" rxcui="407990">
<ATC code="H05BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEXTROMETHORPHAN" rxcui="3289">
<ATC code="R05DA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large increase of the plasma concentrations of dextromethorphan with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>126-CINACALCET.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CINACALCET" rxcui="407990">
<ATC code="H05BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of flecanaide with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the flecainide during the treatment with cinacalcet.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>126-CINACALCET.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CINACALCET" rxcui="407990">
<ATC code="H05BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MEQUITAZINE" rxcui="29528">
<ATC code="R06AD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>126-CINACALCET.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CINACALCET" rxcui="407990">
<ATC code="H05BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with cinacalcet.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>126-CINACALCET.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CINACALCET" rxcui="407990">
<ATC code="H05BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of propafenone with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the propafenone during the treatment with cinacalcet.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>126-CINACALCET.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CINACALCET" rxcui="407990">
<ATC code="H05BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the cinacalcet and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>127-CIPROFLOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIPROFLOXACIN" rxcui="2551">
<ATC code="J01MA02" />
<ATC code="S01AE03" />
<ATC code="S02AA15" />
<ATC code="S03AA07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AGOMELATINE" rxcui="306718">
<ATC code="N06AX22" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>127-CIPROFLOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIPROFLOXACIN" rxcui="2551">
<ATC code="J01MA02" />
<ATC code="S01AE03" />
<ATC code="S02AA15" />
<ATC code="S03AA07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="N06BC01" />
<ATC code="V04CG3" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>127-CIPROFLOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIPROFLOXACIN" rxcui="2551">
<ATC code="J01MA02" />
<ATC code="S01AE03" />
<ATC code="S02AA15" />
<ATC code="S03AA07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLOZAPINE" rxcui="2626">
<ATC code="N05AH02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of clozapine with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the clozapine during the treatment with the ciprofloxacin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>127-CIPROFLOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIPROFLOXACIN" rxcui="2551">
<ATC code="J01MA02" />
<ATC code="S01AE03" />
<ATC code="S02AA15" />
<ATC code="S03AA07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA0" />
<ATC code="L04AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>127-CIPROFLOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIPROFLOXACIN" rxcui="2551">
<ATC code="J01MA02" />
<ATC code="S01AE03" />
<ATC code="S02AA15" />
<ATC code="S03AA07" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Variation, possibly large, of the concentrations of phenytoin in the case of treatment with ciprofloxacin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and testing of the plasma concentrations of the anticonvulsant during the treatment with ciprofloxacin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>127-CIPROFLOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIPROFLOXACIN" rxcui="2551">
<ATC code="J01MA02" />
<ATC code="S01AE03" />
<ATC code="S02AA15" />
<ATC code="S03AA07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ROPINIROLE" rxcui="72302">
<ATC code="N04BC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of ropinirole with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the ropinirole during the treatment with the ciprofloxacin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>127-CIPROFLOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIPROFLOXACIN" rxcui="2551">
<ATC code="J01MA02" />
<ATC code="S01AE03" />
<ATC code="S02AA15" />
<ATC code="S03AA07" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrythmias, especially of torsades de pointes. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>127-CIPROFLOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CIPROFLOXACIN" rxcui="2551">
<ATC code="J01MA02" />
<ATC code="S01AE03" />
<ATC code="S02AA15" />
<ATC code="S03AA07" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>128-CITRATES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CITRATES" code="V09HX" /></DRUG1>
<DRUG2>
<CLASS name="ALUMINUM (SALTS)" code="A02AD0-001" /></DRUG2>
<DESCRIPTION>Risk of facilitation of systemic uptake of the aluminum, especially in case of altered renal function. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the aluminum based gastrointestinal medications at a different time (more than 2 hours apart if possible) from the citrates, including natural citrates (citrus fruit juices). </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>129-CLADRIBINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLADRIBINE" rxcui="44157">
<ATC code="L01BB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LAMIVUDINE" rxcui="68244">
<ATC code="J05AF05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cladribine by the lamivudine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>12-URSODEOXYCHOLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="URSODEOXYCHOLIC ACID" rxcui="">
<ATC code="A05AA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of variation of blood concentrations of ciclosporin</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of clarithyromycin and inhibition of the formation of its active metabolite</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of the cholesterol lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the carbamazepine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushings syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with clarithromycin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EBASTINE" rxcui="23796">
<ATC code="R06AX22" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias in predisposed subjects (congenital long QT syndrome)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERIBULINE" rxcui="1045453">
<ATC code="L01XX41" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of eribuline by the clarithromycin.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ETRAVIRINE" rxcui="475969">
<ATC code="J05AG04" />
</DRUG>
</DRUG2>
<DESCRIPTION>In the treatment of infections with Mycobacterium avium complex, risk of decrease of the effectiveness of the clarithromycin due to increase of its hepatic metabolism by the etravirine</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FIDAXOMICIN" rxcui="1111103">
<ATC code="A07AA12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the fidaxomicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GLIBENCLAMIDE" rxcui="4815">
<ATC code="A10BB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GLIMEPIRIDE" rxcui="25789">
<ATC code="A10BD06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Increase of the concentrations of the clarithromycin and of its active metabolite due to decrease of its hepatic metabolism by the protease inhibitor</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of treatment. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LINEZOLIDE" rxcui="190376">
<ATC code="J01XX08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the linezolide by the clarithromycin due to increase of its absorption</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LUMEFANTRINE" rxcui="847728">
<ATC code="P01BF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If this is possible, interrupt the medication tending to induce torsades de pointes. If administering these medications together cannot be avoided, testing of the QT before hand and EKG monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MIZOLASTINE" rxcui="61455">
<ATC code="R06AX25" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PRAVASTATIN" rxcui="42463">
<ATC code="C10AA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentration of the pravastatin by the clarithromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring during the treatment with the antibiotic</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypoglycemia due to increase of the plasma concentrations of the repaglinide</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the hypoglycemic agent during the treatment with the clarithromycin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the rifabutin (uveitis) due to increase of its concentrations and those of its active metabolite by the clarithromycin. In addition, increase of the metabolism of the clarithromycin by the rifabutin, with increase of the concentrations of its active metabolite</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the two medications together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and risk of lower effectiveness of the clarithromycin, especially with the HIV patient, due to increase of its hepatic metabolism by the rifampacin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (contentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de points</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG2>
<DESCRIPTION>Risk of hypoglycemia due to increase of the plasma concentrations of the antidiabetic</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Risk of increase of the theophyllinemia, particularly with children</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VENLAFAXINE" rxcui="39786">
<ATC code="N06AX16" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of venlafaxine with risk of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>130-CLARITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VINCA ALKALOIDS" code="L01CA" /></DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the clarithromycin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical and biological monitoring. Possibly, use another antibiotic. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>131-CLINDAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLINDAMYCIN" rxcui="2582">
<ATC code="D10AF01" />
<ATC code="G01AA10" />
<ATC code="J01FF01" />
<ATC code="D10AF51" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the clindamycin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>131-CLINDAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLINDAMYCIN" rxcui="2582">
<ATC code="D10AF01" />
<ATC code="G01AA10" />
<ATC code="J01FF01" />
<ATC code="D10AF51" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforced testing of the blood dosages of ciclosporin and possible increase of its dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>131-CLINDAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLINDAMYCIN" rxcui="2582">
<ATC code="D10AF01" />
<ATC code="G01AA10" />
<ATC code="J01FF01" />
<ATC code="D10AF51" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
<ATC code="L04AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforced testing of the blood dosages of tacrolimus and possible increase of its dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>132-CLOBAZAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLOBAZAM" rxcui="21241">
<ATC code="N05BA09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of these anticonvulsants, with risk of overdose, due to inhibition of their hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol and possible adjustment of the dosage of the anticonvulsant taken with it as well.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>133-CLOMIPRAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLOMIPRAMINE" rxcui="2597">
<ATC code="N06AA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the clomipramine due to decrease of its hepatic metabolism by the bupropion</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the clomipramine during the treatment with the bupropion. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>134-CLONAZEPAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLONAZEPAM" rxcui="2598">
<ATC code="N03AE01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the active metabolite of the carbamazepine. In addition, decrease of the plasma concentrations of the clonazepam due to increase of its hepatic metabolism by the carbamazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, plasma dosages, and possible adjustment of the dosages of the two anticonvulsants</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>135-CLONIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLONIDINE" rxcui="2599">
<ATC code="C02AC01" />
<ATC code="N02CX02" />
<ATC code="S01EA04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG2>
<DESCRIPTION>Described for desipramine, imipramine:

inhibition of the antihypertensive effect of the clonidine (antagonism at the level of the adrenergic receptors)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>135-CLONIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLONIDINE" rxcui="2599">
<ATC code="C02AC01" />
<ATC code="N02CX02" />
<ATC code="S01EA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>135-CLONIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLONIDINE" rxcui="2599">
<ATC code="C02AC01" />
<ATC code="N02CX02" />
<ATC code="S01EA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>135-CLONIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLONIDINE" rxcui="2599">
<ATC code="C02AC01" />
<ATC code="N02CX02" />
<ATC code="S01EA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="YOHIMBINE" rxcui="220982">
<ATC code="G04BE04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Possible inhibition of the antihypertensive activity due to antagonism at the level of the receptors</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>136-CLOPIDOGREL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLOPIDOGREL" rxcui="32968">
<ATC code="B01AC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage due to addition of the platelet antiagregation action

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-aside from validated indications for this combination of drugs in acute coronary syndromes. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>136-CLOPIDOGREL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLOPIDOGREL" rxcui="32968">
<ATC code="B01AC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PACLITAXEL" rxcui="56946">
<ATC code="L01CD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of the paclitaxel by the clopidogrel, with risk of increase of the undesirable effects.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>136-CLOPIDOGREL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLOPIDOGREL" rxcui="32968">
<ATC code="B01AC04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and testing of the plasma concentrations of phenytoin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>136-CLOPIDOGREL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLOPIDOGREL" rxcui="32968">
<ATC code="B01AC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of the repaglinide by the clopidogrel, with risk of increase of the undesirable effects.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>137-CLOZAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLOZAPINE" rxcui="2626">
<ATC code="N05AH02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BENZODIAZEPINES AND RELATED" code="N05-001" /></DRUG2>
<DESCRIPTION>Accrued risk of drop in blood pressure with respiratory and/or cardiac arrest.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>137-CLOZAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLOZAPINE" rxcui="2626">
<ATC code="N05AH02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the serious hematological effects </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>137-CLOZAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLOZAPINE" rxcui="2626">
<ATC code="N05AH02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIPROFLOXACIN" rxcui="2551">
<ATC code="J01MA02" />
<ATC code="S01AE03" />
<ATC code="S02AA15" />
<ATC code="S03AA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of clozapine with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the clozapine during the treatment with the ciprofloxacin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>137-CLOZAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLOZAPINE" rxcui="2626">
<ATC code="N05AH02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of clozapine with signs of overdose</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring; if needed, adjustment of the dosage of the clozapine during the treatment with the fluvoxamine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>137-CLOZAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLOZAPINE" rxcui="2626">
<ATC code="N05AH02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the phenytoin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>137-CLOZAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLOZAPINE" rxcui="2626">
<ATC code="N05AH02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the rifampicin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>138-COBICISTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="V03AX03" />
<ATC code="J05AR09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the amiodarone due to decrease of its metabolism by the cobicistat</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>138-COBICISTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="V03AX03" />
<ATC code="J05AR09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cobicistat due to the increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>138-COBICISTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="V03AX03" />
<ATC code="J05AR09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentratons of the cobicistat or of the inhibitor of CYP3A4</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>To know the risks and levels of severity of each interaction, consult the specific authorization for sale to the public ("Authorisation de la Mise sur le Marche" a French document) of each medication.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>138-COBICISTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="V03AX03" />
<ATC code="J05AR09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the concentrations of itraconazole by the cobicistat</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together. Large doses of itraconazole (>200 mg per day) are not recommended. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>138-COBICISTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="V03AX03" />
<ATC code="J05AR09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>138-COBICISTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="V03AX03" />
<ATC code="J05AR09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>138-COBICISTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="V03AX03" />
<ATC code="J05AR09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large increase of the metabolite of the rifabutin, with risk of increase of its toxicity (uveitis, neutropenia). Furthermore, possible decrease of the concentrations of cobicistat</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Adjustment of the dosage of the rifabutin (in principle, reduction of the doses by half).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>138-COBICISTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="V03AX03" />
<ATC code="J05AR09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>138-COBICISTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="V03AX03" />
<ATC code="J05AR09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TENEFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG2>
<DESCRIPTION>With the atazanavir, the darunavir or the lopinavir boosted by cobicistat, increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In case of administration of these together, the dose of tenofovir alafenamide must be limited to 10 mg per day. The combination with the other protease inhibitors of HIV has not been studied.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>138-COBICISTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="V03AX03" />
<ATC code="J05AR09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VINCA ALKALOIDS" code="L01CA" /></DRUG2>
<DESCRIPTION>Increase of the neurotoxicity of the antimitotic due to decrease of its hepatic metabolism by the cobicistat</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring and possible adjustment of the dosage of the antimitotic</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>139-COCAINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COCAINE" rxcui="2653">
<ATC code="S02DA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DISULFIRAM" rxcui="3554">
<ATC code="N07BB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of cocaine due to decrease of its metabolism by the disulfiram, with increased risk of torsades de pointes</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>13-ACITRETIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACITRETIN" rxcui="16818">
<ATC code="D05BB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ALCOHOL (DRINK OR INGREDIENT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>With women of child bearing age, risk of transformation of the acitretin into etretinate, a powerful agent of birth defects and malformations with a very prolonged half life (120 days), exposing the woman to a major risk of these birth defects and malformations of the child in case of pregnancy, during the treatment and two months after it ends. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>13-ACITRETIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACITRETIN" rxcui="16818">
<ATC code="D05BB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the hepatotoxicity of the methotrexate </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these substances together is judged necessary, strengthen liver function testing. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>140-COLCHICINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the colchicine and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>140-COLCHICINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of addition of the undesirable neuromuscular effects and increase of the toxicity of the colchicine with risk of overdose due to inhibition of its elimination by the ciclosporin, espceially in cases of pre-existing renal insufficiency</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>140-COLCHICINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="FIBRATES" code="C01AB-001" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolysis</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring, particularly at the beginning of the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>140-COLCHICINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the undesirable effects of the colchicine, with potentially fatal consequences</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>140-COLCHICINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS)" code="C10AA" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolysis</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring, especially at the beginning of the administration of these substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>140-COLCHICINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the undesirable effects of the colchicine, with potentially fatal consequences</DESCRIPTION>
<SEVERITY>Contraindication:</SEVERITY>
<COMMENT>--with the macrolides</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>140-COLCHICINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="MACROLIDES (EXCEPT SPIRAMYCIN)" code="J01FA" /></DRUG2>
<DESCRIPTION>Increase of the undesirable effects of the colchicine, with potentially fatal consequences</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>140-COLCHICINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPRVIR" code="OMPA" /></DRUG2>
<DESCRIPTION>Increase od the plasma concentrations of the colchicine due to decrease of its hepatic metabolism by the therapy with ombitasvir + paritaprevir</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>-with patients having renal and/or hepatic insufficiency</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>140-COLCHICINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PRISTINAMYCIN" rxcui="66958">
<ATC code="J01FG01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the undesirable effects of the colchicine, with potentially fatal consequences</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>140-COLCHICINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the colchicine, due to increase of its plasma concentrations by the verapamil</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>141-COLISTIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="COLISTIN" rxcui="2709">
<ATC code="A07AA10" />
<ATC code="J01XB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="CURARES" code="M03A-001" /></DRUG2>
<DESCRIPTION>Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitor the degree of curarization at the end of anesthesia.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>141-CURARES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CURARES" code="M03A-001" /></DRUG1>
<DRUG2>
<CLASS name="AMINOGLYCOSIDES" code="J01GB-001" /></DRUG2>
<DESCRIPTION>Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitor the degree of curarization at the end of anesthesia</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>141-CURARES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CURARES" code="M03A-001" /></DRUG1>
<DRUG2>
<DRUG name="COLISTIN" rxcui="2709">
<ATC code="J01XB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitor the degree of the curarization at the end of anesthesia.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>141-CURARES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CURARES" code="M03A-001" /></DRUG1>
<DRUG2>
<CLASS name="LINCOSANIDES" code="J01FF0" /></DRUG2>
<DESCRIPTION>Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitor the degree of curarisation at the end of anesthesia.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>141-CURARES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CURARES" code="M03A-001" /></DRUG1>
<DRUG2>
<DRUG name="POLYMYXIN B" rxcui="8536">
<ATC code="A07AA05" />
<ATC code="J01XB02" />
<ATC code="S01AA18" />
<ATC code="S02AA11" />
<ATC code="S03AA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitor the degree of curarisation at the end of anesthesia.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>142-CRIZOTINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CRIZOTINIB" rxcui="1148495">
<ATC code="L01XE16" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SUBSTRATES AT RISK OF CYP3A4" code="L01N01" /></DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of these molecules due to decrease of their metabolism and/or increase of their bioavailability by the crizotinib</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>144-NON-DEPOLARIZING-CURARES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON-DEPOLARIZING CURARES" code="M03A-002" /></DRUG1>
<DRUG2>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG2>
<DESCRIPTION>With the glucocorticoids by IV route: risk of severe myopathy, reversible after a possibly long period (several months).</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>145-CYANOCOBALAMIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CYANOCOBALAMIN" rxcui="11248">
<ATC code="B03BA01" />
<ATC code="B03BA02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="H2 RECEPTOR ANTAGONISTS" code="A02BA-001" /></DRUG2>
<DESCRIPTION>Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>145-CYANOCOBALAMIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CYANOCOBALAMIN" rxcui="11248">
<ATC code="B03BA01" />
<ATC code="B03BA02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG2>
<DESCRIPTION>Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>146-TETRACYCLINE-ANTIBIOTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TETRACYCLINE ANTIBIOTICS" code="J01AA" /></DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tetracycline antibiotic and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>146-TETRACYCLINE-ANTIBIOTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TETRACYCLINE ANTIBIOTICS" code="J01AA" /></DRUG1>
<DRUG2>
<DRUG name="CALCIUM" rxcui="1895">
<ATC code="A12AA" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the tetracycline antibiotics</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the calcium salts at a different time from the tetracycline antibiotic (more than two hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>146-TETRACYCLINE-ANTIBIOTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TETRACYCLINE ANTIBIOTICS" code="J01AA" /></DRUG1>
<DRUG2>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the tetracycline antibiotics administered by oral route: decrease of the digestive absorption of the tetracycline antibiotics (formation of complexes)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the iron salts at a different time from the tetracycline antibiotics (more than 2 hours apart, if possible). </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>146-TETRACYCLINE-ANTIBIOTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TETRACYCLINE ANTIBIOTICS" code="J01AA" /></DRUG1>
<DRUG2>
<CLASS name="RETINOIDS" code="D05-D10" /></DRUG2>
<DESCRIPTION>Risk of intracranial hypertension</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>146-TETRACYCLINE-ANTIBIOTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TETRACYCLINE ANTIBIOTICS" code="J01AA" /></DRUG1>
<DRUG2>
<DRUG name="STRONTIUM" rxcui="81638">
<ATC code="V10BX01" />
<ATC code="M05BX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the strontium </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the strontium at a different time from the tetracycline antibiotics (more than two hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>146-TETRACYCLINE-ANTIBIOTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TETRACYCLINE ANTIBIOTICS" code="J01AA" /></DRUG1>
<DRUG2>
<DRUG name="VITAMIN A" rxcui="11246">
<ATC code="A11CA" />
<ATC code="A11CA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>In case of intake of 10,000 IU/day and more: risk of intracranial hypertension </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>146-TETRACYCLINE-ANTIBIOTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TETRACYCLINE ANTIBIOTICS" code="J01AA" /></DRUG1>
<DRUG2>
<DRUG name="ZINC" rxcui="11416">
<ATC code="A12CB" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the tetracycline antibiotics</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the zinc salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>147-CYCLOPHOSPHAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CYCLOPHOSPHAMIDE" rxcui="3002">
<ATC code="L01AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PENTOSTATIN" rxcui="8011">
<ATC code="L01XX08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of pulmonary toxicity which could be fatal</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>148-CYPROHEPTADINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CYPROHEPTADINE" rxcui="3013">
<ATC code="R06AX02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)" code="N06AB" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the antidepressant</DESCRIPTION>
<SEVERITY>Take into account </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>149-CYPROTERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of cyproterone with risk of lower contraceptive effectiveness</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In its use as a hormonal contraceptive: </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>149-CYPROTERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cyproterone</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In its indications as an anti-androgen, clinical monitoring and if possible adjustment of the dosage of the cyproterone during the administration with the bosentan and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>149-CYPROTERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cyproterone</DESCRIPTION>
<SEVERITY>Not recommended:</SEVERITY>
<COMMENT>-when used as a hormonal contraceptive: use of another method of contraception in particular a barrier type, is preferred during the length of the administration of these substances together and a cycle following</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>149-CYPROTERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cyproterone</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-in its use as a hormonal contraceptive: use instead another method of contraception in particular a barrier type, during the length of the administration of these substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>149-CYPROTERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cyproterone, due to increase of its hepatic metabolism by the St Johns Wort </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>149-CYPROTERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PERAMPANEL" rxcui="1356552">
<ATC code="N03AX2" />
</DRUG>
</DRUG2>
<DESCRIPTION>For doses of perampenel &gt;or = to 12 mg/day, risk of decrease of the effectiveness of the cyproterone.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>In its use as a hormonal contraceptive: use instead another method of contraception in particular a barrier type, during the length of the administration of these substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>149-CYPROTERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of antagonism of the effects of the progestin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Do not take a progestin treatment fewer than 12 hours after the ulipristal is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)" rxcui="3992">
<ATC code="A01AD01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="HALOGENATED HYDROCARBON ANESTHETICS" code="N01AB0-001" /></DRUG2>
<DESCRIPTION>Serious ventricular arrhythmias due to increased cardiac sensitization

</DESCRIPTION>
<SEVERITY>Precautions for use</SEVERITY>
<COMMENT>Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg per hour for an adult.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)" rxcui="3992">
<ATC code="A01AD01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG2>
<DESCRIPTION>Serious ventricular arrhythmias due to increased cardiac sensitization</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)" rxcui="3992">
<ATC code="A01AD01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>Serious ventricular arrhythmias due to increased cardiac sensitization</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)" rxcui="3992">
<ATC code="A01AD01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS" code="N06A" /></DRUG2>
<DESCRIPTION>Serious ventricular arrhythmias due to increased cardiac sensitization.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>150-CYTOTOXICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CYTOTOXICS" code="L01" /></DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of thrombosis and hemorrhage accompanying tumors. In addition, possible interaction between the vitamin K antagonist and the chemotherapy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>150-CYTOTOXICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CYTOTOXICS" code="L01" /></DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Excessive immunodepression with risk of lymphoproliferative syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>150-CYTOTOXICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CYTOTOXICS" code="L01" /></DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Risk of onset of convulsions due to decrease of the digestive absorption of the phenytoin only by the cytotoxic, or risk of increase of the toxicity or loss of effectiveness of the cytotoxic due to the increase of its hepatic metabolism by the phenytoin or the fosphenytoin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>150-CYTOTOXICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CYTOTOXICS" code="L01" /></DRUG1>
<DRUG2>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG2>
<DESCRIPTION>Risk of general vaccine disease, possibly fatal</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--and during the 6 months following the end of the chemotherapy</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>For post surgical indications:</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of more than double the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Doubling of the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of more than double the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of more than double the plasma concentrations of dabagitan, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150 mg/day in one dose.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="103704">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
<ATC code="L04AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of dabigatran</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="103704">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>151-DABIGATRAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DABIGATRAN" rxcui="103704">
<ATC code="B01AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150mg/day in one dose, or even 75mg/day in case of moderate renal insufficiency.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>152-DACARBAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DACARBAZINE" rxcui="3098">
<ATC code="L01AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FOTEMUSTINE" rxcui="25287">
<ATC code="L01AD05" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dacarbazine in large doses: risk of pulmonary toxicity (adult respiratory distress syndrome).

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Do not use these medications simultaneously, but wait a week between the last administration of fotemustine and the first day of the treatment with dacarbazine. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>153-DACLATASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DACLATASVIR" rxcui="1606218">
<ATC code="J05AX14" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Only in the combination daclatasvir/sofosbuvir:

Possibly abrupt onset of bradycardia, that can have fatal consequences</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of these medications together cannot be avoided, strict clinical monitoring and EKG, in particular during the first weeks of treatment with thedaclatasvir/sofosbuvir combination</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>153-DACLATASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DACLATASVIR" rxcui="1606218">
<ATC code="J05AX14" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>With the exception of the dexamethasone administered in a single dose. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>153-DACLATASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DACLATASVIR" rxcui="1606218">
<ATC code="J05AX14" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.</DESCRIPTION>
<SEVERITY>Contraindication:</SEVERITY>
<COMMENT>-with rifampicin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>153-DACLATASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DACLATASVIR" rxcui="1606218">
<ATC code="J05AX14" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the concentrations of daclatasvir by the inhibitor.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>The dose of daclatasvir must be decreased to 30 mg 1 time per day in case of administration with the inhibitor.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>153-DACLATASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DACLATASVIR" rxcui="1606218">
<ATC code="J05AX14" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the St Johns Wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>154-DALFOPRISTIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DALFOPRISTIN" rxcui="229369">
<ATC code="J01FG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIHYDROERGOTAMINE" rxcui="3418">
<ATC code="N02CA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>154-DALFOPRISTIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DALFOPRISTIN" rxcui="229369">
<ATC code="J01FG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>154-DALFOPRISTIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DALFOPRISTIN" rxcui="229369">
<ATC code="J01FG02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the treatment with these medications together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>154-DALFOPRISTIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DALFOPRISTIN" rxcui="229369">
<ATC code="J01FG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>155-DANAZOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DANAZOL" rxcui="3102">
<ATC code="G03XA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage due to the direct effect on coagulation and/or the fibrinolytic systems.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the danazol and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>155-DANAZOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DANAZOL" rxcui="3102">
<ATC code="G03XA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the carbamazepine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>155-DANAZOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DANAZOL" rxcui="3102">
<ATC code="G03XA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of ciclosporin due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>155-DANAZOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DANAZOL" rxcui="3102">
<ATC code="G03XA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="INSULIN" rxcui="631657">
<ATC code="A10AC01" />
<ATC code="A10AC02" />
<ATC code="A10AC03" />
<ATC code="A10AC04" />
<ATC code="A10AD01" />
<ATC code="A10AD02" />
<ATC code="A10AD03" />
<ATC code="A10AD04" />
<ATC code="A10AD05" />
<ATC code="A10AE01" />
<ATC code="A10AE02" />
<ATC code="A10AE03" />
<ATC code="A10AE04" />
<ATC code="A10AE05" />
<ATC code="A10AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Diabetes inducing effect of the danazol</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>155-DANAZOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DANAZOL" rxcui="3102">
<ATC code="G03XA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to decrease of the metabolism of the simvastatin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>155-DANAZOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DANAZOL" rxcui="3102">
<ATC code="G03XA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG2>
<DESCRIPTION>Diabetes inducing effect of the danazol</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the antidiabetic during the treatment with the danazol and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>155-DANAZOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DANAZOL" rxcui="3102">
<ATC code="G03XA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
<ATC code="L04AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the tacrolimus due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the tacrolimus and adjustment of its dosage during the administration of it with the danazol and after it is stopped, with testing of the renal function.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>156-DANTROLENE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DANTROLENE" rxcui="3105">
<ATC code="M03CA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="DIHYDROPYRIDINES" code="C08CA-002" /></DRUG2>
<DESCRIPTION>With the dantrolene administered via IV: cases of fatal ventricular fibrillations are constantly observed in animals when verapamil and dantrolene are administered via IV. The administration of a calcium channel blocker and dantrolene is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>156-DANTROLENE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DANTROLENE" rxcui="3105">
<ATC code="M03CA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>156-DANTROLENE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DANTROLENE" rxcui="3105">
<ATC code="M03CA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>157-DAPOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DAPOXETINE" rxcui="69394">
<ATC code="G04BX14" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects, especially of the vertigo or fainting type</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>157-DAPOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DAPOXETINE" rxcui="69394">
<ATC code="G04BX14" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="MEDICATIONS AT THE ORIGIN OF ORTHOSTATIC HYPOTENSION" code="N05AA-001" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects, especially of the vertigo and fainting type</DESCRIPTION>
<SEVERITY>Nor recommended</SEVERITY>
<COMMENT>-with the type 5 phosphodiesterase inhibitors </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>158-DAPSONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DAPSONE" rxcui="3108">
<ATC code="D10AX05" />
<ATC code="J04BA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AF01" />
<ATC code="J05AR01" />
<ATC code="J05AR04" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hematological toxicity (addition of effects of bone marrow toxicity)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent CBC</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>159-DAPTOMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DAPTOMYCIN" rxcui="22299">
<ATC code="J01XX09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS)" code="C10AA" /></DRUG2>
<DESCRIPTION>Risk of addition of undesirable effects (dose dependent) of the rhabdomyolysis type.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these substances together cannot be avoided, reinforce biological monitoring (CPK levels more than once a week) and strict clinical monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>15-AFATINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of afatinib by increase of its absorption by the amiodarone.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommendedthat the amiodarone be administered as great a distance from the afatanib as possible, preferably at an interval of 6 or of 12 hours from the dose of afatinib.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>15-AFATINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of afatinib due to increase of its metabolisn by these substances</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these substances together and 1 to 2 weeks after they are stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>15-AFATINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of afatinib by increase of its absorption by the ciclosporin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommendedthat the ciclosporin be administered as great a distance from the afatanib as possible, preferably at an interval of 6 or of 12 hours from the dose of afatinib.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>15-AFATINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of afatinib by increase of its absorption by the erythromycin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommended that the erythromycin be administered as great a distance from the afatanib as possible, preferably at an interval of 6 or of 12 hours from the dose of afatinib.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>15-AFATINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of afatinib by increase of its absorption by the protease inhibiter.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommended that the protease inhibitor be administered as great a distance from the afatanib as possible, preferably at an interval of 6 or of 12 hours from the dose of afatinib.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>15-AFATINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of afatinib by increase of its absorption by the itraconazole.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommended that the itraconazole be administered as great a distance from the afatanib as possible, preferably at an interval of 6 or of 12 hours from the dose of afatinib.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>15-AFATINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of afatinib by increase of its absorption by the ketoconazole.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommended that the ketoconazole be administered as great a distance from the afatanib as possible, preferably at an interval of 6 or of 12 hours from the dose of afatinib.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>15-AFATINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PRIMIDONE " rxcui="8691">
<ATC code="N03AA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the afatinib due to the increase of its metabolism by the primidone</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these together and 1 to 2 weeks after they are stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>15-AFATINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the afatinib due to increase of its metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these together and 1 to 2 weeks after they are stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>15-AFATINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of afatinib by increase of its absorption by the verapamil.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommended that the verapamil be administered as great a distance from the afatanib as possible, preferably at an interval of 6 or of 12 hours from the dose of afatinib.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>160-DARIFENACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DARIFENACIN" rxcui="136198">
<ATC code="G04BD10" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of felcainide, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the flecainide during the treatment with darifenacin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>160-DARIFENACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DARIFENACIN" rxcui="136198">
<ATC code="G04BD10" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the metoprolol, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with darifenacin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>160-DARIFENACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DARIFENACIN" rxcui="136198">
<ATC code="G04BD10" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of propafenone, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the propafenone during the treatment with darifenacin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>161-DASABUVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DASABUVIR" rxcui="1597381">
<ATC code="J05AX16" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ETHINYLESTRADIOL" rxcui="4124">
<ATC code="G03AA15" />
<ATC code="G03AB07" />
<ATC code="G03AA09" />
<ATC code="G03AB05" />
<ATC code="G03AA12" />
<ATC code="G03CA01" />
<ATC code="L02AA03" />
<ATC code="G03AA01" />
<ATC code="G03AA10" />
<ATC code="G03AB06" />
<ATC code="G03AA07" />
<ATC code="G03AB03" />
<ATC code="G03AA03" />
<ATC code="G03AB02" />
<ATC code="G03AA08" />
<ATC code="G03AA04" />
<ATC code="G03AB01" />
<ATC code="G03AA13" />
<ATC code="G03AA05" />
<ATC code="G03AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hepatoxicity</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>161-DASABUVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DASABUVIR" rxcui="1597381">
<ATC code="J05AX16" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GEMFIBROZIL" rxcui="4719">
<ATC code="C10AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of the dasabuvir by the gemfibrozil</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>161-DASABUVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DASABUVIR" rxcui="1597381">
<ATC code="J05AX16" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Risk of reduction of the plasma concentrations of the dasabuvir by the inducer.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>161-DASABUVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DASABUVIR" rxcui="1597381">
<ATC code="J05AX16" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the dasabuvir by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>161-DASABUVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DASABUVIR" rxcui="1597381">
<ATC code="J05AX16" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MITOTANE" rxcui="7004">
<ATC code="L01XX23" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the dasabuvir by the mitotane</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>162-DEFERASIROX.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With acetylsalicyclic acid in anti-inflammatory doses (&gt;=1 gr per dose and/or &gt;= 3 gr per day) or for antalgic or antipyretic doses (&gt;=500 mg per dose and/or &lt;3 gr per day): increase of the risk of digestive ulceration and hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>162-DEFERASIROX.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of deferasirox

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitor the ferritinemia during and after the treatment with the enzymatic inducer. If needed, adjustment of the dosage of deferasirox.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>162-DEFERASIROX.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Increase of the risk of causing ulcers and digestive hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>162-DEFERASIROX.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of causing ulcers and digestive hemorrhage </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>162-DEFERASIROX.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUSULFAN" rxcui="1828">
<ATC code="L01AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the toxocity of the bufulfan by decrease of its clearance by the deferasirox.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>162-DEFERASIROX.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEFERIPRONE" rxcui="11645">
<ATC code="V03AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hyperchelation</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>162-DEFERASIROX.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEFEROXAMINE" rxcui="3131">
<ATC code="V03AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hyperchelation</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>162-DEFERASIROX.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the deferasirox</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, strict clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>162-DEFERASIROX.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of deferasirox</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitor the ferritinemia during and after the treatment with the enzymatic inducer. If needed, adjust the dosage of deferasirox.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>163-DEFERIPRONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEFERIPRONE" rxcui="11645">
<ATC code="V03AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hyperchelation</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>164-DEFEROXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEFEROXAMINE" rxcui="3131">
<ATC code="V03AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ASCORBIC ACID" rxcui="1151">
<ATC code="A11GA" />
<ATC code="A11GA01" />
<ATC code="A11GB" />
<ATC code="A11GB01" />
<ATC code="G01AD03" />
<ATC code="S01XA15" />
</DRUG>
</DRUG2>
<DESCRIPTION>With large doses of the ascorbic acid and by intravenous route: 

cardiac function anomalies, even acute heart failure (generally reversible by ending administration of the Vitamin C).</DESCRIPTION>
<SEVERITY>Precaution for use:</SEVERITY>
<COMMENT>In the case of hemochromatosis, only give Vitamin C after having started treatment with the deferoxamine. Monitor cardiac function when these substances are administered together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>164-DEFEROXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEFEROXAMINE" rxcui="3131">
<ATC code="V03AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hyperchelation</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>165-DEFIBROTIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEFIBROTIDE" rxcui="1311089">
<ATC code="B01AX01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PLATELET AGGREGATION INHIBITORS" code="B01AC-001" /></DRUG2>
<DESCRIPTION>Increased risk of hemorrhage</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>165-DEFIBROTIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEFIBROTIDE" rxcui="1311089">
<ATC code="B01AX01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG2>
<DESCRIPTION>Increased risk of hemorrhage.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>165-DEFIBROTIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEFIBROTIDE" rxcui="1311089">
<ATC code="B01AX01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="HEPARINS" code="B01AB" /></DRUG2>
<DESCRIPTION>Increased risk of hemorrhage.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>165-DEFIBROTIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEFIBROTIDE" rxcui="1311089">
<ATC code="B01AX01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THROMBOLYTICS" code="B01AD" /></DRUG2>
<DESCRIPTION>Increased risk of hemorrhage.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>166-DELAMANID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DELAMANID" rxcui="1344662">
<ATC code="J04AK06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations de delamanid due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>166-DELAMANID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DELAMANID" rxcui="1344662">
<ATC code="J04AK06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of delamanid due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>167-DERIVATIVES-OF-AMINOSALICYLIC-ACID-(ASA).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DERIVATIVES OF AMINOSALICYLIC ACID (ASA)" code="A07EC-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTIPURINES" code="ANTIPUR" /></DRUG2>
<DESCRIPTION>Risk of increase of the myelosuppression effect of the immunomodulator by inhibition of its hepatic metabolism by the ASA derivative, especially with patients presenting a partial deficit of thiopurine methyltransferase (TMPT)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>168-NITRATE-DERIVATIVES-AND-RELATED.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NITRATE DERIVATIVES AND RELATED" code="C01D-001" /></DRUG1>
<DRUG2>
<CLASS name="TYPE 5 PHOSPHODIESTERASE INHIBITORS" code="G04BE" /></DRUG2>
<DESCRIPTION>Risk of significant hypotension (synergic effect) capable of aggravating the state of myocardial ischemia and especially provoking an acute coronary accident</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>168-NITRATE-DERIVATIVES-AND-RELATED.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NITRATE DERIVATIVES AND RELATED" code="C01D-001" /></DRUG1>
<DRUG2>
<CLASS name="MEDICATIONS THAT LOWER BLOOD PRESSURE " code="MLBP" /></DRUG2>
<DESCRIPTION>Increase of the risk of hypotension, especially orthostatic.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>168-NITRATE-DERIVATIVES-AND-RELATED.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NITRATE DERIVATIVES AND RELATED" code="C01D-001" /></DRUG1>
<DRUG2>
<DRUG name="RIOCIGUAT" rxcui="1439816">
<ATC code="C02KX05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of significant hypotension (synergic effect).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>169-DESIPRAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DESIPRAMINE" rxcui="3247">
<ATC code="N06AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the desipramine due to decrease of its hepatic metabolism by the bupropion</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the desipramine during the treatment with the bupropion.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>16-AGOMELATINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AGOMELATINE" rxcui="306718">
<ATC code="N06AX22" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIPROFLOXACIN" rxcui="2551">
<ATC code="J01MA02" />
<ATC code="S01AE03" />
<ATC code="S02AA15" />
<ATC code="S03AA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects. </DESCRIPTION>
<SEVERITY>Not Recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>16-AGOMELATINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AGOMELATINE" rxcui="306718">
<ATC code="N06AX22" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>170-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMINOGLUTETHIMIDE" rxcui="677">
<ATC code="L02BG01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Adjustment of the dosage of the dexamethasone. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>170-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing&#39;s syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>170-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DACLATASVIR" rxcui="1606218">
<ATC code="J05AX14" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>With the exception of dexamethasone administered in a single dose. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>170-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="D10AF52" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing&#39;s syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>170-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing&#39;s syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>170-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing&#39;s syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>170-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing&#39;s syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>170-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC0" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing&#39;s syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>170-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PRAZIQUANTEL" rxcui="8628">
<ATC code="P02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Separate the administration of the two medications by at least a week.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>170-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RILPIVIRINE" rxcui="1102270">
<ATC code="J05AG05" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>With the exception of dexamethasone administered in a single dose.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>170-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMEPREVIR" rxcui="1482790">
<ATC code="J05AE14" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir by increase of its hepatic metabolism by the dexamethasone</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>With the exception of dexamethasone administered in a single dose.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>170-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing&#39;s syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>170-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing&#39;s syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>171-DEXTRAN-40.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXTRAN 40" rxcui="42635">
<ATC code="B05AA05" />
<ATC code="B03AC06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)" code="B01AB-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>171-DEXTRAN-40.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXTRAN 40" rxcui="42635">
<ATC code="B05AA05" />
<ATC code="B03AC06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENT)" code="B01AB-003" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>172-DEXTROMETHORPHAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXTROMETHORPHAN" rxcui="3289">
<ATC code="R05DA09" />
<ATC code="N07XX59" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CINACALCET" rxcui="407990">
<ATC code="H05BX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large increase of the plasma concentrations of dextromethorphan with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>172-DEXTROMETHORPHAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXTROMETHORPHAN" rxcui="3289">
<ATC code="R05DA09" />
<ATC code="N07XX59" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>172-DEXTROMETHORPHAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXTROMETHORPHAN" rxcui="3289">
<ATC code="R05DA09" />
<ATC code="N07XX59" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>173-DIAZEPAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIAZEPAM" rxcui="3322">
<ATC code="N05BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUSPIRONE" rxcui="1827">
<ATC code="N05BE01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the buspirone</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>173-DIAZEPAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIAZEPAM" rxcui="3322">
<ATC code="N05BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Warn the patients of the increase of risk when driving an automobile or using machinery. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>173-DIAZEPAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIAZEPAM" rxcui="3322">
<ATC code="N05BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Unpredictable variations: the plasma concentrations of phenytoin can increase, with signs of overdose, but also decrease or remain stable.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and testing of the plasma concentrations of phenytoin. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>173-DIAZEPAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIAZEPAM" rxcui="3322">
<ATC code="N05BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the diazepam, with risk of overdose, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol and possible adjustment of the dosage of the anticonvulsant taken with it as well. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>174-DIDANOSINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIDANOSINE" rxcui="3364">
<ATC code="J05AF02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ALLOPURINOL" rxcui="519">
<ATC code="M04AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of didanosine and of its undesirable effects

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>174-DIDANOSINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIDANOSINE" rxcui="3364">
<ATC code="J05AF02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GANCICLOVIR" rxcui="4678">
<ATC code="J05AB06" />
<ATC code="S01AD09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the didanosine, and especially the mitochondrial toxicity, due to substantial increase of its concentrations. In addition, risk of decrease of the effectiveness of the ganciclovir due to decrease of its concentrations, if the two medications are ingested in an interval of less than 2 hours</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>174-DIDANOSINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIDANOSINE" rxcui="3364">
<ATC code="J05AF02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PENTAMIDINE" rxcui="7994">
<ATC code="P01CX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of pancreatitis due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of the blood amylase level. Do not use these two medications together if the blood amylase level is at the high range of normal. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>174-DIDANOSINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIDANOSINE" rxcui="3364">
<ATC code="J05AF02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIBAVIRIN" rxcui="9344">
<ATC code="J05AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the mitochrondrial toxicity of the didanosine due to increase of its active metabolite</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>174-DIDANOSINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIDANOSINE" rxcui="3364">
<ATC code="J05AF02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TENOFOVIR DISOPROXIL" rxcui="300195">
<ATC code="J05AF07" />
<ATC code="J05AR06" />
<ATC code="J05AR08" />
<ATC code="J05AR09" />
<ATC code="J05AR03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of failure of the antiretroviral treatment, even emergence of resistance. In addition, increase of the risk of the mitchondrial toxicity of the didanosine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>174-DIDANOSINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIDANOSINE" rxcui="3364">
<ATC code="J05AF02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="THALIDOMIDE" rxcui="10432">
<ATC code="L04AX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>174-DIDANOSINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIDANOSINE" rxcui="3364">
<ATC code="J05AF02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of pancreatitis and of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring and monitoring of the amylasemia. Do not administer these substances together if the amylasemia is at the high range of normal. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Depression of self-regulation (excessive bradycardia) and difficulties with atrioventricular conduction. In addition, increase of the digoninemia due to decrease of the clearance of digoxin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and, if there is reason for it, testing of the digoxinemia and adjustment of the dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AZITHROMYCIN" rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the digoxinemia during treatment with the azithromycin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>Difficulties with autoregulation (bradycardia, sinus arrest) and difficulties with sinoauricular and atrioventricular conduction</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CALCIUM" rxcui="1895">
<ATC code="A12AA" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of serious arrhythmias, even lethal ones with the calcium salts administered via IV</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>-with the calcium salts by IV route, except for parenteral supplementation.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine and decrease of the digoxinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Exercise caution in the interpretation of the plasma concentrations.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the clarithromycin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Depression of autoregulation (excessive bradycardia) and disorders of atrioventricular conduction. In addition, increase of the digoxinemia due to decrease of the metabolism of the digoxin. Clinical monitoring and EKG. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Reduce the doses of digoxin by half. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the erythromycin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="HYDROQUINIDINE" rxcui="27220">
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction).</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG. In the case of unexpected results, test the digoxinemia and adjust the dosage. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="POTASSIUM LOWERING AGENTS" code="C03-001" /></DRUG2>
<DESCRIPTION>Hypokaliemia producing toxic effects of the digitalics</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Correct beforehand all hypokaliemia and do clinical, electrolytic, and EKG monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Increase of the digoxinemia, more marked for IV route, due to increase of the absorption of the digoxin or decrease of its renal clearance.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and, if there is reason for them, EKG and monitoring of the digoxinemia, with possible adjustment of the dosage of digoxin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia with nausea, vomiting, arrhythmias.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and, if there is reason for them, EKG, and monitoring of the digoxinemia with adjustment of the dosage of the digoxin during the treatment with the itraconazole and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MIDODRINE" rxcui="6963">
<ATC code="C01CA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Difficulties with autoregulation (increase of the bradycardia inducing effect of the midodrine) and difficulties with atrioventricular conduction.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If this combination cannot be avoided, reinforce clinical monitoring and EKG. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digoxinemia, by reason of the enzyme inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (acute decompensated heart failure). </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>In the case of the two substances being taken together by accident, do not stop the St Johns wort abruptly, but test the plasma concentrations (or the effectiveness) of the digoxin before and then after the St Johns wort is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="OMEPRAZOLE" rxcui="7646">
<ATC code="A02BC01" />
<ATC code="A02BD05" />
<ATC code="A02BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Moderate increase of the digoxinemia due to increase of its absorption by the omeprazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and monitoring of the digoxinemia, particularly with an older patient. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia with nausea, vomiting, arrhythmias.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and, if there is reason for them, EKG and monitoring of the digoxinemia, with adjustment of the dosage of the digxoin during the treatment with the posaconazole and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the digoxinemia, especially with older patients</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with propafenone and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG. In the case of an unexpected result, test the digoxinemia and adjust the dosage. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUININE" rxcui="9071">
<ATC code="P01BC01" />
<ATC code="M09AA72" />
<ATC code="M09AA" />
</DRUG>
</DRUG2>
<DESCRIPTION>Moderate increase of the digoxinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG, if needed, with possible adjustment of the doses of digoxin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RANOLAZINE" rxcui="35829">
<ATC code="C01EB18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical, biological, and possibly EKG monitoring. Adjustment of the dosage of the digoxin if needed.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SUCRALFATE" rxcui="10156">
<ATC code="A02BX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the digoxin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the sucralfate at a different time from the digoxin (more than 2 hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SULFASALAZINE" rxcui="9524">
<ATC code="A07EC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digoxinemia that can reach 50%</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and, possibly, monitoring of the digoxinemia. If there is reason for it, adjustment of the dosage of the digoxin during the treatment with the sulfasalazine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring, and adjustment, if needed, of the dosage of the digoxin during the treatment with the telaprevir and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the telithromycin and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>175-DIGOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Excessive bradycardia and atrioventricular block due to increase of the effects of the digoxin on autoregulation and conduction and due to decrease of the renal and extra-renal elimination of the digoxin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and, possibly, testing of the digoxinemia. If there is reason for it, adjustment of the dosage of the digoxin during the treatment with the verapamil and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>176-DIHYDROERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIHYDROERGOTAMINE" rxcui="3418">
<ATC code="N02CA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DALFOPRISTIN" rxcui="229369">
<ATC code="J01FG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>176-DIHYDROERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIHYDROERGOTAMINE" rxcui="3418">
<ATC code="N02CA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>176-DIHYDROERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIHYDROERGOTAMINE" rxcui="3418">
<ATC code="N02CA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>176-DIHYDROERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIHYDROERGOTAMINE" rxcui="3418">
<ATC code="N02CA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="MACROLIDES (EXCEPT SPIRAMYCIN)" code="J01FA" /></DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>176-DIHYDROERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIHYDROERGOTAMINE" rxcui="3418">
<ATC code="N02CA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUINUPRISTINE" rxcui="135098">
<ATC code="J01FG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>176-DIHYDROERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIHYDROERGOTAMINE" rxcui="3418">
<ATC code="N02CA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>176-DIHYDROERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIHYDROERGOTAMINE" rxcui="3418">
<ATC code="N02CA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TRICLABENDAZOLE" rxcui="38608">
<ATC code="P02BX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
<COMMENT>Wait 24 hours between stopping the triclabendazole and the dose of the medication derived from ergot of rye, and the reverse.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>176-DIHYDROERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIHYDROERGOTAMINE" rxcui="3418">
<ATC code="N02CA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>177-DIHYDROPYRIDINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DIHYDROPYRIDINES" code="C08CA-002" /></DRUG1>
<DRUG2>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG2>
<DESCRIPTION>Hypotension, heart failure with patients having latent or uncontrolled cardiac insufficiency (addition of the negative inotropic effects). The beta blocking agent can furthermore minimize the sympathetic reflex reaction brought into play in the case of excessive hemodynamic repercussion</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>177-DIHYDROPYRIDINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DIHYDROPYRIDINES" code="C08CA-002" /></DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>Hypotension, heart failure in patients with latent or uncontrolled cardiac insufficiency (negative inotropic effect of the dihydropyridines in vitro, more or less marked, and susceptible of adding to the negative inotropic effects of the beta blocking agents). The presence of a beta-blocking treatment can furthermore minimize the sympathetic reflex reaction put into play in cases of excessive hemodynamic repercussion. </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>177-DIHYDROPYRIDINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DIHYDROPYRIDINES" code="C08CA-002" /></DRUG1>
<DRUG2>
<DRUG name="DANTROLENE" rxcui="3105">
<ATC code="M03CA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dantrolene administered via IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered via IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ALFENTANIL " rxcui="480">
<ATC code="N01AH02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the opioid analgesic&#39;s effect of respiratory depression due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Adjust the dosage of the alfentanil when there is treatment with the diltiazem. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>For diltiazem by injection: risk of bradycardia and of atrioventricular block

For diltiazem by mouth: risk of bradycardia or of atrioventricular block, especially in older persons.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-with diltiazem administered intravenously</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol lowering agent</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of the cholesterol lowering agent or another statin not affected by this type of interaction.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG2>
<DESCRIPTION>Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>The administration of these medications together should only be done under strict clinical monitoring and EKG, in particular with older patients or at the beginning of treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest), and disorders of sinoatrial and atrioventricular conduction</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUSPIRONE" rxcui="1827">
<ATC code="N05BE01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the diltiazem, with increase of its undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the buspirone if necessary.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLONIDINE" rxcui="2599">
<ATC code="C02AC01" />
<ATC code="N02CX02" />
<ATC code="S01EA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DANTROLENE" rxcui="3105">
<ATC code="M03CA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantolene together is thus potentially dangerous. However, some patients have received nifedipine and dantolene together without incident</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIHYDROERGOTAMINE" rxcui="3418">
<ATC code="N02CA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Begin the treatment with the calcium channel blocker at the minimum recommended dosages and adjust the doses according to the EKG.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ESMOLOL" rxcui="49737">
<ATC code="C07AB09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac arrest.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-in case of alteration of left ventricular function</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IBRUTINIB" rxcui="1442981">
<ATC code="L01XE27" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the diltiazem</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg/day during the length of time that these medications are administered together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of renal function, and adjustment of the dosage during the treatment with these medications together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the diltiazem), that add to the bradycardia inducing effects of these molecules. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage during the treatment with the diltiazem</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NIFEDIPINE" rxcui="7417">
<ATC code="C08CA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large increase of the concentrations of nefidipine due to decrease of its hepatic metabolism by the diltiazem, with risk of severe hypotension</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="OLAPARIB" rxcui="1597582">
<ATC code="L01XX46" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of olaparib by the diltiazem</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these together cannot be avoided, limit the dose of olaparib to 200 mg twice a day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Do not exceed the dosage of 20 mg/day of simvastatin. If the therapeutic objective is not reached at this dosage, use another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TAMSULOSIN" rxcui="77492">
<ATC code="G04CA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the tamsulosin during the treatment with the enzymatic inhibitor and after it is stopped, if the situation requires.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>178-DILTIAZEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolsim</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>179-DIMETHYL-FUMARATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIMETHYL FUMARATE" rxcui="1373478">
<ATC code="N07XX09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG2>
<DESCRIPTION>Possible increase of the risk of infection</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>17-ALBENDAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALBENDAZOLE" rxcui="430">
<ATC code="P02CA03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of lower effectiveness.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzyme inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>17-ALBENDAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALBENDAZOLE" rxcui="430">
<ATC code="P02CA03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the ritonavir, with risk of lower effectiveness.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzyme inducer [sic] and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>17-ALBENDAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALBENDAZOLE" rxcui="430">
<ATC code="P02CA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of lower effectiveness.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzyme inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>180-DIPROPHYLLINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIPROPHYLLINE" rxcui="3714">
<ATC code="R03DA01" />
<ATC code="R03DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROBENECID" rxcui="8698">
<ATC code="M04AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of overdose due to increase of the plasma concentrations of diprophylline (inhibition of its renal tubular secretion)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reduce the dosage of diprophylline during the treatment with the probenicid</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>181-DIPYRIDAMOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIPYRIDAMOLE" rxcui="3521">
<ATC code="B01AC07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="THEINE" rxcui="">
</DRUG>
</DRUG2>
<DESCRIPTION>With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the theine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Avoid the consumption of theine based products during the 24 hours before myocardial perfusion imaging with dipyridamole</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>181-DIPYRIDAMOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIPYRIDAMOLE" rxcui="3521">
<ATC code="B01AC07" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG2>
<DESCRIPTION>With the dipyridamole by injection: increase of the antihypertensive effect</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>181-DIPYRIDAMOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIPYRIDAMOLE" rxcui="3521">
<ATC code="B01AC07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="V04CG30" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the caffeine </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Interrupt a caffeine based treatment at least 5 days before myocardial perfusion imaging with the dipyridamole and avoid consuming coffee, tea, chocolate, or cola during the 24 hours that precede the test. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>181-DIPYRIDAMOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DIPYRIDAMOLE" rxcui="3521">
<ATC code="B01AC07" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the theophylline</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Interrupt a treatment with theophylline at least 5 days before myocardial perfusion imaging with the dipyridamole.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>182-DISOPYRAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DISOPYRAMIDE" rxcui="3541">
<ATC code="C01BA03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the disopyramide by the inducer.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly adjustment of the dosage of the disopyramide during the administration of these medications together and 1 to 2 weeks after the inducer is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>182-DISOPYRAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DISOPYRAMIDE" rxcui="3541">
<ATC code="C01BA03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the disopyramide due to decrease of its metabolism.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the disopyramide</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>182-DISOPYRAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DISOPYRAMIDE" rxcui="3541">
<ATC code="C01BA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the disopyramide: severe hypoglycemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsade de pointes type.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical, biological and EKG monitoring, </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>183-DISULFIRAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DISULFIRAM" rxcui="3554">
<ATC code="N07BB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the disulfiram and a week after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>183-DISULFIRAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DISULFIRAM" rxcui="3554">
<ATC code="N07BB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="COCAINE" rxcui="2653">
<ATC code="N01BC01" />
<ATC code="R02AD03" />
<ATC code="S01HA01" />
<ATC code="S02DA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of cocaine due to decrease of its metabolism by the disulfirame, with increased risk of the onset of torsades de pointes</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>183-DISULFIRAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DISULFIRAM" rxcui="3554">
<ATC code="N07BB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of behavior and of coordination</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>183-DISULFIRAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DISULFIRAM" rxcui="3554">
<ATC code="N07BB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METRONIDAZOLE" rxcui="6922">
<ATC code="A02BD08" />
<ATC code="A02BD03" />
<ATC code="A02BD02" />
<ATC code="A01AB17" />
<ATC code="D06BX01" />
<ATC code="G01AF01" />
<ATC code="J01XD01" />
<ATC code="P01AB01" />
<ATC code="A02BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of episodes of acute psychosis or confused state, reversible upon stopping the administration of the two substances together</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>183-DISULFIRAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DISULFIRAM" rxcui="3554">
<ATC code="N07BB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Large and rapid increase of the plasma concentrations of phenytoin with signs of toxicity (inhibition of its metabolism)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of these substances together cannot be avoided, clinical monitoring and monitoring of the plasma concentrations of phenytoin during the treatment with the disulfiram and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>184-DIURETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DIURETICS" code="C0E-001" /></DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>For anti-inflammatory doses of acetylsalicylic acid (&gt;=1gr per dose and/or &gt;=3gr per day) or for analgesic or antipyretic doses (&gt;=500 mg per dose and/or &lt;3 gr per day):

Acute renal insufficiency in dehydrated patients due to decrease of the glomerular filtration as a result of a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the anti-hypertensive effect.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Hydrate the patient and monitor renal function at the start of treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>184-DIURETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DIURETICS" code="C0E-001" /></DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Acute renal insufficiency with the patient at risk (older patient and/or dehydrated one) due to decrease of the glomerular filtration (inhibition of the vasodilator prostaglandins due to the NSAIs). Furthermore, reduction of the antihypertensive effect</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Hydrate the patient and monitor renal function at the start of treatment</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>184-DIURETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DIURETICS" code="C0E-001" /></DRUG1>
<DRUG2>
<CLASS name="IODINATED X-RAY CONTRAST MEDIA" code="VO8A-001" /></DRUG2>
<DESCRIPTION>In case of dehydration caused by the diuretics, increased risk of acute functional renal insufficiency, in particular when large doses of the contrast media are used.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Rehydrate before administration of the iodinated product</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>185-LOOP-DIURETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="LOOP DIURETICS" code="C03CA-001" /></DRUG1>
<DRUG2>
<CLASS name="AMINOGLYCOSIDES" code="J01GB-001" /></DRUG2>
<DESCRIPTION>Increase of the nephrotoxic and ototoxic risks of the aminoglycoside (functional renal insufficiency linked to the dehydration caused by the diuretic)

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>The two medications may be taken together when there is monitoring of the state of hydration, of the renal and cochleovestibulary functions, and possibly, of the plasma concentrations of the aminoglycoside</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>185-LOOP-DIURETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="LOOP DIURETICS" code="C03CA-001" /></DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plas ma concentrations of lithium with signs of overdose of lithium as with a low sodium regimen (decrease of the urinary excretion of the lithium)</DESCRIPTION>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>185-LOOP-DIURETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="LOOP DIURETICS" code="C03CA-001" /></DRUG1>
<DRUG2>
<DRUG name="METFORMIN" rxcui="6809">
<ATC code="A10BA02" />
<ATC code="A10BD13" />
<ATC code="A10BD11" />
<ATC code="A10BD05" />
<ATC code="A10BD03" />
<ATC code="A10BD10" />
<ATC code="A10BD07" />
<ATC code="A10BD02" />
<ATC code="A10BD08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics</DESCRIPTION>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>185-LOOP-DIURETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="LOOP DIURETICS" code="C03CA-001" /></DRUG1>
<DRUG2>
<CLASS name="PLATINUM-BASED ANTINEOPLASTIC CANCER DRUGS" code="L01XA" /></DRUG2>
<DESCRIPTION>Risk of addition of the ototoxic and/or nephrotoxic effects</DESCRIPTION>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>186-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)" code="C0E-004" /></DRUG1>
<DRUG2>
<CLASS name="OTHER POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)" code="C0E-004" /></DRUG2>
<DESCRIPTION>Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Contraindication unless there is hypokalemia.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>186-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)" code="C0E-004" /></DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG2>
<DESCRIPTION>Risk of hyperkalemia (possibly lethal) especially when there is renal insufficiency (addition of the effects of the hyperkalemia inducing substances)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>--if administering these medications together is justified, strict testing of the kalemia and of the renal function.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>186-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)" code="C0E-004" /></DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>186-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)" code="C0E-004" /></DRUG1>
<DRUG2>
<CLASS name="POTASSIUM LOWERING DIURETICS" code="C03" /></DRUG2>
<DESCRIPTION>The rational choice of these two medications, useful for some patients, does not exclude the onset of hypokalemia or, in particular with patients having renal insufficiency and diabetes, of hyperkalemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitor the kalemia, possibly EKG and, if there is reason to, reconsider the treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>186-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)" code="C0E-004" /></DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>Risk of hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia producing effects)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-if the administration of the two medications together is justified, strict testing of the kalemia and of the renal function.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>186-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)" code="C0E-004" /></DRUG1>
<DRUG2>
<DRUG name="LITHIUM " rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of lithium with signs of overdose of lithium, as with a low sodium regimen (decrease of the urinary excretion of the lithium)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict monitoring of the plasma concentrations of lithium and possible adjustment of the dosage of the lithium. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>186-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)" code="C0E-004" /></DRUG1>
<DRUG2>
<DRUG name="POTASSIUM" rxcui="8588">
<ATC code="A12BA" />
</DRUG>
</DRUG2>
<DESCRIPTION>Potentially lethal hyperkalemia, especially with renal insufficiency (addition of the hyperkalemia producing effects)</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>-aside from hypokalemia or in case of parenteral use of the potassium salts</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>186-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)" code="C0E-004" /></DRUG1>
<DRUG2>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>187-POTASSIUM-LOWERING-DIURETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="POTASSIUM LOWERING DIURETICS" code="C03" /></DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG2>
<DESCRIPTION>Risk of abrupt arterial hypotension and/or acute renal insufficiency at the beginning of or at an increase in the dosage of a treatment with an angiotensin II antagonist where there is pre-existing fluid depletion. 

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>With arterial hypertension, where there has been pre-existing diuretic treatment that has caused fluid depletion, it is necessary:</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>187-POTASSIUM-LOWERING-DIURETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="POTASSIUM LOWERING DIURETICS" code="C03" /></DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of symptomatic hyponatremia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring. If possible, use another class of diuretics.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>187-POTASSIUM-LOWERING-DIURETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="POTASSIUM LOWERING DIURETICS" code="C03" /></DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the creatinemia without modification of the blood concentrations of the ciclosporin, even in the absence of fluid depletion. Also risk of hyperuricemia and of complications such as gout</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>187-POTASSIUM-LOWERING-DIURETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="POTASSIUM LOWERING DIURETICS" code="C03" /></DRUG1>
<DRUG2>
<CLASS name="POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)" code="C0E-004" /></DRUG2>
<DESCRIPTION>The rational choice of these medications, useful for some patients, does not exclude the onset of hypokalemia or, in particular with patients having renal insufficiency and diabetes, of hyperkalemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitor the kalemia, possibly EKG and, if there is reason to, reconsider the treatment. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>187-POTASSIUM-LOWERING-DIURETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="POTASSIUM LOWERING DIURETICS" code="C03" /></DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>Risk of abrupt arterial hypotension and/or renal insufficiency at the start of or when there is an increase of the dosage of the treatment with the ACE inhibitor in cases of pre-existing fluid depletion </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In arterial hypertension, when there is fluid depletion from previous treatment with a diuretic, it is necessary:</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>188-THIAZIDE-DIURETICS-AND-RELATED.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THIAZIDE DIURETICS AND RELATED" code="C03-003" /></DRUG1>
<DRUG2>
<DRUG name="CALCIUM" rxcui="1895">
<ATC code="A12AA" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypercalcemia due to decrease of the urinary elimination of the calcium. </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>188-THIAZIDE-DIURETICS-AND-RELATED.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THIAZIDE DIURETICS AND RELATED" code="C03-003" /></DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of lithium with signs of overdose of lithium, as with a reduced sodium regimen (decrease of the urinary excretion of the lithium)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering the substances together cannot be avoided, strict monitoring of the plasma concentrations of lithium and adjustment of the dosage of the lithium.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>189-DOCETAXEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DOCETAXEL" rxcui="72962">
<ATC code="L01CD02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the docetaxel due to decrease of its metabolism </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the docetaxel during the treatment with the enzymatic inhibitor.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>189-DOCETAXEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DOCETAXEL" rxcui="72962">
<ATC code="L01CD02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>189-DOCETAXEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DOCETAXEL" rxcui="72962">
<ATC code="L01CD02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable dose-dependent effects of the docetaxel due to inhibition of its metabolism by the enzymatic inhibitor</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the docetaxel during the treatment with the enzymatic inhibitor.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>18-URINARY-ALKALIZERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="URINARY ALKALIZERS" code="B05-001" /></DRUG1>
<DRUG2>
<DRUG name="HYDROQUINIDINE" rxcui="27220">
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the hydroquinidine and risk of overdose (decrease of the renal excretion of the hydroquinidine by alkalinizing of the urine)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and possibly testing of the blood concentrations of the hydroquinidine; if needed, adjustment of the dosage during the alkalinizing treatment and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>18-URINARY-ALKALIZERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="URINARY ALKALIZERS" code="B05-001" /></DRUG1>
<DRUG2>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the quinidine and risk of overdose (decrease of the renal excretion of the quinidine by alkalinizing of the urine).</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and possibly testing of the blood concentrations of quinidine; if needed, adjustment of the dosage during the alkalinizing treatment and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>190-DOLUTEGRAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DOLUTEGRAVIR" rxcui="1433868">
<ATC code="J05AX12" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-in case of resistance to the class of integrase inhibitors</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>190-DOLUTEGRAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DOLUTEGRAVIR" rxcui="1433868">
<ATC code="J05AX12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METFORMIN" rxcui="6809">
<ATC code="A10BA02" />
<ATC code="A10BD13" />
<ATC code="A10BD11" />
<ATC code="A10BD05" />
<ATC code="A10BD03" />
<ATC code="A10BD10" />
<ATC code="A10BD07" />
<ATC code="A10BD02" />
<ATC code="A10BD08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of metformin by the dolutegravir and of its undesirable effects of the lactic acidosis type</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>--With the patient having moderate renal insufficiency (stage 3a, clearance of the creatinin between 45 and 59 ml/min), clinical and biological monitoring, and possible adjustment of the dosage of metformin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>190-DOLUTEGRAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DOLUTEGRAVIR" rxcui="1433868">
<ATC code="J05AX12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the St Johns wort.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>191-DOMPERIDONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DOMPERIDONE" rxcui="3626">
<ATC code="A03FA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of problems with ventricular rhythm, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>191-DOMPERIDONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DOMPERIDONE" rxcui="3626">
<ATC code="A03FA03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of domperidone due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>192-DOPAMINERGICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DOPAMINERGICS" code="N04B-002" /></DRUG1>
<DRUG2>
<CLASS name="ANTIEMITIC NEUROLEPTICS" code="A03FA-001" /></DRUG2>
<DESCRIPTION>Reciprocal antagonism between the dopaminergic and the neuropleptic</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Use an antiemetic that does not have extrapyramidal effects. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>192-DOPAMINERGICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DOPAMINERGICS" code="N04B-002" /></DRUG1>
<DRUG2>
<DRUG name="TETRABENAZINE" rxcui="10390">
<ATC code="N07XX06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Reciprocal antagonism between the dopaminergic and the tetrabenazine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>193-DOPAMINERGICS,-EXCEPT-PARKINSON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DOPAMINERGICS, EXCEPT PARKINSON" code="G02CB-002" /></DRUG1>
<DRUG2>
<CLASS name="ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)" code="N05A-001" /></DRUG2>
<DESCRIPTION>Reciprocal antagonism of the dopamine agonist and the neuroleptics</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>194-DOXORUBICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DOXORUBICIN" rxcui="3639">
<ATC code="L01DB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the doxorubicin due to increase of its plasma concentrations</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>195-DOXYCYCLINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DOXYCYCLINE" rxcui="3640">
<ATC code="J01AA02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentations of the doxycycline due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the doxycycline. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>196-DRONEDARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>196-DRONEDARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the dronedarone and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>196-DRONEDARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DABIGATRAN" rxcui="">
<ATC code="1037042" />
</DRUG>
</DRUG2>
<DESCRIPTION>Doubling of the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>196-DRONEDARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Depression of autoregulation (excessive bradycardia) and disorders of atrioventricular conduction. In addition, increase of the digoxinemia due to decrease of the metabolism of the digoxin. Clinical monitoring and EKG. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Reduce the doses of digoxin by half. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>196-DRONEDARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Start the treatment with the calcium channel blocker with minimum recommended dosages, and adjust the doses according to the EKG.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>196-DRONEDARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DOCETAXEL" rxcui="72962">
<ATC code="L01CD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the docetaxel due to decrease of its metabolism.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the docetaxel during the treatment with the enzyme inhibitor.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>196-DRONEDARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FIDAXOMICIN" rxcui="1111103">
<ATC code="A07AA12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the fidaxomicin.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>196-DRONEDARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Large increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>196-DRONEDARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Large increase of the concentrations of drodedarone due to decrease of its metabolism</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>196-DRONEDARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>196-DRONEDARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT (JUICE AND FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of dronedarone due to inhibition of its metabolism by the grapefruit</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>196-DRONEDARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the quinidine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Start the treatment with the quinidine at the minimum recommended dosages, and adjust the doses according to the EKG. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>196-DRONEDARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>196-DRONEDARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>196-DRONEDARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Start the treatment by the calcium channel blocker with the lowest recommended dosages, and adjust the doses according to the EKG. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>197-DROSPIRENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DROSPIRENONE" rxcui="840781">
<ATC code="G03AA12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of more than double of the concentrations of drosperinone when taken with the boceprevir</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Choose a contraceptive with another progestin, especially in cases of hyperkalemia</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>198-DULOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ENOXACIN" rxcui="3925">
<ATC code="J01MA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the enoxacin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>198-DULOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of flecainide with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the flecainide during the treatment with the duloxetine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>198-DULOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the fluvoxamine</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>198-DULOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MEQUITAZINE" rxcui="29528">
<ATC code="R06AD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the mequitazine due to inhibition of its metabolism by the enzyme inhibitor </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>198-DULOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with the duloxetine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>198-DULOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of propafenone with risk of overdose due to decrease of its hepatic metabolism by the duloxetine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the propafenone during the treatment with the duloxetine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>198-DULOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TAMOXIFEN" rxcui="10324">
<ATC code="L02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the duloxetine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>199-EBASTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EBASTINE" rxcui="23796">
<ATC code="R06AX22" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>199-EBASTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EBASTINE" rxcui="23796">
<ATC code="R06AX22" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>199-EBASTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EBASTINE" rxcui="23796">
<ATC code="R06AX22" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>199-EBASTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EBASTINE" rxcui="23796">
<ATC code="R06AX22" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>199-EBASTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EBASTINE" rxcui="23796">
<ATC code="R06AX22" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE " code="G02CB-001" /></DRUG1>
<DRUG2>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or rapid elevation of blood pressure</DESCRIPTION>
<SEVERITY>Not Recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE " code="G02CB-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTIPARKINSONIAN ANTICHOLINERGICS" code="N04AA-001" /></DRUG2>
<DESCRIPTION>Risk of increase of neuropsychological disorders

</DESCRIPTION>
<SEVERITY>Precaution for use:</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE " code="G02CB-001" /></DRUG1>
<DRUG2>
<CLASS name="MACROLIDES (EXCEPT SPIRAMYCIN)" code="J01FA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dopaminergic with possible increase of its activity or appearance of signs of overdose. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE " code="G02CB-001" /></DRUG1>
<DRUG2>
<CLASS name="ALPHA SYMPATHOMIMETICS (ORAL AND/OR NASAL)" code="R01AA" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or rapid elevation of blood pressure

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE " code="G02CB-001" /></DRUG1>
<DRUG2>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or rapid elevation of blood pressure

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>1-ABATACEPT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ABATACEPT " rxcui="614391">
<ATC code="L04AA24" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTI-TNF ALPHA" code="4ABO" /></DRUG2>
<DESCRIPTION>Increase of immunosupression</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>1-ABATACEPT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ABATACEPT " rxcui="614391">
<ATC code="L04AA24" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG2>
<DESCRIPTION>Risk of possibly fatal generalized vaccine disease 

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>as well as for the three months following the end of the treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>200-ECONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ECONAZOLE" rxcui="3743">
<ATC code="G01AF05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Regardless of the route of administration of the econazole:

increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with econazole and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the atazanavir due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of the two substances together proves necessary, adjustment of the dosage of the atazanavir with regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATOVAQUONE" rxcui="60212">
<ATC code="P01AX06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of atovaquone by the enzymatic inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIHYDROERGOTAMINE" rxcui="3418">
<ATC code="N02CA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FOSAMPRENAVIR" rxcui="358262">
<ATC code="J05AE07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the amprenavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="INDINAVIR" rxcui="114289">
<ATC code="J05AE02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the indinavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease by about half of the concentrations of rifabutin, due to increase of its hepatic metabolism by the efavirenz</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Adjustment of the dosage of the rifabutin during the treatment with efavirenz.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the efavirenz</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these substances together cannot be avoided, strict clinical monitoring and adjustment of the dosage of the voriconazole and of the efavirenz during the administration of the two together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>202-ELTROMBOPAG.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ELTROMBOPAG" rxcui="711942">
<ATC code="B02BX05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS)" code="C10AA" /></DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the statins, due to inhibition of their hepatic recapture</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the statin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>203-ELVITEGRAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ELVITEGRAVIR" rxcui="1306286">
<ATC code="J05AX11" />
<ATC code="J05AR09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>Decrease of the concentrations of ethinylestradiol, with risk of lower contraceptive effectiveness. Furthermore, increase of the concentrations of the progestin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use an estroprogestin contraceptive with at leaset 30g of ethinylestradiol. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>203-ELVITEGRAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ELVITEGRAVIR" rxcui="1306286">
<ATC code="J05AX11" />
<ATC code="J05AR09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase pf the plasma concentrations of elvitegravir by decrease of its metabolism by the itraconazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>With the elvitegravir co-administered with cobicistat, clinical monitoring. Limit the maximum dose of itraconazole to 200 mg/day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>203-ELVITEGRAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ELVITEGRAVIR" rxcui="1306286">
<ATC code="J05AX11" />
<ATC code="J05AR09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of elvitegravir by decrease of its metabolism by the ketoconazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>With the elvitegravir co-administered with cobicistat, clinical monitoring. Limit the maximum dose of ketoconazole to 200 mg/day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>203-ELVITEGRAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ELVITEGRAVIR" rxcui="1306286">
<ATC code="J05AX11" />
<ATC code="J05AR09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the minimal concentrations of elvitegravir</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>204-ENOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ENOXACIN" rxcui="3925">
<ATC code="J01MA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="N06BC01" />
<ATC code="V04CG30" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of caffeine, which can lead to agitation and hallucinations, due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>204-ENOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ENOXACIN" rxcui="3925">
<ATC code="J01MA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the enoxacin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>204-ENOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ENOXACIN" rxcui="3925">
<ATC code="J01MA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ROPINIROLE" rxcui="72302">
<ATC code="N04BC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of ropinirole with signs of overdose due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the ropinirole during the treatment with the enoxacin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>204-ENOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ENOXACIN" rxcui="3925">
<ATC code="J01MA04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Overdose of theophylline due to substantial decrease of its metabolism</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>205-ENTACAPONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ENTACAPONE" rxcui="60307">
<ATC code="N04BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the entacapone and of the iron due to chelation of the latter by the entacapone</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the iron salts at a different time from the entacapone (more than 2 hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>206-ENZALUTAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ENZALUTAMIDE" rxcui="1307298">
<ATC code="L02BB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GEMFIBROZIL" rxcui="4719">
<ATC code="C10AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the active fraction of the enzalutamide</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reduce the dose of enzalutamide by half when it is administered with the gemfibrozil</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>207-EPLERENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EPLERENONE" rxcui="298869">
<ATC code="C03DA04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hyperkalemia, especially with older patients</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict testing of the kalemia and of the renal function during the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>207-EPLERENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EPLERENONE" rxcui="298869">
<ATC code="C03DA04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>Increase of the risk of hyperkalemia, especially with older patients.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict testing of the kalemia and of the renal function during the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>207-EPLERENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EPLERENONE" rxcui="298869">
<ATC code="C03DA04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of the eplerenone by the inhibitor and of its undesirable effects, especially hyperkalemia</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-ERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DALFOPRISTIN" rxcui="229369">
<ATC code="J01FG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye). </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-ERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-ERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-ERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="MACROLIDES (EXCEPT SPIRAMYCIN)" code="J01FA" /></DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremeties (decrease of the hepatic elimination of the ergotamine).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-ERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="OXPRENOLOL" rxcui="7801">
<ATC code="C07AA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforced clinical monitoring, in particular during the first weeks of the administration of these medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-ERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPRANOLOL" rxcui="8787">
<ATC code="C07AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforced clinical monitoring, in particular during the first weeks of the administration of these medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-ERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUINUPRISTINE" rxcui="135098">
<ATC code="J01FG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of the ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-ERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of the ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-ERGOTAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TRICLABENDAZOLE" rxcui="38608">
<ATC code="P02BX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of the ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
<COMMENT>Wait 24 hours between stopping the triclabendazole and the ergotaine, and the reverse</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>209-ERIBULINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERIBULINE" rxcui="1045453">
<ATC code="L01XX41" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of eribuline by the ciclosporin.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>209-ERIBULINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERIBULINE" rxcui="1045453">
<ATC code="L01XX41" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of eribuline by the clarithromycin.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>209-ERIBULINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERIBULINE" rxcui="1045453">
<ATC code="L01XX41" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYME INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of eribuline by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>209-ERIBULINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERIBULINE" rxcui="1045453">
<ATC code="L01XX41" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of eribuline by the ritonavir.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>209-ERIBULINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERIBULINE" rxcui="1045453">
<ATC code="L01XX41" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of eribuline by the St John&#39;s wort.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>209-ERIBULINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERIBULINE" rxcui="1045453">
<ATC code="L01XX41" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of eribuline by the verapamil. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE" code="G02CB-001" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or rapid elevation of blood pressure

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Risk of constriction of coronary blood vessels or of those of the extremities (ergotism), or of rapid elevation of blood pressure.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of constriction of the coronary arteries or of those of the extremities (ergotism), or of rapid elevation of blood pressure.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPVIR" code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the vasoconstrictor alkaloid of ergot of rye by decrease of its hepatic metabolism by the therapy with the two medications. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="ALPHA SYMPATHOMIMETICS (ORAL AND/OR NASAL)" code="R01AA" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or of rapid elevation of blood pressure

.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or of rapid elevation of blood pressure

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="TRIPTANS" code="N02CC-001" /></DRUG2>
<DESCRIPTION>Risk of arterial hypertension, of constriction of coronary arteries

</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
<COMMENT>Wait 6 to 24 hours, depending on the triptan, between its dose and that of the ergot alkaloid.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of afatinib by increase of its absorption by the erythromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommendedthat the erythromycin be administered as far as possible from the afatinib, preferably at an interval of 6 to 12 hours from the dose of afatinib.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ALFENTANIL" rxcui="480">
<ATC code="N01AH02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the opioid analgesic&#39;s effect of respiratory depression due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Adjust the dosage of the alfentanil when administered with the erythromycin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol lowering agent</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of the cholesterol lowering medication. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUSPIRONE" rxcui="1827">
<ATC code="N05BE01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing&#39;s syndrome</DESCRIPTION>
<SEVERITY>Take into account </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia due to increase of its absorption </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the erithromycin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EBASTINE" rxcui="23796">
<ATC code="R06AX22" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FIDAXOMICIN" rxcui="1111103">
<ATC code="A07AA12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the fidaxomicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GLIBENCLAMIDE" rxcui="4815">
<ATC code="A10BB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, strengthen self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GLIMEPIRIDE" rxcui="25789">
<ATC code="A10BD06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, reinforce self- monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these medications are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LUMEFANTRINE" rxcui="847728">
<ATC code="P01BF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MIZOLASTINE" rxcui="61455">
<ATC code="R06AX25" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="L01XE31" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the nintedanib due to increase of its absorption by the erythromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PRAVASTATIN" rxcui="42463">
<ATC code="C10AA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the erythromycin administered by oral route: increase of the plasma concentration of the pravastatin by the erythromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring during the treatment with the antibiotic.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Overdose of theophylline due to decrease of its hepatic elimination, more particularly dangerous in children</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VENLAFAXINE" rxcui="39786">
<ATC code="N06AX16" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of venlafaxine with risk of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG; if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VINCA ALKALOIDS" code="L01CA" /></DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the erythromycin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical and biological monitoring. Possibly use another antibiotic.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>211-ESMOLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ESMOLOL" rxcui="49737">
<ATC code="C07AB09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>211-ESMOLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ESMOLOL" rxcui="49737">
<ATC code="C07AB09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="CLASS IA ANTIARRHYTHMICS" code="C01B-002" /></DRUG2>
<DESCRIPTION>Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>211-ESMOLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ESMOLOL" rxcui="49737">
<ATC code="C07AB09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac arrest</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-in case of alteration of left ventricular function</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>211-ESMOLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ESMOLOL" rxcui="49737">
<ATC code="C07AB09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>211-ESMOLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ESMOLOL" rxcui="49737">
<ATC code="C07AB09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-in case of alteration of left ventricular function</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>212-ESTRAMUSTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ESTRAMUSTINE" rxcui="4089">
<ATC code="L01XX11" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLODRONIC ACID" rxcui="3350">
<ATC code="M05BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of estramustine by the clodronate</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>212-ESTRAMUSTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ESTRAMUSTINE" rxcui="4089">
<ATC code="L01XX11" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CALCIUM" rxcui="1895">
<ATC code="A12AA" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the estramustine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the calcium salts at a different time from the estramustine (more than 2 hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>212-ESTRAMUSTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ESTRAMUSTINE" rxcui="4089">
<ATC code="L01XX11" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the angioneurotic edema type (angioedema)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>213-NON-CONTRACEPTIVE-ESTROGENS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON-CONTRACEPTIVE ESTROGENS" code="G03C-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the effectiveness of the estrogen 

.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the anticonvulsant inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>213-NON-CONTRACEPTIVE-ESTROGENS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON-CONTRACEPTIVE ESTROGENS" code="G03C-001" /></DRUG1>
<DRUG2>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the effectiveness of the estrogen</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the boceprevir.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>213-NON-CONTRACEPTIVE-ESTROGENS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON-CONTRACEPTIVE ESTROGENS" code="G03C-001" /></DRUG1>
<DRUG2>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG2>
<DESCRIPTION>Risk of clinical hypothyroidism in cases of estrogen replacement therapy.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring; possible adjustment of the doses of the thyroid hormone for menopausal women taking estrogens.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>213-NON-CONTRACEPTIVE-ESTROGENS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON-CONTRACEPTIVE ESTROGENS" code="G03C-001" /></DRUG1>
<DRUG2>
<DRUG name="OXCARBAZEPINE" rxcui="32624">
<ATC code="N03AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the hormonal treatment, due to increase of its hepatic metabolism by the oxcarbazepine.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the treatment with the oxcarbazepin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>213-NON-CONTRACEPTIVE-ESTROGENS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON-CONTRACEPTIVE ESTROGENS" code="G03C-001" /></DRUG1>
<DRUG2>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the effectiveness of the estrogen.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the telaprevir and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG1>
<DRUG2>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of the estrogen-progestin or of the progestatif, with risk of lower contraceptive effectiveness.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use another method of contraception, in particular a barrier type, during the treatment with the aprepitant and a cycle after. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG1>
<DRUG2>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Except for the combination with ethinylestradiol (0.035 mg)/norethisterone (1mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the boceprevir.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use an additional or alternative reliable contraceptive method during the length of the administration of these together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG1>
<DRUG2>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use a reliable contraceptive method, additional or alternative, during the length of time that the two substances are administered together and for a cycle after. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG1>
<DRUG2>
<DRUG name="ELVITEGRAVIR" rxcui="1306286">
<ATC code="J05AX11" />
<ATC code="J05AR09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of ethinylestradiol, with risk of lower contraceptive effectiveness. In addition, increase of the concentrations of the progestin </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use a combined estrogen-progestin contraceptive with at least 30g of ethinylestradiol</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG1>
<DRUG2>
<DRUG name="GRISEOFULVIN" rxcui="5021">
<ATC code="D01AA08" />
<ATC code="D01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the contraceptive effectiveness due to increase of its hepatic metabolism </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Another method of contraception, in particular a barrier type, should be used during the time the two substances are administered together and a cycle after. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the contraceptive effectiveness, due to increase of the hepatic metabolism of the hormonal contraceptive by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another method of contraception, in particular a barrier type, should be used during the time the substances are administered together and a cycle after. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of the hormonal contraceptive due to the increase of its hepatic metabolism by the ritonavir.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another method of contraception, in particular a barrier type (condom or IUD), should be used during the length of the treatment with these medications together and a cycle following. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG1>
<DRUG2>
<DRUG name="LAMOTRIGINE" rxcui="28439">
<ATC code="N03AX09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-avoid starting an oral contraceptive during the period of adjustment of the dosage of the lamotrigine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG1>
<DRUG2>
<DRUG name="ST JOHN'S WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the hormonal contraceptive, by reason of the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect, of the contraceptive, which can possibly have serious consequences (pregnancy).</DESCRIPTION>
<SEVERITY>CONTRAINDICATON</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG1>
<DRUG2>
<DRUG name="MODAFINIL" rxcui="30125">
<ATC code="N06BA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the contraceptive effectiveness, during the treatment and one cycle after the end of the treatment with the modafinil, due to its enzymatic inducer potential</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Use oral contraceptives with 50 micrograms of estrogen or another method of contraception </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG1>
<DRUG2>
<DRUG name="RUFINAMIDE" rxcui="69036">
<ATC code="N03AF03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Moderate decrease of the concentrations of ethinylestradiol</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Another contraceptive method, in particular a barrier type, should be used. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG1>
<DRUG2>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the telaprevir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use a reliable contraceptive method, additional or alternative, during the time these are administered together and two cycles following. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG1>
<DRUG2>
<DRUG name="TOPIRAMATE" rxcui="38404">
<ATC code="38404" />
</DRUG>
</DRUG2>
<DESCRIPTION>For doses of topiramate &gt;=200 mg/day: Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of estrogen </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another method of contraception, in particular a barrier type, should be used.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG1>
<DRUG2>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of antagonism of the effects of the estrogen-progestin contraceptive.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Use an additional contraceptive method of the barrier type for several days after the ulipristal is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG1>
<DRUG2>
<DRUG name="VEMURAFENIB" rxcui="1147220">
<ATC code="L01XE15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the combined estrogen-progestin contraceptive with the consequence of a risk of ineffectiveness </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>215-ETANERCEPT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ETANERCEPT" rxcui="214555">
<ATC code="L04AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ANAKINRA" rxcui="72435">
<ATC code="L04AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of serious infections and neutropenia</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>216-ETHINYLESTRADIOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ETHINYLESTRADIOL" rxcui="4124">
<ATC code="G03AA15" />
<ATC code="G03AB07" />
<ATC code="G03AA09" />
<ATC code="G03AB05" />
<ATC code="G03AA12" />
<ATC code="G03CA01" />
<ATC code="L02AA03" />
<ATC code="G03AA01" />
<ATC code="G03AA10" />
<ATC code="G03AB06" />
<ATC code="G03AA07" />
<ATC code="G03AB03" />
<ATC code="G03AA03" />
<ATC code="G03AB02" />
<ATC code="G03AA08" />
<ATC code="G03AA04" />
<ATC code="G03AB01" />
<ATC code="G03AA13" />
<ATC code="G03AA05" />
<ATC code="G03AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DASABUVIR" rxcui="1597381">
<ATC code="J05AX16" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hepatotoxicity</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>216-ETHINYLESTRADIOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ETHINYLESTRADIOL" rxcui="4124">
<ATC code="G03AA15" />
<ATC code="G03AB07" />
<ATC code="G03AA09" />
<ATC code="G03AB05" />
<ATC code="G03AA12" />
<ATC code="G03CA01" />
<ATC code="L02AA03" />
<ATC code="G03AA01" />
<ATC code="G03AA10" />
<ATC code="G03AB06" />
<ATC code="G03AA07" />
<ATC code="G03AB03" />
<ATC code="G03AA03" />
<ATC code="G03AB02" />
<ATC code="G03AA08" />
<ATC code="G03AA04" />
<ATC code="G03AB01" />
<ATC code="G03AA13" />
<ATC code="G03AA05" />
<ATC code="G03AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ETORICOXIB" rxcui="307296">
<ATC code="M01AH05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of ethinylestradiol by the etoricoxib</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>216-ETHINYLESTRADIOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ETHINYLESTRADIOL" rxcui="4124">
<ATC code="G03AA15" />
<ATC code="G03AB07" />
<ATC code="G03AA09" />
<ATC code="G03AB05" />
<ATC code="G03AA12" />
<ATC code="G03CA01" />
<ATC code="L02AA03" />
<ATC code="G03AA01" />
<ATC code="G03AA10" />
<ATC code="G03AB06" />
<ATC code="G03AA07" />
<ATC code="G03AB03" />
<ATC code="G03AA03" />
<ATC code="G03AB02" />
<ATC code="G03AA08" />
<ATC code="G03AA04" />
<ATC code="G03AB01" />
<ATC code="G03AA13" />
<ATC code="G03AA05" />
<ATC code="G03AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPREVIR" code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the hepatotoxicity.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>217-ETHOSUXIMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ETHOSUXIMIDE" rxcui="4135">
<ATC code="N03AD51" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of ethosuximide</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, plasma dosage of the ethosuximide and possible increase of its dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>218-ETORICOXIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ETORICOXIB" rxcui="307296">
<ATC code="M01AH05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ETHINYLESTRADIOL" rxcui="4124">
<ATC code="G03AA15" />
<ATC code="G03AB07" />
<ATC code="G03AA09" />
<ATC code="G03AB05" />
<ATC code="G03AA12" />
<ATC code="G03CA01" />
<ATC code="L02AA03" />
<ATC code="G03AA01" />
<ATC code="G03AA10" />
<ATC code="G03AB06" />
<ATC code="G03AA07" />
<ATC code="G03AB03" />
<ATC code="G03AA03" />
<ATC code="G03AB02" />
<ATC code="G03AA08" />
<ATC code="G03AA04" />
<ATC code="G03AB01" />
<ATC code="G03AA13" />
<ATC code="G03AA05" />
<ATC code="G03AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of ethinylestradiol by the etoricoxib</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>219-ETRAVIRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ETRAVIRINE" rxcui="475969">
<ATC code="J05AG04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>In the treatment of infections with Mycobacterium avium complex, risk of decrease of the effectiveness of the clarithromycin due to increase of its hepatic metabolism by the etravirine</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>21-ALDESLEUKIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALDESLEUKIN" rxcui="70223">
<ATC code="L03AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IODINATED X-RAY CONTRAST MEDIA" code="VO8A-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of reaction to the contrast media in cases of previous treatment with interleukin2: 

skin rash or more rarely low blood pressure, oliguria, or even renal failure</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>220-EVEROLIMUS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EVEROLIMUS" rxcui="141704">
<ATC code="L01XE10" />
<ATC code="L04AA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the everolimus by the ciclosporin. The nephrotoxicity of the ciclosprorin is also increased when the two medications are administered together</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the everolimus, possibly adjustment of the dosage, and testing of the renal function, during the administration of the two together and after it is stopped  </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>220-EVEROLIMUS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EVEROLIMUS" rxcui="141704">
<ATC code="L01XE10" />
<ATC code="L04AA18" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>Increase of the risk of angioedema</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>220-EVEROLIMUS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EVEROLIMUS" rxcui="141704">
<ATC code="L01XE10" />
<ATC code="L04AA18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the everolimus due to decrease of its hepatic metabolism by the verapamil</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the two medications together and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>221-EXEMESTANE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EXEMESTANE" rxcui="258494">
<ATC code="L02BG06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the exemestane due to increase of its hepatic metabolism by the enzymatic inducer</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>222-EZETIMIBE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EZETIMIBE" rxcui="341248">
<ATC code="C10BA05" />
<ATC code="C10AX09" />
<ATC code="C10BA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>For one thing, increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to increase of the concentrations of ezetimibe; for another thing, possible increase of the concentrations of ciclosporin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>222-EZETIMIBE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EZETIMIBE" rxcui="341248">
<ATC code="C10BA05" />
<ATC code="C10AX09" />
<ATC code="C10BA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FENOFIBRATE" rxcui="8703">
<ATC code="C10AB05" />
<ATC code="C10BA03" />
<ATC code="C10BA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of gallstones due to increase of the biliary excretion of cholesterol</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>223-FELBAMATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FELBAMATE" rxcui="24812">
<ATC code="N03AX10" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the active metabolite of the carbamazepine. In addition, decrease of the plasma concentrations of felbamate due to increase of its hepatic metabolism by the carbamazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, plasma dosages, and possible adjustment of the dosages of the two anticonvulsants.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>223-FELBAMATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FELBAMATE" rxcui="24812">
<ATC code="N03AX10" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the felbamate and increase of the plasma concentrations of the phenobarbital, with risk of overdose.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and testing of the plasma concentrations of phenobarbital with adjustment of the dosage if needed. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>223-FELBAMATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FELBAMATE " rxcui="24812">
<ATC code="N03AX10" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin with risk of overdose, due to inhibition of its metabolism by the felbamate</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, testing of the plasma concentrations of phenytoin, and if needed, adjustment of its dosage during the treatment with the felbamate.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>223-FELBAMATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FELBAMATE" rxcui="24812">
<ATC code="N03AX10" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the valproic acid, with risk of overdose</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring, and possible adjustment of the dosage of the valproate or of the valpromide during the treatment with the felbamate and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>224-FENOFIBRATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FENOFIBRATE" rxcui="8703">
<ATC code="C10AB05" />
<ATC code="C10BA03" />
<ATC code="C10BA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the nephrotoxicity of the ciclosporin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring of the renal function, during and after the administration of the two medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>224-FENOFIBRATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FENOFIBRATE" rxcui="8703">
<ATC code="C10AB05" />
<ATC code="C10BA03" />
<ATC code="C10BA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EZETIMIBE" rxcui="341248">
<ATC code="C10BA05" />
<ATC code="C10AX09" />
<ATC code="C10BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of gallstones due to increase of the biliary excretion of cholesterol</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>225-FENTANYL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FENTANYL" rxcui="4337">
<ATC code="N01AH01" />
<ATC code="N02AB03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the anticonvulsant</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Choose another opioid.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>225-FENTANYL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FENTANYL" rxcui="4337">
<ATC code="N01AH01" />
<ATC code="N02AB03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the opioid analgesic&#39;s effect of respiratory depression due to slight decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is treatment with a strong inhibitor of CYP3A4.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>225-FENTANYL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FENTANYL" rxcui="4337">
<ATC code="N01AH01" />
<ATC code="N02AB03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Choose another opioid.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>226-IRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="INJECTABLE IRON SALTS" rxcui="1431591">
<ATC code="B03AC" />
<ATC code="B03AC01" />
<ATC code="B03AC02" />
<ATC code="B03AC03" />
<ATC code="B03AC05" />
<ATC code="B03AC06" />
<ATC code="B03AC07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Lypothymia, even loss of consciousness attributed to the rapid release of the iron in its complex form and to the saturation of the transferrin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>226-IRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ACETOHYDROXAMIC ACID" rxcui="16728">
<ATC code="G04BX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of these two medications due to chelation of the iron</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>226-IRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BISPHOSPHONATES" code="M05B-001" /></DRUG2>
<DESCRIPTION>For the iron salts administered via oral route: decrease of the digestive absorption of the bisphosphonates</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the iron salts at a different time from the bisphosphonates (from 30 minutes minimum to more than 2 hours apart, if possible, depending on the bisphosphonate).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>226-IRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CALCIUM" rxcui="1895">
<ATC code="A12AA" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the iron salts by oral route: decrease of the digestive absorption of the iron salts</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the iron salts at a different time from meals and in the absence of calcium. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>226-IRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="TETRACYCLINE ANTIBIOTICS" code="J01AA" /></DRUG2>
<DESCRIPTION>With the tetracycline antibiotics administered by oral route: decrease of the digestive absorption of the tetracycline antibiotics (formation of complexes)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the iron salts at a different time from the tetracycline antibiotics (more than 2 hours apart if possible). </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>226-IRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ENTACAPONE" rxcui="60307">
<ATC code="N04BX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the entacapone and of the iron due to chelation of the latter by the entacapone</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the iron salts at a different time from the entacapone (more than 2 hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>226-IRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="FLUOROQUINOLONES" code="J01MA-001" /></DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the fluoroquinolones</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the iron salts at a different time from the fluoroquinolones (more that 2 hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>226-IRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the thyroid hormones</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the thyroid hormones at a different time from the iron (more than 2 hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>226-IRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
<ATC code="N04BA02" />
<ATC code="N04BA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the levodopa</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the iron salts at a different time from the levodopa (more than 2 hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>226-IRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHYLDOPA" rxcui="6876">
<ATC code="C02AB" />
<ATC code="C02LB" />
<ATC code="C02AB01" />
<ATC code="C02LB01" />
<ATC code="C02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the methyldopa (formation of complexes)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the iron salts at a different time from the methyldopa (more than two hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>226-IRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PENICILLAMINE" rxcui="7975">
<ATC code="M01CC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the penicillamine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the iron salts at a different time from the penicillamine (more than 2 hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>226-IRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STRONTIUM" rxcui="81638">
<ATC code="V10BX01" />
<ATC code="M05BX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the strontium.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the strontium at a different time from the iron salts (more than two hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>226-IRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZINC" rxcui="11416">
<ATC code="A12CB" />
<ATC code="A12CB01" />
<ATC code="A12CB02" />
<ATC code="A12CB03" />
<ATC code="B05X" />
<ATC code="B05XA" />
<ATC code="B05XA12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the zinc by the iron</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the iron salts at a different time from the zinc (more than 2 hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>227-FIBRATES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FIBRATES" code="C01AB-001" /></DRUG1>
<DRUG2>
<CLASS name="OTHER FIBRATES" code="C01AB-001" /></DRUG2>
<DESCRIPTION>Increased risk of undesirable effects of the rhabdomyolosis type and of pharmacodynamic antagonism between the two molecules</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>227-FIBRATES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FIBRATES" code="C01AB-001" /></DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fibrate and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>227-FIBRATES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FIBRATES" code="C01AB-001" /></DRUG1>
<DRUG2>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolosis</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring, particularly at the beginning of the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>227-FIBRATES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FIBRATES" code="C01AB-001" /></DRUG1>
<DRUG2>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS)" code="C10AA" /></DRUG2>
<DESCRIPTION>Risk of addition of undesirable effects (dose-dependent) of the rhabdomyolosis type. Furthermore, with the gemfibrozil, decrease of the metabolism of the simvastatin and of the rosuvastatin, which increases the muscular risk, as well as the nephrotoxicity of the rosuvastatin</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with the gemfibrozil and the simvastatin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>228-FIDAXOMICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FIDAXOMICIN" rxcui="1111103">
<ATC code="A07AA12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the fidaxomicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>228-FIDAXOMICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FIDAXOMICIN" rxcui="1111103">
<ATC code="A07AA12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the fidaxomicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>228-FIDAXOMICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FIDAXOMICIN" rxcui="1111103">
<ATC code="A07AA12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the fidaxomicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>228-FIDAXOMICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FIDAXOMICIN" rxcui="1111103">
<ATC code="A07AA12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the fidaxomicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>228-FIDAXOMICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FIDAXOMICIN" rxcui="1111103">
<ATC code="A07AA12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="D10AF52" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the fidaxomicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>228-FIDAXOMICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FIDAXOMICIN" rxcui="1111103">
<ATC code="A07AA12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the fidaxomicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>228-FIDAXOMICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FIDAXOMICIN" rxcui="1111103">
<ATC code="A07AA12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the fidaxomicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>229-FINGOLIMOD.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FINGOLIMOD" rxcui="1012892">
<ATC code="L04AA27" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BRADYCARDIA INDUCING DRUGS" code="C0N0S0" /></DRUG2>
<DESCRIPTION>Increase of the bradycardia inducing effects which can have fatal consequences. The beta-blocking agents are even more at risk since they inhibit the adrenergic compensation mechanisms</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Clinical monitoring and continuous EKG during the 24 hours following the first dose.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>22-ALFENTANIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALFENTANIL" rxcui="480">
<ATC code="N01AH02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With cimetidine used in doses greater than or equal to 800mg/day: increase of the opioid analgesic&#39;s effect of respiratory depression due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Adjust the dosage of the alfentanil when administered with the cimetidine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>22-ALFENTANIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALFENTANIL" rxcui="480">
<ATC code="N01AH02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the opioid analgesic&#39;s effect of respiratory depression due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Adjust the dosage of the alfentanil when administered with the diltiazem. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>22-ALFENTANIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALFENTANIL" rxcui="480">
<ATC code="N01AH02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the opioid analgesic&#39;s effect of respiratory depression due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Adjust the dosage of the alfentanil when administered with the erythromycin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>22-ALFENTANIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALFENTANIL" rxcui="480">
<ATC code="N01AH02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the opioid analgesic&#39;s effect of respiratory depression due to decrease of its hepatic metabolism

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Adjust the dosage of the alfentanil when administered with the fluconazole</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>22-ALFENTANIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALFENTANIL" rxcui="480">
<ATC code="N01AH02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the opioid analgesic&#39;s effect of respiratory depression due to decrease of its hepatic metabolism

.</DESCRIPTION>
<SEVERITY>Precaution for use </SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the opioid analgesic when administered with a strong inhibitor of CYP3A4.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>230-FLECAINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ABIRATERONE" rxcui="1100072">
<ATC code="L02BX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the abiraterone</DESCRIPTION>
<SEVERITY>Precautions for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the abiraterone</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>230-FLECAINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the flecainide due to decrease of its hepatic metabolism by the bupropion</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the bupropion.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>230-FLECAINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CINACALCET" rxcui="407990">
<ATC code="H05BX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of flecanaide with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the flecainide during the treatment with cinacalcet.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>230-FLECAINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DARIFENACIN" rxcui="136198">
<ATC code="G04BD10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of flecainide, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the flecainide during the treatment with darifenacin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>230-FLECAINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of flecainide with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the flecainide during the treatment with the duloxetine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>230-FLECAINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MIRABEGRON" rxcui="1300786">
<ATC code="G04BD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the flecainide by decrease of its metabolism by the mirabegron</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the flecainide during the administration of it and the mirabegron together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>230-FLECAINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TERBINAFINE" rxcui="37801">
<ATC code="D01AE15" />
<ATC code="D01BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the terbinafine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the terbinafine. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ALFENTANIL" rxcui="480">
<ATC code="N01AH02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the opioid analgesic&#39;s effect of respiratory depression due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Adjust the dosage of the alfentanil when there is treatment with the fluconazole</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of lengthening of the QT interval</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, especially with strong doses of fluconazole (800 mg/day)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluconazole and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="APIXABAN " rxcui="1364430">
<ATC code="B01AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the apixaban by the flucoonazole, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>For doses of fluconazole &gt;=200 mg per day: possible increase of the undesirable effects of the carbamazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Adjust the dosage of carbamazepine, during and after the end of the antifungal treatment</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the undesirable effects of the colchicine, with potentially fatal consequences</DESCRIPTION>
<SEVERITY>Not Recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DOMPERIDONE" rxcui="3626">
<ATC code="A03FA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="HALOFANTRINE" rxcui="50749">
<ATC code="P01BX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If this is possible, interrupt the fluconazole. If administering these medications together cannot be avoided, testing beforhand of the QT and EKG monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Risk of increase of the blood concentrations of the immunosuppressant due to inhibition of its metabolism and of the creatinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of renal function, and adjustment of the immunosuppressant's dosage during the administration of the substances together and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IVACAFTOR" rxcui="1243041">
<ATC code="R07AX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of ivacaftor, with risks of increase of its undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reduce the dose by half, that is 150 mg/day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LOSARTAN" rxcui="52175">
<ATC code="C09CA01" />
<ATC code="C09DB06" />
<ATC code="C09DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the losartan, due to inhibition of the formation of its active metabolite by the fluconazole</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>--with midazolam by mouth</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NEVIRAPINE" rxcui="53654">
<ATC code="J05AG01" />
<ATC code="J05AR07" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Doubling of the concentrations of nevirapine with risk of increase of its undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the nevirapine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="OLAPARIB" rxcui="1597582">
<ATC code="L01XX46" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of olaparib by the fluconazole</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, limit the dose of olaparib to 200mg twice a day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="OXYCODONE" rxcui="7804">
<ATC code="N02AA55" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the undesirable effects, especially respiratory ones, of the oxycodone due to decrease of its metabolism by the fluconazole.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the oxycodone during the treatment with the fluconazole and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Increase of the plasma oncentrations of phenytoin that can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the treatment with the two medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the fluconazole by increase of its metabolism by the rifampacin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIVAROXABAN" rxcui="1114195">
<ATC code="B01AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the rivaroxaban by the fluconazole, with increase of the risk of bleeding </DESCRIPTION>
<SEVERITY>Not recommeded</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG2>
<DESCRIPTION>Increase of the half life of the sulfonamide with possible onset of hypoglycemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the sulfonamide during the treatment with the fluconazole.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>231-FLUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with risk of overdose (decrease of the clearance of the theophylline)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the fluconazole and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>232-FLUCYTOSINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUCYTOSINE" rxcui="4451">
<ATC code="D01AE21" />
<ATC code="J02AX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZIDOVUDINE (AZT)" rxcui="11413">
<ATC code="J05AF01" />
<ATC code="J05AR01" />
<ATC code="J05AR04" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hematological toxicity (addition of effects of bone marrow toxicity)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent CBC</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>233-FLUDARABINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUDARABINE" rxcui="24698">
<ATC code="L01BB05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PENTOSTATIN" rxcui="8011">
<ATC code="L01XX08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of pulmonary toxicity that could be fatal. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>234-FLUOROQUINOLONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FLUOROQUINOLONES" code="J01MA-001" /></DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>234-FLUOROQUINOLONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FLUOROQUINOLONES" code="J01MA-001" /></DRUG1>
<DRUG2>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the fluoroquinolones</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the iron salts at a different time from the fluoroquinolones (more that 2 hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>234-FLUOROQUINOLONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FLUOROQUINOLONES" code="J01MA-001" /></DRUG1>
<DRUG2>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG2>
<DESCRIPTION>Possible increase of the risk of tendinitis, even of rupture of the tendon (exceptional), particularly in patients receiving prolonged corticotherapy </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>234-FLUOROQUINOLONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FLUOROQUINOLONES" code="J01MA-001" /></DRUG1>
<DRUG2>
<DRUG name="MYCOPHENOLATE MOFETIL" >
<ATC code="MYCOPHEN" />
<ATC code="OLIC" />
<ATC code="ACID" />
<ATC code="MYCOPHEN" />
<ATC code="OLATE" />
<ATC code="MOFETIL" />
<ATC code="MYCOPHEN" />
<ATC code="OLIC" />
<ATC code="ACID" />
<ATC code="MYCOPHEN" />
<ATC code="OLIC" />
<ATC code="ACID" />
<ATC code="7145" />
<ATC code="L04AA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness. </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>234-FLUOROQUINOLONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FLUOROQUINOLONES" code="J01MA-001" /></DRUG1>
<DRUG2>
<DRUG name="STRONTIUM" rxcui="81638">
<ATC code="V10BX01" />
<ATC code="M05BX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the strontium</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the strontium at a different time from the fluoroquinolones (more than two hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>234-FLUOROQUINOLONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FLUOROQUINOLONES" code="J01MA-001" /></DRUG1>
<DRUG2>
<DRUG name="SUCRALFATE" rxcui="10156">
<ATC code="A02BX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the fluoroquinolones</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the sucralfate at a different time from the fluoroquinolone (more than 2 hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>234-FLUOROQUINOLONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FLUOROQUINOLONES" code="J01MA-001" /></DRUG1>
<DRUG2>
<DRUG name="ZINC" rxcui="11416">
<ATC code="A12CB" />
<ATC code="A12CB01" />
<ATC code="A12CB02" />
<ATC code="A12CB03" />
<ATC code="B05X" />
<ATC code="B05XA" />
<ATC code="B05XA12" />
<ATC code="B05XA12" />
<ATC code="B05XA12" />
<ATC code="B05XA12" />
<ATC code="B05XA12" />
<ATC code="B05XA12" />
<ATC code="B05XA12" />
<ATC code="B05XA12" />
<ATC code="B05XA12" />
<ATC code="B05XA12" />
<ATC code="B05XA12" />
<ATC code="B05XA12" />
<ATC code="B05XA12" />
<ATC code="B05XA12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the fluoroquinolones</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the zinc salts at a different time from the fluoroquinlones (more than 2 hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>235-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)" code="L01BC-001" /></DRUG1>
<DRUG2>
<DRUG name="FOLINIC ACID" rxcui="6313">
<ATC code="B03BB" />
<ATC code="B03BB01" />
<ATC code="B03BB51" />
</DRUG>
</DRUG2>
<DESCRIPTION>Strengthening of the effects, both cytostatic and undesirable, of the fluorouracil. </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>235-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)" code="L01BC-001" /></DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If taking these medications together cannot be avoided, more frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the cytotoxic and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>235-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)" code="L01BC-001" /></DRUG1>
<DRUG2>
<DRUG name="INTERFERON ALFA" rxcui="1431112">
<ATC code="L03AB01" />
<ATC code="5879" />
<ATC code="L03AB04" />
<ATC code="5880" />
<ATC code="L03AB05" />
<ATC code="202912" />
<ATC code="L03AB06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the gastrointestinal toxicity of the fluorouracil</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>235-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)" code="L01BC-001" /></DRUG1>
<DRUG2>
<DRUG name="METRONIDAZOLE" rxcui="6922">
<ATC code="A02BD08" />
<ATC code="A02BD03" />
<ATC code="A02BD02" />
<ATC code="A01AB17" />
<ATC code="D06BX01" />
<ATC code="G01AF01" />
<ATC code="J01XD01" />
<ATC code="P01AB01" />
<ATC code="A02BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the toxicity of the fluourouracil due to decrease of its clearance</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>235-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)" code="L01BC-001" /></DRUG1>
<DRUG2>
<DRUG name="ORNIDAZOLE" rxcui="7701">
<ATC code="G01AF06" />
<ATC code="J01XD03" />
<ATC code="P01AB03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the toxicity of the fluorouracil due to decrease of its clearance</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>236-FLUOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, testing of the plasma concentrations of carbamazepine, and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>236-FLUOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MEQUITAZINE" rxcui="29528">
<ATC code="R06AD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzymatic inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>236-FLUOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the metoprolol, especially with excessive bradycardia, due to inhibition of its metabolism by the fluoxetine. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring, if needed, adjustment of the dosage of the metoprolol during the length of the treatment with the fluoxetine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>236-FLUOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NEBIVOLOL" rxcui="31555">
<ATC code="C07AB12" />
<ATC code="C07BB12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the nebivolol, especially with excessive bradycardia, due to inhibition of its metabolism by the antidepressant </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring; if needed, adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>236-FLUOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name=" FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the metabolism of the phenytoin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly testing of the plasma concentrations of phenytoin. If needed, adjustment of the dosage during the treatment with the fluoxetine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>236-FLUOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RISPERIDONE" rxcui="35636">
<ATC code="N05AX08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the fluoxetine, with risk of increase of its undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and, if needed, adjustment of the dosage of the risperidone. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>236-FLUOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TAMOXIFEN" rxcui="10324">
<ATC code="L02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the fluoxetine. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>236-FLUOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the vortioxetine due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with fluoxetine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AGOMELATINE" rxcui="306718">
<ATC code="N06AX22" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of agomelatine, with risk of increase of the undesirable effects.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, testing of the plasma concentrations of carbamazepine and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLOZAPINE" rxcui="2626">
<ATC code="N05AH02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of clozapine with signs of overdose</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring; if needed, adjustment of the dosage of the clozapine during the treatment with the fluvoxamine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the fluvoxamine</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LIDOCAINE" rxcui="6387">
<ATC code="C01BB01" />
<ATC code="C05AD01" />
<ATC code="D04AB01" />
<ATC code="N01BB02" />
<ATC code="R02AD02" />
<ATC code="S01HA07" />
<ATC code="S02DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N07BC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of methodone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strengthen clinical monitoring and EKG; if needed, adjustment of the dosage of the methadone during the treatment with the fluvoxamine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MEXILETINE" rxcui="6926">
<ATC code="C01BB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the mexiletine, due to inhibition of its metabolism by the fluvoxamine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG. Adjustment of the dosage of the mexiletine during the treatment with the fluvoxamine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="OLANZAPINE" rxcui="61381">
<ATC code="N05AH03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of the olanzapine, with risk of increase of the undesirable effects, due to decrease of its hepatic metabolism by the fluvoxamine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the olanzapine during the treatment with fluvoxamine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the hepatic metabolism of the phenytoin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly testing of the plasma concentrations of phenytoin. If needed, adjustment of the dosage of the phenytoin during the treatment with the fluvoxamine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIRFENIDONE" rxcui="1592254">
<ATC code="L04AX05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of pirfenidone with signs of overdose</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPRANOLOL" rxcui="8787">
<ATC code="C07AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of propranolol due to inhibition of its hepatic metabolism, with increase of the activity and of the undesirable effects, for example: significant bradycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring, and, if needed, adjustment of the dosage of the propranolol during the treatment with the fluvoxamine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ROPINIROLE" rxcui="72302">
<ATC code="N04BC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of ropinirole, with risk of overdose, due to decrease of its hepatic metabolism by the fluvoxamine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the ropinirole during the treatment with fluvoxamine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUVOXAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with signs of overdose (decrease of the hepatic metabolism of the theophylline) </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia; if needed, adjustment of the dosage of the theophylline during the treatment with fluvoxamine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>238-FOLATES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FOLATES" code="V03-" /></DRUG1>
<DRUG2>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the phenobarbital, due to increase of its metabolism of which the folates represent one of the cofactors</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, testing of the plasma concentrations, and adjustment, if there is reason for it, of the dosage of the phenobarbital during the folic supplementation and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>238-FOLATES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FOLATES" code="V03-" /></DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of phenytoin due to increase of its metabolism of which the folates represent one of the cofactors</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and testing of the plasma concentrations of phenytoin. Possible adjustment of the dosage of the phenytoin during the folic supplementation and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>239-FOSAMPRENAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FOSAMPRENAVIR" rxcui="358262">
<ATC code="J05AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUPRENORPHINE" rxcui="1819">
<ATC code="N02AE01" />
<ATC code="N07BC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase or of decrease of the effects of the A to take into account buprenorphine [sic], simultaneously by inhibition and acceleration of its metabolism by the protease inhibitor</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>239-FOSAMPRENAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FOSAMPRENAVIR" rxcui="358262">
<ATC code="J05AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of lower effectiveness of the amprenavir.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>239-FOSAMPRENAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FOSAMPRENAVIR" rxcui="358262">
<ATC code="J05AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MARAVIROC" rxcui="620216">
<ATC code="J05AX09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Significant decrease of the concentrations of amprenavir that can lead to a loss of viralogical response</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>239-FOSAMPRENAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FOSAMPRENAVIR" rxcui="358262">
<ATC code="J05AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the ampernavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring and possible adjustment of the dosage of methadone.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>239-FOSAMPRENAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FOSAMPRENAVIR" rxcui="358262">
<ATC code="J05AE07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NEVIRAPINE" rxcui="53654">
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of lower effectiveness of the amprenavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>23-ALFUZOSIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALFUZOSIN" rxcui="17300">
<ATC code="G04CA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of the alfuzosin and of its undesirable effects. 

.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>23-ALFUZOSIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALFUZOSIN" rxcui="17300">
<ATC code="G04CA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPVIR" code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the alfuzosin by decrease of its hepatic metabolism by the therapy with the two medications.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>240-FOSCARNET.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FOSCARNET" rxcui="33562">
<ATC code="J05AD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PENTAMIDINE" rxcui="7994">
<ATC code="P01CX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of severe hypocalcemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of the calcemia and supplementation if necessary.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>241-FOTEMUSTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FOTEMUSTINE " rxcui="25287">
<ATC code="L01AD05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DACARBAZINE" rxcui="3098">
<ATC code="L01AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dacarbazine in large doses: risk of pulmonary toxicity (adult acute respiratory distress syndrome ).

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Do not use these medications simultaneously, but wait a week between the last administration of fotemustine and the first day of the treatment with dacarbazine. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>242-FUROSEMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FUROSEMIDE" rxcui="460">
<ATC code="C03CA01" />
<ATC code="C03CB01" />
<ATC code="C03EB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Decrease of the diuretic effect which can reach 50%</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Possibly use higher doses of furosemide. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>243-GANCICLOVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GANCICLOVIR" rxcui="4678">
<ATC code="J05AB06" />
<ATC code="S01AD09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIDANOSINE" rxcui="3364">
<ATC code="J05AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the didanosine, and especially the mitochondrial toxicity, due to substantial increase of its concentrations. In addition, risk of decrease of the effectiveness of the ganciclovir due to decrease of its concentrations, if the two medications are ingested in an interval of less than 2 hours</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>243-GANCICLOVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GANCICLOVIR" rxcui="4678">
<ATC code="J05AB06" />
<ATC code="S01AD09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the two medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>243-GANCICLOVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GANCICLOVIR" rxcui="4678">
<ATC code="J05AB06" />
<ATC code="S01AD09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AF01" />
<ATC code="J05AR01" />
<ATC code="J05AR04" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hematological toxicity (addition of effects of bone marrow toxicity)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Stop the zidovudine temporarily; CBC, and, reintroduce, if possible, the zidovudine in small doses. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>244-GEMFIBROZIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GEMFIBROZIL" rxcui="4719">
<ATC code="C10AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DASABUVIR" rxcui="1597381">
<ATC code="J05AX16" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of the dasabuvir by the gemfibrozil</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>244-GEMFIBROZIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GEMFIBROZIL" rxcui="4719">
<ATC code="C10AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ENZALUTAMIDE" rxcui="1307298">
<ATC code="L02BB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the active fraction of the enzalutamide</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reduce the dose of enzalutamide by half when administered with the gemfibrozil.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>244-GEMFIBROZIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GEMFIBROZIL" rxcui="4719">
<ATC code="C10AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIOGLITAZONE" rxcui="33738">
<ATC code="A10BG03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the glitazone due to decrease of its hepatic metabolism by the gemfibrozil</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, strict clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>244-GEMFIBROZIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GEMFIBROZIL" rxcui="4719">
<ATC code="C10AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of severe hypoglycemia, even coma, due to substantial increase of the plasma concentrations of repaglinide by the gemfiborzil</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>245-GLIBENCLAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GLIBENCLAMIDE" rxcui="4815">
<ATC code="A10BB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduced effectiveness of the glibenclamide due to decrease of its plasma concentrations, because of the inducer effect of the bosentan. Furthermore, cases of hepatoxicity have been reported with these substances administered together. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of the glycemia, adjustment of the treatment if needed, and monitoring of the hepatic biological constants </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>245-GLIBENCLAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GLIBENCLAMIDE" rxcui="4815">
<ATC code="A10BB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, strengthen self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>245-GLIBENCLAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GLIBENCLAMIDE" rxcui="4815">
<ATC code="A10BB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, strengthen self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>246-GLIMEPIRIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GLIMEPIRIDE" rxcui="25789">
<ATC code="A10BB12" />
<ATC code="A10BD06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>246-GLIMEPIRIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GLIMEPIRIDE" rxcui="25789">
<ATC code="A10BB12" />
<ATC code="A10BD06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="D10AF52" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>247-GLINIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLINIDES" code="A10BX-001" /></DRUG1>
<DRUG2>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG2>
<DESCRIPTION>All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>247-GLINIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLINIDES" code="A10BX-001" /></DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, and reinforce, especially at the beginning of treatment, self-monitoring of blood glucose.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>248-GLIPIZIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GLIPIZIDE" rxcui="4821">
<ATC code="A10BB07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of the glipizide at the origin of potentially severe hypoglycemia. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during and after the treatment with voriconazole.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>249-GLIPTINS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLIPTINS" code="A10B-001" /></DRUG1>
<DRUG2>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG2>
<DESCRIPTION>All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>249-GLIPTINS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLIPTINS" code="A10B-001" /></DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>Increase of the risk of the onset of angioedema, due to the reduction of the activity of the enzyme dipetidyl peptidase-4 (DDP-4) by the gliptin, in patients treated with the angiotensin converting enzyme inhibitor</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>24-ALISKIREN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09XA02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG2>
<DESCRIPTION>Risk of hyperkalemia, of renal insufficiency, of increase of cardiovascular mortality</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>-for patients with diabetes or renal insufficiency</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>24-ALISKIREN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09XA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>The plasma concentrations of aliskiren increase by nearly 5 times and increase of the risk of its undesirable effects. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>24-ALISKIREN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09XA02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>Risk of hyperkalemia, of renal insufficiency, of increase of cardiovascular mortality</DESCRIPTION>
<SEVERITY>Contraindication </SEVERITY>
<COMMENT>-for patients with diabetes or renal insufficiency</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>24-ALISKIREN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09XA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>The plasma concentrations of aliskiren increase by nearly 6 times and increase of the risk of its undesirable effects. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>24-ALISKIREN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09XA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT" >
<ATC code="JUICE" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the aliskiren when grapefruit is consumed</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>24-ALISKIREN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09XA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.

</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>24-ALISKIREN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09XA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SACUBITRIL" rxcui="1656328">
</DRUG>
</DRUG2>
<DESCRIPTION>With diabetic patients or those with renal insufficiency, increase of the undesirable effects such as hypotension, hyperkaliemia</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>24-ALISKIREN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09XA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>250-ANTI-LYMPHOCYTE-GLOBULINS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTI-LYMPHOCYTE GLOBULINS" code="L04AA0-001" /></DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Excessive immunodepression with risk of lymphoproliferative disorders (LPDs)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>250-ANTI-LYMPHOCYTE-GLOBULINS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTI-LYMPHOCYTE GLOBULINS" code="L04AA0-001" /></DRUG1>
<DRUG2>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG2>
<DESCRIPTION>Risk of possibly fatal general illness. This risk is increased in older patients already immunodepressed by the underlying disease.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>In particular, use an inactivated vaccine when one exists (poliomyelitis)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage

</DESCRIPTION>
<SEVERITY>Not recommended with:</SEVERITY>
<COMMENT>-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG1>
<DRUG2>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG2>
<DESCRIPTION>Glucocorticoids (general and rectal routes): possible impact of the corticotherapy on the metabolism of the Vitamin K antagonist and on that of the factors of coagulation. Risk of hemorrhage specific to the corticotherapy (digestive mucosa, vascular fragility) in large doses or in treatment prolonged beyond 10 days. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>When administering substances from these groups together is justified, strengthen monitoring: if the situation requires, with the vitamin K antagonists, biological testing on the 8th day, then every two weeks after that during the corticotherapy and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great with patients who have Addisons disease treated with hydrocortisone and in cases of organ transplants</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Increase of the risk of ulceration and of gastrointestinal hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG1>
<DRUG2>
<CLASS name="NON-DEPOLARIZING CURARES" code="M03A-002" /></DRUG2>
<DESCRIPTION>With the glucocorticoids by IV route: risk of severe myopathy, reversible after a possibly long period (several months).</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG1>
<DRUG2>
<CLASS name="FLUOROQUINOLONES" code="J01MA-001" /></DRUG2>
<DESCRIPTION>Possible increase of the risk of tendinitis, even of rupture of the tendon (exceptional), particularly in patients receiving corticotherapy for a prolonged period</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG1>
<DRUG2>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Described for prednisolone. 

Decrease of the plasma concentrations of the isoniazid. Mechanism proposed: increase of the hepatic metabolism of the isoniazid and decrease of that of the glucocorticoides</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in patients with Addisons disease treated with hydrocortisone and in cases of transplants</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG1>
<DRUG2>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG2>
<DESCRIPTION>With the exception of inhaled and local routes, and for doses greater than 10mg/day of prednisone-equivalent (or &gt; 2mg/kg/day for a child or &gt; 20mg/day for a child weighing more than 10 kg) during more than two weeks and for the &quot;bolus&quot; of corticoids: risk of possibly fatal general vaccine disease.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>And during the 3 months following the end of the therapy with the corticoid.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>252-GLUCOSAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GLUCOSAMINE" rxcui="4845">
<ATC code="M01AX05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the Vitamin K Antagonist</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>253-GLYCEROL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GLYCEROL" rxcui="4910">
<ATC code="A06AG04" />
<ATC code="A06AX01" />
<ATC code="A16AX09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict monitoring of the plasma concentrations of lithium and possible adjustment of the dosage of the lithium. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>254-GRISEOFULVIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRISEOFULVIN" rxcui="5021">
<ATC code="D01AA08" />
<ATC code="D01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the griseofulvin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with griseofulvin and a week after it is stopped </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>254-GRISEOFULVIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRISEOFULVIN" rxcui="5021">
<ATC code="D01AA08" />
<ATC code="D01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the contraceptive effectiveness due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Another method of contraception, in particular a barrier type, should be used during the time the two substances are administered together and a cycle after. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>254-GRISEOFULVIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRISEOFULVIN" rxcui="5021">
<ATC code="D01AA08" />
<ATC code="D01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use a reliable contraceptive method, additional or alternative, during the length of time these substances are administered together and a cycle following.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>255-GUANETHIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GUANETHIDINE" rxcui="5036">
<ATC code="C02CC02" />
<ATC code="S01EX01" />
<ATC code="C02LF01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>With the guanethidine used by IV route: risk of unforeseeable vascular reactions, especially hypotension</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Interrupt the treatment with the MAOI two weeks before the treatment with guanethidine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>256-HALOFANTRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="HALOFANTRINE" rxcui="50749">
<ATC code="P01BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If this is possible, interrupt the fluconazole. If the administration of these substances together cannot be avoided, testing beforehand of the QT and EKG monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>256-HALOFANTRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="HALOFANTRINE" rxcui="50749">
<ATC code="P01BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arryhthmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If this is possible, interrupt the inhibitor. If administering these medications together cannot be avoided, testing beforehand of the QT and EKG monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>256-HALOFANTRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="HALOFANTRINE" rxcui="50749">
<ATC code="P01BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If this is possible, interrupt the macrolide. If administering the substances together cannot be avoided, testing of the QT interval before the beginning of the treatment and EKG monitoring</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>256-HALOFANTRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="HALOFANTRINE" rxcui="50749">
<ATC code="P01BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT (JUICE AND FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>256-HALOFANTRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="HALOFANTRINE" rxcui="50749">
<ATC code="P01BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>257-HALOPERIDOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="HALOPERIDOL" rxcui="5093">
<ATC code="N05AD01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>NB: Carbamazepine is one of the Anticonvulsant Enzymatic Inducers

Clinical monitoring and, if needed, adjustment of the dosage during the treatment with the carbamazepine and after it is stopped</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and, if needed, adjustment of the dosage during the treatment with the carbamazepine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>257-HALOPERIDOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="HALOPERIDOL" rxcui="5093">
<ATC code="N05AD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the haloperidol and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and, if needed, adjustment of the dosage during the treatment with the rifampicin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>258-HALOTHANE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="HALOTHANE" rxcui="5095">
<ATC code="N01AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS" code="R03C-001" /></DRUG2>
<DESCRIPTION>In cases of obstetrical surgery, increased uterine inertia with risk of hemorrhage; furthermore serious ventricular arrhythmias, due to increase of the cardiac reactivity</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Interrupt treatment with the beta-2 mimetics if the anesthesia must be done with halothane</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>258-HALOTHANE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="HALOTHANE" rxcui="5095">
<ATC code="N01AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Serious ventricular arrhythmias due to increase of cardiac sensitization</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>259-HEPARINS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HEPARINS" code="B01AB" /></DRUG1>
<DRUG2>
<CLASS name="PLATELET AGGREGATION INHIBITORS" code="B01AC-001" /></DRUG2>
<DESCRIPTION>Increased risk of hemorrhage </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>259-HEPARINS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HEPARINS" code="B01AB" /></DRUG1>
<DRUG2>
<DRUG name="DEFIBROTIDE" rxcui="1311089">
<ATC code="B01AX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Accrued risk of hemorrhage</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>25-ALLOPURINOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALLOPURINOL" rxcui="519">
<ATC code="M04AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the allopurinol and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>25-ALLOPURINOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALLOPURINOL" rxcui="519">
<ATC code="M04AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIDANOSINE" rxcui="3364">
<ATC code="J05AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of didanosine and of its undesirable effects

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>25-ALLOPURINOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALLOPURINOL" rxcui="519">
<ATC code="M04AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="AMINOPENICILLINS" code="J01CA" /></DRUG2>
<DESCRIPTION>Increased risk of cutaneous reactions

</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>25-ALLOPURINOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALLOPURINOL" rxcui="519">
<ATC code="M04AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VIDARABINE" rxcui="11194">
<ATC code="S01AD06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of neurological disorders (trembling, confusion) due to partial inhibition of the metabolism of the antiviral</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>260-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)" code="B01AB-001" /></DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)</DESCRIPTION>
<SEVERITY>Not recommended with</SEVERITY>
<COMMENT>-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>260-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)" code="B01AB-001" /></DRUG1>
<DRUG2>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>If the administration of these together cannot be avoided, strengthen clinical monitoring and, if the situation requires, biological monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>260-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)" code="B01AB-001" /></DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering the substances together cannot be avoided, strict clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>260-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)" code="B01AB-001" /></DRUG1>
<DRUG2>
<DRUG name="DEXTRAN 40" rxcui="42635">
<ATC code="B05AA05" />
<ATC code="B03AC06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40)

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>260-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)" code="B01AB-001" /></DRUG1>
<DRUG2>
<CLASS name="THROMBOLYTICS" code="B01AD" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>261-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(PREVENTIVE-DOSES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)" code="B01AB-002" /></DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>The combination of medications acting at different levels of hemeostasis increases the risk of bleeding. Thus, with patients under 65 years of age, adding heparin or similar substances in preventive doses to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical and possibly biological monitoring.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>261-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(PREVENTIVE-DOSES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)" code="B01AB-002" /></DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>262-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)" code="B01AB-003" /></DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)</DESCRIPTION>
<SEVERITY>Not recommended with</SEVERITY>
<COMMENT>-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>262-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)" code="B01AB-003" /></DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering the substances together cannot be avoided, strict clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>262-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)" code="B01AB-003" /></DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>When the heparin alternates with the vitamin K antagonist, strengthen clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>262-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)" code="B01AB-003" /></DRUG1>
<DRUG2>
<DRUG name="DEXTRAN 40" rxcui="42635">
<ATC code="B05AA05" />
<ATC code="B03AC06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40) </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>262-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)" code="B01AB-003" /></DRUG1>
<DRUG2>
<CLASS name="THROMBOLYTICS" code="B01AD" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>263-UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)" code="B01AB-004" /></DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring. </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>263-UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)" code="B01AB-004" /></DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>264-THYROID-HORMONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Risk of clinically low thyroid in patients with hypothyroidism, due to increase of the metabolism of the T3 and of the T4

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of the serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with the inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>264-THYROID-HORMONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG1>
<DRUG2>
<DRUG name="CALCIUM" rxcui="1895">
<ATC code="A12AA" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of absorption of the thyroid hormones</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the calcium salts at a different time from the thyroid hormones (more than 2 hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>264-THYROID-HORMONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG1>
<DRUG2>
<DRUG name="CHLOROQUINE" rxcui="2393">
<ATC code="P01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of clinical hypothyroidism in patients taking thyroid hormones in substitution therapy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of the serum concentrations of T3 and T4 and adjustment of the dosage of the thyroid hormone, if needed, during the treatment with the antimalarial and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>264-THYROID-HORMONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG1>
<DRUG2>
<CLASS name="NON-CONTRACEPTIVE ESTROGENS" code="G03C-001" /></DRUG2>
<DESCRIPTION>Risk of clinical hypothyroidism in cases of estrogen substitution therapy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring; possible adjustment of the doses of the thyroid hormone for menopausal women taking estrogens.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>264-THYROID-HORMONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG1>
<DRUG2>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the thyroid hormones</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the thyroid hormones at a different time from the iron (more than 2 hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>264-THYROID-HORMONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG1>
<DRUG2>
<DRUG name="IMATINIB" rxcui="282388">
<ATC code="L01XE01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the thyroid hormones</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>264-THYROID-HORMONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the thyroid hormones due to the increase of their hepatic metabolism by the ritonavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring and possible adjustment of the dosage of the thyroid hormones.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>264-THYROID-HORMONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG1>
<DRUG2>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of disequilibrium of the thyroid replacement therapy in cases where there is treatment with orlistat</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>264-THYROID-HORMONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG1>
<DRUG2>
<DRUG name="PROGUANIL" rxcui="2382">
<ATC code="P01BB01" />
<ATC code="P01BB51" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of clinically low thyroid with patients having thyroid replacement therapy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of the serum concentrations of T3 and T4 and adjustment if needed of the dosage of the thyroid hormone during the treatment with the antimalarial and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>264-THYROID-HORMONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG1>
<DRUG2>
<CLASS name="CHELATING RESINS" code="C10-V0" /></DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the thyroid hormones</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the thyroid hormones at a different time from the resin (more than 2 hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>264-THYROID-HORMONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG1>
<DRUG2>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Described for phenytoin, rifampicin, and carbamazepine. [sic]

Risk of clinical hypothyroidism in patients with low thyroid, due to increase of the metabolism of the T3 and T4</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of the serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with rifabutin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>264-THYROID-HORMONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of clinically low thyroid in patients with already low thyroid due to increase of the metabolism of the T3 and the T4.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of serum concentrations of T3 and T4 and adjustment if needed of the dosage of the thyroid hormones during treatment with rifampicin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>264-THYROID-HORMONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG1>
<DRUG2>
<DRUG name="SUCRALFATE" rxcui="10156">
<ATC code="A02BX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the thyroid hormones</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the thyroid hormones at a different time from the sulcralfate (more than 2 hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>264-THYROID-HORMONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG1>
<DRUG2>
<DRUG name="SUNITINIB" rxcui="357977">
<ATC code="L01XE04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the thyroid hormones</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>265-MINERAL-OILS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MINERAL OILS" code="A06AA-" /><ATC code="D02AA" />
</DRUG1>
<DRUG2>
<DRUG name="LATEX CONDOMS" >
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of rupture of the condom when used with lubricants containing mineral oils (paraffin oil, silicone oil, etc...)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Use hydrosoluble lubricants (glycerin, polyacrylamide...).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>266-HYDROCORTISONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="HYDROCORTISONE" rxcui="5492">
<ATC code="A01AC03" />
<ATC code="A07EA02" />
<ATC code="D07XA01" />
<ATC code="H02AB09" />
<ATC code="S01BA02" />
<ATC code="S01CB03" />
<ATC code="S02BA01" />
<ATC code="D07AC16" />
<ATC code="D07CA01" />
<ATC code="S01CA03" />
<ATC code="S02CA03" />
<ATC code="S03CA04" />
<ATC code="D07BA04" />
<ATC code="S01BB01" />
<ATC code="D07AB11" />
<ATC code="D07AB02" />
<ATC code="D07BB04" />
<ATC code="R01AD60" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>267-HYDROQUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="HYDROQUINIDINE" rxcui="27220">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="URINARY ALKALIZERS" code="B05-001" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the hydroquinidine and risk of overdose (decrease of the renal excretion of the hydroquinidine due to alkalinizing of the urine )</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and, possibly testing of the concentrations of the hydroquinidine; if needed, adjustment of the dosage during the alkalinizing treatment and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>267-HYDROQUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="HYDROQUINIDINE" rxcui="27220">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction).</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG. In the case of unexpected results, test the digoxinemia and adjust the dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>267-HYDROQUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="HYDROQUINIDINE" rxcui="27220">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of tinnitis and/or loss of hearing acuity: cinchonism linked to a decrease of the hepatic metabolism of the antiarrythmic by the itraconazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of the plasma concentrations of the antiarrythmic and possible decrease of its dosage if necessary.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>268-HYDROXYCARBAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="HYDROXYCARBAMIDE " rxcui="5552">
<ATC code="L01XX05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG2>
<DESCRIPTION>When indicated for a patient with drepanocytosis (sickle cell anemia), theoretical risk of general fatal vaccine disease. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Administering these together should be considered only if the benefits are estimated to be greater than the this risk.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>269-HYDROXYCHLOROQUINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="HYDROXYCHLOROQUINE" rxcui="5521">
<ATC code="P01BA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the metoprolol used in heart failure: risk of increase of the undesirable effects of metoprolol due to decrease of its hepatic metabolism by the hydroxycloroquine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the hydroxychloroquine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>269-HYDROXYCHLOROQUINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="HYDROXYCHLOROQUINE" rxcui="5521">
<ATC code="P01BA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the therapeutic effect of the hydroxychloroquine, due to increase of its metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the hydroxychloroquine during the treatment with rifampicin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>269-HYDROXYCHLOROQUINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="HYDROXYCHLOROQUINE" rxcui="5521">
<ATC code="P01BA02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes </DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with the citalopram, the domperidone, the escitalopram, the hydroxyzine and the piperaquine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>26-ALPHA-BLOCKERS-FOR-UROLOGICAL-USE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ALPHA BLOCKERS FOR UROLOGICAL USE" code="G04CA-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTIHYPERTENSIVE ALPHA BLOCKERS" code="C02CA0-001" /></DRUG2>
<DESCRIPTION>Increase of the hypotensive effect. Risk of severe orthostatic hypotension. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>26-ALPHA-BLOCKERS-FOR-UROLOGICAL-USE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ALPHA BLOCKERS FOR UROLOGICAL USE" code="G04CA-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS" code="C0-001" /></DRUG2>
<DESCRIPTION>Increase of the hypotensive effect. Increased risk of orthostatic hypotension </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>26-ALPHA-BLOCKERS-FOR-UROLOGICAL-USE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ALPHA BLOCKERS FOR UROLOGICAL USE" code="G04CA-001" /></DRUG1>
<DRUG2>
<CLASS name="TYPE 5 PHOSPHODIESTERASE INHIBITORS" code="G04BE" /></DRUG2>
<DESCRIPTION>Risk of orthostatic hypotension, especially in older patients

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-with doxazosin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>270-HYPERKALEMIA-INDUCING-MEDICATIONS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HYPERKALEMIA INDUCING MEDICATIONS" code="M01A-001" /></DRUG1>
<DRUG2>
<CLASS name="OTHER HYPERKALEMIA INDUCING MEDICATIONS" code="M01A-001" /></DRUG2>
<DESCRIPTION>Risk of increase of hyperkalemia, potentially lethal. </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>271-HYPNOTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HYPNOTICS" code="N05-R06" /></DRUG1>
<DRUG2>
<CLASS name="OTHER HYPNOTICS" code="N05-R06" /></DRUG2>
<DESCRIPTION>Increase of central nervous system depression</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>272-POTASSIUM-LOWERING-MEDICATIONS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="POTASSIUM LOWERING AGENTS" code="C03-001" /></DRUG1>
<DRUG2>
<CLASS name="OTHER POTASSIUM LOWERING AGENTS" code="C03-001" /></DRUG2>
<DESCRIPTION>Increased risk of hypokalemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of kalemia with correction if needed.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>272-POTASSIUM-LOWERING-MEDICATIONS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="POTASSIUM LOWERING AGENTS" code="C03-001" /></DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Hypokaliemia that promotes the toxic effects of the digitalics.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Correct beforehand any hypokaliemia and maintain clinical monitoring, electrolite monitoring, and electrocardiographic monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>272-POTASSIUM-LOWERING-MEDICATIONS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="POTASSIUM LOWERING AGENTS" code="C03-001" /></DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Correct any hypokalemia before administering the product and maintain clinical monitoring, electrolyte monitoring and electrocardiographic monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>273-HYPONATREMIA-INDUCING-MEDICATIONS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HYPONATREMIA INDUCING MEDICATIONS" code="C03EA" /></DRUG1>
<DRUG2>
<CLASS name="OTHER HYPONATREMIA INDUCING MEDICATIONS" code="C03EA" /></DRUG2>
<DESCRIPTION>Increase of the risk of hyponatremia</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>274-IBRUTINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IBRUTINIB" rxcui="1442981">
<ATC code="L01XE27" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the amiodarone</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg per day during the length of time these medications are administered together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>274-IBRUTINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IBRUTINIB" rxcui="1442981">
<ATC code="L01XE27" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the diltiazem</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg/day during the length of time these medications are administered together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>274-IBRUTINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IBRUTINIB" rxcui="1442981">
<ATC code="L01XE27" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of irutinib due to decrease of its hepatic metabolism by the verapamil</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring and reduction of the dose of ibrutinib to 140mg per day during the length of time these medications are administered together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>275-IDELALISIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IDELALISIB" rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="CALCIUM CHANNEL BLOCKERS " code="CO8CA-001" /></DRUG2>
<DESCRIPTION>Increase of the undesirable effects of the calcium channel blocker, of the orthostatic hypotension sort, especially with older patients</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the calcium channel blocker during the treatment with idelalisib and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>275-IDELALISIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IDELALISIB" rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the anticonvulsant enzymatic inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>275-IDELALISIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IDELALISIB" rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of idelalisib due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>275-IDELALISIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IDELALISIB" rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>275-IDELALISIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IDELALISIB" rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the inducer.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>275-IDELALISIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IDELALISIB" rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SUBSTRATES AT RISK OF CYP3A4" code="L01N01" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the substrate due to decrease of its hepatic metabolism by the idelalisib.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>276-IFOSFAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IFOSFAMIDE" rxcui="5657">
<ATC code="L01AA06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the neurotoxicity of the ifosfamide</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>276-IFOSFAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IFOSFAMIDE" rxcui="5657">
<ATC code="L01AA06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG2>
<DESCRIPTION>Risk of increase of the neurotoxicity of the ifosfamide due to increase of its hepatic metabolism by the phenobarbital</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>276-IFOSFAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IFOSFAMIDE" rxcui="5657">
<ATC code="L01AA06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VEMURAFENIB" rxcui="1147220">
<ATC code="L01XE15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the ifosfamide, with increase of its active metabolite and increased toxicity</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG1>
<DRUG2>
<DRUG name="ALCOHOL (DRINK OR INGREDIENT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hypertensive and/or hyperthermic effects of the tyramine present in certain alcoholic drinks (chianti, certain beers, etc.)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Avoid taking alcoholic beverages and medications containing alcohol. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG1>
<DRUG2>
<CLASS name="ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)" code="A01AD" /></DRUG2>
<DESCRIPTION>Serious ventricular arrhythmias due to increased cardiac sensitization.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Limit the amount, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG1>
<DRUG2>
<DRUG name="DEXTROMETHORPHAN" rxcui="3289">
<ATC code="N07XX59" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG1>
<DRUG2>
<DRUG name="GUANETHIDINE" rxcui="5036">
<ATC code="C02CC02" />
<ATC code="S01EX01" />
<ATC code="C02LF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the guanethidine used by IV route: risk of unforeseeable vascular reactions, especially hypotension</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
<COMMENT>Interrupt the treatment with the MAOI two weeks before the treatment with guanethidine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG1>
<DRUG2>
<CLASS name="CATECHOL-O-METHYLTRANSFERASE INHIBITORS (COMT) " code="COMT" /></DRUG2>
<DESCRIPTION>Increase of the pharmacological effects, and especially increase in blood pressure and contraction of the blood vessels by the catecholamines due to the combined inhibition of their metabolism</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG1>
<DRUG2>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)" code="N06AB" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Wait two weeks between the discontinuation of the MAOI and the start of the treatment with the SSRI, and at least a week between the end of treatment with the SSRI (except fluoxetine: five weeks) and the start [sic]. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG1>
<DRUG2>
<CLASS name="MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS" code="N06A" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
<COMMENT>Wait two weeks between stopping the MAOI and the start of the other treatment, and at least a week between the end of that treatment and the start of the MAOI.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG1>
<DRUG2>
<DRUG name="MIDODRINE" rxcui="6963">
<ATC code="C01CA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Hypertensive crises (inhibition of the metabolism of the pressor amines). Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI is stopped.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG1>
<DRUG2>
<DRUG name="PETHIDINE " rxcui="6754">
<ATC code="N02AB02" />
<ATC code="N02AG03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG1>
<DRUG2>
<DRUG name="RESERPINE" rxcui="9260">
<ATC code="C02AA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Psychomotor agitation, convulsions, hypertension</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG1>
<DRUG2>
<CLASS name="ALPHA SYMPATHOMIMETICS (ORAL AND/OR NASAL ROUTES)" code="R01AA" /></DRUG2>
<DESCRIPTION>Hypertensive crises (inhibition of the metabolism of the pressor amines). Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI is stopped</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG1>
<DRUG2>
<CLASS name="ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)" code="C01CA" /></DRUG2>
<DESCRIPTION>Increase of the pressor action of the sympathomimetic, most often moderate.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Only use under strict medical monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG1>
<DRUG2>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG2>
<DESCRIPTION>Paroxysmal hypertension, hyperthermia that can be fatal. Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI has been stopped</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG1>
<DRUG2>
<DRUG name="TETRABENAZINE" rxcui="10390">
<ATC code="N07XX06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypertensive crises. Because of the duration of the action of the MAOI, this interaction is still theoretically possible two weeks after the MAOI is stopped</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG1>
<DRUG2>
<DRUG name="TIANEPTINE" rxcui="38252">
<ATC code="N06AX14" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of drop in blood pressure, paroxysmal hypertension, hyperthermia, convulsions, death</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG1>
<DRUG2>
<DRUG name="TRAMADOL" rxcui="10689">
<ATC code="N02AX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome: diarrhea, sweats, trembling, confusion, even coma</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG1>
<DRUG2>
<CLASS name="TRIPTANS METABOLIZED BY THE MAO" code="N02CC-002" /></DRUG2>
<DESCRIPTION>Risk of arterial hypertension, of constriction of the coronary arteries </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG1>
<DRUG2>
<CLASS name="TRIPTANS NOT METABOLIZED BY THE MAO" code="NO2CC-003" /></DRUG2>
<DESCRIPTION>Risk of arterial hypertension, of constriction of the coronary arteries </DESCRIPTION>
<SEVERITY>Not recommended </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG1>
<DRUG2>
<DRUG name="DEXTROMETHORPHAN" rxcui="3289">
<ATC code="R05DA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of appearance of serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma</DESCRIPTION>
<SEVERITY>Not Recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG1>
<DRUG2>
<CLASS name="MAOI-B " code="N04BD0-001" /></DRUG2>
<DESCRIPTION>Risk of rapid elevation of blood pressure, due to loss of selectivity on the monoamine oxydase, especially in case of eating food rich in tyramine (cheese, beer, ...)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG1>
<DRUG2>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)" code="N06AB" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these substances together cannot be avoided, very strict clinical monitoring. Begin the administration at minimum recommended dosages.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG1>
<DRUG2>
<CLASS name="MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS" code="N06A" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, confusion, even coma</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these substances together cannot be avoided, very strict clinical monitoring. Begin the administration of the substances together with minimum recommended dosages. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG1>
<DRUG2>
<DRUG name="ST JOHN'S WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG1>
<DRUG2>
<DRUG name="PETHIDINE " rxcui="6754">
<ATC code="N02AB02" />
<ATC code="N02AG03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG1>
<DRUG2>
<CLASS name="ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)" code="C01CA" /></DRUG2>
<DESCRIPTION>By extrapolation from the non selective MAOIs: risk of increase of the pressor action.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>To be used only under strict medical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG1>
<DRUG2>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or rapid elevation of blood pressure</DESCRIPTION>
<SEVERITY>Contraindication:</SEVERITY>
<COMMENT>with the bupropion</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG1>
<DRUG2>
<DRUG name="TRAMADOL" rxcui="10689">
<ATC code="N02AX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome: diarrhea, sweats, trembling, confusion, even coma</DESCRIPTION>
<SEVERITY>Not Recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG1>
<DRUG2>
<CLASS name="TRIPTANS METABOLIZED BY THE MAO" code="N02CC-002" /></DRUG2>
<DESCRIPTION>Risk of arterial hypertension, of constriction of coronary arteries</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG1>
<DRUG2>
<CLASS name="TRIPTANS NOT METABOLIZED BY THE MAO" code="NO2CC-003" /></DRUG2>
<DESCRIPTION>Risk of arterial hypertension, of constriction of coronary arteries</DESCRIPTION>
<SEVERITY>Not Recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>279-MAOI-B.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MAOI-B " code="N04BD0-001" /></DRUG1>
<DRUG2>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypertensive crises</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>279-MAOI-B.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MAOI-B " code="N04BD0-001" /></DRUG1>
<DRUG2>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG2>
<DESCRIPTION>Risk of rapid elevation of blood pressure, due to loss of selectivity on the monamine oydase, especially in case of consuming food rich in tyramine (cheese, beer,)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>279-MAOI-B.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MAOI-B " code="N04BD0-001" /></DRUG1>
<DRUG2>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)" code="N06AB" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>279-MAOI-B.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MAOI-B " code="N04BD0-001" /></DRUG1>
<DRUG2>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
<ATC code="N04BA02" />
<ATC code="N04BA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of orthostatic hypotension</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>279-MAOI-B.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MAOI-B " code="N04BD0-001" /></DRUG1>
<DRUG2>
<DRUG name="PETHIDINE " rxcui="6754">
<ATC code="N02AB02" />
<ATC code="N02AG03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Symptoms of central nervous system excitability, evoking a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>279-MAOI-B.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MAOI-B " code="N04BD0-001" /></DRUG1>
<DRUG2>
<DRUG name="TRAMADOL" rxcui="10689">
<ATC code="N02AX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>279-MAOI-B.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MAOI-B " code="N04BD0-001" /></DRUG1>
<DRUG2>
<CLASS name="TRIPTANS METABOLIZED BY THE MAO" code="N02CC-002" /></DRUG2>
<DESCRIPTION>Risk of arterial hypertension, of constriction of the coronary arteries</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>279-MAOI-B.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MAOI-B " code="N04BD0-001" /></DRUG1>
<DRUG2>
<CLASS name="TRIPTANS NOT METABOLIZED BY THE MAO" code="NO2CC-003" /></DRUG2>
<DESCRIPTION>Risk of arterial hypertension, of constriction of the coronary arteries</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>27-ALPHA-TOCOPHEROL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALPHA-TOCOPHEROL" rxcui="11256">
<ATC code="A11HA03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>With the vitamin E used in doses greater than or equal to 500 mg per day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with vitamin E and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>280-IMATINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IMATINIB" rxcui="282388">
<ATC code="L01XE01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these together cannot be avoided, strict clinical monitorinig and frequent testing of the INR</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>280-IMATINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IMATINIB" rxcui="282388">
<ATC code="L01XE01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the thyroid hormones</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant (especially for the ciclosporin, extremely large for the tacrolimus)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage of the immunosuppressant during the administration of the medications together and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these must be administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<CLASS name="CYTOTOXICS" code="L01" /></DRUG2>
<DESCRIPTION>Excessive immunodepression with risk of lymphoproliferative syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="DALFOPRISTIN" rxcui="229369">
<ATC code="J01FG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the treatment with these medications together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the treatment with these medications together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the blood concentrations of the immunosuppressant due to the inhibition of its metabolism and of the creatinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<CLASS name="ANTI-LYMPHOCYTE GLOBULINS" code="L04AA0-001" /></DRUG2>
<DESCRIPTION>Excessive immunodepression with risk of lymphoproliferative disorders (LPDs)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the blood concentrations and of the effectiveness of the immunosuppressant, due to increase of its hepatic metabolism by the inducer

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increase the dosage of the immunosuppressant according to tests of the blood concentrations. Reduce the dosage after the inducer is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and adjustment of its dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and possible adjustment of the dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and possible adjustment of the dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the blood concentrations of the immunosuppressant, due to the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect which can have possibly serious consequences (rejection of a graft).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="NICARDIPINE" rxcui="7396">
<ATC code="C08CA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to inhibition of its metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage of the immunosuppressant during the treatment and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT (JUICE AND FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the bioavailability of the immunosuppressant and as a result of its undesirable effects. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these substances are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="PRISTINAMYCIN" rxcui="66958">
<ATC code="J01FG01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of its dosage during the administration of the medications together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="QUINUPRISTINE" rxcui="135098">
<ATC code="J01FG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the two substances together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="RANOLAZINE" rxcui="35829">
<ATC code="C01EB18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to inhibition of its metabolism by the ranolazine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring and possible adjustment of the dosage of the immunosuppressant.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant (decrease of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the telaprevir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of its dosage during the administration of the substances together and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these substances are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG2>
<DESCRIPTION>Risk of general vaccinal disease, possibly fatal. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>And during the 3 months following the treatment. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="VEMURAFENIB" rxcui="1147220">
<ATC code="L01XE15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the immunosuppressants, with the consequence of a risk of ineffectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>281-IMMUNOSUPPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the voriconazole

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-with the everolimus, the sirolimus, and the temsirolimus</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-INDINAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="INDINAVIR" rxcui="114289">
<ATC code="J05AE02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the indinavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>282-INDINAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="INDINAVIR" rxcui="114289">
<ATC code="J05AE02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NEVIRAPINE" rxcui="53654">
<ATC code="J05AG01" />
<ATC code="J05AR07" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the indinavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<CLASS name="ANDROGENS" code="A14AA0" /></DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the androgen and as a result of its effectiveness, due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring during the administrations of these substances together and 1 to 2 weeks after the inducer is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="ARIPIPRAZOLE" rxcui="89013">
<ATC code="N05AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the aripiprazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the aripiprazole during the administration of these substances together and 1 to 2 weeks after the inducer is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="BEDAQUILINE" rxcui="1364504">
<ATC code="J04AK05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="BORTEZOMIB" rxcui="358258">
<ATC code="L01XX32" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="CABAZITAXEL" rxcui="996051">
<ATC code="L01CD04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HA01" />
<ATC code="G03HB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cyproterone</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>--in its use as a hormonal contraceptive: use instead another method of contraception in particular a barrier type, during the length of the time these substances are administered together and a cycle after</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="DACLATASVIR" rxcui="1606218">
<ATC code="J05AX14" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>-with the rifampicin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="DASABUVIR" rxcui="1597381">
<ATC code="J05AX16" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the dasabuvir by the inducer.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="DISOPYRAMIDE" rxcui="3541">
<ATC code="C01BA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the disopyramide by the inducer</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly adjustment of the dosage of the disopyramide during the administration of these substances together and 1 to 2 weeks after the inducer is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="DOCETAXEL" rxcui="72962">
<ATC code="L01CD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="DOLUTEGRAVIR" rxcui="1433868">
<ATC code="J05AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-in case of resistance to the class of integrase inhibitors</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="ERIBULINE" rxcui="1045453">
<ATC code="L01XX41" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of eribuline by the inducer.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>Decrease of the contraceptive effectiveness, due to increase of the hepatic metabolism of the hormonal contraceptive by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another method of contraception, in particular a barrier type, should be used during the treatment with these substances together and a cycle following. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="HYDROCORTISONE" rxcui="5492">
<ATC code="A01AC03" />
<ATC code="A07EA02" />
<ATC code="C05AA01" />
<ATC code="D07AA02" />
<ATC code="D07XA01" />
<ATC code="H02AB09" />
<ATC code="S01BA02" />
<ATC code="S01CB03" />
<ATC code="S02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Decrease of the blood concentrations and of the effectiveness of the immunosuppressant, due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increase the dosage of the immunosuppressant according to tests of the blood concentrations. Reduce the dosage after the inducer is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="IRINOTECAN" rxcui="51499">
<ATC code="L01XX19" />
</DRUG>
</DRUG2>
<DESCRIPTION>Probable decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="ISAVUCONAZOLE" rxcui="1720882">
<ATC code="J02AC05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of isavuconazole due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="IVACAFTOR" rxcui="1243041">
<ATC code="R07AX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the concentrations of the ivacaftor, with risk of loss of effectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="LURASIDONE" rxcui="1040028">
<ATC code="N05AE05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the lurasidone due to increase of its hepatic metabolism by the inducer.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="MACITENTAN" rxcui="1442132">
<ATC code="C02KX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of macitentan due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="MARAVIROC" rxcui="620216">
<ATC code="J05AX09" />
</DRUG>
</DRUG2>
<DESCRIPTION>In the absence of co-administration with a strong inhibitor of CYP3A4, decrease of the concentrations of maraviroc by the inducer.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>The dose of maraviroc must be increased to 600mg twice a day in this situation. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N07BC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increase the frequency of the doses of methadone (2 to 3 times a day instead of a single dose per day).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="MIANSERIN" rxcui="6929">
<ATC code="N06AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of ineffectiveness of the mianserin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="OLAPARIB" rxcui="1597582">
<ATC code="L01XX46" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease, possibly very large depending on the inducer, of the plasma concentrations of the olaparib due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPREVIR" code="OMPA" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the bitherapy due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="OXYCODONE" rxcui="7804">
<ATC code="N02AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the oxycodone due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Possible adjustment of the dosage of oxycodone</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG2>
<DESCRIPTION>Decrease of the contraceptive effectiveness of the hormonal contraceptive, due to increase of its hepatic metabolism by the inducer. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another method of contraception, in particular a barrier type, should be used during the length of time that these substances are administered together and one cycle following.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<CLASS name="NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT" code="G03-003" /></DRUG2>
<DESCRIPTION>Decrease of the effectiveness of the progestogen</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="REGORAFENIB" rxcui="1312397">
<ATC code="L01XE21" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of regorafenib due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="RILPIVIRINE" rxcui="1102270">
<ATC code="J05AG05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Significant decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="SERTRALINE" rxcui="36437">
<ATC code="N06AB06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of ineffectiveness of the treatment by the antidepressant </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="SIMEPREVIR" rxcui="1482790">
<ATC code="J05AE14" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="SOFOSBUVIR" rxcui="1484911">
<ATC code="J05AX15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the inducer.</DESCRIPTION>
<SEVERITY>Contraindication </SEVERITY>
<COMMENT>--wth the rifampicin </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="TENEFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the tenofovir alafenamide due to decrease of its absorption by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administration of these together cannot be avoided, clinical monitoring during the administration and 1 to 2 weeks after the inducer is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="VEMURAFENIB" rxcui="1147220">
<ATC code="L01XE15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the vermurafenib, with lower effectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="VISMODEGIB" rxcui="1242987">
<ATC code="L01XX43" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of vismodegib due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>283-ENZYMATIC-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG1>
<DRUG2>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the vortioxetine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the administration with the inducer and 1 to 2 weeks after the inducer is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>284-CATECHOL-O-METHYLTRANSFERASE-INHIBITORS-(COMT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CATECHOL-O-METHYLTRANSFERASE INHIBITORS (COMT) " code="COMT" /></DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>Increase of the pharmacological effects, and especially increase in blood pressure and contraction of the blood vessels, by the catecholamines due to the combined inhibition of their metabolism</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>285-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TYPE 5 PHOSPHODIESTERASE INHIBITORS" code="G04BE" /></DRUG1>
<DRUG2>
<CLASS name="ALPHA BLOCKERS FOR UROLOGICAL USE" code="G04CA-001" /></DRUG2>
<DESCRIPTION>Risk of orthostatic hypotension, especially with older patients

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-with the doxazosin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>285-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TYPE 5 PHOSPHODIESTERASE INHIBITORS" code="G04BE" /></DRUG1>
<DRUG2>
<CLASS name="ANTIHYPERTENSIVE ALPHA BLOCKERS" code="C02CA0-001" /></DRUG2>
<DESCRIPTION>Risk of orthostatic hypotension, especially with older patients</DESCRIPTION>
<SEVERITY>Not recommended </SEVERITY>
<COMMENT>-with the doxazosine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>285-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TYPE 5 PHOSPHODIESTERASE INHIBITORS" code="G04BE" /></DRUG1>
<DRUG2>
<CLASS name="NITRATE DERIVATIVES AND RELATED" code="C01D-001" /></DRUG2>
<DESCRIPTION>Risk of significant hypotension (synergic effect) capable of aggravating the state of myocardial ischemia and provoking an acute cardiac accident</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>285-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TYPE 5 PHOSPHODIESTERASE INHIBITORS" code="G04BE" /></DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase (very large for the avanafil and the vardenafil) of the plasma concentrations of the type 5 phosphodiesterase inhibitor, with risk of hypotension (severe with the vardenafil)</DESCRIPTION>
<SEVERITY>To know the risks and the levels of constraint for each Type 5 phosphodiesterase inhibitor with the strong inhibitors of CYP3A4, consult the AMM ["Authorisation de la mise au march", a French document for all medications authorized to be marketed in France with information about them] specific for each one of them.</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>285-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TYPE 5 PHOSPHODIESTERASE INHIBITORS" code="G04BE" /></DRUG1>
<DRUG2>
<DRUG name="RIOCIGUAT" rxcui="1439816">
<ATC code="C02KX05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large drop in blood pressure (synergic effect)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>286-XANTHINE-OXYDASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="XANTHINE OXYDASE INHIBITORS" code="M04AA0" /></DRUG1>
<DRUG2>
<CLASS name="ANTIPURINES" code="ANTIPUR" /></DRUG2>
<DESCRIPTION>Possibly serious medullary insufficiency</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>286-XANTHINE-OXYDASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="XANTHINE OXYDASE INHIBITORS" code="M04AA0" /></DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>With large doses of the inhibitor, increase of the plasma concentrations of theophylline due to inhibition of its metabolism. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and testing of the theohyllinemia up to two to three weeks after the beginning of the treatment with the inhibitor; if there is reason for it, adjustment of the dosage during the treatment with these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>For anti-inflammatory doses of acetylsalicylic acid (&gt;=1gr per dose and/or &gt;=3gr per day) or for analgesic or antipyretic doses (&gt;=500 mg per dose and/or &lt;3 gr per day):

Acute renal insufficiency in dehydrated patients due to decreased glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Hydrate the patient and monitor renal function at the beginning of treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG1>
<DRUG2>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09XA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hyperkalemia, of renal insufficiency, of increase of mortality from cardiovascular disease</DESCRIPTION>
<SEVERITY>Contraindication:</SEVERITY>
<COMMENT>-for patients with diabetes or renal insufficiency</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG2>
<DESCRIPTION>In situations where the administration of these medications together is possible, increased risk of degradation of renal function, even acute renal insufficiency, and increase of the hyperkalemia as well as hypotension and fainting or loss of consciousness. </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Acute renal insufficiency with patients at risk (older patients, dehydrated ones, those taking diuretics, those having altered renal function) due to decrease of the glomerular filtration (inhibition of the vasodilating prostaglandins due to the NSAIs). These effects are generally reversible. Furthermore, reduction of the antihypertensive effect.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Hydrate the patient and monitor renal function at the beginning of treatment and regularly during the administration of these substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG1>
<DRUG2>
<CLASS name="POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)" code="C0E-004" /></DRUG2>
<DESCRIPTION>Risk of hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia producing effects)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>--if the administration of these medications together is justified, strict testing of the kalemia and of the renal function.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG1>
<DRUG2>
<CLASS name="POTASSIUM LOWERING DIURETICS" code="C03" /></DRUG2>
<DESCRIPTION>Risk of abrupt arterial hypotension and/or acute renal insufficiency at the start of or when there is an increase of the dosage of the treatment with the ACE inhibitor in cases of pre-existing fluid depletion </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In arterial hypertension, when there is fluid depletion from a previous treatment with a diuretic, it is necessary:</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG1>
<DRUG2>
<DRUG name="EPLERENONE" rxcui="298869">
<ATC code="C03DA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hyperkalemia, especially with older patients.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict testing of the kalemia and of renal function during the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG1>
<DRUG2>
<DRUG name="ESTRAMUSTINE" rxcui="4089">
<ATC code="L01XX11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the angioneurotic edema type (angioedema) </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG1>
<DRUG2>
<DRUG name="EVEROLIMUS" rxcui="141704">
<ATC code="L04AA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of angioedema</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG1>
<DRUG2>
<CLASS name="GLIPTINS" code="A10B-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of the onset of angioedema, due to reduction of the activity of the enzyme dipetidyl peptidase-4 (DDP-4) by the gliptin, in patients treated with the ACE inhibitor</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG1>
<DRUG2>
<DRUG name="INSULIN" rxcui="631657">
<ATC code="A10AC01" />
<ATC code="A10AC02" />
<ATC code="A10AC03" />
<ATC code="A10AC04" />
<ATC code="A10AD01" />
<ATC code="A10AD02" />
<ATC code="A10AD03" />
<ATC code="A10AD04" />
<ATC code="A10AD05" />
<ATC code="A10AE01" />
<ATC code="A10AE02" />
<ATC code="A10AE03" />
<ATC code="A10AE04" />
<ATC code="A10AE05" />
<ATC code="A10AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforce self-monitoring of blood glucose</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of lithium which can reach toxic values (decrease of the renal excretion of the lithium)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the use of an ACE inhibitor is indispensable, strict monitoring of the plasma concentrations of lithium and adjustment of the dosage of the lithium. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG1>
<DRUG2>
<DRUG name="GOLD" rxcui="1311190">
<ATC code="V10AX06" />
<ATC code="M01CB01" />
<ATC code="M01CB02" />
<ATC code="M01CB03" />
<ATC code="M01CB04" />
<ATC code="M01CB05" />
<ATC code="V10AX06" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the gold salts administered by IV route: risk of nitritoid reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly a drop in blood pressure)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG1>
<DRUG2>
<DRUG name="POTASSIUM" rxcui="8588">
<ATC code="A12BA" />
</DRUG>
</DRUG2>
<DESCRIPTION>Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Unless there is hypokalemia.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG1>
<DRUG2>
<DRUG name="RACECADOTRIL" rxcui="16738">
<ATC code="A07XA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the angioedema type. </DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--in case of preceding angioedema with ACE inhibitors</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG1>
<DRUG2>
<DRUG name="SACUBITRIL" rxcui="1656328">
<ATC code="C09DX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of angiodema</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG1>
<DRUG2>
<DRUG name="SPIRONOLACTONE" rxcui="9997">
<ATC code="C03DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the spironolactone at dosages from 12.5 to 50 mg per day, and with low doses of ACE inhibitors

In the treatment of class III or IV heart failure (NYHA) with an ejection fraction &lt;35% and previous treatment with an ACE inhibitor + a loop diuretic: risk of hyperkalemia, potentially lethal, in case of failure to follow the prescribed doses for this combination of medications.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Verify the absence of pre-existing hyperkalemia and renal insufficiency. Strict biological monitoring of the kalemia and of the creatinemia (1 time per week during the first month, then one time per month thereafter). </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG1>
<DRUG2>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG2>
<DESCRIPTION>The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in diabetic patients treated with glucose lowering sulfonamides. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for the glucose lowering sulfonamides)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforce self-monitoring of blood glucose.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS) " code="C10AA" /></DRUG1>
<DRUG2>
<DRUG name="FUSIDIC ACID" rxcui="4608">
<ATC code="D06AX01" />
<ATC code="D09AA02" />
<ATC code="J01XC01" />
<ATC code="S01AA13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Stop the treatment with the HMG Co-A reductase inhibitor before starting a treatment with fusidic acid or use another antibiotic</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS) " code="C10AA" /></DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR Possible adjustment of the dosage of the vitamin K antagonist</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS) " code="C10AA" /></DRUG1>
<DRUG2>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolysis</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring, especially at the beginning of the administration of these substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS) " code="C10AA" /></DRUG1>
<DRUG2>
<DRUG name="DAPTOMYCIN" rxcui="22299">
<ATC code="J01XX09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of addition of the undesirable effects (dose dependent) of the rhabdomyolysis type.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of these medications together cannot be avoided, reinforce biological monitoring (dosage of the CPK more than once a week) and strict clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS) " code="C10AA" /></DRUG1>
<DRUG2>
<DRUG name="ELTROMBOPAG" rxcui="711942">
<ATC code="B02BX05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the statins, due to inhibition of their hepatic recapture</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the statin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS) " code="C10AA" /></DRUG1>
<DRUG2>
<CLASS name="FIBRATES" code="C01AB-001" /></DRUG2>
<DESCRIPTION>Risk of addition of undesirable effects (dose-dependent) of the rhabdomyolosis type. Furthermore, with the gemfibrozil, decrease of the metabolism of the simvastatin and of the rosuvastatin, which increases the muscular risk, as well as the nephrotoxicity of the rosuvastatin</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with the gemfibrosil and the simvastatin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS) " code="C10AA" /></DRUG1>
<DRUG2>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of the statin and of its undesirable effects of the rhabdomyolosis type.</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with the rosuvastatin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS) " code="C10AA" /></DRUG1>
<DRUG2>
<DRUG name="LENALIDOMIDE" rxcui="342369">
<ATC code="L04AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of the onset of rhabdomyolysis</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforce clinical and biological monitoring, especially during the first weeks of treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of afatinib due to increase of its absorption by the protease inhibitor</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommended that that the protease inhibitor be administered as far from the afatinib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="ALBENDAZOLE" rxcui="430">
<ATC code="P02CA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the ritonavir, with risk of reduction of its effectiveness.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG2>
<DESCRIPTION>Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the protease inhibitor due to increase of its hepatic metabolism by the inducer

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Variation of the effect of the vitamin K antagonist, most often by decreasing it</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the length of the treatment</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Use weaker doses of atorvastatin. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="ATOVAQUONE" rxcui="60212">
<ATC code="P01AX06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease, possibly very large, of the plasma concentrations of the atovaquone due to increase of its metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<CLASS name="OTHER CORTICOIDES, ESPECIALLY INHALED ONES" code="D07AC-001" /></DRUG2>
<DESCRIPTION>In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome, even of adrenal insufficiency </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of the boceprevir and of the lopinavir (or darunavir or fosamprenavir), with risk of therapeutic failure </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="BUPRENORPHINE" rxcui="1819">
<ATC code="N02AE01" />
<ATC code="N07BC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of the clarithromycin and of its active metabolite due to decrease of its hepatic metabolism by the protease inhibitor</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of treatment with these medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cyyproterone.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>--in its use as a hormonal contraceptive: use instead another method ofcontraception in particular a barrier type, during the administration of these substances together and a cycle following</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia, more marked for intravenous route, due to increase of the absorption of the digoxin or decrease of its renal clearance.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and, if there is reason for them, EKG and monitoring of the digoxinemia, with possible adjustment of the dosage of digoxin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="ERIBULINE" rxcui="1045453">
<ATC code="L01XX41" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of eribuline by the ritonavir</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of the hormonal contraceptive, because of the increase of its hepatic metabolism by the ritonavir.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another method of contraception, in particular a barrier type (condom or IUD), should be used during the length of the treatment with these medications together and a cycle following. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the thyroid hormones due to increase of their hepatic metabolism by the ritonavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring and possible adjustment of the dosage of the thyroid hormones.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and adjustment of its dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentration of the ritonavir boosted protease inhibitor or of the CYP3A4 inhibitor.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>To know the risks and levels of severity of each ritonavir boosted protease inhibitor taken with the strong inhibitors of CYP3A4, consult the specificauthorization for sale to the public ("Authorisation de la Mise sur le Marche" a French document) for each one of them. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the concentrations of itraconazole by the protease inhibitor</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these together. Administering large doses of itraconazole (>200 mg per day) is not recommended.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="LAMOTRIGINE" rxcui="28439">
<ATC code="N03AX09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism by the ritonavir</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT> -Avoid beginning the treatment with ritonavir during the period of adjustment of the dosage of lamotrigine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="LUMEFANTRINE" rxcui="847728">
<ATC code="P01BF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N07BC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the ritonavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring and possible adjustment of the dosage of methadone. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the protease inhibitor, due to the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (reduction of the antiretroviral effectiveness)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>In the case of the substances being taken together by accident, do not stop the St Johns wort abruptly, but test the plasma concentrations (or the effectiveness) of the protease inhibitor before and then after the St Johns wort is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="MIZOLASTINE" rxcui="61455">
<ATC code="R06AX25" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="L01XE31" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of nintedanib due to increase of its absorption by the ritonavir boosted protease inhibitor</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the contraceptive effectiveness because of decrease of the concentrations of hormonal contraceptive, due to the increase of its hepatic metabolism by the ritonavir</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another method of contraception, in particular a barrier type (condom or IUD), should be used during the time the substances are administered together and one cycle following. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the protease inhibitor (even more so when the dosage of the rifabutin is large) for one thing, and risk of increase of the undesirable effects (uveitis) of the rifabutin, for another thing.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of the protease inhibitor, due to increase of its hepatic metabolism by the rifampicin.

For the combination (saquinavir + ritonavir):

risk of severe hepatocellular toxicity</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Until additional information about the ritonavir "boosted" protease inhibitors is available.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="ROSUVASTATIN" rxcui="301542">
<ATC code="C10AA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the rosuvastatin due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolisis type (decrease of the hepatic metoblism of the simvastatin).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of the telaprevir and of the darunavir or of the fosamprenavir, with risk of therapeutic failure.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="TENEFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG2>
<DESCRIPTION>With the atazanavir, the darunavir or the lopinavir, increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In case of administration of these together, the dose of tenofovir alafenamide must be limited to 10 mg per day. The administration with the other protease inhibitors of HIV has not been studied.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the theophylline, due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the protease inhibitor and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03XB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the ritonavir</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Choose a therapeutic alternative that is little or not at all metabolized.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="VENLAFAXINE" rxcui="39786">
<ATC code="N06AX16" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of venlafaxine with risk of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<CLASS name="VINCA ALKALOIDS" code="L01CA" /></DRUG2>
<DESCRIPTION>Increase of the toxicity of the antimitotic, due to decrease of its hepatic metabolism by the protease inhibitor. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring and possible adjustment of the dosage of the antimitotic. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large reduction of the concentrations of the antifungal due to increase of its metabolism by the ritonavir, with risk of failure of the treatment</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>28-ALPRAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALPRAZOLAM" rxcui="596">
<ATC code="N05BA12" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Possible increase of the sedative effect of the alprazolam</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>290-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="METABOLIZED TYROSINE-KINASE INHIBITORS" code="L01XE" /></DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the enzymatic inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>290-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="METABOLIZED TYROSINE-KINASE INHIBITORS" code="L01XE" /></DRUG1>
<DRUG2>
<CLASS name="H2 RECEPTOR ANTAGONISTS" code="A02BA-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the bioavailability of the tyrosine-kinase inhibitor, by reason of its pH dependent absorption</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>-except with the vandetanib.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>290-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="METABOLIZED TYROSINE-KINASE INHIBITORS" code="L01XE" /></DRUG1>
<DRUG2>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the bioavailability of the tyrosine-kinase inhibitor, by reason of its pH dependent absorption</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>-except with the imatinib and the vandetanib</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>290-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="METABOLIZED TYROSINE-KINASE INHIBITORS" code="L01XE" /></DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the tyrosine kinase inhibitor due to decrease of its metabolism</DESCRIPTION>
<SEVERITY>Not recommeded:</SEVERITY>
<COMMENT>--with the axitinib, the bosutinib, the ceritinib, the cobimetinib, the dabrafenib, the dasatinib, the nilotinib, the sunitinib</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>290-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="METABOLIZED TYROSINE-KINASE INHIBITORS" code="L01XE" /></DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the tyrosine-kinase inhibitor, due to increase of its metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>290-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="METABOLIZED TYROSINE-KINASE INHIBITORS" code="L01XE" /></DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>291-DIRECT-THROMBIN-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="DIRECT THROMBIN INHIBITORS" code="BO1AE" /></DRUG1>
<DRUG2>
<DRUG name="OTHER MEDICATIONS ACTING ON HEMOSTASIS" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG2>
<DESCRIPTION>Risk of constriction of the coronary arteries or of those of the extremities (ergotism), or of rapid elevation of blood pressure.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="ALFENTANIL" rxcui="480">
<ATC code="N01AH02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the opioid analgesic&#39;s effect of respiratory depression due to decrease of its hepatic metabolism

.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is treatment with a strong inhibitor of CYP3A4</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="ALFUZOSIN" rxcui="17300">
<ATC code="G04CA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of the alfuzosin and of its undesirable effects</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="ALRRAZOLAM" rxcui="596">
<ATC code="N05BA12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Possible increase of the sedative effect of the alprazolam</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<CLASS name="CALCIUM CHANNEL BLOCKERS" code="CO8CA-001" /></DRUG2>
<DESCRIPTION>Increase of the undesirable effects of the calcium channel blockers, most often of the hypotension type, especially in older patients.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and dosage adjustment during the treatment with the enzyme inhibitor and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<CLASS name="URINARY ANTISPASMODICS" code="DFST" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with darifenacine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="APIXABAN" rxcui="1364430">
<ATC code="B01AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the apixaban by the inhibitor, with increased risk of bleeding</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="BEDAQUILINE" rxcui="1364504">
<ATC code="J04AK05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If taking these medications together is necessary, more frequent EKG and monitoring of the transaminases are recommended.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="BORTEZOMIB" rxcui="358258">
<ATC code="L01XX32" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects, especially neurological, of the bortezomib due to decrease of its metabolism.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the bortezomib during the length of the treatment with the enzyme inhibitor.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of the undesirable effects of the bosentan, especially of hepatic attacks, due to decrease of its metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring during the administration of these together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="BRENTUXIMAB" rxcui="1147320">
<ATC code="L01XC12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of the active metabolite of the brentuximab, with risk of neutropenia</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="CABAZITAXEL" rxcui="996051">
<ATC code="L01CD04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable dose dependent effects of the cabazitaxel due to inhibition of its metabolism by the enzyme inhibitor</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the cabazitaxel during the treatment with the enzyme inhibitor</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="V03AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of the cobicistat or of the inhibitor of CYP3A4</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>To know the risks and levels of severity of each interaction,consult the specific authorization for sale to the public ("Authorisation de la Mise sur le Marche" a French document) for each one of them.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the undesirable effects of the colchicine, with potentially fatal consequences</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with the macrolides</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="DACLATASVIR" rxcui="1606218">
<ATC code="J05AX14" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of daclatasvir by the inhibitor</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>The dose of daclatasvir should be decreased to 30mg once a day when it is administered with the inhibitor. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="DAPOXETINE" rxcui="69394">
<ATC code="G04BX14" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects, especially of the vertigo or fainting type. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="DISOPYRAMIDE" rxcui="3541">
<ATC code="C01BA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the disopyramide due to decrease of its metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the disopyramide.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="DOCETAXEL" rxcui="72962">
<ATC code="L01CD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable dose-dependent effects of the docetaxel due to inhibition of its metabolism by the enzyme inhibitor</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the docetaxel during the treatment with the enzyme inhibitor.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="DOMPERIDONE" rxcui="3626">
<ATC code="A03FA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of domperidone due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large increase of the concentrations of dronedarone due to decrease of its metabolism</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="EPLERENONE" rxcui="298869">
<ATC code="C03DA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of the eplerenone by the inhibitor and of its undesirable effects, especially hyperkalemia</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="FENTANYL" rxcui="4337">
<ATC code="N02AB03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the opioid analgesic&#39;s effect of respiratory depression due to slight decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the opioid analgesic when there is also treatment with a strong inhibitor of CYP3A4.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="HALOFANTRINE" rxcui="50749">
<ATC code="P01BX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If this is possible, interrupt the inhibitor. If administering these medications together cannot be avoided, testing beforehand of the QT and EKG monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="IDELALISIB" rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increaese of the plasma concentrations of idelalisib due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<CLASS name="TYPE 5 PHOSPHODIESTERASE INHIBITORS " code="G04BE" /></DRUG2>
<DESCRIPTION>Increase (very large for avanafil and vardenafil) of the plasma concentrations of the type 5 phospodiesterase inhibitor, with risk of hypotension (severe with vardenafil)</DESCRIPTION>
<SEVERITY>Contraindication - Not recommended - Precaution for use</SEVERITY>
<COMMENT>To know the risks and levels of severity for each type 5 phospodiesterase inhibitor, consult the specific authorization for sale to the public ("Authorisation de la Mise sur le Marche" a French document) for each one of them.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of the ritonavir boosted protease inhibitor or of the inhibitor of CYP3A4 </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>To know the risks and levels of severity for each protease inhibitor boosted by ritonavir with the strong inhibitors of CYP3A4, consult the specific authorization for sale to the public (Authorisation de la Mise sur le March a French document) for each one of them.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<CLASS name="METABOLIZED TYROSINE-KINASE INHIBITORS" code="L01XE" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the tyrosine kinase inhibitor due to decrease of its metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-with axitinib, bosutinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="IRINOTECAN" rxcui="51499">
<ATC code="L01XX19" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the irinotecan due to increase of the plasma concentrations of its active metabolite</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="ISAVUCONAZOLE" rxcui="1720882">
<ATC code="J02AC05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of isavuconazole due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with the ketoconazole</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the inhibitor).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="IVACAFTOR" rxcui="1243041">
<ATC code="R07AX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large increase of the concentrations of ivacaftor, with risks of increase of its undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reduce the dose by a fourth, that is 150 mg every other day. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="LOMITAPIDE" rxcui="1364479">
<ATC code="C10AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the lomitapide due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="LURASIDONE" rxcui="1040028">
<ATC code="N05AE05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the lurasidone due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="MARAVIROC" rxcui="620216">
<ATC code="J05AX09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of maraviroc by the inhibitor.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>The dose of maraviroc must be decreased to 150 mg twice a day when administered with this inhibitor. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="METHYLPREDNISOLONE" rxcui="6902">
<ATC code="D07AA01" />
<ATC code="D10AA02" />
<ATC code="H02AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>In case of prolonged use, increase of the plasma concentration of the corticoid due to decrease of its hepatic metabolism by the in inhibitor, with risk of appearance of a cushings syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>--with the midazolam by mouth</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="OLAPARIB" rxcui="1597582">
<ATC code="L01XX46" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the olaparib by the inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these together cannot be avoided, limit the dose of olaparib to 150 mg twice a day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPREVIR" code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the ombitsavir + paritaprevir combination due to decrease of its hepatic metabolism by the inhibitor.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
<COMMENT>--except with ritonavir</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="OXYCODONE" rxcui="7804">
<ATC code="N02AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the undesirable effects, especially respiratory ones, of the oxycodone due to decrease of its metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of oxycodone during the treatment with the inhibitor and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="PANOBINOSTAT" rxcui="1603350">
<ATC code="L01XX42" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects, especially cardiac ones, of the panobinostat due to decrease of its metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG. Possible adjustment of the dosage of the panobinostat</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk increase of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="QUETIAPINE" rxcui="51272">
<ATC code="N05AH04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large increase of the concentrations of quetiapine, with risk of overdose</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="QUININE" rxcui="9071">
<ATC code="P01BC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the quinine, especially ventricular arrhythmias and neurosensory disorders (cinchonism).</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-with the protease inhibitors</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A" code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="RANOLAZINE" rxcui="35829">
<ATC code="C01EB18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of ranolazine due to decrease of its metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A" code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="REGORAFENIB" rxcui="1312397">
<ATC code="L01XE21" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of regorafenib due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="RIOCIGUAT" rxcui="1439816">
<ATC code="C02KX05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of riociquat due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="RIVAROXABAN" rxcui="1114195">
<ATC code="B01AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of rivaroxaban, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="SIMEPREVIR" rxcui="1482790">
<ATC code="J05AE14" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of simeprevir due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<CLASS name="SUBSTRATES AT RISK OF CYP3A4" code="L01N01" /></DRUG2>
<DESCRIPTION>Increase of the undesirable effects specific to each substrate, with frequently severe consequences</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="SUFENTANIL" rxcui="56795">
<ATC code="N01AH03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the opioid analgesic&#39;s effect of respiratory depression due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is also treatment with a strong inhibitor of CYP3A4.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="TAMSULOSIN" rxcui="77492">
<ATC code="G04CA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects, especially of the cardiac arrhythmia type. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>with the patient who has severe renal or hepatic insufficiency</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="TRASTUZUMAB EMTANSINE" rxcui="1371041">
<ATC code="L01XC14" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the DM1, a componant element of the trastuzumab emtansine, due to inhibition of its metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL " rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the inhibitor</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the verapamil during the treatment with the inhibitor, and after it is stopped, if the situation requires. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="ZOLPIDEM" rxcui="39993">
<ATC code="N05CF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Slight increase of the sedative effect of the zolpidem</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>292-STRONG-INHIBITORS-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STRONG INHIBITORS OF CYP3A4 " code="J02-J05" /></DRUG1>
<DRUG2>
<DRUG name="ZOPICLONE" rxcui="40001">
<ATC code="N05CF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Slight increase of the sedative effect of the zopiclone</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) " code="N06AB" /></DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) " code="N06AB" /></DRUG1>
<DRUG2>
<CLASS name="ORAL ANTICOAGULANTS " code="B01A-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and, if the situation requires, more frequent testing of the INR. Possible adjustment of the dosage of the oral anticoagulant during the administration with the SSRI and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) " code="N06AB" /></DRUG1>
<DRUG2>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the tricyclic antidepressant with risk of convulsions and increase of the undesirable effects

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring and, if necessary, adjustment of the dosage </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) " code="N06AB" /></DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) " code="N06AB" /></DRUG1>
<DRUG2>
<DRUG name="CYPROHEPTADINE" rxcui="3013">
<ATC code="R06AX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the antidepressant</DESCRIPTION>
<SEVERITY>Take into account </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) " code="N06AB" /></DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Wait at least two weeks between the discontinuation of the irreversible MAOI and the start of treatment with the SSRI, and at least a week between the end of treatment with the SSRI (except fluoxetine: five weeks) and the beginning. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) " code="N06AB" /></DRUG1>
<DRUG2>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these substances together cannot be avoided, very strict clinical monitoring. Begin the administration with minimum recommended dosages.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) " code="N06AB" /></DRUG1>
<DRUG2>
<CLASS name="MAOI-B " code="N04BD0-001" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) " code="N06AB" /></DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) " code="N06AB" /></DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) " code="N06AB" /></DRUG1>
<DRUG2>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of therapeutic failure when there is concomitant treatment with orlistat</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) " code="N06AB" /></DRUG1>
<DRUG2>
<DRUG name="TRAMADOL " rxcui="10689">
<ATC code="N02AX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of appearance of convulsions and/or a serotonin syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) " code="N06AB" /></DRUG1>
<DRUG2>
<CLASS name="TRIPTANS" code="N02CC-001" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>294-INSULIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="INSULIN" rxcui="631657">
<ATC code="A10AC01" />
<ATC code="A10AC02" />
<ATC code="A10AC03" />
<ATC code="A10AC04" />
<ATC code="A10AD01" />
<ATC code="A10AD02" />
<ATC code="A10AD03" />
<ATC code="A10AD04" />
<ATC code="A10AD05" />
<ATC code="A10AE01" />
<ATC code="A10AE02" />
<ATC code="A10AE03" />
<ATC code="A10AE04" />
<ATC code="A10AE05" />
<ATC code="A10AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ALCOHOL (DRINK OR INGREDIENT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Avoid taking alcoholic beverages and medications containing alcohol.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>294-INSULIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="INSULIN" rxcui="631657">
<ATC code="A10AC01" />
<ATC code="A10AC02" />
<ATC code="A10AC03" />
<ATC code="A10AC04" />
<ATC code="A10AD01" />
<ATC code="A10AD02" />
<ATC code="A10AD03" />
<ATC code="A10AD04" />
<ATC code="A10AD05" />
<ATC code="A10AE01" />
<ATC code="A10AE02" />
<ATC code="A10AE03" />
<ATC code="A10AE04" />
<ATC code="A10AE05" />
<ATC code="A10AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SOMATOSTATIN ANALOGS" code="H01CB0-001" /></DRUG2>
<DESCRIPTION>Risk of hypoglycemia or hyperglycemia: decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient of the risk of hypoglycemia or hyperglycemia, strengthen self-monitoring of blood glucose, and adjust the dosage of the insulin if needed during the treatment with the somatostatin analog.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>294-INSULIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="INSULIN" rxcui="631657">
<ATC code="A10AC01" />
<ATC code="A10AC02" />
<ATC code="A10AC03" />
<ATC code="A10AC04" />
<ATC code="A10AD01" />
<ATC code="A10AD02" />
<ATC code="A10AD03" />
<ATC code="A10AD04" />
<ATC code="A10AD05" />
<ATC code="A10AE01" />
<ATC code="A10AE02" />
<ATC code="A10AE03" />
<ATC code="A10AE04" />
<ATC code="A10AE05" />
<ATC code="A10AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS" code="R03C-001" /></DRUG2>
<DESCRIPTION>Elevation of the glycemia by the beta-2 mimetic</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strengthen blood and urine monitoring</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>294-INSULIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="INSULIN" rxcui="631657">
<ATC code="A10AC01" />
<ATC code="A10AC02" />
<ATC code="A10AC03" />
<ATC code="A10AC04" />
<ATC code="A10AD01" />
<ATC code="A10AD02" />
<ATC code="A10AD03" />
<ATC code="A10AD04" />
<ATC code="A10AD05" />
<ATC code="A10AE01" />
<ATC code="A10AE02" />
<ATC code="A10AE03" />
<ATC code="A10AE04" />
<ATC code="A10AE05" />
<ATC code="A10AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG2>
<DESCRIPTION>All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>294-INSULIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="INSULIN" rxcui="631657">
<ATC code="A10AC01" />
<ATC code="A10AC02" />
<ATC code="A10AC03" />
<ATC code="A10AC04" />
<ATC code="A10AD01" />
<ATC code="A10AD02" />
<ATC code="A10AD03" />
<ATC code="A10AD04" />
<ATC code="A10AD05" />
<ATC code="A10AE01" />
<ATC code="A10AE02" />
<ATC code="A10AE03" />
<ATC code="A10AE04" />
<ATC code="A10AE05" />
<ATC code="A10AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>294-INSULIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="INSULIN" rxcui="631657">
<ATC code="A10AC01" />
<ATC code="A10AC02" />
<ATC code="A10AC03" />
<ATC code="A10AC04" />
<ATC code="A10AD01" />
<ATC code="A10AD02" />
<ATC code="A10AD03" />
<ATC code="A10AD04" />
<ATC code="A10AD05" />
<ATC code="A10AE01" />
<ATC code="A10AE02" />
<ATC code="A10AE03" />
<ATC code="A10AE04" />
<ATC code="A10AE05" />
<ATC code="A10AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CHLORPROMAZINE" rxcui="2403">
<ATC code="N05AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With large dosages (100 mg per day of chlorpromazine): elevation of the glycemia (decrease of the freeing of the insulin)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>294-INSULIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="INSULIN" rxcui="631657">
<ATC code="A10AC01" />
<ATC code="A10AC02" />
<ATC code="A10AC03" />
<ATC code="A10AC04" />
<ATC code="A10AD01" />
<ATC code="A10AD02" />
<ATC code="A10AD03" />
<ATC code="A10AD04" />
<ATC code="A10AD05" />
<ATC code="A10AE01" />
<ATC code="A10AE02" />
<ATC code="A10AE03" />
<ATC code="A10AE04" />
<ATC code="A10AE05" />
<ATC code="A10AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DANAZOL" rxcui="3102">
<ATC code="G03XA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Diabetes inducing effect of the danazol </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these substances together cannot be avoided, inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>294-INSULIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="INSULIN " rxcui="5856">
<ATC code="A10AC01" />
<ATC code="A10AC02" />
<ATC code="A10AC03" />
<ATC code="A10AC04" />
<ATC code="A10AD01" />
<ATC code="A10AD02" />
<ATC code="A10AD03" />
<ATC code="A10AD04" />
<ATC code="A10AD05" />
<ATC code="A10AE01" />
<ATC code="A10AE02" />
<ATC code="A10AE03" />
<ATC code="A10AE04" />
<ATC code="A10AE05" />
<ATC code="A10AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strengthen self-monitoring of blood glucose</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>295-INTERFERON-ALFA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="INTERFERON ALFA" >
<ATC code="1431112" />
<ATC code="L03AB01" />
<ATC code="5879" />
<ATC code="L03AB04" />
<ATC code="5880" />
<ATC code="L03AB05" />
<ATC code="202912" />
<ATC code="L03AB06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)" code="L01BC-001" /></DRUG2>
<DESCRIPTION>Increase of the gastrointestinal toxicity of the fluorouracil</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>296-IPILIMUMAB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IPILIMUMAB" rxcui="1094833">
<ATC code="L01XC11" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ORAL ANTICOAGULANTS " code="B01A-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of digestive system hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>297-IRINOTECAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IRINOTECAN" rxcui="51499">
<ATC code="L01XX19" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Probable decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>297-IRINOTECAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IRINOTECAN" rxcui="51499">
<ATC code="L01XX19" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the irinotecan due to increase of the plasma concentrations of its active metabolite</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>297-IRINOTECAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IRINOTECAN" rxcui="51499">
<ATC code="L01XX19" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>298-ISAVUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISAVUCONAZOLE" rxcui="1720882">
<ATC code="J02AC05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of isavuconazole due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>298-ISAVUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISAVUCONAZOLE" rxcui="1720882">
<ATC code="J02AC05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of isavuconazole due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with the ketoconazole</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>298-ISAVUCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISAVUCONAZOLE" rxcui="1720882">
<ATC code="J02AC05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHN'S WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of isavuconazole due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>299-ISONIAZID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="HALOGENATED HYDROCARBON ANESTHETICS" code="N01AB0-001" /></DRUG2>
<DESCRIPTION>Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites.

.

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>299-ISONIAZID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>299-ISONIAZID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DISULFIRAM" rxcui="3554">
<ATC code="N07BB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of behavior and of coordination</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>299-ISONIAZID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG2>
<DESCRIPTION>Described for the prednisolone. 

Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>299-ISONIAZID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of ketoconazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>299-ISONIAZID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Overdose of phenytoin (decrease of its metabolism)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>299-ISONIAZID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PYRAZINAMIDE" rxcui="8987">
<ATC code="J04AK01" />
<ATC code="J04AM05" />
<ATC code="J04AM06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Addition of the hepatotoxic effects.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>299-ISONIAZID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring of this classic combination. In case of hepatitis, stop the isoniazid.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>299-ISONIAZID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="J05AF04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>29-ALUMINUM-(SALTS).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ALUMINUM (SALTS)" code="A02AD0-001" /></DRUG1>
<DRUG2>
<CLASS name="CITRATES" code="V09HX" /></DRUG2>
<DESCRIPTION>Risk of facilitating systemic uptake of the aluminum salts especially when there is altered renal function

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take aluminum based gastrointestinal medications at a different time (more than 2 hours apart if possible) from the citrates, including the natural ones such as citrus fruits and juices. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>2-ABIRATERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ABIRATERONE" rxcui="1100072">
<ATC code="L02BX03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS " code="N03A-001" /></DRUG2>
<DESCRIPTION>Notable decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>2-ABIRATERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ABIRATERONE" rxcui="1100072">
<ATC code="L02BX03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the abiraterone.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the abiraterone</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>2-ABIRATERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ABIRATERONE" rxcui="1100072">
<ATC code="L02BX03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the abiraterone.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the metopolol during the treatment with the abiraterone</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>2-ABIRATERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ABIRATERONE" rxcui="1100072">
<ATC code="L02BX03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the abiraterone</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the abiraterone</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>2-ABIRATERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ABIRATERONE" rxcui="1100072">
<ATC code="L02BX03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Substantial decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>300-ISOPRENALINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISOPRENALINE" rxcui="6054">
<ATC code="C01CA02" />
<ATC code="R03AB02" />
<ATC code="R03CB01" />
<ATC code="R03AK02" />
<ATC code="R03CB51" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="HALOGENATED HYDROCARBON ANESTHETICS" code="N01AB0-001" /></DRUG2>
<DESCRIPTION>Serious ventricular arrhythmias due to increase of cardiac sensitization

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of afatinib due to increase of its absorption by the itraconazole. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommended that the itraconazole be administered as far distant from the afatinib as possible, preferably at an interval of 6 to 12 hours away from the dose of afatinib. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09XA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase by nearly six times of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="H2 RECEPTOR ANTAGONISTS" code="A02BA-001" /></DRUG2>
<DESCRIPTION>Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG2>
<DESCRIPTION>Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the proton pump inhibitor</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the itraconazole and a week after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of aprepitant due to decrease of its hepatic metabolism by the intraconazole.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OTHER CORTICOIDES, ESPECIALLY INHALED ONES" code="D07AC-001" /></DRUG2>
<DESCRIPTION>In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the itraconazole, with risk of appearance of Cushings syndrome, even adrenal insufficiency </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUPRENORPHINE" rxcui="1819">
<ATC code="N02AE01" />
<ATC code="N07BC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUSPIRONE" rxcui="1827">
<ATC code="N05BE01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUSULFAN" rxcui="1828">
<ATC code="L01AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the busulfan in large doses: doubling of the concentrations of busulfan by the itraconazole</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="VO3AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the concentrations of itraconazole by the cobicistat</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these together. The administration of large doses of itraconazole (>200mg per day) is not recommended</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of more than double the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing&#39;s syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia with nausea, vomiting, arrhythmias</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and, if there is reason for them, EKG and monitoring of the digoxinemia with adjustment of the dosage of the digoxin during the treatment with the itraconazole and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EBASTINE" rxcui="23796">
<ATC code="R06AX22" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ELVITEGRAVIR" rxcui="1306286">
<ATC code="J05AR09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of elvitegravir due to decrease of its metabolism by the itraconazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>With the elvitegravir in combination with cobicistat, clinical monitoring. Limit the maximum dose of itraconazole to 200 mg/day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="HYDROQUINIDINE" rxcui="27220">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of tinnitis and/or loss of hearing acuity: cinchonism linked to a decrease of the hepatic metabolism of the antiarrhythmic by the itraconazole </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of the plasma concentrations of the antiarrhythmic and possible decrease of its dosage if necessary.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immusuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these substances are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant and possible adjustment of the dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYME INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the inducer.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Risk of increase of the concentrations of itraconazole by the protease inhibitor</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together. Administering large doses of itraconazole (>200 mg per day) is not recommended.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LERCANIDIPINE" rxcui="135056">
<ATC code="C08CA13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects, especially of edema, due to decrease of the hepatic metabolism of the dihydorpyridine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LUMEFANTRINE" rxcui="847728">
<ATC code="P01BF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If this is possible, interrupt the torsadegenic medication. If administering these two together cannot be avoided, testing of the QT beforehand and EKG monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MIZOLASTINE" rxcui="61455">
<ATC code="R06AX25" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="L01XE31" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the nintedanib due to increase of its absorption by the itraconazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes, as well as tinnitis and/or decrease of auditory acuity (cinchonism), due to decrease of the hepatic metabolism of the quinidine</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SALMETEROL" rxcui="36117">
<ATC code="R03AC12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the itraconazole</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolosis type (decrease of the hepatic metabolism of the simvastatin)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of telaprevir and of the itraconazole. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. Avoid large doses of itraconazole (>200 mg per day). </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TENEFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In case of co-administration with the itraconazole, the dose of tenofovir alafenamide should be limited to 10 mg per day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TRABECTEDIN" rxcui="1716278">
<ATC code="L01CX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of the trabectedin by the itraconazole</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together is necessary, clinical monitoring and possible adjustment of the dosage of the trabectedin during the length of the treatment with the itraconazole.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VENLAFAXINE" rxcui="39786">
<ATC code="N06AX16" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of venlafaxine with risk of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>301-ITRACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VINCA ALKALOIDS" code="L01CA" /></DRUG2>
<DESCRIPTION>Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the itraconazole</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>302-IVABRADINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the inducer

.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of these substances together and after the inducer is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>302-IVABRADINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AZITHROMYCIN " rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes. In addition, increase of the plasma concentrations of the ivabradine due to decrease of its metabolism by the azithromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>302-IVABRADINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the diltiazem), that add to the bradycardia inducing effects of these molecules</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>302-IVABRADINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the inhibitor).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>302-IVABRADINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the josamycin).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>302-IVABRADINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>302-IVABRADINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT (JUICE AND FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the ivabradine and of its undesirable effects (inhibition of its intestinal metabolism by the grapefruit).</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>302-IVABRADINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the rifampicin </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of the two substances together and after the rifampicin is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>302-IVABRADINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the verapamil), that add to the bradycardia inducing effects of these molecules</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>303-IVACAFTOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVACAFTOR" rxcui="1243041">
<ATC code="R07AX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of ivacaftor, with risks of increase of its undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reduce the dose by half, that is 150 mg/day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>303-IVACAFTOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVACAFTOR" rxcui="1243041">
<ATC code="R07AX02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Large decrease of the concentrations of the ivacaftor, with risk of loss of effectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>303-IVACAFTOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IVACAFTOR" rxcui="1243041">
<ATC code="R07AX02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Large increase of the concentrations of ivacaftor, with risks of increase of its undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reduce the dose by a fourth, that is 150 mg every other day. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>304-JOSAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose, due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and. if needed, plasma dosage and possible reduction of the dosage of the carbamazepine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>304-JOSAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the blood concentrations of ciclosporin and of the creatinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration with the macrolide and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>304-JOSAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DISOPYRAMIDE" rxcui="3541">
<ATC code="C01BA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the disopyramide: severe hypoglyclemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsades de pointes type</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Regular clinical, biological and electrocardiographic monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>304-JOSAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EBASTINE" rxcui="23796">
<ATC code="R06AX22" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>304-JOSAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="HALOFANTRINE" rxcui="50749">
<ATC code="P01BX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If this is possible, interrupt the macrolide. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>304-JOSAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the josamycin).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>304-JOSAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>304-JOSAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SILDENAFIL" rxcui="136411">
<ATC code="G04BE03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of sildenafil, with risk of hypotension</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Start the treatment with sildenafil at the minimun dose when it is administered with josamycin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>304-JOSAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
<ATC code="L04AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of tacrolimus and of the creatinemia, due to inhibition of the hepatic metabolism of the tacrolimus by the josamycin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>304-JOSAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Risk of increase of the theophyllinemia, particularly with children</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of afatinib due to increase of its absorption by the ketoconazole.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommended that the ketoconazole be administered as far from the afatinib as possible, preferably at an interval of 6 or 12 hours away from doses of the afatinib</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="H2 RECEPTOR ANTAGONISTS" code="A02BA-001" /></DRUG2>
<DESCRIPTION>Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG2>
<DESCRIPTION>Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the anitsecretory</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OTHER CORTICOIDES, ESPECIALLY INHALED ONES " code="D07AC-001" /></DRUG2>
<DESCRIPTION>In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the ketoconazole, with risk of appearance of Cushings syndrome, even adrenal insufficiency </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUPRENORPHINE" rxcui="1819">
<ATC code="N02AE01" />
<ATC code="N07BC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of more than double of the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EBASTINE" rxcui="23796">
<ATC code="R06AX22" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias with predisposed patients (congenital long QT syndrome)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ELVITEGRAVIR" rxcui="1306286">
<ATC code="J05AR09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of elvitegravir due to decrease of its metabolism by the ketoconazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>With the elvitegravir combined with cobicistat, clinical monitoring. Limit the maximum dose of ketoconazole to 200 mg/day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FIDAXOMICIN" rxcui="1111103">
<ATC code="A07AA12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the fidaxomicine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these substances are administered together, strict monitoring of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of ketoconazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LERCANIDIPINE" rxcui="135056">
<ATC code="C08CA13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydropyridine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LUMEFANTRINE" rxcui="847728">
<ATC code="P01BF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand, and EKG monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MIZOLASTINE" rxcui="61455">
<ATC code="R06AX25" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NEVIRAPINE" rxcui="53654">
<ATC code="J05AG01" />
<ATC code="J05AR07" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="L01XE31" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of nintedanib due to increase of its absorption by the ketoconazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SALMETEROL" rxcui="36117">
<ATC code="R03AC12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the ketoconazole</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolisis type (decrease of the hepatic metabolism of the cholesterol lowering substance)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Use a statin not affected by this type of interaction.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TENEFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In case of co-administration with the ketoconazole, the dose of tenofovir alafenamide must be limited to 10 mg per day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VENLAFAXINE" rxcui="39786">
<ATC code="N06AX16" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of vanlafaxine with risk of overdose </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>305-KETOCONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VINCA ALKALOIDS" code="L01CA" /></DRUG2>
<DESCRIPTION>Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the ketoconazole</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>306-LAMIVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LAMIVUDINE" rxcui="68244">
<ATC code="J05AF05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLADRIBINE" rxcui="44157">
<ATC code="L01BB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cladribine by the lamivudine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>306-LAMIVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LAMIVUDINE" rxcui="68244">
<ATC code="J05AF05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>307-LAMOTRIGINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LAMOTRIGINE" rxcui="28439">
<ATC code="N03AX09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the neurological effects (vertigo, ataxia, diplopia) of the carbamazepine when the lamotrigine is introduced</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the carbamazepine. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>307-LAMOTRIGINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LAMOTRIGINE" rxcui="28439">
<ATC code="N03AX09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-avoid starting an oral contraceptive during the period of adjustment of the dosage of the lamotrigine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>307-LAMOTRIGINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LAMOTRIGINE" rxcui="28439">
<ATC code="N03AX09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism by the ritonavir</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-Avoid beginning the treatment with ritonavir during the period of adjustment of the dosage of the lamotrigine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>307-LAMOTRIGINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LAMOTRIGINE" rxcui="28439">
<ATC code="N03AX09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="OXCARBAZEPINE" rxcui="32624">
<ATC code="N03AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of the lamotrigine with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and testing of the plasma concentrations, with adjustment of the dosage of the lamotrigine if needed.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>307-LAMOTRIGINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LAMOTRIGINE" rxcui="28439">
<ATC code="N03AX09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG2>
<DESCRIPTION>Increased risk of serious cutaneous reactions (Lyell&#39;s syndrome). In addition, increase of the plasma concentrations of lamotrigine (decrease of its hepatic metabolism by the sodium valproate)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If this combination of medications is judged necessary, strict clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>308-LANSOPRAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LANSOPRAZOLE" rxcui="17128">
<ATC code="A02BC03" />
<ATC code="A02BD07" />
<ATC code="A02BD03" />
<ATC code="A02BD02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="L04AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the tacrolimus</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of these medications together and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>309-LEDIPASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Only with the bitherapy ledipasvir/sofosbuvir, onset of bradycardia, possibly abruptly, which can have fatal consequences.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these together cannot be avoided, strict monitoring of patients is recommended, in particular during the first weeks of treatment with the bitherapy (clinical monitoring and EKG).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>309-LEDIPASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the anticonvulsant enzymatic inducer.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>309-LEDIPASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG2>
<DESCRIPTION>Decrease of the concentrations of the ledipasvir when the proton pump inhibitor is administered before the ledipasvir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommended that the proton pump inhibitor and the ledipasvir be administered simultaneously </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>309-LEDIPASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS)" code="C10AA" /></DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of the statin and of its undesirable effects of the rhabdomyolysis type</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with the rosuvastatin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>309-LEDIPASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>309-LEDIPASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the ripampicin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>309-LEDIPASVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TENOFOVIR DISOPROXIL" rxcui="300195">
<ATC code="J05AF07" />
</DRUG>
</DRUG2>
<DESCRIPTION>When co-administered with a protease inhibitor, increase of the plasma concentrations of the tenofovir by the ledipasvir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring, especially of the renal function</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>30-AMBRISENTAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMBRISENTAN" rxcui="358274">
<ATC code="C02KX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Doubling of the concentrations of ambrisentan, with increase of the vasodilator effect (severe headaches )</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>310-LENALIDOMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LENALIDOMIDE" rxcui="342369">
<ATC code="L04AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS)" code="C10AA" /></DRUG2>
<DESCRIPTION>Increased risk of onset of rhabdomyolysis</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strengthen clinical and biological monitoring, especially during the first weeks of treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>311-LERCANIDIPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LERCANIDIPINE" rxcui="135056">
<ATC code="C09BB02" />
<ATC code="C08CA13" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Moderate increase of the blood concentrations of the immunosuppressant and more notable increase of the concentrations of the lercanidipine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Separate the time when the two medications are taken. Blood concentration dosage of the immunosuppressant, and adjustment if necessary of its dosage during the administration of the medications together and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>311-LERCANIDIPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LERCANIDIPINE" rxcui="135056">
<ATC code="C09BB02" />
<ATC code="C08CA13" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydorpyridine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>311-LERCANIDIPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LERCANIDIPINE" rxcui="135056">
<ATC code="C09BB02" />
<ATC code="C08CA13" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydropyridine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>311-LERCANIDIPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LERCANIDIPINE" rxcui="135056">
<ATC code="C09BB02" />
<ATC code="C08CA13" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT (JUICE AND FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects, especially of edema, due to decrease of the intestinal metabolism of the dihydropyridine</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>312-LEVOCARNITINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVOCARNITINE" rxcui="42955">
<ATC code="A16AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the levocarnitine and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>313-LEVODOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BACLOFEN" rxcui="1292">
<ATC code="M03BX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of aggravation of the Parkinsonian syndrome or of undesirable central effects (visual hallucinations, confusion, headaches)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>313-LEVODOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the levodopa</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the iron salts at a different time from the levodopa (more than 2 hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>313-LEVODOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="MAOI-B " code="N04BD0-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of orthostatic hypotension</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>313-LEVODOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHYLDOPA" rxcui="6876">
<ATC code="C02AB" />
<ATC code="C02AB01" />
<ATC code="C02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly decrease of the doses of levodopa.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>313-LEVODOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTIEMITIC NEUROLEPTICS" code="A03FA-001" /></DRUG2>
<DESCRIPTION>Reciprocal antagonism between the levodopa and the neuroleptic 

</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Use an antiemitic without extrapyramidal effects.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>313-LEVODOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)" code="N05A-001" /></DRUG2>
<DESCRIPTION>Reciprocal antagonism between the levodopa and the neuroleptics</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>With a parkinsons patient, use the minimum effective doses of each of the two medications. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>313-LEVODOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RESERPINE" rxcui="9260">
<ATC code="C02AA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Inhibition of the effects of the levodopa</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>313-LEVODOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SPIRAMYCIN" rxcui="9991">
<ATC code="J01FA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>When administered with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the levodopa. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>313-LEVODOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TETRABENAZINE" rxcui="10390">
<ATC code="N07XX06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Reciprocal antagonism between the levodopa and the tetrabenazine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>314-LEVOFLOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LEVOFLOXACINE" rxcui="82122">
<ATC code="J01MA12" />
<ATC code="S01AE05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administrations of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>315-LIDOCAINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LIDOCAINE" rxcui="6387">
<ATC code="C01BB01" />
<ATC code="C05AD01" />
<ATC code="D04AB01" />
<ATC code="N01BB02" />
<ATC code="R02AD02" />
<ATC code="S01HA07" />
<ATC code="S02DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone</DESCRIPTION>
<SEVERITY>Precautions for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>315-LIDOCAINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LIDOCAINE" rxcui="6387">
<ATC code="C01BB01" />
<ATC code="C05AD01" />
<ATC code="D04AB01" />
<ATC code="N01BB02" />
<ATC code="R02AD02" />
<ATC code="S01HA07" />
<ATC code="S02DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG2>
<DESCRIPTION>With the lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment if needed of the dosage of the lidocaine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>315-LIDOCAINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LIDOCAINE" rxcui="6387">
<ATC code="C01BB01" />
<ATC code="C05AD01" />
<ATC code="D04AB01" />
<ATC code="N01BB02" />
<ATC code="R02AD02" />
<ATC code="S01HA07" />
<ATC code="S02DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>Negative inotropic effect with risk of acute decompensated heart failure</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>315-LIDOCAINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LIDOCAINE" rxcui="6387">
<ATC code="C01BB01" />
<ATC code="C05AD01" />
<ATC code="D04AB01" />
<ATC code="N01BB02" />
<ATC code="R02AD02" />
<ATC code="S01HA07" />
<ATC code="S02DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>315-LIDOCAINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LIDOCAINE" rxcui="6387">
<ATC code="C01BB01" />
<ATC code="C05AD01" />
<ATC code="D04AB01" />
<ATC code="N01BB02" />
<ATC code="R02AD02" />
<ATC code="S01HA07" />
<ATC code="S02DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>316-LINCOSANIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="LINCOSANIDES" code="J01FF0" /></DRUG1>
<DRUG2>
<CLASS name="CURARES" code="M03A-001" /></DRUG2>
<DESCRIPTION>Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitor the degree of curarisation at the end of anesthesia.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>317-LINEZOLIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LINEZOLIDE" rxcui="190376">
<ATC code="J01XX08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the linezolide by the clarithromycin, due to increase of its absorption</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>317-LINEZOLIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LINEZOLIDE" rxcui="190376">
<ATC code="J01XX08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the linezolide due to increase of its hepatic metabolism by the rifampicin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible increase of the dosage of the linezolide during the treatment with the rifampicin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ACETAZOLAMIDE" rxcui="167">
<ATC code="S01EC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness</DESCRIPTION>
<SEVERITY>Precautions for use</SEVERITY>
<COMMENT>Strict monitoring of the the plasma concentrations of lithium and possible adjustment of the dosage of lithium.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG2>
<DESCRIPTION>Increase of the the plasma concentrations of lithium that can attain toxic values (decrease of the renal excretion of the lithium)

.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the use of the angiotensin II antagonist is indispensable, strict monitoring of the the plasma concentrations of lithium and adjustment of the dosage</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Increase of the the plasma concentrations of lithium that can reach toxic values (decrease of the renal excretion of the lithium)

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering the substances together cannot be avoided, monitor the the plasma concentrations of lithium closely and adjust the dosage of the lithium during the administration of the substances together and after the NSAI is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="N06BC01" />
<ATC code="V04CG30" />
</DRUG>
</DRUG2>
<DESCRIPTION>In case of sudden discontinuation of consumption of coffee or of medications containing caffeine, risk of increase of the the plasma concentrations of lithium</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CALCITONIN" rxcui="36118">
<ATC code="H05BA" />
<ATC code="H05BA03" />
<ATC code="H05BA02" />
<ATC code="H05BA01" />
<ATC code="H05BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the calcitonin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of neurotoxicity manifesting as disorders of the cerebellum, confusion, drowsiness, ataxia. These disorders are reversible when the treatment with lithium is stopped</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="LOOP DIURETICS" code="C03CA-001" /></DRUG2>
<DESCRIPTION>Increase of the the plasma concentrations of lithium with signs of overdose of lithium as with a low sodium regimen (decrease of the urinary excretion of the lithium) </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these substances together cannot be avoided, strict monitoring of the the plasma concentrations of lithium and adjustment of the dosage of lithium. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)" code="C0E-004" /></DRUG2>
<DESCRIPTION>Increase of the the plasma concentrations of lithium with signs of overdose of lithium, as with a low sodium regimen (decrease of the urinary excretion of the lithium)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict monitoring of the the plasma concentrations of lithium and possible adjustment of the dosage of the lithium. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THIAZIDE DIURETICS AND RELATED" code="C03-003" /></DRUG2>
<DESCRIPTION>Increase of the the plasma concentrations of lithium with signs of overdose of lithium, as with a low sodium regimen (decrease of the urinary excretion of the lithium) </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering the substances together cannot be avoided, strict monitoring of the the plasma concentrations of lithium and adjustment of the dosage of the lithium. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GLYCEROL" rxcui="4910">
<ATC code="A06AG04" />
<ATC code="A06AX01" />
<ATC code="A16AX09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict monitoring of the the plasma concentrations of lithium and possible adjustment of the dosage of lithium.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>Increase of the the plasma concentrations of lithium which can reach toxic values (decrease of the renal excretion of the lithium)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the use of an ACE inhibitor is indispensable, strict monitoring of the the plasma concentrations of lithium and adjustment of the dosage of the lithium. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)" code="N06AB" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MANNITOL" rxcui="6628">
<ATC code="A06AD16" />
<ATC code="B05BC01" />
<ATC code="B05CX04" />
<ATC code="R05CB16" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict monitoring of the the plasma concentrations of lithium and possible adjustment of the dosage of lithium. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHYLDOPA " rxcui="6876">
<ATC code="C02AB" />
<ATC code="C02LB" />
<ATC code="C02AB01" />
<ATC code="C02LB01" />
<ATC code="C02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the the plasma concentrations of lithium which can attain toxic values, with signs of overdose of lithium </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of lithium. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METRONIDAZOLE" rxcui="6922">
<ATC code="A02BD08" />
<ATC code="A02BD03" />
<ATC code="A02BD02" />
<ATC code="A01AB17" />
<ATC code="D06BX01" />
<ATC code="G01AF01" />
<ATC code="J01XD01" />
<ATC code="P01AB01" />
<ATC code="A02BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the the plasma concentrations of lithium which can attain toxic values with signs of overdose of lithium.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict monitoring of the the plasma concentrations of lithium and possible adjustment of the dosage of the lithium. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NEUROLEPTICS" code="N05AA-003" /></DRUG2>
<DESCRIPTION>Risk of appearance of neuropsychic signs evocative of a neuroleptic malignant syndrome or of lithium poisoning</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical amd biological monitoring, especially at the beginning of the administration of the substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name=" LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of therapeutic failure when there is concomitant treatment with orlistat</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SODIUM BICARBONATE" rxcui="36676">
<ATC code="A02AH" />
<ATC code="B05CB04" />
<ATC code="B05XA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Avoid excessive sodium and take account of the presence of sodium in certain medications such as antacids.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SODIUM CHLORIDE" rxcui="9863">
<ATC code="A12CA01" />
<ATC code="B05CB01" />
<ATC code="B05XA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Avoid excessive sodium and take account of the presence of sodium in certain medications such as antacids.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="THEOPHYLLINE " rxcui="10438">
<ATC code="R03DA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict monitoring of the lithemia and possible adjustment of the dosage of the the plasma concentrations of lithium.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>318-LITHIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TOPIRAMATE" rxcui="38404">
<ATC code="38404" />
</DRUG>
</DRUG2>
<DESCRIPTION>For doses of topiramate &gt;= 200 mg/day: increase of the the plasma concentrations of lithium that can reach toxic values, with signs of overdose of lithium.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring. Adjustment of the dosage of the lithium. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>319-LOMITAPIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LOMITAPIDE" rxcui="1364479">
<ATC code="C10AX12" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the lomitapide due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>319-LOMITAPIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LOMITAPIDE" rxcui="1364479">
<ATC code="C10AX12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the lomitapide</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>31-AMINOGLUTETHIMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMINOGLUTETHIMIDE" rxcui="677">
<ATC code="L02BG01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Described for warfarin and acenocoumarol. 

Decrease of the effect of the vitamin K antagonist, due to increase of its hepatic metabolism by the aminoglutethimide

.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the Vitamin K antagonist during the treatment with aminoglutethimide and two weeks after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>31-AMINOGLUTETHIMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMINOGLUTETHIMIDE" rxcui="677">
<ATC code="L02BG01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Adjustment of the dosage of the dexamethasone. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>320-LOMUSTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LOMUSTINE" rxcui="6466">
<ATC code="L01AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the lomustine)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>321-LOSARTAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LOSARTAN" rxcui="52175">
<ATC code="C09CA01" />
<ATC code="C09DB06" />
<ATC code="C09DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the losartan, due to inhibition of the formation of its active metabolite by the fluconazole</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>322-LUMEFANTRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LUMEFANTRINE" rxcui="847728">
<ATC code="P01BF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If this is possible, interrupt the substance tending to cause torsades de pointes. If administering the two together cannot be avoided, testing of the QT before hand and EKG monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>322-LUMEFANTRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LUMEFANTRINE" rxcui="847728">
<ATC code="P01BF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If this is possible, interrupt the substance tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>322-LUMEFANTRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LUMEFANTRINE" rxcui="847728">
<ATC code="P01BF01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>322-LUMEFANTRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LUMEFANTRINE" rxcui="847728">
<ATC code="P01BF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If this is possible, interrupt the substance tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>322-LUMEFANTRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LUMEFANTRINE" rxcui="847728">
<ATC code="P01BF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If this is possible, interrupt the substance tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>323-LURASIDONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LURASIDONE" rxcui="1040028">
<ATC code="N05AE05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the lurasidone due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>323-LURASIDONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LURASIDONE" rxcui="1040028">
<ATC code="N05AE05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the lurasidone due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>CONTRANDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>323-LURASIDONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LURASIDONE" rxcui="1040028">
<ATC code="N05AE05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHN'S WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the lurasidone due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>323-LURASIDONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LURASIDONE" rxcui="1040028">
<ATC code="N05AE05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GRAGEFRUIT (JUICE AND FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the lurasidone due to decrease of its metabolism by the grapefruit</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>324-MACITENTAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MACITENTAN" rxcui="1442132">
<ATC code="C02KX04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of macitentan due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>324-MACITENTAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MACITENTAN" rxcui="1442132">
<ATC code="C02KX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of macitentan due to increase of its metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>325-MACROLIDES-(EXCEPT-SPIRAMYCIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MACROLIDES (EXCEPT SPIRAMYCIN)" code="J01FA" /></DRUG1>
<DRUG2>
<CLASS name="DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE" code="G02CB-001" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dopaminergic with possible increase of its activity or appearance of signs of overdose. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>325-MACROLIDES-(EXCEPT-SPIRAMYCIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MACROLIDES (EXCEPT SPIRAMYCIN)" code="J01FA" /></DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the macrolide and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>325-MACROLIDES-(EXCEPT-SPIRAMYCIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MACROLIDES (EXCEPT SPIRAMYCIN)" code="J01FA" /></DRUG1>
<DRUG2>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the undesirable effects of the colchicine, with potentially fatal consequences</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>325-MACROLIDES-(EXCEPT-SPIRAMYCIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MACROLIDES (EXCEPT SPIRAMYCIN)" code="J01FA" /></DRUG1>
<DRUG2>
<DRUG name="DIHYDROERGOTAMINE" rxcui="3418">
<ATC code="N02CA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>325-MACROLIDES-(EXCEPT-SPIRAMYCIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MACROLIDES (EXCEPT SPIRAMYCIN)" code="J01FA" /></DRUG1>
<DRUG2>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremeties (decrease of the hepatic elimination of the ergotamine).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>326-MANNITOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MANNITOL" rxcui="6628">
<ATC code="A06AD16" />
<ATC code="B05BC01" />
<ATC code="B05CX04" />
<ATC code="R05CB16" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict monitoring of the the plasma concentrations of lithium and possible adjustment of the dosage of the lithium. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>327-MARAVIROC.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MARAVIROC" rxcui="620216">
<ATC code="J05AX09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FOSAMPRENAVIR" rxcui="358262">
<ATC code="J05AE07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Significant decrease of the concentrations of amprenavir that could lead to a loss of the virological response</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>327-MARAVIROC.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MARAVIROC" rxcui="620216">
<ATC code="J05AX09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>In the absence of the administration at the same time with a strong inhibitor of CYP3A4, decrease of the concentrations of maraviroc by the inducer</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>The dose of maraviroc must be increased to 600 mg twice a day in this situation. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>327-MARAVIROC.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MARAVIROC" rxcui="620216">
<ATC code="J05AX09" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the concentrations of maraviroc by the inhibitor</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>The dose of maraviroc must be reduced to 150 mg twice a day if it is taken with this inhibitor.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>327-MARAVIROC.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MARAVIROC" rxcui="620216">
<ATC code="J05AX09" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of maraviroc that could lead to a loss of the virological response</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>328-MEDICATIONS-AT-THE-ORIGIN-OF-A-SEROTONIN-SYNDROME.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MEDICATIONS AT THE ORIGIN OF A SEROTONIN SYNDROME" code="N06A-002" /></DRUG1>
<DRUG2>
<CLASS name="OTHER MEDICATIONS AT THE ORIGIN OF A SEROTONIN SYNDROME" code="N06A-002" /></DRUG2>
<DESCRIPTION>Risk of appearance or of increased severity of a serotonin syndrome in case of administering any of these medications with any of the others.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>329-MEDICATIONS-AT-THE-ORIGIN-OF-ORTHOSTATIC-HYPOTENSION.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MEDICATIONS AT THE ORIGIN OF ORTHOSTATIC HYPOTENSION" code="N05AA-001" /></DRUG1>
<DRUG2>
<DRUG name="DAPOXETINE" rxcui="69394">
<ATC code="G04BX14" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects, especially of the vertigo and fainting type</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-with the type 5 phospohdisterase inhibitors</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>329-MEDICATIONS-AT-THE-ORIGIN-OF-ORTHOSTATIC-HYPOTENSION.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MEDICATIONS AT HE ORIGIN OF ORTHOSTATIC HYPOTENSION" code="N05AA-001" /></DRUG1>
<DRUG2>
<CLASS name="MEDICATIONS THAT LOWER BLOOD PRESSURE " code="MLBP" /></DRUG2>
<DESCRIPTION>Risk of increase of hypotension, especially orthostatic</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>32-AMINOGLYCOSIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AMINOGLYCOSIDES " code="J01GB-001" /></DRUG1>
<DRUG2>
<CLASS name="OTHER AMINOGLYCOSIDES " code="J01GB-001" /></DRUG2>
<DESCRIPTION>Increased risk of nephrotoxicity and ototoxicity (the ototoxicity is cumulative in cases of successive administrations of the aminoglycosides)</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>-in case of simultaneous administration</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>32-AMINOGLYCOSIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AMINOGLYCOSIDES " code="J01GB-001" /></DRUG1>
<DRUG2>
<DRUG name="AMPHOTERICIN B " rxcui="732">
<ATC code="A01AB04" />
<ATC code="A07AA07" />
<ATC code="G01AA03" />
<ATC code="J02AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the amphotericin B administered intravenously:

increased risk of nephrotoxicity </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>32-AMINOGLYCOSIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AMINOGLYCOSIDES " code="J01GB-001" /></DRUG1>
<DRUG2>
<DRUG name="ATALUREN" rxcui="">
<ATC code="M09AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the renal toxicity of the aminoglycoside.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>32-AMINOGLYCOSIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AMINOGLYCOSIDES " code="J01GB-001" /></DRUG1>
<DRUG2>
<DRUG name="BOTULINUM TOXIN" rxcui="1716">
<ATC code="M03AX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the effects of the botulinum toxin with the aminoglycosides (due to extrapolation from the effects observed during the course of the botulism)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Use another antibiotic</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>32-AMINOGLYCOSIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AMINOGLYCOSIDES " code="J01GB-001" /></DRUG1>
<DRUG2>
<DRUG name="CEFALOTIN" rxcui="2236">
<ATC code="J01DB03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the nephrotoxicity of the aminoglycosides by the cefalotin is under discussion</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of renal function</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>32-AMINOGLYCOSIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AMINOGLYCOSIDES " code="J01GB-001" /></DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Larger increase of the creatinemia than with ciclosporin alone, with increase of the nephrotoxic risk </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>32-AMINOGLYCOSIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AMINOGLYCOSIDES " code="J01GB-001" /></DRUG1>
<DRUG2>
<CLASS name="CURARES" code="M03A-001" /></DRUG2>
<DESCRIPTION>Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitor the degree of curarization at the end of anesthesia</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>32-AMINOGLYCOSIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AMINOGLYCOSIDES " code="J01GB-001" /></DRUG1>
<DRUG2>
<CLASS name="LOOP DIURETICS" code="C03CA-001" /></DRUG2>
<DESCRIPTION>Increase of the nephrotoxic and ototoxic risks of the aminoglycoside (functional renal insufficiency linked to the dehydration caused by the diuretic)

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>The two medications may be taken together when there is monitoring of the state of hydration, of the renal and cochleovestibulary functions, and, possibly, of the plasma concentrations of the aminoglycoside.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>32-AMINOGLYCOSIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AMINOGLYCOSIDES " code="J01GB-001" /></DRUG1>
<DRUG2>
<CLASS name="PLATINUM-BASED ANTINEOPLASTIC DRUGS" code="ORGAPLA" /></DRUG2>
<DESCRIPTION>Addition of the nephrotoxic and/or ototoxic effects, especially in the case of pre-existing renal insufficiency</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>32-AMINOGLYCOSIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AMINOGLYCOSIDES " code="J01GB-001" /></DRUG1>
<DRUG2>
<DRUG name="POLYMYXIN B" rxcui="8536">
<ATC code="A07AA05" />
<ATC code="J01XB02" />
<ATC code="S01AA18" />
<ATC code="S02AA11" />
<ATC code="S03AA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Addition of the nephrotoxic effects

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these substances together cannot be avoided, strict monitoring with an indisputable bacteriological justification</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>32-AMINOGLYCOSIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AMINOGLYCOSIDES " code="J01GB-001" /></DRUG1>
<DRUG2>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
<ATC code="L04AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>330-MEDICATIONS-AT-RISK-WHEN-WITHDRAWING-FROM-TOBACCO.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MEDICATIONS AT RISK WHEN WITHDRAWING FROM TOBACCO" code="N0-R0-002" /></DRUG1>
<DRUG2>
<CLASS name="NICOTINE SUBSTITUTION TREATMENT" code="N07BA" /></DRUG2>
<DESCRIPTION>Risk of overdose when replacing tobacco by the replacement therapy</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>331-MEDICATIONS-THAT-LOWER-BLOOD-PRESSURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MEDICATIONS THAT LOWER BLOOD PRESSURE " code="MLBP" /></DRUG1>
<DRUG2>
<CLASS name="NITRATE DERIVATIVES AND RELATED" code="C01D-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hypotension, especially orthostatic</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>331-MEDICATIONS-THAT-LOWER-BLOOD-PRESSURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MEDICATIONS THAT LOWER BLOOD PRESSURE " code="MLBP" /></DRUG1>
<DRUG2>
<CLASS name="MEDICATIONS AT THE ORIGIN OF ORTHOSTATIC HYPOTENSION" code="N05AA-001" /></DRUG2>
<DESCRIPTION>Risk of increase of hypotension, especially orthostatic</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>332-MEDICATIONS-THAT-LOWER-THE-EPILEPTIC-THRESHOLD.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MEDICATIONS THAT LOWER THE EPILEPTIC THRESHOLD" code="N05AA-002" /></DRUG1>
<DRUG2>
<CLASS name="OTHER MEDICATIONS THAT LOWER THE EPILEPTIC THRESHOLD" code="N05AA-002" /></DRUG2>
<DESCRIPTION>Accrued risk of convulsions</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>333-ATROPINIC-MEDICATIONS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATROPINIC MEDICATIONS" code="R06AA" /></DRUG1>
<DRUG2>
<CLASS name="OTHER ATROPINIC MEDICATIONS" code="R06AA" /></DRUG2>
<DESCRIPTION>Addition of the undesirable atropinic effects such as urinary retention, constipation, dry mouth </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>334-METHEMOGLOBINIZIN-MEDICATIONS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="METHEMOGLOBINIZING MEDICATIONS " code="METGL" /></DRUG1>
<DRUG2>
<CLASS name="OTHER METHEMOGLOBINIZING MEDICATIONS " code="METGL" /></DRUG2>
<DESCRIPTION>Risk of addition of the effects of the methomoglobinizing agents.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>335-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS" code="N06A" /></DRUG1>
<DRUG2>
<DRUG name="ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)" rxcui="">
<ATC code="3992" />
</DRUG>
</DRUG2>
<DESCRIPTION>Serious ventricular arrhythmias due to increased cardiac sensitization.</DESCRIPTION>
<SEVERITY>Precautions for use</SEVERITY>
<COMMENT>Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>335-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS" code="N06A" /></DRUG1>
<DRUG2>
<CLASS name="ORAL ANTICOAGULANTS " code="B01A-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and, if the situation requires, more frequent testing of the INR. Possible adjustment of the dosage of the oral anticoagulant during the administration of these medications together and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>335-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS" code="N06A" /></DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Wait two weeks between stopping the MAOI and the start of the other treatment, and at least a week between the end of that treatment and the start of the MAOI. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>335-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS" code="N06A" /></DRUG1>
<DRUG2>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, confusion, even coma</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these substances together cannot be avoided, very strict clinical monitoring. Begin the administration of the substances together with minimum recommended dosages.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>335-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS" code="N06A" /></DRUG1>
<DRUG2>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of therapeutic failure when there is concomitant treatment with orlistat</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>335-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS" code="N06A" /></DRUG1>
<DRUG2>
<CLASS name="ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)" code="C01CA" /></DRUG2>
<DESCRIPTION>Paroxysmal hypertension with possibility of ventricular arrhythmias (inhibition of the entry of the sympathomimetic into the sympathic fiber)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>336-NEPHROTOXIC-MEDICATIONS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NEPHROTOXIC MEDICATIONS " code="J01-J05" /></DRUG1>
<DRUG2>
<CLASS name="OTHER NEPHROTOXIC MEDICATIONS " code="J01-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the nephrotoxicity</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>337-OTOTOXIC-MEDICATIONS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OTOTOXIC MEDICATIONS" code="J01GB-J01XA" /></DRUG1>
<DRUG2>
<CLASS name="OTHER OTOTOXIC MEDICATIONS" code="J01GB-J01XA" /></DRUG2>
<DESCRIPTION>Increase of the ototoxicity</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>338-SEDATIVE-MEDICATIONS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SEDATIVE MEDICATIONS" code="N04-N05-N06" /></DRUG1>
<DRUG2>
<DRUG name="ALCOHOL (DRINK OR INGREDIENT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increase by the alcohol of the sedative effect of these substances. The alteration of alertness can make driving vehicles or using machines dangerous</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Avoid taking alcoholic beverages or medications containing alcohol.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>338-SEDATIVE-MEDICATIONS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SEDATIVE MEDICATIONS" code="N04-N05-N06" /></DRUG1>
<DRUG2>
<CLASS name="OTHER SEDATIVE MEDICATIONS" code="N04-N05-N06" /></DRUG2>
<DESCRIPTION>Increase of central nervous center depression. The alteration of alertness can make driving vehicles or using machines dangerous</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>--with sodium oxybate</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>339-MEFLOQUINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MEFLOQUINE" rxcui="6694">
<ATC code="P01BF02" />
<ATC code="P01BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUININE" rxcui="9071">
<ATC code="P01BC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Wait at least 12 hours between the end of the administration via IV of the quinine and the beginning of the administration of the mefloquine. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of afatinib by increase of its absorption by the amiodarone. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommended that the amiodarone be administered as far as possible from the afatinib, preferably at an interval of 6 to 12 hours from the dose of afatinib.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage 

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the amiodarone and a week after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)" code="C07AB-001" /></DRUG2>
<DESCRIPTION>Disorders of autoregulation and conduction (suppression of the compensatory sympathetic mechanisms)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring and EKG</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of ciclosporin, due to decrease of its hepatic metabolism, with risk of nephrotoxic effects

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Blood concentration dosages of ciclosporin, testing of the renal function, and adjustment of the dosage of the ciclosporin during the treatment with the amiodarone.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="VO3AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the amiodarone due to decrease of its metabolism by the cobicistat</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DABIGATRAN" rxcui="">
<ATC code="1037042" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of dabigatran, with greater risk of bleeding

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>For post surgical indications:</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DACLATASVIR" rxcui="1606218">
<ATC code="J05AX14" />
</DRUG>
</DRUG2>
<DESCRIPTION>Only with the bitherapy daclatasvir/sofosbuvir:

Appearance of bradycardia, possibly abrupt, that can have fatal consequences.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these drugs together cannot be avoided, clinical monitoring and strict EKG, in particular during the first weeks of treatment with the bitherapy</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Depression of autoregulation (excessive bradycardia) and difficulties with atrioventricular conduction. Furthermore, increase of the blood concentrations of digoxin due to decrease of the clearance of the digoxin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG and, if there is need for it, testing of the digoxinemia and adjustment of the dosage of the digoxin. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>For diltiazem by injection: risk of bradycardia and of atrioventricular block

For diltiazem by mouth: risk of bradycardia or of atrioventricular block, especially in older persons.</DESCRIPTION>
<SEVERITY>Not recommended </SEVERITY>
<COMMENT>-with diltiazem administered by IV</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ESMOLOL" rxcui="49737">
<ATC code="C07AB09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of contractility, autoregulation, and electrical conduction (suppression of the compensatory sympathetic mechanisms)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FIDAXOMICIN " rxcui="1111103">
<ATC code="A07AA12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the fidaxomicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of lengthening of the QT interval</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, particularly with large doses of fluconazole (800mg/d)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IBRUTINIB" rxcui="1442981">
<ATC code="L01XE27" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of ibrutinib by decease of its hepatic metabolism by the amiodarone</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg per day during the time these two medications are administered together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LEDIPASVIR" rxcui="1591922">
<ATC code="LEDIPASV" />
<ATC code="SOFOSBUV" />
<ATC code="1591942" />
<ATC code="J05AX65" />
</DRUG>
</DRUG2>
<DESCRIPTION>Only with the ledipasvir/sofosbuvir bitherapy, appearance of bradycardia, possibly abrupt, that can have fatal consequences</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the use of these medications together cannot be avoided, close monitoring of patients is recommended, in particular during the first weeks of treatment with the bitherapy (clinical monitoring and EKG).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LIDOCAINE" rxcui="6387">
<ATC code="C01BB01" />
<ATC code="C05AD01" />
<ATC code="D04AB01" />
<ATC code="N01BB02" />
<ATC code="R02AD02" />
<ATC code="S01HA07" />
<ATC code="S02DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="L01XE31" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of nintedanib due to increase of its absorption by the amiodarone.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="OLAPARIB" rxcui="1597582">
<ATC code="L01XX46" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of olaparib by the amiodarone</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these together cannot be avoided, limit the dose of olaparib to 200 mg twice a day with the amiodarone. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPVIR" code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the amiodarone due to decrease of its hepatic metabolism by the therapy with ombitasvir+paritaprevir</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the amiodarone and of its active metabolite

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and, if needed, EKG</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the phenytoin with signs of overdose, in particular neurological ones (decrease of the hepatic metabolism of the phenytoin)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, testing of the plasma concentrations of phenytoin and possible adjustment of its dosage</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin).</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SOFOSBUVIR" rxcui="1484911">
<ATC code="J05AX15" />
<ATC code="LEDIPASV" />
<ATC code="SOFOSBUV" />
<ATC code="1591939" />
<ATC code="1591940" />
<ATC code="J05AX65" />
<ATC code="J05AX65" />
<ATC code="J05AX65" />
<ATC code="J05AX65" />
<ATC code="J05AX65" />
<ATC code="J05AX65" />
<ATC code="J05AX65" />
<ATC code="J05AX65" />
<ATC code="J05AX65" />
<ATC code="J05AX65" />
<ATC code="J05AX65" />
<ATC code="J05AX65" />
<ATC code="J05AX65" />
<ATC code="J05AX65" />
<ATC code="J05AX65" />
<ATC code="J05AX65" />
</DRUG>
</DRUG2>
<DESCRIPTION>Only when administered with the combinations daclatasvir/sofosbuvir or ledispasvir/sofosbuvir:

Possibly abrupt appearance of bradycardia, which can have fatal consequences.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, strict clinical monitoring and EKG, in particular during the first weeks of treatment with the combinations with sofosbuvir.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
<ATC code="L04AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of tacrolimus due to inhibition of its metabolism by the amiodarone.

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of tacrolimus, testing of the renal function, and adjustment of the dosage of tacrolimus during the administration of it and the amiodarone together and when the amiodarone is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TAMSULOSIN" rxcui="77492">
<ATC code="G04CA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the tamsulosin due to inhibition of its hepatic metabolism

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the tamsulosin during the treatment with the enzymatic inhibitor and after it is stopped, if the situation requires. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>For verapamil by injection: 

-risk of bradycardia or of atrioventricular block. 

For verapamil by mouth:

-risk of bradycardia or of atrioventricular block, especially with older patients</DESCRIPTION>
<SEVERITY>Not recommended with:</SEVERITY>
<COMMENT>-verapamil administered via IV</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>33-AMIODARONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes, due to possible decrease of the metabolism of the amiodarone</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG, and possible adjustment of the dosage of the amiodarone.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>340-MEQUITAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MEQUITAZINE" rxcui="29528">
<ATC code="R06AD07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>340-MEQUITAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MEQUITAZINE" rxcui="29528">
<ATC code="R06AD07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CINACALCET" rxcui="407990">
<ATC code="H05BX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>340-MEQUITAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MEQUITAZINE" rxcui="29528">
<ATC code="R06AD07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the mequitazine due to inhibition of its metabolism by the enzyme inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>340-MEQUITAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MEQUITAZINE" rxcui="29528">
<ATC code="R06AD07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06CA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>340-MEQUITAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MEQUITAZINE" rxcui="29528">
<ATC code="R06AD07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>340-MEQUITAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MEQUITAZINE" rxcui="29528">
<ATC code="R06AD07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TERBINAFINE" rxcui="37801">
<ATC code="D01AE15" />
<ATC code="D01BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>341-METFORMIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METFORMIN" rxcui="6809">
<ATC code="A10BA02" />
<ATC code="A10BD13" />
<ATC code="A10BD11" />
<ATC code="A10BD05" />
<ATC code="A10BD03" />
<ATC code="A10BD10" />
<ATC code="A10BD07" />
<ATC code="A10BD02" />
<ATC code="A10BD08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ALCOHOL (DRINK OR INGREDIENT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of lactic acidosis when there is acute alcohol intoxication, particularly in cases of fasting or undernourishment, or in cases of liver failure</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Avoid taking alcoholic beverages and medications containing alcohol. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>341-METFORMIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METFORMIN" rxcui="6809">
<ATC code="A10BA02" />
<ATC code="A10BD13" />
<ATC code="A10BD11" />
<ATC code="A10BD05" />
<ATC code="A10BD03" />
<ATC code="A10BD10" />
<ATC code="A10BD07" />
<ATC code="A10BD02" />
<ATC code="A10BD08" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="LOOP DIURETICS" code="C03CA-001" /></DRUG2>
<DESCRIPTION>Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Do not use metformin when the creatinemia is greater than 15mg/l (135 mol/l) for men, and 12 mg/l (110mol/l) for women.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>341-METFORMIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METFORMIN" rxcui="6809">
<ATC code="A10BA02" />
<ATC code="A10BD13" />
<ATC code="A10BD11" />
<ATC code="A10BD05" />
<ATC code="A10BD03" />
<ATC code="A10BD10" />
<ATC code="A10BD07" />
<ATC code="A10BD02" />
<ATC code="A10BD08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DOLUTEGRAVIR" rxcui="1433868">
<ATC code="J05AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of metformin by the dolutegravir and of its undesirable effects of the lactic acidosis type</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>--with the patient having moderate renal insufficiency (stage 3a, clearance of the creatinine between 45 and 59 ml/min), clinical and biological monitoring , and possible adjustment of the dosage of metformin </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>341-METFORMIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METFORMIN" rxcui="6809">
<ATC code="A10BA02" />
<ATC code="A10BD13" />
<ATC code="A10BD11" />
<ATC code="A10BD05" />
<ATC code="A10BD03" />
<ATC code="A10BD10" />
<ATC code="A10BD07" />
<ATC code="A10BD02" />
<ATC code="A10BD08" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IODINATED X-RAY CONTRAST MEDIA" code="VO8A-001" /></DRUG2>
<DESCRIPTION>Lactic acidosis linked to elevated concentrations of metformin in relation to the functional renal insufficiency induced by the radiological exam.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>342-METHADONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="MORPHINE LIKE ANTITUSSIVES" code="R05DA0-001" /></DRUG2>
<DESCRIPTION>Increased risk of respiratory depression, which can be fatal in case of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>342-METHADONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="TRUE MORPHINE ANTITUSSIVES" code="R0GDA0-002" /></DRUG2>
<DESCRIPTION>Increased risk of respiratory depression which can be fatal in case of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>342-METHADONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of methadone, with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism by the boceprevir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring and possible adjustment of the dosage of methadone.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>342-METHADONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strengthen clinical and electrocardiographic monitoring; if needed, adjustment of the dosage of the methadone during treatment with the cimetidine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>342-METHADONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strengthen clinical and electrocardiographic monotoring; if needed, adjustment of the dosage of the methadone during the treatment with the fluvoxamine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>342-METHADONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FOSAMPRENAVIR" rxcui="358262">
<ATC code="J05AE07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the amprenavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring and possible adjustment of the dosage of methadone. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>342-METHADONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increase the frequency of the doses of methadone (2 to 3 times a day instead of once a day). </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>342-METHADONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the ritonavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring and possible adjustment of the dosage of methadone. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>342-METHADONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="AGONIST-ANTAGONIST OPIOIDS " code="NO2A-001" /></DRUG2>
<DESCRIPTION>Decrease of the effect of the methadone due to competitive blockage of the receptors.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>342-METHADONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with the citalopram, the domperidone, the escitalopram, the hydroxyzine and the piperaquine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>343-METHENAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHENAMINE" rxcui="6832">
<ATC code="J01XX05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SULFAMETHIZOLE" rxcui="10179">
<ATC code="B05CA04" />
<ATC code="J01EB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Precipitation of crystals in the urinary tract (due to the acidification of the urine)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>344-METHOTREXATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)</DESCRIPTION>
<SEVERITY>With doses of methotrexate > 20 mg/week</SEVERITY>
<COMMENT>Contraindication  with acetylsalicylic acid used in anatalgic, antipyretic, or anti-inflammatory doses</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>344-METHOTREXATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ACITRETIN" rxcui="16818">
<ATC code="D05BB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the hepatoxicity of the methotrexate</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these substances together is judged necessary, strengthen liver function testing </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>344-METHOTREXATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Increase of the hematological toxicity of the methotrexate (decrease of the renal clearance of the methotrexate by the NSAIs).</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>--for doses of methotrexate greater than 20mg per week</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>344-METHOTREXATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the methotrexate due to decrease of its elimination</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>--with the methotrexate in doses > 20mg /week</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>344-METHOTREXATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the toxicity of the methotrexate and of the ciclosporin with increase of the creatinemia: reciprocal decrease of the clearances of the two medications</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosages of ciclosporin and of methotrexate. Adjustment of the dosage if necessary during the administration of the two together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>344-METHOTREXATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIPROFLOXACIN" rxcui="2551">
<ATC code="J01MA02" />
<ATC code="S01AE03" />
<ATC code="S02AA15" />
<ATC code="S03AA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>344-METHOTREXATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PENICILLINS" code="J01C" /></DRUG2>
<DESCRIPTION>Increase of the effects and of the hematological toxicity of the methothrexate: inhibition of the renal tubular secretion of the methotrexate by the penicillins</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>344-METHOTREXATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROBENECID" rxcui="8698">
<ATC code="M04AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the toxicity of the methotrexate: inhibition of the renal tubular secretion of the methotrexate by the probenecid</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>344-METHOTREXATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTIBACTERIAL SULFONAMIDES" code="JO1E" /></DRUG2>
<DESCRIPTION>Increase of the hematological toxicity of the methotrexate</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Concentration dosage of methotrexate. Adjustment of the dosage if necessary during the administration of the substances together and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>344-METHOTREXATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TRIMETHOPRIM" rxcui="10829">
<ATC code="J01EA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>345-METHYLDOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHYLDOPA" rxcui="6876">
<ATC code="C02AB" />
<ATC code="C02AB01" />
<ATC code="C02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the methyldopa (formation of complexes)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the iron salts at a different time from the methyldopa (more than two hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>345-METHYLDOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHYLDOPA" rxcui="6876">
<ATC code="C02AB" />
<ATC code="C02AB01" />
<ATC code="C02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible decrease of the doses of levodopa.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>345-METHYLDOPA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHYLDOPA" rxcui="6876">
<ATC code="C02AB" />
<ATC code="C02AB01" />
<ATC code="C02AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="N05AN01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of lithium which can attain toxic values, with signs of overdose of lithium</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of lithium. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>346-METHYLPREDNISOLONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHYLPREDNISOLONE" rxcui="6902">
<ATC code="D07AA01" />
<ATC code="D10AA02" />
<ATC code="H02AB04" />
<ATC code="D07CA02" />
<ATC code="S01CA08" />
<ATC code="H02BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>For doses of 0.5g to 1 g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Testing of the INR 2 to 4 days after the bolus of mythylprednisolone or in the presence of signs of hemorrhage</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>346-METHYLPREDNISOLONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHYLPREDNISOLONE" rxcui="6902">
<ATC code="D07AA01" />
<ATC code="D10AA02" />
<ATC code="H02AB04" />
<ATC code="D07CA02" />
<ATC code="S01CA08" />
<ATC code="H02BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia Mecanism proposed: decrease of the hepatic elimination of the ciclosporin</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>346-METHYLPREDNISOLONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METHYLPREDNISOLONE" rxcui="6902">
<ATC code="D07AA01" />
<ATC code="D10AA02" />
<ATC code="H02AB04" />
<ATC code="D07CA02" />
<ATC code="S01CA08" />
<ATC code="H02BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>In case of prolonged use, increase of the plasma concentrations of the corticoid, because of decrease of its hepatic metabolism by the inhibitor, with risk of appearance of cushing syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>347-METOPROLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
<ATC code="C07BB52" />
<ATC code="C07AB52" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ABIRATERONE" rxcui="1100072">
<ATC code="L02BX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the abiraterone.</DESCRIPTION>
<SEVERITY>Precaution for use:</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the metropolol during the treatment with the abiraterone</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>347-METOPROLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
<ATC code="C07BB52" />
<ATC code="C07AB52" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the metoprolol used for heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the bupropion</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the bupropion</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>347-METOPROLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
<ATC code="C07BB52" />
<ATC code="C07AB52" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the metoprolol used for heart failure, and the cimetidine used at dosages greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with cimetidine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>347-METOPROLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
<ATC code="C07BB52" />
<ATC code="C07AB52" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CINACALCET" rxcui="407990">
<ATC code="H05BX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the metopolol during the treatment with cinacalcet.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>347-METOPROLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
<ATC code="C07BB52" />
<ATC code="C07AB52" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DARIFENACIN" rxcui="136198">
<ATC code="G04BD10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the metoprolol, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with darifenacin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>347-METOPROLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
<ATC code="C07BB52" />
<ATC code="C07AB52" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with the duloxetine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>347-METOPROLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
<ATC code="C07BB52" />
<ATC code="C07AB52" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06CA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the metoprolol, with especially excessive bradycardia, due to inhibition of its metabolism by the fluoxetine </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring; if needed, adjustment of the dosage of the metoprolol during the length of the treatment with the fluoxetine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>347-METOPROLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
<ATC code="C07BB52" />
<ATC code="C07AB52" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="HYDROXYCHLOROQUINE" rxcui="5521">
<ATC code="P01BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the metoprolol used in heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the hydroxychloroquine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the hydroxychloroquine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>347-METOPROLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
<ATC code="C07BB52" />
<ATC code="C07AB52" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MIRABEGRON" rxcui="1300786">
<ATC code="G04BD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the metoprolol used in heart failure, increase of the plasma concentrations of the metoprolol due to decrease of its metabolism by the mirabegron</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the metoprolol during the administration of it with the mirabegron</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>347-METOPROLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
<ATC code="C07BB52" />
<ATC code="C07AB52" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the metoprolol, especially with excessive bradycardia, due to inhibition of its metabolism by the paroxetine </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring; if needed, adjustment of the dosage of the metoprolol during the treatment with the paroxetine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>347-METOPROLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
<ATC code="C07BB52" />
<ATC code="C07AB52" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>347-METOPROLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
<ATC code="C07BB52" />
<ATC code="C07AB52" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>347-METOPROLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
<ATC code="C07BB52" />
<ATC code="C07AB52" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TERBINAFINE" rxcui="37801">
<ATC code="D01BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>348-METRONIDAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METRONIDAZOLE" rxcui="6922">
<ATC code="A02BD08" />
<ATC code="A02BD03" />
<ATC code="A02BD02" />
<ATC code="A01AB17" />
<ATC code="D06BX01" />
<ATC code="G01AF01" />
<ATC code="J01XD01" />
<ATC code="P01AB01" />
<ATC code="A02BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>348-METRONIDAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METRONIDAZOLE" rxcui="6922">
<ATC code="A02BD08" />
<ATC code="A02BD03" />
<ATC code="A02BD02" />
<ATC code="A01AB17" />
<ATC code="D06BX01" />
<ATC code="G01AF01" />
<ATC code="J01XD01" />
<ATC code="P01AB01" />
<ATC code="A02BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUSULFAN" rxcui="1828">
<ATC code="L01AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>348-METRONIDAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METRONIDAZOLE" rxcui="6922">
<ATC code="A02BD08" />
<ATC code="A02BD03" />
<ATC code="A02BD02" />
<ATC code="A01AB17" />
<ATC code="D06BX01" />
<ATC code="G01AF01" />
<ATC code="J01XD01" />
<ATC code="P01AB01" />
<ATC code="A02BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DISULFIRAM" rxcui="3554">
<ATC code="N07BB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of episodes of acute psychosis or of confused state, reversible upon stopping the administration of the two substances together</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>348-METRONIDAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METRONIDAZOLE" rxcui="6922">
<ATC code="A02BD08" />
<ATC code="A02BD03" />
<ATC code="A02BD02" />
<ATC code="A01AB17" />
<ATC code="D06BX01" />
<ATC code="G01AF01" />
<ATC code="J01XD01" />
<ATC code="P01AB01" />
<ATC code="A02BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)" code="L01BC-001" /></DRUG2>
<DESCRIPTION>Increase of the toxicity of the fluorouracil due to decrease of its clearance</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>348-METRONIDAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METRONIDAZOLE" rxcui="6922">
<ATC code="A02BD08" />
<ATC code="A02BD03" />
<ATC code="A02BD02" />
<ATC code="A01AB17" />
<ATC code="D06BX01" />
<ATC code="G01AF01" />
<ATC code="J01XD01" />
<ATC code="P01AB01" />
<ATC code="A02BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the the plasma concentrations of lithium which can attain toxic values with signs of overdose of lithium.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict monitoring of the the plasma concentrations of lithium and possible adjustment of the dosage of the lithium. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>348-METRONIDAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METRONIDAZOLE" rxcui="6922">
<ATC code="A02BD08" />
<ATC code="A02BD03" />
<ATC code="A02BD02" />
<ATC code="A01AB17" />
<ATC code="D06BX01" />
<ATC code="G01AF01" />
<ATC code="J01XD01" />
<ATC code="P01AB01" />
<ATC code="A02BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>349-METYRAPONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="METYRAPONE" rxcui="6923">
<ATC code="V04CD01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Risk of false negative results of the test with metyrapone, due to a decrease of its plasma concentrations, because of increase of its hepatic metabolism by the phenytoin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Double the dosage of the metyrapone.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>34-AMLODIPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMLODIPINE" rxcui="17767">
<ATC code="C08CA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication).</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>350-MEXILETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MEXILETINE" rxcui="6926">
<ATC code="C01BB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="N06BC01" />
<ATC code="V04CG30" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of caffeine, due to inhibition of its hepatic metabolism by the mexiletine</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>350-MEXILETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MEXILETINE" rxcui="6926">
<ATC code="C01BB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the mexiletine, due to inhibition of its metabolism by the fluvoxamine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG. Adjustment of the dosage of the mexiletine during the treatment with the fluvoxamine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>350-MEXILETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MEXILETINE" rxcui="6926">
<ATC code="C01BB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Decrease of the antiarrhythmic activity, of the plasma concentrations, and of the half life of the mexiletine (increase of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the mexiletine; if there is reason for it, adjustment of the dosage of the mexiletine during the treatment with the phenytoin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>350-MEXILETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MEXILETINE" rxcui="6926">
<ATC code="C01BB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with risk of overdose (decrease of the hepatic metabolism of the theophylline)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the mexiletine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>351-MIANSERIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIANSERIN" rxcui="6929">
<ATC code="N06AX03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Risk of ineffectiveness of the mianserin </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>352-MICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MICONAZOLE" rxcui="6932">
<ATC code="A01AB09" />
<ATC code="A07AC01" />
<ATC code="D01AC02" />
<ATC code="G01AF04" />
<ATC code="J02AB01" />
<ATC code="S02AA13" />
<ATC code="D01AC52" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Unpredictable hemorrhages, possibly serious</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>352-MICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MICONAZOLE" rxcui="6932">
<ATC code="A01AB09" />
<ATC code="A07AC01" />
<ATC code="D01AC02" />
<ATC code="G01AF04" />
<ATC code="J02AB01" />
<ATC code="S02AA13" />
<ATC code="D01AC52" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>352-MICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MICONAZOLE" rxcui="6932">
<ATC code="A01AB09" />
<ATC code="A07AC01" />
<ATC code="D01AC02" />
<ATC code="G01AF04" />
<ATC code="J02AB01" />
<ATC code="S02AA13" />
<ATC code="D01AC52" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG2>
<DESCRIPTION>With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MIDAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the midazolam by the anticonvulsant

</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MIDAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage during the treatment with the diltiazem</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MIDAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of midazolam due to reduction of its hepatic metabolism, with increase of sedation</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>--with the midazolam by mouth</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MIDAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation</DESCRIPTION>
<SEVERITY>Not recommended:</SEVERITY>
<COMMENT>--with the midazolam by mouth</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MIDAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of midazolam by the St Johns wort</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MIDAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPREVIR" code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism by the ombitasvir+ paritaprevir</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MIDAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of absence of effect of the midazolam, with very large decrease of its plasma concentrations, due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MIDAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ROXITHROMYCIN" rxcui="9478">
<ATC code="J01FA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Slight increase of sedation</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MIDAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism with increase of sedation</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage during the treatment with the stiripentol.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MIDAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of midazolam (decrease of its hepatic metabolism with increase of sedation)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of midazolam during the treatment with the verapamil.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>354-MIDECAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDECAMYCIN" rxcui="30005">
<ATC code="J01FA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the blood concentrations of ciclosporin and of the creatinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after the macrolide is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>355-MIDODRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDODRINE" rxcui="6963">
<ATC code="C01CA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of autoregulation (increase of the bradycardia inducing effect of the midodrine) and disorders of atrioventricular conduction</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these substances together cannot be avoided, strengthen clinical monitoring and EKG.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>355-MIDODRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDODRINE" rxcui="6963">
<ATC code="C01CA17" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>Hypertensive crises (inhibition of the metabolism of the pressor amines). Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI is stopped.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="METABOLIZED ANTICONVULSANTS" code="N03A-002" /></DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations and of the effectiveness of the anticonvulsant

.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG2>
<DESCRIPTION>Risk of ineffectiveness of the treatment by the proton pump inhibitor due to decrease of its metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the vitamin K antagonist, by reason of its enzymatic inducer effect, with risk of reduction of effectiveness, even complete loss of the effect, which could have possibly serious consequences (thrombolitic event)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>In case of an accidental use of the two substances together, do not stop the St Johns Wort suddenly, but test the INR before and then after the St Johns Wort is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BEDAQUILINE" rxcui="1364504">
<ATC code="J04AK05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations and of the effectiveness of the carbamazepine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="V03AX03" />
<ATC code="J05AR09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HA01" />
<ATC code="G03HB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cyproterone, due to increase of its hepatic metabolism by the St Johns Wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DACLATASVIR" rxcui="1606218">
<ATC code="J05AX14" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DASABUVIR" rxcui="1597381">
<ATC code="J05AX16" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the dasabuvir by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN" rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digoxinemia, because of the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (acute decompensated heart failure).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>In the case of the two substances being taken by accident, do not stop the St Johns Wort abruptly but test the plasma concentrations (or the effectiveness) of the digoxin before and then after the St Johns Wort is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DOLUTEGRAVIR" rxcui="1433868">
<ATC code="J05AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERIBULINE" rxcui="1045453">
<ATC code="L01XX41" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of eribuline by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the hormonal contraceptive, because of the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect which can have possibly serious consequences (pregnancy).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IDELALISIB" rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Decrease of the blood concentrations of the immunosuppressant, because of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which could have possibly serious consequences (rejection of a graft)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the protease inhibitor, due to the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (reduction of the antiretroviral effectiveness)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>In the case of the substances being taken together by accident, do not stop the St Johns Wort abruptly, but test the plasma concentrations (or the effectiveness) of the protease inhibitor before and then after the St Johns Wort is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="METABOLIZED TYROSINE-KINASE INHIBITORS " code="L01XE" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the tyrosine-kinase inhibitor, due to increase of its metabolism by the St Johns Wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)" code="N06AB" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IRINOTECAN" rxcui="51499">
<ATC code="L01XX19" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ISAVUCONAZOLE" rxcui="1720882">
<ATC code="J02AC05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of isavuconazole due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the ivabradine due to increase of its metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolidm by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LOMITAPIDE" rxcui="1364479">
<ATC code="C10AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the lomitapide</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LURASIDONE" rxcui="1040028">
<ATC code="N05AE05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the lurasidone due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MACITENTAN" rxcui="1442132">
<ATC code="C02KX0" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of macitentan due to increase of its metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MARAVIROC" rxcui="620216">
<ATC code="J05AX09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of maraviroc that could lead to a loss of virological response</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of midazolam by the St Johns wort</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NEVIRAPINE" rxcui="53654">
<ATC code="J05AG01" />
<ATC code="J05AR07" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of significant decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="L01XE31" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the nintedanib due to decrease of its absorption by the St Johns Wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="OXYCODONE" rxcui="7804">
<ATC code="N02AA55" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the oxycodone due to increase of its metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Possible adjustment of the dosage of the oxycodone.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the hormonal contraceptive, because of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (pregnancy)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the time the substances are administered together and after the St Johns wort is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUETIAPINE" rxcui="51272">
<ATC code="N05AH04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="REGORAFENIB" rxcui="1312397">
<ATC code="L01XE21" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of regorafenib due to increase of its metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RILPIVIRINE" rxcui="1102270">
<ATC code="J05AG05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMEPREVIR" rxcui="1482790">
<ATC code="J05AE14" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the effectiveness of the cholesterol lowering agent due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SOFOSBUVIR" rxcui="">
<ATC code="J05AX15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of sofobusvir due to decrease of its intestinal absorption by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of very large decrease of the concentrations of telaprevir</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of the hepatic metabolism of the telithromycin by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the theophylline, because of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (onset of an obstructive pulmonary syndrome) </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>In case of accidental use of the substances together, do not stop the St Johns wort abruptly but test the plasma concentrations (or the effectiveness) of the medication taken with it before and then after stopping the St Johns wort. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the St Johns wort, with decrease of its therapeutic effect</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Choose a therapeutic alternative that is little or not metabolized.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large reduction of the concentrations of verapamil, with risk of loss of its therapeutic effect</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VISMODEGIB" rxcui="1242987">
<ATC code="L01XX43" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of vismodegib</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large reduction of the concentrations of voriconazole, with risk of loss of its therapeutic effect</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>357-MINERALOCORTICOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MINERALOCORTICOIDS" code="H02AA0" /></DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great in patients with Addisons disease treated with the hydrocortisone and in the case of transplants.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>357-MINERALOCORTICOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MINERALOCORTICOIDS" code="H02AA0" /></DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in persons with Addison&#39;s disease treated with the hydrocortisone and in the case of transplants</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>358-MIRABEGRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIRABEGRON" rxcui="1300786">
<ATC code="G04BD12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the flecainide by decrease of its metabolism by the mirabegron</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the flecainide during the administration of these medications together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>358-MIRABEGRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIRABEGRON" rxcui="1300786">
<ATC code="G04BD12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the metoprolol used in heart failure, increase of the plasma concentrations of the metoprolol due to decrease of its metabolism by the mirabegron</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the metoprolol during the administration of these medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>358-MIRABEGRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIRABEGRON" rxcui="1300786">
<ATC code="G04BD12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the propafenone by decrease of its metabolism by the mirabegron</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the propafenone during the administration with the mirabegron</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>359-MITOMYCIN-C.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MITOMYCIN C" rxcui="632">
<ATC code="L01DC03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VINCA ALKALOIDS" code="L01CA" /></DRUG2>
<DESCRIPTION>Risk of increase of the pulmonary toxicity of the mitomycin and of the vinca-alkaloids</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>35-AMPHOTERICIN-B.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMPHOTERICIN B " rxcui="732">
<ATC code="J02AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="AMINOGLYCOSIDES " code="J01GB-001" /></DRUG2>
<DESCRIPTION>With the amphotericin B administered intravenously: increased risk of nephrotoxicity</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>35-AMPHOTERICIN-B.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMPHOTERICIN B " rxcui="732">
<ATC code="J02AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the amphotericin B administered intravenously:

greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances).</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>35-AMPHOTERICIN-B.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMPHOTERICIN B " rxcui="732">
<ATC code="J02AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
<ATC code="L04AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the amphotericin B administered intravenously: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances).</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>35-AMPHOTERICIN-B.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AMPHOTERICIN B " rxcui="732">
<ATC code="J02AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZIDOVUDINE" rxcui="11413">
<ATC code="J05AF01" />
<ATC code="J05AR01" />
<ATC code="J05AR04" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the amphotericin B administered intravenously:

increase of the hematological toxicity (addition of effects of bone marrow toxicity)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent CBC.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>360-MITOTANE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MITOTANE" rxcui="7004">
<ATC code="L01XX23" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DASABUVIR" rxcui="1597381">
<ATC code="J05AX16" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the dasabuvir by the mitotane</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>360-MITOTANE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MITOTANE" rxcui="7004">
<ATC code="L01XX23" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SPIRONOLACTONE" rxcui="9997">
<ATC code="C03DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of blockage of the action of the mitotane by the spironolactone</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>361-MIZOLASTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIZOLASTINE" rxcui="61455">
<ATC code="R06AX25" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>361-MIZOLASTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIZOLASTINE" rxcui="61455">
<ATC code="R06AX25" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>361-MIZOLASTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIZOLASTINE" rxcui="61455">
<ATC code="R06AX25" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>361-MIZOLASTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIZOLASTINE" rxcui="61455">
<ATC code="R06AX25" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>361-MIZOLASTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIZOLASTINE" rxcui="61455">
<ATC code="R06AX25" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>361-MIZOLASTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIZOLASTINE" rxcui="61455">
<ATC code="R06AX25" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>362-MOCLOBEMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MOCLOBEMIDE" rxcui="30121">
<ATC code="N06AG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the moclobemide, due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring with possible adjustment of the dosage of moclobemide</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>363-MODAFINIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MODAFINIL" rxcui="30125">
<ATC code="N06BA07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the blood concentrations and of the effectiveness of the immunosuppressant</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>363-MODAFINIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MODAFINIL" rxcui="30125">
<ATC code="N06BA07" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the contraceptive effectiveness, during the treatment and one cycle after the end of the treatment with the modafinil, due to its enzymatic inducer potential</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Use oral contraceptives containing estrogens and progestins that have 50 micrograms of estrogen or another method of contraception. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>363-MODAFINIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MODAFINIL" rxcui="30125">
<ATC code="N06BA07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SOFOSBUVIR" rxcui="1484911">
<ATC code="J05AX15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the modafinil</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>364-MONTELUKAST.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MONTELUKAST" rxcui="88249">
<ATC code="R03DC03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Risk of lower effectiveness of the montelukast due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>364-MONTELUKAST.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MONTELUKAST" rxcui="88249">
<ATC code="R03DC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of lower effectiveness of the montelukast due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the rifampicin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>365-MORPHINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MORPHINE" rxcui="7052">
<ATC code="N02AA01" />
<ATC code="N02AG01" />
<ATC code="R05DA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>366-OPIOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OPIOIDS" code="N0-R0" /></DRUG1>
<DRUG2>
<CLASS name="BARBITURATES" code="N05CA-001" /></DRUG2>
<DESCRIPTION>Increased risk of respiratory depression, which could be fatal in case of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>366-OPIOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OPIOIDS" code="N0-R0" /></DRUG1>
<DRUG2>
<CLASS name="BENZODIAZEPINES AND RELATED" code="N05-001" /></DRUG2>
<DESCRIPTION>Increased risk of respiratory depression, which could be fatal in case of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>367-AGONIST-ANTAGONIST-OPIOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AGONIST-ANTAGONIST OPIOIDS " code="NO2A-001" /></DRUG1>
<DRUG2>
<CLASS name="STEP II OPIOID ANALGESICS" code="N02A-003" /></DRUG2>
<DESCRIPTION>Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>367-AGONIST-ANTAGONIST-OPIOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AGONIST-ANTAGONIST OPIOIDS " code="NO2A-001" /></DRUG1>
<DRUG2>
<CLASS name="STEP III OPIOID ANALGESICS" code="N02A-002" /></DRUG2>
<DESCRIPTION>Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>367-AGONIST-ANTAGONIST-OPIOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AGONIST-ANTAGONIST OPIOIDS " code="NO2A-001" /></DRUG1>
<DRUG2>
<CLASS name="TRUE MORPHINE ANTITUSSIVES" code="R0GDA0-002" /></DRUG2>
<DESCRIPTION>Decrease of the antalgic or antitussive effect of the opioid, due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome</DESCRIPTION>
<SEVERITY>Not recommended </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>367-AGONIST-ANTAGONIST-OPIOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AGONIST-ANTAGONIST OPIOIDS " code="NO2A-001" /></DRUG1>
<DRUG2>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N07BC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the effect of the methadone due to competitive blocking of the receptors</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>367-AGONIST-ANTAGONIST-OPIOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AGONIST-ANTAGONIST OPIOIDS " code="NO2A-001" /></DRUG1>
<DRUG2>
<CLASS name="PARTIAL AGONIST OPIOIDS" code="PARAG" /></DRUG2>
<DESCRIPTION>Risk of decrease of the antalgic effect and/or of appearance of a withdrawal syndrome</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>368-PARTIAL-AGONIST-OPIOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PARTIAL AGONIST OPIOIDS" code="PARAG" /></DRUG1>
<DRUG2>
<CLASS name="STEP II OPIOID ANALGESICS" code="N02A-003" /></DRUG2>
<DESCRIPTION>Risk of decrease of the antalgic effect</DESCRIPTION>
<SEVERITY>Not Recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>368-PARTIAL-AGONIST-OPIOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PARTIAL AGONIST OPIOIDS" code="PARAG" /></DRUG1>
<DRUG2>
<CLASS name="STEP III OPIOID ANALGESICS" code="N02A-002" /></DRUG2>
<DESCRIPTION>Risk of decrease of the antalgic effect</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>368-PARTIAL-AGONIST-OPIOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PARTIAL AGONIST OPIOIDS" code="PARAG" /></DRUG1>
<DRUG2>
<CLASS name="AGONIST-ANTAGONIST OPIOIDS " code="NO2A-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the antalgic effect and/or appearance of a withdrawal syndrome</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>368-PARTIAL-AGONIST-OPIOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PARTIAL AGONIST OPIOIDS" code="PARAG" /></DRUG1>
<DRUG2>
<CLASS name="OPIOIDS FOR REPLACEMENT THERAPY" code="N07BC" /></DRUG2>
<DESCRIPTION>Risk of appearance of a withdrawal syndrome</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>369-OPIOIDS-FOR-REPLACEMENT-THERAPY.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OPIOIDS FOR REPLACEMENT THERAPY" code="N07BC" /></DRUG1>
<DRUG2>
<CLASS name="PARTIAL AGONIST OPIOIDS" code="PARAG" /></DRUG2>
<DESCRIPTION>Risk of appearance of a withdrawal syndrome </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>36-ANAGRELIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ANAGRELIDE" rxcui="596724">
<ATC code="L01XX35" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of hemorrhagic events </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>36-ANAGRELIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ANAGRELIDE" rxcui="596724">
<ATC code="L01XX35" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PLATELET AGGREGATION INHIBITORS" code="B01AC-001" /></DRUG2>
<DESCRIPTION>Increase of hemorraghic events </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>36-ANAGRELIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ANAGRELIDE" rxcui="596724">
<ATC code="L01XX35" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>370-MYCOPHENOLATE-MOFETIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MYCOPHENOLATE MOFETIL" rxcui="7145">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG2>
<DESCRIPTION>Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>370-MYCOPHENOLATE-MOFETIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MYCOPHENOLATE MOFETIL" rxcui="7145">
<ATC code="L04AA06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="FLUOROQUINOLONES" code="J01MA-001" /></DRUG2>
<DESCRIPTION>Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>370-MYCOPHENOLATE-MOFETIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MYCOPHENOLATE MOFETIL" rxcui="7145">
<ATC code="L04AA06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="AMINOPENICILLINS" code="J01CA" /></DRUG2>
<DESCRIPTION>Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>370-MYCOPHENOLATE-MOFETIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MYCOPHENOLATE MOFETIL" rxcui="7145">
<ATC code="L04AA06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG2>
<DESCRIPTION>Risk of general vaccine disease, possibly fatal.

</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>And during the 3 months following the end of the treatment</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>371-MYCOPHENOLATE-SODIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MYCOPHENOLATE SODIUM " rxcui="408142">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG2>
<DESCRIPTION>Risk of general vaccine disease, possibly fatal </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>And during the 3 months following the end of the treatment with these substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>372-NEBIVOLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NEBIVOLOL" rxcui="31555">
<ATC code="C07AB12" />
<ATC code="C07BB12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring; if needed, adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>372-NEBIVOLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NEBIVOLOL" rxcui="31555">
<ATC code="C07AB12" />
<ATC code="C07BB12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring; if needed adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>373-NEUROLEPTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NEUROLEPTICS" code="N05AA-003" /></DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>Vasidilator effect and risk of hypotension, especially orthostatic (additive effect)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>373-NEUROLEPTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NEUROLEPTICS" code="N05AA-003" /></DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of appearance of neuropsychic signs evocative of a neuroleptic malignant syndrome or of lithium poisoning</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>373-NEUROLEPTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NEUROLEPTICS" code="N05AA-003" /></DRUG1>
<DRUG2>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of therapeutic failure when there is concomitant treatment with orlistat</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>374-ANTIEMETIC-NEUROLEPTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIEMITIC NEUROLEPTICS" code="A03FA-001" /></DRUG1>
<DRUG2>
<CLASS name="DOPAMINERGICS" code="N04B-002" /></DRUG2>
<DESCRIPTION>Reciprocal antagonism between the dopaminergic and the neuropleptic</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Use an antiemetic without extrapyramidal effects. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>374-ANTIEMETIC-NEUROLEPTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIEMITIC NEUROLEPTICS" code="A03FA-001" /></DRUG1>
<DRUG2>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
<ATC code="N04BA02" />
<ATC code="N04BA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Reciprocal antagonism between the levodopa and the neuroleptic</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Use an antiemitic without extrapyramidal effects.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>375-ANTIPSYCHOTIC-NEUROLEPTICS-(EXCEPT-CLOZAPINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)" code="N05A-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTIPARKINSONIAN DOPAMINERGICS" code="N04B-001" /></DRUG2>
<DESCRIPTION>Reciprocal antagonism of the dopaminergic and the neuroleptics. The dopaminergic can cause or increase the psychotic disorders. When a treatment with neuroleptics is necessary for a parkinsons patient treated with dopaminergics, these latter must be decreased progressively until they are stopped (their abrupt discontinuation exposes the patient to a risk of &quot;neuroleptic malignant syndrome&quot; (NMS)).</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>375-ANTIPSYCHOTIC-NEUROLEPTICS-(EXCEPT-CLOZAPINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)" code="N05A-001" /></DRUG1>
<DRUG2>
<CLASS name="DOPAMINERGICS, EXCEPT PARKINSON" code="G02CB-002" /></DRUG2>
<DESCRIPTION>Reciprocal antagonism of the dopamine agonist and the neuroleptics</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>375-ANTIPSYCHOTIC-NEUROLEPTICS-(EXCEPT-CLOZAPINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)" code="N05A-001" /></DRUG1>
<DRUG2>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
<ATC code="N04BA02" />
<ATC code="N04BA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Reciprocal antagonism of the levodopa and the neuroleptics</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>With a parkinsons patient, use the minimum effective doses of each of the two medications. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>376-NEUROLEPTICS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NEUROLEPTICS THAT TEND TO INDUCE TORSADES DE POINTES" code="N05A-002" /></DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>-with citalopram, domperidone, escitalopram, hydroxyzine and piperaquine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>377-NEVIRAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NEVIRAPINE" rxcui="53654">
<ATC code="J05AG01" />
<ATC code="J05AR07" />
<ATC code="J05AR05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR Possible adjustment of the dosage of the vitamin K antagonist</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>377-NEVIRAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NEVIRAPINE" rxcui="53654">
<ATC code="J05AG01" />
<ATC code="J05AR07" />
<ATC code="J05AR05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the atanazavir due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of these medications together proves necessary, adjustment of the dosage of the atazanavir with regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>377-NEVIRAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NEVIRAPINE" rxcui="53654">
<ATC code="J05AG01" />
<ATC code="J05AR07" />
<ATC code="J05AR05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Doubling of the concentrations of nevirapine with risk of increase of its undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the nevirapine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>377-NEVIRAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NEVIRAPINE" rxcui="53654">
<ATC code="J05AG01" />
<ATC code="J05AR07" />
<ATC code="J05AR05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FOSAMPRENAVIR" rxcui="358262">
<ATC code="J05AE07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the amprenavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>377-NEVIRAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NEVIRAPINE" rxcui="53654">
<ATC code="J05AG01" />
<ATC code="J05AR07" />
<ATC code="J05AR05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="INDINAVIR" rxcui="114289">
<ATC code="J05AE02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the indinavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>377-NEVIRAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NEVIRAPINE" rxcui="53654">
<ATC code="J05AG01" />
<ATC code="J05AR07" />
<ATC code="J05AR05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole, for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>377-NEVIRAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NEVIRAPINE" rxcui="53654">
<ATC code="J05AG01" />
<ATC code="J05AR07" />
<ATC code="J05AR05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of significant decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>377-NEVIRAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NEVIRAPINE" rxcui="53654">
<ATC code="J05AG01" />
<ATC code="J05AR07" />
<ATC code="J05AR05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>377-NEVIRAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NEVIRAPINE" rxcui="53654">
<ATC code="J05AG01" />
<ATC code="J05AR07" />
<ATC code="J05AR05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the nevirapine.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of the substances together cannot be avoided, strict clinical monitoring and possible adjustment of the dosage of the voriconazole during the administration of the substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>378-NICARDIPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NICARDIPINE" rxcui="7396">
<ATC code="C08CA04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage of the immunosuppressant during the treatment with nicardipine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>379-NIFEDIPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NIFEDIPINE" rxcui="7417">
<ATC code="C08CA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of addition of undesirable effects of the gum disorders type</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Use another dihydropyridine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>379-NIFEDIPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NIFEDIPINE" rxcui="7417">
<ATC code="C08CA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the hypotensive effect of the nifedipine due to inhibition of its hepatic metabolism by the cimetidine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring: adjust the dosage of the nifedipine during the treatment with the cimetidine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>379-NIFEDIPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NIFEDIPINE" rxcui="7417">
<ATC code="C08CA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large increase of the concentrations of nefedipine due to decrease of its hepatic metabolism by the diltiazem, with risk of severe hypotension</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>37-ANAKINRA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ANAKINRA" rxcui="72435">
<ATC code="L04AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTI-TNF ALPHA" code="4ABO" /></DRUG2>
<DESCRIPTION>Increased risk of serious infections and of neutropenia.</DESCRIPTION>
<SEVERITY> Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>37-ANAKINRA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ANAKINRA" rxcui="72435">
<ATC code="L04AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ETANERCEPT" rxcui="214555">
<ATC code="L04AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of serious infections and of neutropenia</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>380-NIMODIPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NIMODIPINE" rxcui="7426">
<ATC code="C08CA06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism by the inducer

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the inducer and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>380-NIMODIPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NIMODIPINE" rxcui="7426">
<ATC code="C08CA06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the rifampicin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>380-NIMODIPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NIMODIPINE" rxcui="7426">
<ATC code="C08CA06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG2>
<DESCRIPTION>With the nimodipine by oral route, and by extrapolation, by injection: risk of increase of the hypotensive effect of the nimodipine due to increase of its plasma concentrations (decrease of its metabolism by the valproic acid).</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the nintedanib by increase of its absorption by the amiodarone</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZAPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the nintedanib by decrease of its absorption by the carbamazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the nintedanib by increase of its absorption by the ciclosporin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="D10AF52" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the nintedanib by increase of its absorption by the erythromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the nintedanib by increase of its absorption by the ritonavir boosted protease inhibitor</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the nintedanib by increase of its absorption by the itraconazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the nintedanib by increase of its absorption by the ketoconazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the nintedanib by decrease of its absorption by the St Johns Wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the nintedanib by decrease of its absorption by the phenytoin or the fosphenytoin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the nintedanib by decrease of its absorption by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the nintedanib by increase of its absorption by the verapamil</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>382-NORFLOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NORFLOXACIN" rxcui="7517">
<ATC code="J01MA06" />
<ATC code="S01AE02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="V04CG30" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of caffeine, due to decrease of the hepatic metabolism of the caffeine</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>382-NORFLOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NORFLOXACIN" rxcui="7517">
<ATC code="J01MA06" />
<ATC code="S01AE02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de points. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>382-NORFLOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NORFLOXACIN" rxcui="7517">
<ATC code="J01MA06" />
<ATC code="S01AE02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>383-NORTRIPTYLINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NORTRIPTYLINE" rxcui="7531">
<ATC code="N06AA10" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the nortriptyline due to decrease of its hepatic metabolism by the bupropion</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the nortriptyline during the treatment with the bupropion.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>384-NOSCAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NOSCAPINE" rxcui="7533">
<ATC code="R05DA07" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>385-OLANZAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OLANZAPINE" rxcui="61381">
<ATC code="N05AH03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the olanzapine and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the carbamazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and if needed, adjustment of the dosage of the olanzapine. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>385-OLANZAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OLANZAPINE" rxcui="61381">
<ATC code="N05AH03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of the olanzapine, with risk of increase of its undesirable effects, due to decrease of its hepatic metabolism by the fluvoxamine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the olanzapine during the treatment with fluvoxamine.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>386-OLAPARIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OLAPARIB" rxcui="1597582">
<ATC code="L01XX46" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of olaparib by the amiodarone</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, limit the dose of olaparib to 200 mg twice a day with the amiodarone</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>386-OLAPARIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OLAPARIB" rxcui="1597582">
<ATC code="L01XX46" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of olaparib by the diltiazam</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, limit the dose of olaparib to 200 mg twice a day. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>386-OLAPARIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OLAPARIB" rxcui="1597582">
<ATC code="L01XX46" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of olaparib by the fluconazole</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, limit the dose of olaparib to 200 mg twice a day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>386-OLAPARIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OLAPARIB" rxcui="1597582">
<ATC code="L01XX46" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYME INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease, possibly very large depending on the inducer, of the plasma concentrations of the olaparib due to increase of its hepatique metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>386-OLAPARIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OLAPARIB" rxcui="1597582">
<ATC code="L01XX46" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of olaparib by the inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, limit the dose of olaparib to 150 mg twice a day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>386-OLAPARIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OLAPARIB" rxcui="1597582">
<ATC code="L01XX46" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of olaparib by the verapamil.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, limit the dose of olaparid to 200 mg twice a day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>387-OMBITASVIR-PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="FUSIDIC ACID" rxcui="4608">
<ATC code="D06AX01" />
<ATC code="D09AA02" />
<ATC code="J01XC01" />
<ATC code="S01AA13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the fusidic acid due to decrease of its hepatic metabolism by the bitherapy.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>387-OMBITASVIR-PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the vasoconstrictor alkaloid of ergot of rye due to decrease of its hepatic metabolism by the bitherapy.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>387-OMBITASVIR-PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="ALFUZOSIN" rxcui="17300">
<ATC code="G04CA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the alfuzosin due to decrease of its hepatic metabolism by the bitherapy.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>387-OMBITASVIR-PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the amiodarone due to decrease of its hepatic metabolism by the bitherapy.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>387-OMBITASVIR-PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the atorvastatin due to decrease of its hepatic metabolism by the bitherapy.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>387-OMBITASVIR-PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the colchicine due to decrease of its hepatic metabolism by the bitherapy.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
<COMMENT>--with patients having renal and/or hepatic insufficiency</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>387-OMBITASVIR-PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="ETHINYLESTRADIOL" rxcui="4124">
<ATC code="G03AA15" />
<ATC code="G03AB07" />
<ATC code="G03AA09" />
<ATC code="G03AB05" />
<ATC code="G03AA12" />
<ATC code="G03CA01" />
<ATC code="L02AA03" />
<ATC code="G03AA01" />
<ATC code="G03AA10" />
<ATC code="G03AB06" />
<ATC code="G03AA07" />
<ATC code="G03AB03" />
<ATC code="G03AA03" />
<ATC code="G03AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hepatotoxicity</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>387-OMBITASVIR-PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the bitherapy due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>387-OMBITASVIR-PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the bitherapy due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
<COMMENT>--except with the ritonavir</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>387-OMBITASVIR-PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism by the bitherapy</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>387-OMBITASVIR-PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the pimozide due to decrease of its hepatic metabolism by the bitherapy</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>387-OMBITASVIR-PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="QUETIAPINE" rxcui="51272">
<ATC code="N05AH04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the quetiapine due to decrease of its hepatic metabolism by the bitherapy</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>387-OMBITASVIR-PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the quinidine due to decrease of its hepatic metabolism by the bitherapy</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>387-OMBITASVIR-PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="SILDENAFIL" rxcui="136411">
<ATC code="G04BE03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the sildenafil due to decrease of its hepatic metabolism by the bitherapy</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>387-OMBITASVIR-PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the simvastatin due to decrease of its hepatic metabolism by the bitherapy</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>387-OMBITASVIR-PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the ticagrelor due to decrease of its hepatic metabolism by the bitherapy</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>388-OMEPRAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OMEPRAZOLE" rxcui="7646">
<ATC code="A02BC01" />
<ATC code="A02BD05" />
<ATC code="A02BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Moderate increase of the digoxinemia due to increase of its absorption by the omeprazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and monitoring of the digoxinemia, particularly with an older patient. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>388-OMEPRAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OMEPRAZOLE" rxcui="7646">
<ATC code="A02BC01" />
<ATC code="A02BD05" />
<ATC code="A02BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the tacrolimus</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the tacrolimus, testing of the renal function and adjustment of the dosage during the administration of the substances together and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>389-ONDANSETRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ONDANSETRON" rxcui="26225">
<ATC code="A04AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="APOMORPHINE" rxcui="1043">
<ATC code="G04BE07" />
<ATC code="N04BC07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Severe hypotension and loss of consciousness have been reported when ondansetron is administered with apomorphine</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>389-ONDANSETRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ONDANSTRON" rxcui="26225">
<ATC code="A04AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>389-ONDANSETRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ONDANSETRON" rxcui="26225">
<ATC code="A04AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TRAMADOL" rxcui="10689">
<ATC code="N02AX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the intensity and of the duration of the analgesic effect of the tramadol and risk of decrease of the antiemetic effect of the ondansetron</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>38-AGONIST-OPIOID-ANALGESICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AGONIST OPIOID ANALGESICS" code="N01A-N02A" /></DRUG1>
<DRUG2>
<CLASS name="OTHER AGONIST OPIOID ANALGESICS" code="N01A-N02A" /></DRUG2>
<DESCRIPTION>Increased risk of respiratory depression which can be fatal in case of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>38-AGONIST-OPIOID-ANALGESICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AGONIST OPIOID ANALGESICS" code="N01A-N02A" /></DRUG1>
<DRUG2>
<CLASS name="MORPHINE LIKE ANTITUSSIVES" code="R05DA0-001" /></DRUG2>
<DESCRIPTION>Increased risk of respiratory depression, which can be fatal in cases of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>38-AGONIST-OPIOID-ANALGESICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AGONIST OPIOID ANALGESICS" code="N01A-N02A" /></DRUG1>
<DRUG2>
<CLASS name="TRUE MORPHINE ANTITUSSIVES" code="R0GDA0-002" /></DRUG2>
<DESCRIPTION>Increased risk of respiratory depression which can be fatal in cases of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>390-GOLD.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GOLD" rxcui="1311190">
<ATC code="M01CB" />
<ATC code="M01CB01" />
<ATC code="M01CB02" />
<ATC code="M01CB03" />
<ATC code="M01CB04" />
<ATC code="M01CB05" />
<ATC code="V10AX06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>With the gold salts administered by IV route: risk of &quot;nitritoid&quot; reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly sudden drop in blood pressure)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>391-PLATINUM-BASED-ANTINEOPLASTIC-CANCER-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PLATINUM-BASED ANTINEOPLASTIC CANCER DRUGS" code="L01XA" /></DRUG1>
<DRUG2>
<CLASS name="AMINOGLYCOSIDES" code="J01GB-001" /></DRUG2>
<DESCRIPTION>Addition of the nephrotoxic and/or ototoxic effects, especially in the case of pre-existing renal insufficiency</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>391-PLATINUM-BASED-ANTINEOPLASTIC-CANCER-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PLATINUM-BASED ANTINEOPLASTIC CANCER DRUGS" code="L01XA" /></DRUG1>
<DRUG2>
<CLASS name="LOOP DIURETICS" code="C03CA-001" /></DRUG2>
<DESCRIPTION>Risk of addition of the ototoxic and/or nephrotoxic effects</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>392-ORLISTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the amiodarone and of its active metabolite

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and, if needed, EKG</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>392-ORLISTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG2>
<DESCRIPTION>Risk of therapeutic failure when there is concomitant treatment with orlistat</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>392-ORLISTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the orlistat and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>392-ORLISTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the blood concentrations of ciclosporin due to decrease of its intestinal absorption, with risk of loss of the immunosuppressive activity</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Take the orlistat at a different time from the ciclosporin (at least three hours apart). Reinforce testing of the blood dosages of ciclosporin, especially at the beginning of the administration of the two medications together, and at the time of a possible increase of the dosage of the orlistat.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>392-ORLISTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG2>
<DESCRIPTION>Risk of disequilibrium of the thyroid replacement therapy when there is treatment with orlistat</DESCRIPTION>
<SEVERITY>Take into account </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>392-ORLISTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ORLISTAT " rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)" code="N06AB" /></DRUG2>
<DESCRIPTION>Risk of therapeutic failure when there is concomitant treatment with orlistat</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>392-ORLISTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of therapeutic failure when there is concomitant treatment with orlistat</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>392-ORLISTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS" code="N06A" /></DRUG2>
<DESCRIPTION>Risk of therapeutic failure when there is concomitant treatment with orlistat</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>392-ORLISTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NEUROLEPTICS" code="N05AA-003" /></DRUG2>
<DESCRIPTION>Risk of therapeutic failure when there is concomitant treatment with orlistat</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>392-ORLISTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN D" code="A11CC" /></DRUG2>
<DESCRIPTION>Decrease of the absorption of the vitamin D</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>393-ORNIDAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ORNIDAZOLE" rxcui="7701">
<ATC code="G01AF06" />
<ATC code="J01XD03" />
<ATC code="P01AB03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)" code="L01BC-001" /></DRUG2>
<DESCRIPTION>Increase of the toxicity of the fluorouracil due to decrease of its clearance</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>394-OXCARBAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OXCARBAZEPINE" rxcui="32624">
<ATC code="N03AF02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NON-CONTRACEPTIVE ESTROGENS" code="G03C-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the hormonal treatment, due to increase of its hepatic metabolism by the oxcarbazepine.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the treatment with the oxcarbazepine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>394-OXCARBAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OXCARBAZEPINE" rxcui="32624">
<ATC code="N03AF02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LAMOTRIGINE" rxcui="28439">
<ATC code="N03AX09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of the lamotrigine with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and testing of the plasma concentrations, with adjustment of the dosage of the lamotrigine if needed.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>394-OXCARBAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OXCARBAZEPINE" rxcui="32624">
<ATC code="N03AF02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PERAMPANEL" rxcui="1356552">
<ATC code="N03AX22" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease by half of the concentrations of perampanel and slight increase of those of the oxcarbazepine.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>394-OXCARBAZEPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OXCARBAZEPINE" rxcui="32624">
<ATC code="N03AF02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TOPIRAMATE" rxcui="38404">
<ATC code="38404" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and, if needed, adjustment of the dosage of the topiramate during the treatment with the oxcarbazepine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>395-OXPRENOLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OXPRENOLOL" rxcui="7801">
<ATC code="C07AA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforce clinical monitoring, in particular during the first weeks of the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>396-OXYCODONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OXYCODONE" rxcui="7804">
<ATC code="N02AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the undesirable effects, especially respiratory ones, of the oxycodone due to decrease of its metabolism by the fluconazole</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the oxycodone during the treatment with the fluconazole and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>396-OXYCODONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OXYCODONE" rxcui="7804">
<ATC code="N02AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYME INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the oxycodone due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Possible adjustment of the dosage of the oxycodone</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>396-OXYCODONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OXYCODONE" rxcui="7804">
<ATC code="N02AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the undesirable effects, especially respiratory ones, of the oxycodone due to decrease of its metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the oxycodone during the treatment with the inhibitorand after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>396-OXYCODONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OXYCODONE" rxcui="7804">
<ATC code="N02AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHN'S WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the oxycodone due to increase of its metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Possible adjustment of the dosage of the oxycodone</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>397-PACLITAXEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PACLITAXEL" rxcui="56946">
<ATC code="L01CD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLOPIDOGREL" rxcui="32968">
<ATC code="B01AC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of the paclitaxel by the clopidogrel, with risk of increase of the undesirable effects. </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>398-GRAPEFRUIT-(JUICE-OR-FRUIT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRAPEFRUIT" >
<ATC code="JUICE" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09XA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the aliskiren when grapefruit is consumed</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>398-GRAPEFRUIT-(JUICE-OR-FRUIT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRAPEFRUIT" >
<ATC code="JUICE" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the cholesterol lowering medication, with risk of appearance of undesirable effects, especially muscular ones</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>398-GRAPEFRUIT-(JUICE-OR-FRUIT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRAPEFRUIT" >
<ATC code="JUICE" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AVANAFIL" rxcui="1291301">
<ATC code="G04BE10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the avanafil, with risk of hypotension

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>398-GRAPEFRUIT-(JUICE-OR-FRUIT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRAPEFRUIT" >
<ATC code="JUICE" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUSPIRONE" rxcui="1827">
<ATC code="N05BE01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the buspirone due to decrease of its metabolism by the grapefruit</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>398-GRAPEFRUIT-(JUICE-OR-FRUIT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRAPEFRUIT" >
<ATC code="JUICE" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine, with risk of overdose, due to inhibition of its metabolism by the grapefruit</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>398-GRAPEFRUIT-(JUICE-OR-FRUIT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRAPEFRUIT" >
<ATC code="JUICE" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of dronedarone due to inhibition of its metabolism by the grapefruit</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>398-GRAPEFRUIT-(JUICE-OR-FRUIT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRAPEFRUIT" >
<ATC code="JUICE" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="HALOFANTRINE" rxcui="50749">
<ATC code="P01BX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>398-GRAPEFRUIT-(JUICE-OR-FRUIT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRAPEFRUIT" >
<ATC code="JUICE" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Increase of the bioavailability of the immunosuppressant and as a result of its undesirable effects</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>398-GRAPEFRUIT-(JUICE-OR-FRUIT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRAPEFRUIT" >
<ATC code="JUICE" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the ivabradine and of its undesirable effects (inhibition of its intestinal metabolism by the grapefruit)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>398-GRAPEFRUIT-(JUICE-OR-FRUIT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRAPEFRUIT" >
<ATC code="JUICE" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LERCANIDIPINE" rxcui="135056">
<ATC code="C08CA13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects, especially edema, due to decrease of the intestinal metabolism of the dihydropyridine</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>398-GRAPEFRUIT-(JUICE-OR-FRUIT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRAPEFRUIT" >
<ATC code="JUICE" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LURASIDONE" rxcui="1040028">
<ATC code="N05AE05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the lurasidone due to decrease of its metabolism by the grapefruit</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>398-GRAPEFRUIT-(JUICE-OR-FRUIT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRAPEFRUIT" >
<ATC code="JUICE" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="REGORAFENIB" rxcui="1312397">
<ATC code="L01XE21" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of regorafenib due to decrease of its hepatic metabolism by the grapefruit</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>398-GRAPEFRUIT-(JUICE-OR-FRUIT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRAPEFRUIT" >
<ATC code="JUICE" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SERTRALINE" rxcui="36437">
<ATC code="N06AB06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Sometimes large increase of the plasma concentrations of the antidepressant with certain patients due to decrease of intestinal metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>398-GRAPEFRUIT-(JUICE-OR-FRUIT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRAPEFRUIT" >
<ATC code="JUICE" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large increase of the plasma concentrations of the cholesterol lowering medication, with risk of onset of undesirable effects, especially muscular ones.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>398-GRAPEFRUIT-(JUICE-OR-FRUIT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRAPEFRUIT" >
<ATC code="JUICE" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG2>
<DESCRIPTION>Doubling of the plasma concentrations of the platelet aggregation inhibitor, with risk of increase of the undesirable effects, especially hemorrhagic</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>398-GRAPEFRUIT-(JUICE-OR-FRUIT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRAPEFRUIT" >
<ATC code="JUICE" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VARDENAFIL" rxcui="306674">
<ATC code="G04BE09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the vardenafil, with risk of hypotension</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>398-GRAPEFRUIT-(JUICE-OR-FRUIT).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRAPEFRUIT" >
<ATC code="JUICE" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
<ATC code="FRUIT" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of verapamil, with risk of onset of undesirable effects</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>399-PANOBINOSTAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PANOBINOSTAT" rxcui="1603350">
<ATC code="L01XX42" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects, especially cardiac ones, of the panobinostat due to decrease of its metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG. Possible adjustment of the dosage of the panobinostat</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>39-STEP-II-OPIOID-ANALGESICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STEP II OPIOID ANALGESICS" code="N02A-003" /></DRUG1>
<DRUG2>
<CLASS name="AGONIST-ANTAGONIST OPIOIDS " code="NO2A-001" /></DRUG2>
<DESCRIPTION>Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>39-STEP-II-OPIOID-ANALGESICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STEP II OPIOID ANALGESICS" code="N02A-003" /></DRUG1>
<DRUG2>
<CLASS name="PARTIAL AGONIST OPIOIDS" code="PARAG" /></DRUG2>
<DESCRIPTION>Risk of decrease of the antalgic effect</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>3-ACETAZOLAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETAZOLAMIDE" rxcui="167">
<ATC code="S01EC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the undesirable effects, and especially of metabolic acidosis, of the acetylsalicylic acid in large doses and of the acetazolamide, due to decrease of the elimination of the acetylsalicylic acid by the acetazolamide</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>3-ACETAZOLAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETAZOLAMIDE" rxcui="167">
<ATC code="S01EC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and, if needed, testing of the plasma concentrations of carbamazepine and possible reduction of its dosage. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>3-ACETAZOLAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETAZOLAMIDE" rxcui="167">
<ATC code="S01EC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict monitoring of the plasma concentrations of lithium and possible adjustment of the dosage of the lithium.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>3-ACETAZOLAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETAZOLAMIDE" rxcui="167">
<ATC code="S01EC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG2>
<DESCRIPTION>Increase of the hyperammonemia, with incresed risk of encephalopathy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>400-PARACETAMOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PARACETAMOL" rxcui="161">
<ATC code="N02BE01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage when taking paracetamol in maximal doses (4g/day) for at least 4 days</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the paracetamol and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>401-PAROXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, testing of the plasma concentrations of carbamazepine, and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>401-PAROXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MEQUITAZINE" rxcui="29528">
<ATC code="R06AD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>401-PAROXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the metoprolol, with especially excessive bradycardia, due to inhibition of its metaboilsm by the paroxetine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring; if needed, adjustment of the dosage of the metoprolol during the length of the treatment with the paroxetine and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>401-PAROXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NEBIVOLOL" rxcui="31555">
<ATC code="C07AB12" />
<ATC code="C07BB12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring; if needed adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>401-PAROXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>C0NTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>401-PAROXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RISPERIDONE" rxcui="35636">
<ATC code="N05AX08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the paroxetine, with risk of increase of the undesirable effects. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and, if needed, adjustment of the dosage of the risperidone. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>401-PAROXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TAMOXIFEN" rxcui="10324">
<ATC code="L02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the paroxetine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>401-PAROXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the paroxetine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>402-PEFLOXACIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PEFLOXACIN" rxcui="7960">
<ATC code="J01MA03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>403-PEG-INTERFERON-ALFA-2A.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PEG-INTERFERON ALFA-2A" rxcui="120608">
<ATC code="L03AB11" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELBIVUDINE" rxcui="474128">
<ATC code="J05AF11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of peripheral neuropathy</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>404-PEMETREXED.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PEMETREXED" rxcui="68446">
<ATC code="L01BA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-in case of weak to moderate renal function </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>404-PEMETREXED.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PEMETREXED" rxcui="68446">
<ATC code="L01BA04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the NSAIs)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>--in case of weak to moderate renal function </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>405-PENEMS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PENEMS" code="J01DH" /></DRUG1>
<DRUG2>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG2>
<DESCRIPTION>Risk of onset of convulsive crises, due to rapid decrease of the plasma concentrations of the valproic acid, that can become undetectable.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>406-PENICILLAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PENICILLAMINE" rxcui="7975">
<ATC code="M01CC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the penicillamine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the iron salts at a different time from the penicillamine (more than 2 hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>407-PENICILLINS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PENICILLINS" code="J01C" /></DRUG1>
<DRUG2>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effects and of the hematological toxicity of the methothrexate: inhibition of the renal tubular secretion of the methotrexate by the penicillins</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>408-AMINOPENICILLINS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AMINOPENICILLINS" code="J01CA" /></DRUG1>
<DRUG2>
<DRUG name="ALLOPURINOL" rxcui="519">
<ATC code="M04AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of cutaneous reactions

</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>408-AMINOPENICILLINS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="AMINOPENICILLINS" code="J01CA" /></DRUG1>
<DRUG2>
<DRUG name="MYCOPHENOLATE MOFETIL" rxcui="7145">
<ATC code="L04AA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>409-PENTAMIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PENTAMIDINE" rxcui="7994">
<ATC code="P01CX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIDANOSINE" rxcui="3364">
<ATC code="J05AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of pancreatitis due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of the blood amylase level. Do not use these two medications together if the blood amylase level is at the high range of normal. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>409-PENTAMIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PENTAMIDINE" rxcui="7994">
<ATC code="P01CX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FOSCARNET" rxcui="33562">
<ATC code="J05AD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of severe hypocalcemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of the calcemia and supplementation if necessary.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>409-PENTAMIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PENTAMIDINE" rxcui="7994">
<ATC code="P01CX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="J05AR07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>409-PENTAMIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PENTAMIDINE" rxcui="7994">
<ATC code="P01CX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>40-STEP-III-OPIOID-ANALGESICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STEP III OPIOID ANALGESICS" code="N02A-002" /></DRUG1>
<DRUG2>
<CLASS name="AGONIST-ANTAGONIST OPIOIDS " code="NO2A-001" /></DRUG2>
<DESCRIPTION>Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>40-STEP-III-OPIOID-ANALGESICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="STEP III OPIOID ANALGESICS" code="N02A-002" /></DRUG1>
<DRUG2>
<CLASS name="PARTIAL AGONIST OPIOIDS" code="PARAG" /></DRUG2>
<DESCRIPTION>Risk of decrease of the antalgic effect</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>410-PENTOSTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PENTOSTATIN" rxcui="8011">
<ATC code="L01XX08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CYCLOPHOSPHAMIDE" rxcui="3002">
<ATC code="L01AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of pulmonary toxicity which could be fatal</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>410-PENTOSTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PENTOSTATIN" rxcui="8011">
<ATC code="L01XX08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUDARABINE" rxcui="24698">
<ATC code="L01BB05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of pulmonary toxicity which could be fatal</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>411-PENTOXIFYLLINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PENTOXIFYLLINE" rxcui="8013">
<ATC code="C04AD03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage

</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>411-PENTOXIFYLLINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PENTOXIFYLLINE" rxcui="8013">
<ATC code="C04AD03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the pentoxifylline and a week after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>411-PENTOXIFYLLINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PENTOXIFYLLINE" rxcui="8013">
<ATC code="C04AD03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with risk of overdose (competition at the level of the hepatic metabolism of the theophylline)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the pentoxifylline and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>412-PERAMPANEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PERAMPANEL" rxcui="1356552">
<ATC code="N03AX22" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Large decrease (up to two thirds) of the concentrations of perampanel

</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>412-PERAMPANEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PERAMPANEL" rxcui="1356552">
<ATC code="N03AX22" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HA01" />
<ATC code="G03HB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>For doses of perampanel &gt; or = to 12 mg/day, risk of decrease of the effectiveness of the cyproterone</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>For its indication as a hormonal contraceptive: the use of another method of contraception in particular a barrier type is preferred for the length of time these substances are taken together and a cycle following</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>412-PERAMPANEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PERAMPANEL" rxcui="1356552">
<ATC code="N03AX22" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="OXCARBAZEPINE" rxcui="32624">
<ATC code="N03AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease by half of the concentrations of perampanel and slight increase of those of the oxcarbazepine.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>412-PERAMPANEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PERAMPANEL" rxcui="1356552">
<ATC code="N03AX22" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG2>
<DESCRIPTION>For doses of perampanel &gt;=12 mg/day: Risk of decrease of the contraceptive effectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another method of contraception, in particular a barrier type, should be used.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>412-PERAMPANEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PERAMPANEL" rxcui="1356552">
<ATC code="N03AX22" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease (up to two thirds) of the concentrations of perampanel</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>413-PETHIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PETHIDINE " rxcui="6754">
<ATC code="N02AB02" />
<ATC code="N02AG03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>413-PETHIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PETHIDINE " rxcui="6754">
<ATC code="N02AB02" />
<ATC code="N02AG03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>413-PETHIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PETHIDINE " rxcui="6754">
<ATC code="N02AB02" />
<ATC code="N02AG03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="MAOI-B " code="N04BD0-001" /></DRUG2>
<DESCRIPTION>Symptoms of central nervous system excitability evoking a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>414-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG1>
<DRUG2>
<DRUG name="CHOLIC ACID " rxcui="1440856">
<ATC code="A05AA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Antagonist effect of the barbiturate</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>414-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Progressive decrease of the plasma concentrations of carbamazepine and of its active metabolite without apparent modification of its anticonvulsive effectiveness</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>Use prudence with respect to the interpretation of the plasma concentrations.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>414-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG1>
<DRUG2>
<DRUG name="FELBAMATE" rxcui="24812">
<ATC code="N03AX10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the felbamate and increase of the plasma concentrations of the phenobarbital, with risk of overdose.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and testing of the plasma concentrations of phenobarbital with adjustment of the dosage if needed. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>414-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG1>
<DRUG2>
<CLASS name="FOLATES" code="V03-" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the phenobarbital, due to increase of its metabolism of which the folates represent one of the cofactors</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, testing of the plasma concentrations, and adjustment, if there is reason for it, of the dosage of the phenobarbital during the folic supplementation and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>414-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG1>
<DRUG2>
<DRUG name="IFOSFAMIDE" rxcui="5657">
<ATC code="L01AA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the neurotoxicity of the ifosfamide due to increase of its hepatic metabolism by the phenobarbital</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>414-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG1>
<DRUG2>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>414-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>In cases of previous treatment with the phenobarbital or the primidone, and the addition of phenytoin, increase of the plasma concentrations of phenobarbital that can lead to toxic signs (inhibition of the metabolism by competition)

In cases of previous treatment with the pheyntoin and the addition of phenobarbital or of primidone, unpredictable changes:

--the plasma concentrations of phenytoin are most often decreased (increase of the metabolism) without this decrease affecting the anticonvulsant activity unfavorably. When the phenobarbital or the primidone is stopped, possibility of toxic effects of the phenytoin.

--it can happen that the concentrations of phenytoin are increased (inhibition of the metabolism due to competition)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>414-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG1>
<DRUG2>
<DRUG name="PROPRANOLOL" rxcui="8787">
<ATC code="C07AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the propranolol with reduction of its clinical effects (increase of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>414-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG1>
<DRUG2>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG2>
<DESCRIPTION>Increase of the hyperammonemia with increased risk of encephalopathy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the phenytoin with signs of overdose, in particular neurological ones (decrease of the hepatic metabolism of the phenytoin)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, testing of the plasma concentrations of phenytoin, and possible adjustment of its dosage </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Reciprocal reduction of the plasma concentrations (increase of the metabolism without apparent modification of the anticonvulsive effectiveness)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>Use prudence in the interpretation of the plasma concentrations. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of phenytoin with the possibility of appearance of the usual signs of overdose</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering the substances together cannot be avoided, strict clinical monitoring, plasma concentration dosages of phenytoin, and possible adjustment of its dosage during the treatment with the cimetidine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="CIPROFLOXACIN" rxcui="2551">
<ATC code="J01MA02" />
<ATC code="S01AE03" />
<ATC code="S02AA15" />
<ATC code="S03AA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Variation, possibly large, of the concentrations of phenytoin in the case of treatment with the ciprofloxacin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and testing of the plasma concentrations of the anticonvulsant during the treatment with ciprofloacin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="CLOPIDOGREL" rxcui="32968">
<ATC code="B01AC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and testing of the plasma concentrations of phenytoin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="CLOZAPINE" rxcui="2626">
<ATC code="N05AH02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the phenytoin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<CLASS name="CYTOTOXICS" code="L01" /></DRUG2>
<DESCRIPTION>Risk of onset of convulsions due to decrease of the digestive absorption of the phenytoin only [not the fosphenytoin] by the cytotoxic, or risk of increase of the toxicity or loss of the effectiveness of the cytotoxic due to the increase of its hepatic metabolism by the phenytoin or the fosphenytoin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="DIAZEPAM" rxcui="3322">
<ATC code="N05BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Unpredictable variations: the plasma concentrations of phenytoin can increase, with signs of overdose, but also decrease or remain stable.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and testing of the plasma concentrations of phenytoin. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="DISULFIRAM" rxcui="3554">
<ATC code="N07BB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large and rapid increase of the plasma concentrations of phenytoin with signs of toxicity (inhibition of its metabolism)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of these substances together cannot be avoided, clinical monitoring and monitoring of the plasma concentrations of phenytoin during the treatment with the disulfiram and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="FELBAMATE" rxcui="24812">
<ATC code="N03AX10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin with risk of overdose, due to inhibition of its metabolism by the felbamate</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, testing of the plasma concentrations of phenytoin, and if needed, adjustment of its dosage during the treatment with the felbamate.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin that can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the metabolism of the phenytoin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly testing of the plasma concentrations of phenytoin. If needed, adjustment of the dosage during the treatment with the fluoxetine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the hepatic metabolism of the phenytoin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly testing of the plasma concentrations of phenytoin. If needed, adjustment of the dosage of the phenytoin during the treatment with the fluvoxamine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<CLASS name="FOLATES" code="V03-" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of phenytoin due to increase of its metabolism of which the folates represent one of the cofactors</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and testing of the plasma concentrations of phenytoin. Possible adjustment of the dosage of the phenytoin during the folic supplementation and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="FUROSEMIDE" rxcui="460">
<ATC code="C03CA01" />
<ATC code="C03CB01" />
<ATC code="C03EB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the diuretic effect which can reach 50%</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Possibly use higher doses of furosemide.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Overdose of phenytoin (decrease of its metabolism)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="METYRAPONE" rxcui="6923">
<ATC code="V04CD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of false negative results of the test with metyrapone, due to a decrease of its plasma concentrations, because of the increase of its hepatic metabolism by the phenytoin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Double the dosage of the metyrapone.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="MEXILETINE" rxcui="6926">
<ATC code="C01BB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the antiarrythmic activity, of the plasma concentrations, and of the half life of the mexiletine (increase of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and, possibly monitoring of the plasma concentrations of the mexiletine; if there is reason for it, adjustment of the dosage of the mexiletine during the treatment with the phenytoin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="MICONAZOLE" rxcui="6932">
<ATC code="A01AB09" />
<ATC code="A07AC01" />
<ATC code="D01AC02" />
<ATC code="G01AF04" />
<ATC code="J02AB01" />
<ATC code="S02AA13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="L01XE31" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the nintedanib due to decrease of its absorption by the phenytoin or the fosphenytoin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG2>
<DESCRIPTION>In cases of previous treatment with the phenobarbital or the primidone, and the addition of phenytoin, increase of the plasma concentrations of phenobarbital that can lead to toxic signs (inhibition of the metabolism by competition)

In cases of previous treatment with the phenytoin and the addition of phenobarbital or of primidone, unpredictable changes:

--the plasma concentrations of phenytoin are most often decreased (increase of the metabolism) without this decrease affecting the anticonvulsant activity unfavorably. When the phenobarbital or the primidone is stopped, possibility of toxic effects of the phenytoin.

--it can happen that the concentrations of phenytoin are increased (inhibition of the metabolism due to competition)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="SUCRALFATE" rxcui="10156">
<ATC code="A02BX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the phenytoin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the sucralfate at a different time from the phenytoin (more than 2 hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="SULFAFURAZOLE" rxcui="10207">
<ATC code="J01EB05" />
<ATC code="S01AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="SULFAMETHIZOLE" rxcui="10179">
<ATC code="B05CA04" />
<ATC code="D06BA04" />
<ATC code="J01EB02" />
<ATC code="S01AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="SULFAMETHOXAZOLE" rxcui="10180">
<ATC code="J01EC01" />
<ATC code="J01EE01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism). </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<DRUG name="TICLOPIDINE" rxcui="10594">
<ATC code="B01AC05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin).</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and testing of the plasma concentrations of phenytoin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG1>
<DRUG2>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG2>
<DESCRIPTION>Increase of the hyperammoniemia, with increased risk of encephalopathy

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>416-PILOCARPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PILOCARPINE" rxcui="8328">
<ATC code="N07AX01" />
<ATC code="S01EB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ACETYL-CHOLINESTERASE INHIBITORS " code="NO6DA-001" /></DRUG2>
<DESCRIPTION>Risk of addition of the undesirable cholinergic effects, especially digestive 

</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>417-PIMOZIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>417-PIMOZIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DALFOPRISTIN" rxcui="229369">
<ATC code="J01FG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>417-PIMOZIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>417-PIMOZIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>417-PIMOZIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>417-PIMOZIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>417-PIMOZIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>417-PIMOZIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the pimozide due to decrease of its hepatic metabolism by the combination ombitasvir + paritaprevir</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>417-PIMOZIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>417-PIMOZIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUINUPRISTINE" rxcui="135098">
<ATC code="J01FG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>417-PIMOZIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SERTRALINE" rxcui="36437">
<ATC code="N06AB06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>417-PIMOZIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>417-PIMOZIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TRICLABENDAZOLE" rxcui="38608">
<ATC code="P02BX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the medication that tends to induce torsades de pointes).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
<COMMENT>Wait 24 hours between stopping the triclabendazole and the dose of the medication that tends to induce torsades de pointes and vice versa.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>418-PIOGLITAZONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PIOGLITAZONE" rxcui="33738">
<ATC code="A10BG03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SOMATOSTATIN ANALOGS" code="H01CB0-001" /></DRUG2>
<DESCRIPTION>Risk of hyypoglycemia or hyperglycemia: decrease or increase of the need for glitazone, due to decrease of increase of the secretion of endogenous glucagon</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increase self monitoring of blood glucose and adjust if needed the dosage of the glitazone during the treatment with the somatostatin analog</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>418-PIOGLITAZONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PIOGLITAZONE" rxcui="33738">
<ATC code="A10BG03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GEMFIBROZIL" rxcui="4719">
<ATC code="C10AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the glitazone due to decrease of its hepatic metabolism by the gemfibrozil</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, strict clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>418-PIOGLITAZONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PIOGLITAZONE" rxcui="33738">
<ATC code="A10BG03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the glitazone due to increase of its metabolism by the rifampcin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring; adjustment of the dosage of the glitazone during the treatment with the rifampicin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>419-PIRFENIDONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PIRFENIDONE" rxcui="1592254">
<ATC code="L04AX05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of pirfenidone with signs of overdose</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>41-SOMATOSTATIN-ANALOGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SOMATOSTATIN ANALOGS" code="H01CB0-001" /></DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the ciclosporin administered orally:

reduction of the blood concentrations of ciclosporin (decrease of its intestinal absorption).

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increase the doses of ciclosporin according to testing of the plasma concentrations and reduction of the dosage after the treatment with the somatostatin analogue is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>41-SOMATOSTATIN-ANALOGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SOMATOSTATIN ANALOGS" code="H01CB0-001" /></DRUG1>
<DRUG2>
<DRUG name="INSULIN" rxcui="631657">
<ATC code="A10AC01" />
<ATC code="A10AC02" />
<ATC code="A10AC03" />
<ATC code="A10AC04" />
<ATC code="A10AD01" />
<ATC code="A10AD02" />
<ATC code="A10AD03" />
<ATC code="A10AD04" />
<ATC code="A10AD05" />
<ATC code="A10AE01" />
<ATC code="A10AE02" />
<ATC code="A10AE03" />
<ATC code="A10AE04" />
<ATC code="A10AE05" />
<ATC code="A10AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypoglycemia or hyperglycemia:

decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient of the risk of hypoglycemia or hyperclycemia, strengthen self- monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>41-SOMATOSTATIN-ANALOGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SOMATOSTATIN ANALOGS" code="H01CB0-001" /></DRUG1>
<DRUG2>
<DRUG name="PIOGLITAZONE" rxcui="33738">
<ATC code="A10BG03" />
<ATC code="A10BD05" />
<ATC code="A10BD06" />
<ATC code="A10BD09" />
<ATC code="A10BD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypoglycemia or hyperglycemia: decrease of increase of the need for glitazone, due to decrease or increase of the secretion of endogenous glucogon</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforce self-monitoring of blood glucose and adjust the dosage of glitazone if needed during the treatment with the somatastin analog. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>41-SOMATOSTATIN-ANALOGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SOMATOSTATIN ANALOGS" code="H01CB0-001" /></DRUG1>
<DRUG2>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypoglycemia or hyperglycemia:

decrease or increase of the needs for repaglinde due to decrease or increase of the secretion of endogenous glucagon .</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strengthen self-monitoring of blood glucose, and adjust the dosage of the repaglinide if needed during the treatment with the somatostatin analog.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>41-SOMATOSTATIN-ANALOGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SOMATOSTATIN ANALOGS" code="H01CB0-001" /></DRUG1>
<DRUG2>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG2>
<DESCRIPTION>Risk of hypoglycemia or hyperglycemia:

decrease or increase of the needs for the blood glucose lowering sufonamide, due to decrease or increase of the secretion of endogenous glucagon</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strengthen self-monitoring of blood glucose, and adjust the dosage of the sulfonamide if needed during the treatment with the somatostatin analog. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>420-PITAVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PITAVASTATIN" rxcui="861634">
<ATC code="C10AA08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the pitavastatin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>421-POLYMYXIN-B.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POLYMYXIN B" rxcui="8536">
<ATC code="A07AA05" />
<ATC code="J01XB02" />
<ATC code="S01AA18" />
<ATC code="S02AA11" />
<ATC code="S03AA03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="AMINOGLYCOSIDES" code="J01GB-001" /></DRUG2>
<DESCRIPTION>Addition of the nephrotoxic effects

.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these substances together cannot be avoided, strict monitoring with an indisputable bacteriological justification</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>421-POLYMYXIN-B.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POLYMYXIN B" rxcui="8536">
<ATC code="A07AA05" />
<ATC code="J01XB02" />
<ATC code="S01AA18" />
<ATC code="S02AA11" />
<ATC code="S03AA03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="CURARES" code="M03A-001" /></DRUG2>
<DESCRIPTION>Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitor the degree of curarization at the end of anesthesia</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>422-POSACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the posaconazole

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If possible, plasma dosages of the posaconazole and possible adjustment of its dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>422-POSACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="H2 RECEPTOR ANTAGONISTS" code="A02BA-001" /></DRUG2>
<DESCRIPTION>Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the H2 receptor antagonist</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>--only with the oral suspension form of posaconazole</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>422-POSACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG2>
<DESCRIPTION>Decrease of the absorption of the azole antifungal, due to increase of the gastric pH by the inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>--only for the oral suspension form of posaconazole</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>422-POSACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>422-POSACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>422-POSACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia with nausea, vomiting, arrhythmias.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and, if there is reason for them, EKG and monitoring of the digoxinemia, with adjustment of the dosage of the digoxin during the treatment with the posaconazole and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>422-POSACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these medications are administered together, strict testing of renal function, blood concentration dosages of the immunosuppressant, and possible adjustment of the dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>422-POSACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>422-POSACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>422-POSACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>422-POSACONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VINCA ALKALOIDS" code="L01CA" /></DRUG2>
<DESCRIPTION>Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the posaconazole</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>423-POTASSIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POTASSIUM" rxcui="8588">
<ATC code="A12BA" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG2>
<DESCRIPTION>Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects).</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Avoid administering these substances together unless there is pre-existing hypokalemia. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>423-POTASSIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POTASSIUM" rxcui="8588">
<ATC code="A12BA" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Avoid administration of these substances together unless there is pre-existing hypokalemia.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>423-POTASSIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POTASSIUM" rxcui="8588">
<ATC code="A12BA" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)" code="C0E-004" /></DRUG2>
<DESCRIPTION>Potentially lethal hyperkalemia, especially with patients having renal insufficiency (addition of the hyperkaliemia producing effects)</DESCRIPTION>
<SEVERITY>Contraindication:</SEVERITY>
<COMMENT>-aside from hypokalemia or in case of parenteral use of the potassium salts</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>423-POTASSIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POTASSIUM" rxcui="8588">
<ATC code="A12BA" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Unless there is hypokalemia.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>423-POTASSIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POTASSIUM" rxcui="8588">
<ATC code="A12BA" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Essentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia producing effects) </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Avoid administering these substances together unless there is preexisting hypokalemia. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>424-POVIDONE-IODINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POVIDONE-IODINE" rxcui="8611">
<ATC code="D08AG02" />
<ATC code="D09AA09" />
<ATC code="D11AC06" />
<ATC code="G01AX11" />
<ATC code="R02AA15" />
<ATC code="S01AX18" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="MERCURIAL ANTISEPTICS" code="D08AK0" /></DRUG2>
<DESCRIPTION>Erythema, blisters, even necrosis of skin and mucosa (formation of a caustic complex in the case of concomitant use of mercurial and iodine antiseptics). The interaction depends on the stability of the organo-mercurial at the cutaneous level and on individual sensitivity.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>425-PRAVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PRAVASTATIN" rxcui="42463">
<ATC code="C10AA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentration of the pravastatin by the clarithromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring during the treatment with the antibiotic</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>425-PRAVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PRAVASTATIN" rxcui="42463">
<ATC code="C10AA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the erythromycin administered by oral route: increase of the plasma concentration of the pravastatin by the erythromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring during the treatment with the antibiotic.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>426-PRAZIQUANTEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PRAZIQUANTEL" rxcui="8628">
<ATC code="P02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>426-PRAZIQUANTEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PRAZIQUANTEL" rxcui="8628">
<ATC code="P02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Separate the administration of the two medications by at least a week.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>426-PRAZIQUANTEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PRAZIQUANTEL" rxcui="8628">
<ATC code="P02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of the praziquantal, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the rifampicin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>427-PREDNISOLONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PREDNISOLONE" rxcui="8638">
<ATC code="A07EA01" />
<ATC code="C05AA04" />
<ATC code="D07AA03" />
<ATC code="D07XA02" />
<ATC code="H02AB06" />
<ATC code="R01AD02" />
<ATC code="S01BA04" />
<ATC code="S01CB02" />
<ATC code="S02BA03" />
<ATC code="S03BA02" />
<ATC code="D07CA03" />
<ATC code="S01CA02" />
<ATC code="S02CA01" />
<ATC code="S03CA02" />
<ATC code="D07BA01" />
<ATC code="S01BB02" />
<ATC code="V03AB05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>428-LATEX-CONDOMS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="LATEX CONDOMS" >
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="MINERAL OILS" code="A06AA-" /><ATC code="D02AA" />
</DRUG2>
<DESCRIPTION>Risk of rupture of the condom when used with lubricants containing mineral oils (paraffin oil, silicone oil, etc...)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Use a hydrosoluble lubricant (glycerin, polyacrylamide...).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>429-PRIMIDONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PRIMIDONE " rxcui="8691">
<ATC code="N03AA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the afatinib due to increase of its metabolism by the primidone</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these together and 1 to 2 weeks after they are stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>42-ANDROGENS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANDROGENS" code="A14AA0" /></DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage due to the direct effect on coagulation and/or the fibrinolytic systems.

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Adjustment of the dosage of the Vitamin K antagonist during the treatment with the androgen and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>42-ANDROGENS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANDROGENS" code="A14AA0" /></DRUG1>
<DRUG2>
<CLASS name="ENZYME INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the androgen and consequently of its effectiveness, due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring during the administration of these substances together and 1 to 2 weeks after the inducer is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>430-PRISTINAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PRISTINAMYCIN" rxcui="66958">
<ATC code="J01FG01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the pristinamycin and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>430-PRISTINAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PRISTINAMYCIN" rxcui="66958">
<ATC code="J01FG01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the undesirable effects of the colchicine with potentially fatal consequences</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>430-PRISTINAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PRISTINAMYCIN" rxcui="66958">
<ATC code="J01FG01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function and adjustment of its dosage during the administration of the medications together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>431-PROBENECID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROBENECID" rxcui="8698">
<ATC code="M04AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the uricosuric effect due to competition of the elimination of the uric acid at the level of the renal tubules</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>431-PROBENECID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROBENECID" rxcui="8698">
<ATC code="M04AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIPROPHYLLINE" rxcui="3714">
<ATC code="R03DA01" />
<ATC code="R03DB01" />
<ATC code="R03DA51" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of overdose due to increase of the plasma concentrations of diprophylline (inhibition of its renal tubular secretion)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reduce the dosage of diprophylline during the treatment with the probenicid</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>431-PROBENECID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROBENECID" rxcui="8698">
<ATC code="M04AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the toxicity of the methotrexate: inhibition of the renal tubular secretion of the methotrexate by the probenecid</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>432-PROCARBAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROCARBAZINE" rxcui="8702">
<ATC code="L01XB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Increase of the hypersensitivity reactions (hypereosinophilia, rash), due to increase of the metabolism of the procarbazine by the inducer</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>433-IODINATED-X-RAY-CONTRAST-MEDIA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IODINATED X-RAY CONTRAST MEDIA" code="VO8A-001" /></DRUG1>
<DRUG2>
<DRUG name="ALDESLEUKIN" rxcui="70223">
<ATC code="L03AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of reaction to the contrast media in cases of previous treatment with interleukin2: 

skin rash or more rarely low blood pressure, oliguria or even renal failure</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>433-IODINATED-X-RAY-CONTRAST-MEDIA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IODINATED X-RAY CONTRAST MEDIA" code="VO8A-001" /></DRUG1>
<DRUG2>
<CLASS name="DIURETICS" code="C0E-001" /></DRUG2>
<DESCRIPTION>In case of dehydration caused by the diuretics, increased risk of acute functional renal insufficiency, in particular when large doses of the contrast media are used</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Rehydrate before administration of the iodinated product</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>433-IODINATED-X-RAY-CONTRAST-MEDIA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="IODINATED X-RAY CONTRAST MEDIA" code="VO8A-001" /></DRUG1>
<DRUG2>
<DRUG name="METFORMIN" rxcui="6809">
<ATC code="A10BA02" />
<ATC code="A10BD13" />
<ATC code="A10BD11" />
<ATC code="A10BD05" />
<ATC code="A10BD03" />
<ATC code="A10BD10" />
<ATC code="A10BD07" />
<ATC code="A10BD02" />
<ATC code="A10BD08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Lactic acidosis linked to elevated concentrations of metformin in relation to functional renal insufficiency induced by the radiological exam. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>434-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG1>
<DRUG2>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>(Except IUD), decrease of the concentrations of progestin, with risk of lower contraceptive effectiveness </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use another method of contraception, in particular a barrier type, during the length of time that these are administered together and one cycle after.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>434-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG1>
<DRUG2>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Aside from the combination ethinylestradiol (0.035mg)/norethisterone (1 mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the boceprevir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use an additional or alternative, reliable contraceptive method during the administration of these medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>434-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG1>
<DRUG2>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use an additional or alternative, reliable contraceptive method during the administration of these medications together and a cycle after. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>434-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG1>
<DRUG2>
<DRUG name="GRISEOFULVIN" rxcui="5021">
<ATC code="D01AA08" />
<ATC code="D01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use an additional or alternative, reliable contraceptive method during the administration of these medications together and a cycle after. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>434-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG1>
<DRUG2>
<CLASS name="ENZYME INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the contraceptive effectiveness of the hormonal contraceptive, due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another reliable contraceptive method, in particular a barrier type, should be used during the administration of these medications together and a cycle after. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>434-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Risk of decrease of the contraceptive effectiveness because of decrease of the concentrations of hormonal contraceptive, due to the increase of its hepatic metabolism by the ritonavir </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another method of contraception, in particular a barrier type (condom or IUD), should be used during the time the substances are administered together and one cycle following. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>434-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the hormonal contraceptive, by reason of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (pregnancy) </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>434-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG1>
<DRUG2>
<DRUG name="PERAMPANEL" rxcui="1356552">
<ATC code="N03AX22" />
</DRUG>
</DRUG2>
<DESCRIPTION>For doses of perampanel &gt;=12 mg/day: Risk of decrease of the contraceptive effectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another method of contraception, in particular a barrier type, should be used.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>434-PROGESTIN-CONTRACEPTIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG1>
<DRUG2>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of antagonism of the effects of the progestin contraceptive</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Do not restart the progestin contraceptive treatment fewer than 12 days after stopping the ulipristal.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>435-NON-CONTRACEPTIVE-PROGESTOGENS,-COMBINED-WITH-AN-ESTROGEN-OR-NOT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT" code="G03-003" /></DRUG1>
<DRUG2>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the progestogen</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the bosentan and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>435-NON-CONTRACEPTIVE-PROGESTOGENS,-COMBINED-WITH-AN-ESTROGEN-OR-NOT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT" code="G03-003" /></DRUG1>
<DRUG2>
<CLASS name="ENZYME INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the effectiveness of the progestogen</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>435-NON-CONTRACEPTIVE-PROGESTOGENS,-COMBINED-WITH-AN-ESTROGEN-OR-NOT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT" code="G03-003" /></DRUG1>
<DRUG2>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of antagonism of the effects of the progestogen</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Use an additional contraceptive method of the barrier type for several days after the ulipristal is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>436-PROGUANIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROGUANIL" rxcui="2382">
<ATC code="P01BB01" />
<ATC code="P01BB51" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the proguanil and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>436-PROGUANIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROGUANIL" rxcui="2382">
<ATC code="P01BB01" />
<ATC code="P01BB51" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG2>
<DESCRIPTION>Risk of clinically low thyroid with patients having thyroid replacement therapy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of the serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormone during the treatment with the antimalarial and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>437-PROPAFENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ABIRATERONE" rxcui="1100072">
<ATC code="L02BX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the abiraterone</DESCRIPTION>
<SEVERITY>Precautions for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the abiraterone</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>437-PROPAFENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the inducer

</DESCRIPTION>
<SEVERITY>Precaution of use</SEVERITY>
<COMMENT>Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the administration of it and the inducer together and after the inducer is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>437-PROPAFENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the anticoagulant effect and of the risk of hemorrhage. Mechanism proposed: inhibition of the metabolism of the vitamin K antagonist</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the propafenone and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>437-PROPAFENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG2>
<DESCRIPTION>Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>437-PROPAFENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the propafenone due to decrease of its hepatic metabolism by the bupropion</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the bupropion.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>437-PROPAFENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CINACALCET" rxcui="407990">
<ATC code="H05BX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of propafenone with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the propafenone during the treatment with cinacalcet.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>437-PROPAFENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DARIFENACIN" rxcui="136198">
<ATC code="G04BD10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of propafenone, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin</DESCRIPTION>
<SEVERITY>Precaution for use.</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the propafenone during the treatment with darifenacin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>437-PROPAFENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the digoxinemia, especially with older patients</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with propafenone and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>437-PROPAFENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of propafenone with risk of overdosage due to decrease of its hepatic metabolism by the duloxetine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the propafenone during the treatment with the duloxetine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>437-PROPAFENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ESMOLOL" rxcui="49737">
<ATC code="C07AB09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of contractility, autoregulation and conduction (suppression of the compensatory sympathetic mechanisms)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>437-PROPAFENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the time the substances are administered together and after the St Johns wort is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>437-PROPAFENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MIRABEGRON" rxcui="1300786">
<ATC code="G04BD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the propafenone by decrease of its metabolism by the mirabegron</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the propafenone during the administration of these substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>437-PROPAFENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the propafanone, due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the administration of the substances together and after the rifampicin is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>437-PROPAFENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TERBINAFINE" rxcui="37801">
<ATC code="D01AE15" />
<ATC code="D01BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the terbinafine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the terbinafine. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>437-PROPAFENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="THEOPHYLLINE " rxcui="10438">
<ATC code="R03DA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the theophyllinemia due to decrease of its hepatic metabolism by the propafenone. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>438-PROPRANOLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROPRANOLOL" rxcui="8787">
<ATC code="C07AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforce clinical monitoring, in particular during the first weeks of the administration of these medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>438-PROPRANOLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROPRANOLOL" rxcui="8787">
<ATC code="C07AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of propranolol due to inhibition of its hepatic metabolism, with increase of the activity and of the undesirable effects, for example: significant bradycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring, and, if needed, adjustment of the dosage of the propranolol during the treatment with the fluvoxamine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>438-PROPRANOLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROPRANOLOL" rxcui="8787">
<ATC code="C07AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the propranolol with reduction of its clinical effects (increase of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>438-PROPRANOLOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROPRANOLOL" rxcui="8787">
<ATC code="C07AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>439-PYRAZINAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PYRAZINAMIDE" rxcui="8987">
<ATC code="J04AK01" />
<ATC code="J04AM05" />
<ATC code="J04AM06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Addition of the hepatotoxic effects.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>43-HALOGENATED-HYDROCARBON-ANESTHETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HALOGENATED HYDROCARBON ANESTHETICS" code="N01AB0-001" /></DRUG1>
<DRUG2>
<CLASS name="ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)" code="A01AD" /></DRUG2>
<DESCRIPTION>Serious ventricular arrhythmias due to increased cardiac sensitization

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Limit the amount of adrenaline, for example: less then 0.1 mg of adrenaline in 10 minutes or 0.3 mg per hour for an adult</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>43-HALOGENATED-HYDROCARBON-ANESTHETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HALOGENATED HYDROCARBON ANESTHETICS" code="N01AB0-001" /></DRUG1>
<DRUG2>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG2>
<DESCRIPTION>Reduction of the compensatory cardiovascular reactions by the beta blocking agents. The beta-andrenergic inhibition can be elevated by the beta-mimetics during surgery. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>As a general rule, do not stop the treatment with the beta-blocking agent and, in any event, avoid stopping it abruptly. Inform the anesthesiologist of this treatment. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>43-HALOGENATED-HYDROCARBON-ANESTHETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HALOGENATED HYDROCARBON ANESTHETICS" code="N01AB0-001" /></DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>Reduction of the compensatory cardiovascular reactions by the beta blocking agents. The beta-adrenergic inhibition can be elevated during the surgery by the beta-stimulants.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>As a general rule, do not stop the treatment with the beta blocking agent and, in any case, avoid stopping it abruptly. Inform the anesthesiologist of this treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>43-HALOGENATED-HYDROCARBON-ANESTHETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HALOGENATED HYDROCARBON ANESTHETICS" code="N01AB0-001" /></DRUG1>
<DRUG2>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites.

.

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>43-HALOGENATED-HYDROCARBON-ANESTHETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HALOGENATED HYDROCARBON ANESTHETICS" code="N01AB0-001" /></DRUG1>
<DRUG2>
<DRUG name="ISOPRENALINE" rxcui="6054">
<ATC code="C01CA02" />
<ATC code="R03AB02" />
<ATC code="R03CB01" />
<ATC code="R03AK02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Serious ventricular arrhythmias due to increase of cardiac sensitization </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>43-HALOGENATED-HYDROCARBON-ANESTHETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HALOGENATED HYDROCARBON ANESTHETICS" code="N01AB0-001" /></DRUG1>
<DRUG2>
<CLASS name="ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)" code="C01CA" /></DRUG2>
<DESCRIPTION>Serious ventricular arrhythmias due to increase of cardiac sensitization</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>43-HALOGENATED-HYDROCARBON-ANESTHETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="HALOGENATED HYDROCARBON ANESTHETICS" code="N01AB0-001" /></DRUG1>
<DRUG2>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG2>
<DESCRIPTION>Perioperative hypertension 

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In the case of scheduled surgery, it is preferable to stop the treatment several days before surgery. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>440-PYRIMETHAMINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PYRIMETHAMINE" rxcui="9010">
<ATC code="P01BD01" />
<ATC code="P01BF04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TRIMETHOPRIM" rxcui="10829">
<ATC code="J01EA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular CBC and addition of a treatment with folic acid (regular IM injections). </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>441-QUETIAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUETIAPINE" rxcui="51272">
<ATC code="N05AH04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>441-QUETIAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUETIAPINE " rxcui="51272">
<ATC code="N05AH04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Large increase of the concentrations of quetiapine, with risk of overdose</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>441-QUETIAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUETIAPINE" rxcui="51272">
<ATC code="N05AH04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>441-QUETIAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUETIAPINE" rxcui="51272">
<ATC code="N05AH04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the quetiapine due to decrease of its hepatic metabolism by the ombitasvir+paritaprevir combination</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>441-QUETIAPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUETIAPINE" rxcui="51272">
<ATC code="N05AH04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="URINARY ALKALIZERS" code="B05-001" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the quinidine and risk of overdose (decrease of the renal excretion of the quinidine by alkalinizing of the urine).</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and possibly testing of the quinidinemia; if there is reason for it, adjustment of the dosage during the alkalinizing treatment and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09XA02" />
<ATC code="C09DX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="V03AX03" />
<ATC code="J05AR09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150 mg/day in one dose.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG. In the case of an unexpected result, test the digoxinemia and adjust the dosage. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the quinidine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Start the treatment with quinidine at minimum recommended dosages, and adjust the doses according to the EKG. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes, as well as tinnitis and/or decrease of auditory acuity (cinchonism), due to decrease of the hepatic metabolism of the quinidine</DESCRIPTION>
<SEVERITY> CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the quidinine due to decrease of its hepatic metabolism by the ombitasvir+paritaprevir combination</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TAMOXIFEN" rxcui="10324">
<ATC code="L02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the quinidine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TRICLABENDAZOLE" rxcui="38608">
<ATC code="P02BX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
<COMMENT>Wait 24 hours between stopping the triclabendazole and the dose of the torsade inducing medication, and the reverse.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the quinidine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>443-QUININE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUININE" rxcui="9071">
<ATC code="P01BC01" />
<ATC code="M09AA72" />
<ATC code="M09AA" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer. 

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the quinine during the treatment with the inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>443-QUININE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUININE" rxcui="9071">
<ATC code="P01BC01" />
<ATC code="M09AA72" />
<ATC code="M09AA" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Moderate increase of the digoxinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG, if needed, with possible adjustment of the doses of digoxin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>443-QUININE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUININE" rxcui="9071">
<ATC code="P01BC01" />
<ATC code="M09AA72" />
<ATC code="M09AA" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the quinine, especially ventricular arrhythmias and neurosensory difficulties (cinchonism) </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-with the protease inhibitors </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>443-QUININE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUININE" rxcui="9071">
<ATC code="P01BC01" />
<ATC code="M09AA7" />
<ATC code="M09AA" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MEFLOQUINE" rxcui="6694">
<ATC code="P01BF02" />
<ATC code="P01BC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Wait at least 12 hours between the end of the administration via IV of the quinine and the beginning of the administration of the mefloquine. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>443-QUININE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUININE" rxcui="9071">
<ATC code="P01BC01" />
<ATC code="M09AA72" />
<ATC code="M09AA" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>444-QUINUPRISTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINUPRISTINE" rxcui="135098">
<ATC code="J01FG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIHYDROERGOTAMINE" rxcui="3418">
<ATC code="N02CA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>444-QUINUPRISTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINUPRISTINE" rxcui="135098">
<ATC code="J01FG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>444-QUINUPRISTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINUPRISTINE" rxcui="135098">
<ATC code="J01FG02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>444-QUINUPRISTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINUPRISTINE" rxcui="135098">
<ATC code="J01FG02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>445-RACECADOTRIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RACECADOTRIL" rxcui="16738">
<ATC code="A07XA04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the angioedema type. </DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>-in case of previous angioedema while taking ACE inhibitors</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>446-RALTEGRAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RALTEGRAVIR" rxcui="719872">
<ATC code="J05AX08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of the raltegravir by the rifampicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, doubling the dose of raltegravir can be considered </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>447-RANOLAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RANOLAZINE" rxcui="35829">
<ATC code="C01EB18" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Risk of large decrease of the concentrations of ranolazine

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>447-RANOLAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RANOLAZINE" rxcui="35829">
<ATC code="C01EB18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to inhibition of the metabolism of the atorvastatin by the ranolazine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of the cholesterol lowering agent or another statin not affected by this type of interaction.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>447-RANOLAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RANOLAZINE" rxcui="35829">
<ATC code="C01EB18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring, and possibly EKG. Adjustment of the dosage of the digoxin if needed.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>447-RANOLAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RANOLAZINE" rxcui="35829">
<ATC code="C01EB18" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to inhibition of its metabolism by the ranolazine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring, and possible adjustment of the dosage of the immunosuppressant.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>447-RANOLAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RANOLAZINE" rxcui="35829">
<ATC code="C01EB18" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the concentrations of ranolazine due to decrease of its metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>447-RANOLAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RANOLAZINE" rxcui="35829">
<ATC code="C01EB18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the concentrations of ranolazine. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>447-RANOLAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RANOLAZINE" rxcui="35829">
<ATC code="C01EB18" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type due to inhibition of the metabolism of the simvastatin by the ranolazine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Do not exceed the dosage of 20 mg/day of simvastatin or use another statin not affected by this type of interaction.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>448-REGORAFENIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="REGORAFENIB" rxcui="1312397">
<ATC code="L01XE21" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYME INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of regorafenib due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY> Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>448-REGORAFENIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="REGORAFENIB" rxcui="1312397">
<ATC code="L01XE21" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of regorafenib due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>448-REGORAFENIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="REGORAFENIB" rxcui="1312397">
<ATC code="L01XE21" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of regorafenib due to increase of its metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>448-REGORAFENIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="REGORAFENIB" rxcui="1312397">
<ATC code="L01XE21" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT (JUICE and FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of regorafenib due to decrease of its hepatic metabolism by the grapefruit</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>449-REPAGLINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SOMATOSTATIN ANALOGS" code="H01CB0-001" /></DRUG2>
<DESCRIPTION>Risk of hypoglycemia or hyperglycemia:

decrease or increase of the need for repaglinde due to decrease or increase of the secretion of endogenous glucagon.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strengthen self-monitoring of blood glucose, and adjust the dosage of the repaglinide if needed during the treatment with the somatostatin analog</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>449-REPAGLINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of more than double of the concentrations of the repaglinide due to increase of its absorption</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>449-REPAGLINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypoglycemia due to increase of the plasma concentrations of the repaglinide</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering agent during the treatment with the clarithromycin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>449-REPAGLINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLOPIDOGREL" rxcui="32968">
<ATC code="B01AC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of repaglinide by the clopidogrel, with risk of increase of undesirable effects</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>449-REPAGLINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of repaglinide, due to inhibition of its hepatic metabolism by the deferasirox</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, strict clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>449-REPAGLINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GEMFIBROZIL" rxcui="4719">
<ATC code="C10AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of severe hypoglycemia, even coma, due to large increase of the plasma concentrations of repaglinide by the gemfibrozil</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>449-REPAGLINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TRIMETHOPRIM" rxcui="10829">
<ATC code="J01EA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of these medications together cannot be avoided, strict clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTABUSE (REACTION)" code="123-ANT" /></DRUG1>
<DRUG2>
<DRUG name="ALCOHOL " >
<ATC code="DRINK" />
<ATC code="INGREDIE" />
<ATC code="INGREDIE" />
<ATC code="INGREDIE" />
<ATC code="INGREDIE" />
<ATC code="INGREDIE" />
<ATC code="INGREDIE" />
<ATC code="INGREDIE" />
<ATC code="INGREDIE" />
<ATC code="INGREDIE" />
<ATC code="INGREDIE" />
<ATC code="INGREDIE" />
<ATC code="INGREDIE" />
<ATC code="INGREDIE" />
<ATC code="INGREDIE" />
<ATC code="INGREDIE" />
<ATC code="INGREDIE" />
<ATC code="INGREDIE" />
<ATC code="INGREDIE" />
<ATC code="INGREDIE" />
</DRUG>
</DRUG2>
<DESCRIPTION>Antabuse effect (heat, redness, vomiting, tachycardia)

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of the medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>450-RESERPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RESERPINE" rxcui="9260">
<ATC code="C02AA02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>Psychomotor agitation, convulsions, hypertension</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>450-RESERPINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RESERPINE" rxcui="9260">
<ATC code="C02AA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
<ATC code="N04BA02" />
<ATC code="N04BA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Inhibition of the effects of the levodopa</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>451-CHELATING-RESINS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CHELATING RESINS" code="C10-V0" /></DRUG1>
<DRUG2>
<DRUG name="MEDICATIONS ADMINISTERED BY ORAL ROUTE" >
</DRUG>
</DRUG2>
<DESCRIPTION>Taking chelating resins can decrease the intestinal absorption and, potentially, the effectiveness of other medications taken simultaneously</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>As a general rule, the doses of the resin should be taken at a different time from that of other medications, at an interval of more than 2 hours apart, if possible</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>451-CHELATING-RESINS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CHELATING RESINS" code="C10-V0" /></DRUG1>
<DRUG2>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the thyroid hormones </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the thyroid hormones at a different time from the resin (more than 2 hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>452-RETINOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RETINOIDS" code="D05-D10" /></DRUG1>
<DRUG2>
<CLASS name="OTHER RETINOIDS" code="D05-D10" /></DRUG2>
<DESCRIPTION>Risk of symptoms evocative of hypervitaminosis A</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>452-RETINOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RETINOIDS" code="D05-D10" /></DRUG1>
<DRUG2>
<CLASS name="TETRACYCLINE ANTIBIOTICS" code="J01AA" /></DRUG2>
<DESCRIPTION>Risk of intracranial hypertension</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>452-RETINOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="RETINOIDS" code="D05-D10" /></DRUG1>
<DRUG2>
<DRUG name="VITAMIN A" rxcui="11246">
<ATC code="A11C" />
<ATC code="A11CA" />
<ATC code="A11CA01" />
<ATC code="A11CA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of symptoms evocative of hypervitaminosis A</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>453-RIBAVIRIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIBAVIRIN" rxcui="9344">
<ATC code="J05AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTIPURINES" code="ANTIPUR" /></DRUG2>
<DESCRIPTION>Increased risk of serious undesirable effects, due to inhibition of the metabolism of the immunomodulator by the ribavirin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>453-RIBAVIRIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIBAVIRIN" rxcui="9344">
<ATC code="J05AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIDANOSINE" rxcui="3364">
<ATC code="J05AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the mitochrondrial toxicity of the didanosine due to increase of its active metabolite</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>453-RIBAVIRIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIBAVIRIN" rxcui="9344">
<ATC code="J05AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="J05AF04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>453-RIBAVIRIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIBAVIRIN" rxcui="9344">
<ATC code="J05AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AF01" />
<ATC code="J05AR01" />
<ATC code="J05AR04" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>454-RIFABUTIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATOVAQUONE" rxcui="60212">
<ATC code="P01AX06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Moderate decrease of the plasma concentrations of atovaquone by the enzymatic inducer</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>454-RIFABUTIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the rifabutin (uveitis) due to increase of its concentrations and of those of its active metabolite by the clarithromycin. In addition, increase of the metabolism of the clarithromycin by the rifabutin, with increase of the concentrations of its active metabolite</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the two medications together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>454-RIFABUTIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="J05AR09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large increase of the metabolite of the rifabutin, with risk of increase of its toxicity (uveitis, neutropenia). Furthermore, possible decrease of the concentrations of cobicistat</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Adjustment of the dosage of the rifabutin (in principle, reduction of the doses by half). </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>454-RIFABUTIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AR06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of rifabutin by about half, due to increase of its hepatic metabolism by the efavirenz </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Adjustment of the dosage of the rifabutin during the treatment with efavirenz.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>454-RIFABUTIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ELVITEGRAVIR" rxcui="1306286">
<ATC code="J05AR09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the minimal concentrations of elvitegravir</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>454-RIFABUTIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the treatment with the two medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>454-RIFABUTIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG2>
<DESCRIPTION>Described for phenytoin, rifampicin, and carbamazepine. Risk of clinical hypothyroidism in patients with low thyroid, due to increase of the metabolism of the T3 and T4</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of serum concentrations of T3 and of T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with rifabutin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>454-RIFABUTIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the protease inhibitor (even more so when the dosage of the rifabutin is large) for one thing, and risk of increase of the undesirable effects (uveitis) of the rifabutin for another. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>454-RIFABUTIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>454-RIFABUTIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifabutin for one thing; and risk of increase of the undesirable effects (uveitis) of the rifabutin for another</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of these substances together is judged necessary, clinical monitoring and adjustment of the dosage of the voriconazole (generally doubled) during the treatment with the rifabutin. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ABIRATERONE" rxcui="1100072">
<ATC code="L02BX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the afatinib due to increase of its metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together and 1 to 2 weeks after they are stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ALBENDAZOLE" rxcui="430">
<ATC code="P02CA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of reduction of its effectiveness</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="CALCIUM CHANNEL BLOCKERS" code="CO8CA-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism

</DESCRIPTION>
<SEVERITY>Not recommended </SEVERITY>
<COMMENT>--with the nimodipine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="CLASS IA ANTIARRHYTHMICS" code="C01B-002" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the antiarrythmic (increase of its hepatic metabolism). 

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and possibly monitoring of the plasma concentration of the antiarrythmic. If needed, adjustment of the dosage of the antiarrythmic during the treatment with the rifampicin and after it is stopped (risk of overdose of the antiarrythmic) </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the rifampicin. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the rifampicin and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="APIXABAN" rxcui="1364430">
<ATC code="B01AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the apixaban by the rifampicin, with risk of decrease of the therapeutic effect.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the concentrations of aprepitant</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of atorvastastatin, due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATOVAQUONE" rxcui="60212">
<ATC code="P01AX06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of atorvaquone by the enzymatic inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of boceprevir</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these together cannot be avoided, regular clinical and biological monitoring, especially at the beginning of treatment with the two medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease, large for the rifampicin, of the plasma concentrations of bosentan</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUSPIRONE" rxcui="1827">
<ATC code="N05BE01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the buspirone due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the buspirone during the treatment with rifampicin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the carbamazepine due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, testing of the plasma concentrations and adjustment of the dosage of the carbamazepine during the treatment with the rifampicin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARVEDILOL" rxcui="20352">
<ATC code="C07AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of the carvedilol, due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring and adjustment of the dosage of the carvedilol during the treatment with the rifampicin. When the rifampicin is stopped, risk of large increase of the plasma concentrations of carvedilol imposing a reduction of the dosage and strict clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and risk of lower effectiveness of the clarithromycin, especially with HIV patients, due to increase of its metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLOZAPINE" rxcui="2626">
<ATC code="N05AH02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the rifampicin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="V03AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of deferasirox</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitor the ferritinemia during and after the treatment with the enzymatic inducer. If needed, adjustment of the dosage of deferasirox.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DELAMANID" rxcui="1344662">
<ATC code="J04AK06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of delamanid due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EXEMESTANE" rxcui="258494">
<ATC code="L02BG06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the exemestane due to increase of its hepatic metabolism by the enzymatic inducer</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FENTANYL" rxcui="4337">
<ATC code="N02AB03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Choose another opioid.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the fluconazole due to increase of its metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in patients with Addisons disease treated with hydrocortisone and in cases of transplants</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="HALOPERIDOL" rxcui="5093">
<ATC code="N05AD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the haloperidol and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and, if needed, adjustment of the dosage during the treatment with the rifampicin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG2>
<DESCRIPTION>Risk of clinically low thyroid in patients with already low thyroid, due to increase of the metabolism of the T3 and of the T4.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with the rifampicin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="HYDROXYCHLOROQUINE" rxcui="5521">
<ATC code="P01BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of lower therapeutic effect of the hydroxychloroquine, due to increase of its metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoringand possible adjustment of the dosage of the hydroxychloroquine during the treatment with rifampicin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IDELALISIB" rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of the protease inhibitor, due to increase of its hepatic metabolism by the rifampicin.

For the combination (saquinavir + ritonavir):

risk of severe hepatocellular toxicity</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Until additional data with the ritonavir boosted inhibitors is available.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="METABOLIZED TYROSINE-KINASE INHIBITORS" code="L01XE" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring of this classic combination. In case of hepatitis, stop the isoniazid.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of the two substances together and after the rifampicin is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the two anti-antibiotics (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of ledipasvir due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LINEZOLIDE" rxcui="190376">
<ATC code="J01XX08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the linezolide due to increase of its hepatic metabolism by the rifampicin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible increase of the dosage of the linezolide during the treatment with the rifampicin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METRONIDAZOLE" rxcui="6922">
<ATC code="A01AB17" />
<ATC code="D06BX01" />
<ATC code="G01AF01" />
<ATC code="J01XD01" />
<ATC code="P01AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of absence of effect of the midazolam, with very large decrease of its plasma concentrations, due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="MINERALOCORTICOIDS" code="H02AA0" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in persons with Addison&#39;s disease treated with the hydrocortisone and in cases of organ transplants</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MONTELUKAST" rxcui="88249">
<ATC code="R03DC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the montelukast due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the rifampicin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MORPHINE" rxcui="7052">
<ATC code="N02AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NEVIRAPINE" rxcui="53654">
<ATC code="J05AG01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NIMODIPINE" rxcui="7426">
<ATC code="C08CA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the rifampicin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="L01XE31" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the nintedanib due to decrease of its absorption by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PERAMPANEL" rxcui="1356552">
<ATC code="N03AX22" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease (up to two thirds) of the concentrations of perampanel</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIOGLITAZONE" rxcui="33738">
<ATC code="A10BG03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the glitazone due to increase of its metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring; adjustment of the dosage of the glitazone during the treatment with the rifampicin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the two antibiotics (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PRAZIQUANTEL" rxcui="8628">
<ATC code="P02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of the praziquantal, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the rifampicin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the propafanone, due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precautions for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the administration of the two substances together and after the rifampicin is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPRANOLOL" rxcui="8787">
<ATC code="C07AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUETIAPINE" rxcui="51272">
<ATC code="N05AH04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUININE" rxcui="9071">
<ATC code="P01BC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RALTEGRAVIR" rxcui="719872">
<ATC code="J05AX08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of the raltegravir by the rifampicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these together cannot be avoided, doubling the dose of raltegravir can be considered</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RANOLAZINE" rxcui="35829">
<ATC code="C01EB18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the concentrations of ranolazine. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIVAROXABAN" rxcui="1114195">
<ATC code="B01AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of simvastatin, due to increase of its hepatic metabolism by the rifampicin.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the concentrations of telaprevir</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of the hepatic metabolism of the telithromycin by the rifampicin. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the tenofovir alafenamide due to decrease of its absorption by the rifampicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together and 1 to 2 weeks after the rifampicin is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TERBINAFINE" rxcui="37801">
<ATC code="D01BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the theophylline (increase of its metabolism by enzymatic induction)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and, if needed, monitoring of the theophyllinemia. Adjust, if there is reason to, the dosage of the theophylline during the treatment with the rifampicin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TIAGABINE" rxcui="31914">
<ATC code="N03AG06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>An increase of the dosage of the tiagabine can prove necessary in cases where it is administered with the rifampicin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the rifampicin, with risk of decrease of the therapeutic effect. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Choose a therapeutic alternative that is little or not at all metabolized.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG2>
<DESCRIPTION>Risk of onset of convulsive crises, due to increase of the hepatic metabolism of the valproate by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring, and possible adjustment of the dosage of the anticonvulsant during the treatment with the rifampicin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN D" code="A11CC" /></DRUG2>
<DESCRIPTION>Decrease of the concentrations of vitamin D more marked than in the absence of the treatment with the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Concentration dosage of vitamin D and supplementation if necessary.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZOLPIDEM" rxcui="39993">
<ATC code="N05CF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the zolpidem due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. Possibly use another hypnotic.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>455-RIFAMPICIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZOPICLONE" rxcui="40001">
<ATC code="N05CF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the zopiclone due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. Possibly use another hypnotic.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>456-RILPIVIRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RILPIVIRINE" rxcui="1102270">
<ATC code="J05AG05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="H2 RECEPTOR ANTAGONISTS" code="A02BA-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the rilpivirine</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>If necessary, use an H2 receptor antagonist in one dose per day, to be taken at least 12 hours before or at least 4 hours after.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>456-RILPIVIRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RILPIVIRINE" rxcui="1102270">
<ATC code="J05AG05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of rilpivirine by the proton pump inhibitor (decreased absorption because of increase of the gastric pH)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>456-RILPIVIRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RILPIVIRINE" rxcui="1102270">
<ATC code="J05AG05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
<COMMENT>With the exception of dexamethasone administered in a single dose</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>456-RILPIVIRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RILPIVIRINE" rxcui="1102270">
<ATC code="J05AG05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYME INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>456-RILPIVIRINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RILPIVIRINE" rxcui="1102270">
<ATC code="J05AG05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentratons of rilpivirine due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>457-RIOCIGUAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIOCIGUAT" rxcui="1439816">
<ATC code="C02KX05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NITRATE DERIVATIVES AND RELATED" code="C01D-001" /></DRUG2>
<DESCRIPTION>Risk of serious hypotension (synergic effect)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>457-RIOCIGUAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIOCIGUAT" rxcui="1439816">
<ATC code="C02KX05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="TYPE 5 PHOSPHODIESTERASE INHIBITORS" code="G04BE" /></DRUG2>
<DESCRIPTION>Risk of serious hypotension (synergic effect)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>457-RIOCIGUAT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIOCIGUAT" rxcui="1439816">
<ATC code="C02KX05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of riociguat due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>458-RISPERIDONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RISPERIDONE" rxcui="35636">
<ATC code="N05AX08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the active fraction of the risperidone and of its therapeutic effectiveness due to increase of its hepatic metabolism by the carbamazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and, if needed, adjustment of the dosage of the risperidone.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>458-RISPERIDONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RISPERIDONE" rxcui="35636">
<ATC code="N05AX08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the fluoxetine, with risk of increase of the undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and, if needed, adjustment of the dosage of the risperidone. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>458-RISPERIDONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RISPERIDONE" rxcui="35636">
<ATC code="N05AX08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the paroxetine, with risk of increase of the undesirable effects. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and, if needed, adjustment of the dosage of the risperidone. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>459-RIVAROXABAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIVAROXABAN" rxcui="1114195">
<ATC code="B01AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>459-RIVAROXABAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIVAROXABAN" rxcui="1114195">
<ATC code="B01AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the rivaroxaban by the fluconazole, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>459-RIVAROXABAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIVAROXABAN" rxcui="1114195">
<ATC code="B01AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of rivaroxaban, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>459-RIVAROXABAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RIVAROXABAN" rxcui="1114195">
<ATC code="B01AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>45-CALCIUM-CHANNEL-BLOCKERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CALCIUM CHANNEL BLOCKERS" code="CO8CA-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism

</DESCRIPTION>
<SEVERITY>Not recommended:</SEVERITY>
<COMMENT>with the nimodipine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>45-CALCIUM-CHANNEL-BLOCKERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CALCIUM CHANNEL BLOCKERS" code="CO8CA-001" /></DRUG1>
<DRUG2>
<DRUG name="IDELALISIB " rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the undesirable effects of the calcium channel blockers, of the orthostatic hypotension sort, especially with older patients</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the calcium channel blocker during the treatment with idelalisib and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>45-CALCIUM-CHANNEL-BLOCKERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CALCIUM CHANNEL BLOCKERS" code="CO8CA-001" /></DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the undesirable effects of the calcium channel blockers, most often of the hypotension type, especially in older patients.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and dosage adjustment during the treatment with the enzymatic inhibitor and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>45-CALCIUM-CHANNEL-BLOCKERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CALCIUM CHANNEL BLOCKERS" code="CO8CA-001" /></DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>with the nimodipine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>460-ROPINIROLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ROPINIROLE" rxcui="72302">
<ATC code="N04BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with ropinirole and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>460-ROPINIROLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ROPINIROLE" rxcui="72302">
<ATC code="N04BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CIPROFLOXACIN" rxcui="2551">
<ATC code="J01MA02" />
<ATC code="S01AE03" />
<ATC code="S02AA15" />
<ATC code="S03AA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of ropinirole with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the ropinirole during the treatment with the ciprofloxacin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>460-ROPINIROLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ROPINIROLE" rxcui="72302">
<ATC code="N04BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ENOXACIN" rxcui="3925">
<ATC code="J01MA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of ropinirole with signs of overdose due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the ropinirole during the treatment with the enoxacin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>460-ROPINIROLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ROPINIROLE" rxcui="72302">
<ATC code="N04BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of ropinirole, with risk of overdose, due to decrease of its hepatic metabolism by the fluvoxamine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the ropinirole during the treatment with fluvoxamine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>461-ROSUVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ROSUVASTATIN" rxcui="301542">
<ATC code="C10AA07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the rosuvastatin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>461-ROSUVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ROSUVASTATIN" rxcui="301542">
<ATC code="C10AA07" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the rosuvastatin due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>462-ROXITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ROXITHROMYCIN" rxcui="9478">
<ATC code="J01FA06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of the cholesterol lowering medication</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>462-ROXITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ROXITHROMYCIN" rxcui="9478">
<ATC code="J01FA06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the blood concentrations of ciclosporin and of the creatinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration with the macrolide and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>462-ROXITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ROXITHROMYCIN" rxcui="9478">
<ATC code="J01FA06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Slight increase of sedation</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>462-ROXITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ROXITHROMYCIN" rxcui="9478">
<ATC code="J01FA06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of the cholesterol lowering medication</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>462-ROXITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ROXITHROMYCIN" rxcui="9478">
<ATC code="J01FA06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>462-ROXITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ROXITHROMYCIN" rxcui="9478">
<ATC code="J01FA06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Risk of increase of the theophyllinemia, particularly with children</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>463-RUFINAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RUFINAMIDE" rxcui="69036">
<ATC code="N03AF03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>Moderate decrease of the concentrations of ethinylestradiol</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Another contraceptive method, in particular a barrier type, should be used. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>463-RUFINAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="RUFINAMIDE" rxcui="69036">
<ATC code="N03AF03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG2>
<DESCRIPTION>Possible increase of the concentrations of rufinamide, especially with children who weigh less than 30 kg.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>With children who weigh less than 30 kg: do not exceed the total dose of 600mg/day after the period of titration. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>464-SACUBITRIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SACUBITRIL" rxcui="1656328">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09XA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>With diabetic patients or those with renal insufficiency, increase of the undesirable effects such as hypotension, hyperkaliemia</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>464-SACUBITRIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SACUBITRIL" rxcui="1656328">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>Increase of the risk of angioedema</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>465-SALMETEROL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SALMETEROL" rxcui="36117">
<ATC code="R03AC12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the itraconazole</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>465-SALMETEROL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SALMETEROL" rxcui="36117">
<ATC code="R03AC12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the ketoconazole</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>466-SERTRALINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SERTRALINE" rxcui="36437">
<ATC code="N06AB06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYME INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Risk of ineffectiveness of the antidepressant treatment 

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>466-SERTRALINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SERTRALINE" rxcui="36437">
<ATC code="N06AB06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT (JUICE AND FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increase, sometimes large, of the concentrations of the antidepressant with some patients due to decrease of its intestinal metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>466-SERTRALINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SERTRALINE" rxcui="36437">
<ATC code="N06AB06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>467-SILDENAFIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SILDENAFIL" rxcui="136411">
<ATC code="G04BE03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of sildenafil, with risk of hypotension</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Start the treatment with sildenafil at the minimum dose when it is administered with the josamycin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>467-SILDENAFIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SILDENAFIL" rxcui="136411">
<ATC code="G04BE03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPREVIR" code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the sildenafil due to decrease of its hepatic metabolism by the therapy with the ombitasvir+paritaprevir</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>468-SIMEPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMEPREVIR" rxcui="1482790">
<ATC code="J05AE14" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the dexamethasone</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>With the exception of dexamethasone administered in a single dose</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>468-SIMEPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMEPREVIR" rxcui="1482790">
<ATC code="J05AE14" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYME INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of he plasma concentrations of simeprevir due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>468-SIMEPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMEPREVIR" rxcui="1482790">
<ATC code="J05AE14" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of simeprevir due to decrease of its heptatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>468-SIMEPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMEPREVIR" rxcui="1482790">
<ATC code="J05AE14" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMLODIPINE" rxcui="17767">
<ATC code="C08CA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (dose dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Do not exceed the dosage of 20 mg/day of simvastatin or use another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AZITHROMYCIN " rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of the cholesterol lowering agent or another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type, due to decrease of the metabolism of the simvastatin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of simvastatin, due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to decrease of the metabolism of the simvastatin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DANAZOL" rxcui="3102">
<ATC code="G03XA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type due to decrease of the metabolism of the simvastatin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Do not exceed the dosage of 20mg/day of simvastatin. If the therapeutic objective is not reached at this dosage, use another statin not affected by this type of interaction. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
<COMMENT>Use a statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the effectiveness of the cholesterol lowering agent due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPRVIR" code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the simvastatin due to decrease of its hepatic metabolism by the therapy with ombitavir+paritaprevir</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT (JUICE AND FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Significant increase of the plasma concentrations of the cholesterol lowering agent, with risk of onset of undesirable effects, especially muscular</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RANOLAZINE" rxcui="35829">
<ATC code="C01EB18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to inhibition of the metabolism of the simvastatin by the ranolazine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Do not exceed the dosage of 20 mg/day of simvastatin or use another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of simvastatin due to increase of its hepatic metabolism by the rifampicin.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ROXITHROMYCIN" rxcui="9478">
<ATC code="J01FA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of cholesterol lowering agent.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (dose-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (dose-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (dose-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>469-SIMVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to decrease of the hepatic metabolism of the simvastatin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>For anti-inflammatory doses of acetylsalicylic acid (&gt;=1 g per dose and/or &gt;= 3 g per day) or for analgesic or antipyretic doses (&gt;= 500 mg per dose and/or &lt;=3 gr per day):

Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the synthesis of the renal prostaglandins.

Furthermore, reduction of the antihypertensive effect. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Hydrate the patient and monitor renal function at the beginning of treatment. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG1>
<DRUG2>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09XA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hyperkalemia, of renal insufficiency, of increase of mortality from cardiovascular disease</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>- for patients with diabetes or renal insufficiency</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Acute renal insufficiency with patients at risk (older patient, dehydration, treatment with diuretics, changes in renal function), due to decrease of the glomerular filtration (inhibition of the vasodilater prostaglandins due to the non steroidal anti-inflammatories.) These effects are generally reversible. In addition, reduction of the antihypertensive effect.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Hydrate the patient and monitor renal function at the beginning of treatment and regularly while these substances are administered together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)" code="C0E-004" /></DRUG2>
<DESCRIPTION>Risk of hyperkalemia (potentially lethal) especially in case of renal insufficiancy (addition of the hyperkaliemia inducing effects)/</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>--if the combination of these durgs is justified, strict testing of the kaliemia and of renal function</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="POTASSIUM LOWERING DIURETICS" code="C03" /></DRUG2>
<DESCRIPTION>Risk of abrupt arterial hypotension and/or acute renal insufficiency at the beginning of or at an increase of the dosage of a treatment with an angiotensin II antagonist in cases where there is pre-existing fluid depletion. 

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>With arterial hypertension, where there has been pre-existing diuretic treatment that has caused fluid depletion, it is necessary:</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG1>
<DRUG2>
<DRUG name="EPLERENONE" rxcui="298869">
<ATC code="C03DA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hyperkalemia, especially with older patients

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict testing of the kalemia and of the renal function during the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>In indications where the administration of these substances together is possible, increased risk of degradation of renal function, even acute renal insufficiency, and increase of the hyperkalemia as well as hypotension and fainting or loss of consciousness. </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of lithium that can reach toxic values (decrease of the renal excretion of the lithium)

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the use of an angiotensin II antagonist is indispensable, strict monitoring of the plasma concentrations of lithium and adjustment of the dosage</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG1>
<DRUG2>
<DRUG name="POTASSIUM" rxcui="8588">
<ATC code="A12BA" />
</DRUG>
</DRUG2>
<DESCRIPTION>Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects).</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Avoid administering these substances together unless there is pre-existing hypokelimia. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>470-SIROLIMUS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIROLIMUS" rxcui="35302">
<ATC code="L04AA10" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of sirolimus by the ciclosporin. The nephrotoxicity of the ciclosporin is also increased when the two medications are administered together </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommended that the sirolimus be administered 4 hours after the cyclosporine. Testing of the renal function, during the administration of the two medications together and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>470-SIROLIMUS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SIROLIMUS" rxcui="35302">
<ATC code="L04AA10" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the sirolimus (decrease of its hepatic metabolism by the verapamil)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>471-SODIUM-BICARBONATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SODIUM BICARBONATE" rxcui="36676">
<ATC code="A02AH" />
<ATC code="B05CB04" />
<ATC code="B05XA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Avoid excess amounts of sodium and take into account the presence of sodium in certain medications such as antacids.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>472-SODIUM-CHLORIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SODIUM CHLORIDE" rxcui="9863">
<ATC code="A12CA01" />
<ATC code="B05CB01" />
<ATC code="B05XA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Avoid excessive sodium and take into account the presence of sodium in some medications such as antacids.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>473-SOFOSBUVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SOFOSBUVIR" rxcui="1484911">
<ATC code="J05AX15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Only for interactions with the combinatons daclatasvir/sofosbuvir or ledispavir/sofosbuvir:

Possibly abrupt onset of bradycardia, that can have fatal consequences </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these together cannot be avoided, clinical monitoring and strict EKG, in particular during the first weeks of treatment with the bitherapy.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>473-SOFOSBUVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SOFOSBUVIR" rxcui="1484911">
<ATC code="J05AX15" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYME INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the enzymatic inducer</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with the rifampicin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>473-SOFOSBUVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SOFOSBUVIR" rxcui="1484911">
<ATC code="J05AX15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>473-SOFOSBUVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SOFOSBUVIR" rxcui="1484911">
<ATC code="J05AX15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MODAFINIL" rxcui="30125">
<ATC code="N06BA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the modafinil</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>474-SORBITOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SORBITOL" rxcui="9945">
<ATC code="A06AD18" />
<ATC code="A06AG07" />
<ATC code="B05CX02" />
<ATC code="V04CC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="The French document lists Catioresine Sulfo Calcique" >
</DRUG>
</DRUG2>
<DESCRIPTION>With the resin administered by oral and rectal route: risk of colonic necrosis, possibly fatal</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>474-SORBITOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SORBITOL" rxcui="9945">
<ATC code="A06AD18" />
<ATC code="A06AG07" />
<ATC code="B05CX02" />
<ATC code="V04CC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="The French document lists Catioresine Sulfo Sodique" >
</DRUG>
</DRUG2>
<DESCRIPTION>With the resin administered by oral and rectal route: risk of colonic necrosis, possibly fatal. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>475-SPERMICIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SPERMICIDES" code="R02AA" /></DRUG1>
<DRUG2>
<DRUG name="MEDICATIONS USED BY VAGINAL ROUTE" >
</DRUG>
</DRUG2>
<DESCRIPTION>All topical vaginal treatment is susceptible to disrupting the action of a topical spermicidal contraceptive</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>476-SPIRAMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SPIRAMYCIN" rxcui="9991">
<ATC code="J01FA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>In case of administration with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the levodopa. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>477-SPIRONOLACTONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SPIRONOLACTONE" rxcui="9997">
<ATC code="C03DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>With the spironolactone in dosages from 12.5 to 50 mg per day, and with weak doses of the ACE inhibitor.

In the treatment of class III or IV heart failure (NYHA) with an ejection fraction &lt;35% and previous treatment with an ACE inhibitor + a loop diuretic: risk of hyperkalemia, potentially lethal, in case of failure to follow the prescription conditions for this combination of medications. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Verify the absence of pre-existing hyperkalemia and renal insufficiency. Strict biological monitoring of the kalemia and of the creatinemia (1 time per week during the first month, then one time per month thereafter).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>477-SPIRONOLACTONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SPIRONOLACTONE" rxcui="9997">
<ATC code="C03DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MITOTANE" rxcui="7004">
<ATC code="L01XX23" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of blocking of the action of the mitotane by the spironolactone</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>478-STAVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="05AR07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>478-STAVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="05AR07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PENTAMIDINE" rxcui="7994">
<ATC code="P01CX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>478-STAVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="05AR07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIBAVIRIN" rxcui="9344">
<ATC code="J05AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>478-STAVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="05AR07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="THALIDOMIDE" rxcui="10432">
<ATC code="L04AX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>478-STAVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="05AR07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>478-STAVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="05AR07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>479-STIRIPENTOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the anticonvulsant, with risk of overdose, due to inhibition of its hepatic metabolism by the stiripentol</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol, and possible adjustment of its dosage. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>479-STIRIPENTOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the chlosterol lowering medication)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>479-STIRIPENTOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CAFFEINE " rxcui="1886">
<ATC code="V04CG30" />
</DRUG>
</DRUG2>
<DESCRIPTION>Possible increase of the plasma concentrations of the caffeine, with risk of overdose, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of caffeine. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>479-STIRIPENTOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLOBAZAM" rxcui="21241">
<ATC code="N05BA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of these anticonvulsants, with risk of overdose, due to inhibition of their hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol, and possible adjustment of the dosage of that anticonvulsant as well.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>479-STIRIPENTOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIAZEPAM" rxcui="3322">
<ATC code="N05BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the diazepam, with risk of overdose, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol, and possible adjustment of the dosage of the anticonvulsant as well.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>479-STIRIPENTOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIHYDROERGOTAMINE" rxcui="3418">
<ATC code="N02CA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>479-STIRIPENTOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>479-STIRIPENTOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="HALOFANTRINE" rxcui="50749">
<ATC code="P01BX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>479-STIRIPENTOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant (decrease of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>479-STIRIPENTOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism with increase of sedation</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage during the treatment with the stiripentol.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>479-STIRIPENTOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>479-STIRIPENTOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>479-STIRIPENTOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>479-STIRIPENTOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Possible increase of the theophyllinemia, with risk of overdose, due to inhibition of its hepatic metabolism </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, plasma dosage, and possible adjustment of the dosage of theophylline.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>47-PLATELET-AGGREGATION-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PLATELET AGGREGATION INHIBITORS" code="B01AC-001" /></DRUG1>
<DRUG2>
<DRUG name="ANAGRELIDE" rxcui="596724">
<ATC code="L01XX3" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of hemorrhagic events 

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>47-PLATELET-AGGREGATION-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PLATELET AGGREGATION INHIBITORS" code="B01AC-001" /></DRUG1>
<DRUG2>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>47-PLATELET-AGGREGATION-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PLATELET AGGREGATION INHIBITORS" code="B01AC-001" /></DRUG1>
<DRUG2>
<DRUG name="DEFIBROTIDE" rxcui="1311089">
<ATC code="B01AX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of hemorrhage</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>47-PLATELET-AGGREGATION-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PLATELET AGGREGATION INHIBITORS" code="B01AC-001" /></DRUG1>
<DRUG2>
<CLASS name="HEPARINS" code="B01AB" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>47-PLATELET-AGGREGATION-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PLATELET AGGREGATION INHIBITORS" code="B01AC-001" /></DRUG1>
<DRUG2>
<CLASS name="THROMBOLYTICS" code="B01AD" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>480-STRONTIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STRONTIUM" rxcui="81638">
<ATC code="V10BX01" />
<ATC code="M05BX03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CALCIUM" rxcui="1895">
<ATC code="A12AA" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the calcium salts administered by oral route: decrease of the digestive absorption of the strontium</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the strontium at a different time from the calcium salts (more than two hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>480-STRONTIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STRONTIUM" rxcui="81638">
<ATC code="V10BX01" />
<ATC code="M05BX03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="TETRACYCLINE ANTIBIOTICS" code="J01AA" /></DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the strontium</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the strontium at a different time from the tetracycline antibiotics (more than two hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>480-STRONTIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STRONTIUM" rxcui="81638">
<ATC code="V10BX01" />
<ATC code="M05BX03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the strontium</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the strontium at a different time from the iron salts (more than two hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>480-STRONTIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STRONTIUM" rxcui="81638">
<ATC code="V10BX01" />
<ATC code="M05BX03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="FLUOROQUINOLONES" code="J01MA-001" /></DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the strontium</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the strontium at a different time from the fluoroquinolones (more than two hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>480-STRONTIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="STRONTIUM" rxcui="81638">
<ATC code="V10BX01" />
<ATC code="M05BX03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZINC" rxcui="11416">
<ATC code="A12CB" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the strontium.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the strontium at a different time from the zinc salts (more than two hours apart, if possible). </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>481-SUBSTANCES-WITH-ABSORPTION-REDUCED-BY-GASTRO-INTESTINAL-TARGETED-MEDICATIONS,-ANTACIDS,-AND-ABSORBANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES WITH ABSORPTION REDUCED BY GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS " code="RBGI" /></DRUG1>
<DRUG2>
<CLASS name="GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS" code="A07BC-A02AD" /></DRUG2>
<DESCRIPTION>Decrease of the absorption of these substances</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the gastro-intestinal targeted medications, antacids, absorbants at a different time from these substances (more than 2 hours apart, if possible). </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>482-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<DRUG name="ANAGRELIDE" rxcui="596724">
<ATC code="L01XX35" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>482-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<CLASS name="ANTIPARASITICS THAT TEND TO INDUCE TORSADES DE POINTES" code="P01B-001" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with citalopram, domperidone, escitalopram, hydroxyzine, and piperaquin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>482-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<DRUG name="AZITHROMYCIN " rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>482-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>482-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<CLASS name="BRADYCARDIA INDUCING DRUGS" code="C0N0S0" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>482-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<DRUG name="CIPROFLOXACIN" rxcui="2551">
<ATC code="J01MA02" />
<ATC code="S01AE03" />
<ATC code="S02AA15" />
<ATC code="S03AA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>482-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>482-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<DRUG name="HYDROXYCHLOROQUINE" rxcui="5521">
<ATC code="P01BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with citalopram, domperidone, escitalopram, hydroxyzine and piperaquine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>482-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<CLASS name="POTASSIUM LOWERING AGENTS" code="C03-001" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Correct all hypokaliemia before administering the product and do clinical and electrolyte monitoring and EKG.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>482-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<DRUG name="LEVOFLOXACIN" rxcui="82122">
<ATC code="S01AE05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>482-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N07BC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with citalopram, dromperidone, escitalopram, hydroxyzine, piperaquine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>482-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<CLASS name="NEUROLEPTICS THAT TEND TO INDUCE TORSADES DE POINTES" code="N05A-002" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with citalopram, dromperidone, escitalopram, hydroxyzine, piperaquine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>482-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<DRUG name="NORFLOXACIN" rxcui="7517">
<ATC code="S01AE02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>482-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<DRUG name="ONDANSETRON" rxcui="26225">
<ATC code="A04AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>482-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<DRUG name="ROXITHROMYCIN" rxcui="9478">
<ATC code="J01FA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>482-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<CLASS name="TORSADES DE POINTES INDUCING MEDICATIONS (EXCEPT ANTIPARASITICS, NEUROLEPTICS, METHADONE)" code="C01B" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--For erythromycin, and vicamine, only the forms administerd by IV route are concerned by this interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>483-SUBSTRATES-AT-RISK-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTRATES AT RISK OF CYP3A4" code="L01N01" /></DRUG1>
<DRUG2>
<DRUG name="CRIZOTINIB" rxcui="1148495">
<ATC code="L01XE16" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of these molecules due to decrease of their metabolism and/or increase of their bioavailability by the crizotinib</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>483-SUBSTRATES-AT-RISK-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTRATES AT RISK OF CYP3A4" code="L01N01" /></DRUG1>
<DRUG2>
<DRUG name="IDELALISIB" rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the substrate due to decrease of its hepatic metabolism by the idealisib</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>483-SUBSTRATES-AT-RISK-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTRATES AT RISK OF CYP3A4" code="L01N01" /></DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the undesirable effects particular to each substrate, with frequently severe consequences</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUCRALFATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SUCRALFATE" rxcui="10156">
<ATC code="A02BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the vitamin K antagonist</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the sucralfate at a different time from the vitamin K antagonist (more than 2 hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUCRALFATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SUCRALFATE" rxcui="10156">
<ATC code="A02BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the digoxin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the sucralfate at a different time from the digoxin (more that 2 hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUCRALFATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SUCRALFATE" rxcui="10156">
<ATC code="A02BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="FLUOROQUINOLONES" code="J01MA-001" /></DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the fluorquinolones</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the sucralfate at a different time from the fluoroquinolones (more than 2 hours apart, if possible). </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUCRALFATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SUCRALFATE" rxcui="10156">
<ATC code="A02BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the thyroid hormones. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the thyroid hormones at a different time from the sucralfate (more than 2 hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUCRALFATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SUCRALFATE" rxcui="10156">
<ATC code="A02BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the phenytoin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the sucalfate at a different time from the phenytoin (more than 2 hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUCRALFATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SUCRALFATE" rxcui="10156">
<ATC code="A02BX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SULPIRIDE" rxcui="10239">
<ATC code="N05AL01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the sulpiride</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the sucralfate at a different time from the sulpiride (more than 2 hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>485-SUFENTANIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SUFENTANIL" rxcui="56795">
<ATC code="N01AH03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the opioid analgesics effect of respiratory depression due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is also treatment with a strong inhibitor of CYP3A4. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>486-SULFAFURAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SULFAFURAZOLE" rxcui="10207">
<ATC code="J01EB05" />
<ATC code="S01AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution of use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the antibiotic and a week after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>486-SULFAFURAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SULFAFURAZOLE" rxcui="10207">
<ATC code="J01EB05" />
<ATC code="S01AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>The use of another class of antibiotic is preferred; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>487-SULFAMETHIZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SULFAMETHIZOLE" rxcui="10179">
<ATC code="B05CA04" />
<ATC code="D06BA04" />
<ATC code="J01EB02" />
<ATC code="S01AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the antibiotic treatment and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>487-SULFAMETHIZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SULFAMETHIZOLE" rxcui="10179">
<ATC code="B05CA04" />
<ATC code="D06BA04" />
<ATC code="J01EB02" />
<ATC code="S01AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHENAMINE" rxcui="6832">
<ATC code="J01XX05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Precipitation of crystals in the urinary tract (due to the acidification of the urine)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>487-SULFAMETHIZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SULFAMETHIZOLE" rxcui="10179">
<ATC code="B05CA04" />
<ATC code="D06BA04" />
<ATC code="J01EB02" />
<ATC code="S01AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the antibacterial sulfonamide and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>488-SULFAMETHOXAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SULFAMETHOXAZOLE" rxcui="10180">
<ATC code="J01EC01" />
<ATC code="J01EE01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of the substances together cannot be avoided, more frequent testing of the INR and adjustment of the dosage of the vitamin K antagonist during the treatment with cotrimoxazole and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>488-SULFAMETHOXAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SULFAMETHOXAZOLE" rxcui="10180">
<ATC code="J01EC01" />
<ATC code="J01EE01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the antibacterial sulfonamide and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>489-ANTIBACTERIAL-SULFONAMIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIBACTERIAL SULFONAMIDES" code="JO1E" /></DRUG1>
<DRUG2>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hematological toxicity of the methotrexate</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Concentration dosage of methotrexate. Adjustment of the dosage if necessary during the administration of the substances together and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>48-ANTIARRHYTHMIC-AGENTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIARRHYTHMIC AGENTS" code="C01B-001" /></DRUG1>
<DRUG2>
<CLASS name="OTHER ANTIARRHYTHMIC AGENTS" code="C01B-001" /></DRUG2>
<DESCRIPTION>The combination of two antiarrhythmic agents is very delicate. In the majority of cases, it is contraindicated or not recommended.</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>Not recommended </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG1>
<DRUG2>
<DRUG name="ALCOHOL (DRINK OF INGREDIENT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Antabuse effect, especially for glibenclamide, glipizide, tolbutamide. Increase of the hypoglycemic reaction (inhibition of the compensation reactions) that can make possible the onset of hypoglycemic coma</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Avoid taking alcoholic beverages and medications containing alcohol. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG1>
<DRUG2>
<CLASS name="SOMATOSTATIN ANALOGS" code="H01CB0-001" /></DRUG2>
<DESCRIPTION>Risk of hypoglycemia or hyperglycemia: decrease or increase of the need for the blood glucose lowering sufonamide, due to decrease or increase of the secretion of endogenous glucagon</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforce self-monitoring of blood glucose and adjust the dosage of the blood glucose lowering sulfonamide if needed during the treatment with the somatostatin analog. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG1>
<DRUG2>
<CLASS name="BETA-2 MIMETICS or BETA 2 ADRENERGIC AGONISTS" code="R03C-001" /></DRUG2>
<DESCRIPTION>Elevation of the glycemia by the beta-2 mimetic</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforce blood and urine monitoring. Possibly change to insulin if the situation requires. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG1>
<DRUG2>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG2>
<DESCRIPTION>All the beta blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient and reinforce self-monitoring of blood glucose, especially at the beginning of treatment. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>All the beta blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient and reinforce self-monitoring of blood glucose, especially at the beginning of the treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG1>
<DRUG2>
<DRUG name="CHLORPROMAZINE" rxcui="2403">
<ATC code="N05AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With large doses (100mg per day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin) </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the neuroleptic during the treatment and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypoglycemia due to increase of the plasma concentrations of the antidiabetique</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG1>
<DRUG2>
<DRUG name="DANAZOL" rxcui="3102">
<ATC code="G03XA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Diabetes inducing effect of the danazol</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of the substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the antidiabetic during the treatment with the danazol and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the half life of the sulfonamide with possible onset of manifestations of hypoglymemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the sulfonamide during the treatment with the fluconazole. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in diabetic patients treated with glucose lowering sulfonamides. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for the glucose lowering sulfonamides)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforce self -monitoring of blood glucose.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG1>
<DRUG2>
<DRUG name="MICONAZOLE" rxcui="6932">
<ATC code="A01AB09" />
<ATC code="A07AC01" />
<ATC code="D01AC02" />
<ATC code="G01AF04" />
<ATC code="J02AB01" />
<ATC code="S02AA13" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>491-SULFASALAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SULFASALAZINE" rxcui="9524">
<ATC code="A07EC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digoxinemia that can reach 50%</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and, possibly, monitoring of the digoxinemia. If there is reason for it, adjustment of the dosage of the digoxin during the treatment with the sulfasalazine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>492-SULFINPYRAZONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SULFINPYRAZONE" rxcui="10205">
<ATC code="M04AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the blood concentrations of ciclosporin due to increase of its metabolism by the sulfinpyrazone</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Testing of blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with sulfinpyrazone and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>493-SULPIRIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SULPIRIDE" rxcui="10239">
<ATC code="N05AL01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SUCRALFATE" rxcui="10156">
<ATC code="A02BX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the sulpiride</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the sucralfate at a different time from the sulpiride (more than 2 hours apart, if possible). </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>494-SUNITINIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SUNITINIB" rxcui="357977">
<ATC code="L01XE04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the thyroid hormones</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>495-SUXAMETHONIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SUXAMETHONIUM" rxcui="10154">
<ATC code="M03AB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ACETYLCHOLINESTERASE INHIBITORS" code="ACETCHO" /></DRUG2>
<DESCRIPTION>Risk of lengthening of the motor block, increased in the case of partial deficit of pseudo-cholinesterase </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>496-ALPHA-SYMPATHOMIMETICS-(ORAL-AND-OR-NASAL).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)" code="R01AA" /></DRUG1>
<DRUG2>
<CLASS name="DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE" code="G02CB-001" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or rapid elevation of blood pressure</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>496-ALPHA-SYMPATHOMIMETICS-(ORAL-AND-OR-NASAL).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)" code="R01AA" /></DRUG1>
<DRUG2>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or of rapid elevation of blood pressure</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>496-ALPHA-SYMPATHOMIMETICS-(ORAL-AND-OR-NASAL).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)" code="R01AA" /></DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>Hypertensive crises (inhibition of the metabolism of the pressor amines). Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI is stopped</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>496-ALPHA-SYMPATHOMIMETICS-(ORAL-AND-OR-NASAL).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)" code="R01AA" /></DRUG1>
<DRUG2>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or of rapid elevation of blood pressure</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>497-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)" code="C01CA" /></DRUG1>
<DRUG2>
<CLASS name="HALOGENATED HYDROCARBON ANESTHETICS" code="N01AB0-001" /></DRUG2>
<DESCRIPTION>Serious ventricular arrhythmias due to increase of cardiac sensitization</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>497-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)" code="C01CA" /></DRUG1>
<DRUG2>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG2>
<DESCRIPTION>Paroxysmal hypertension with the possibility of arrhythmias (inhibition of the entry of the sympathomimetic into the sympathic fiber)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>497-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)" code="C01CA" /></DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>Increase of the pressor action of the sympathomimetic, most often moderate. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Only use under strict medical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>497-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)" code="C01CA" /></DRUG1>
<DRUG2>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG2>
<DESCRIPTION>By extrapolation from the non selective MAOIs: risk of increase of the pressor action </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>To be used only under strict medical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>497-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)" code="C01CA" /></DRUG1>
<DRUG2>
<CLASS name="MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS" code="N06A" /></DRUG2>
<DESCRIPTION>Paroxysmal hypertension with possibility of arrhythmias (inhibition of the entry of the sympathomimetic into the sympathic fiber)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>498-INDIRECT-SYMPATHOMIMETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG1>
<DRUG2>
<CLASS name="OTHER INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or of hypertensive crises.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>498-INDIRECT-SYMPATHOMIMETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG1>
<DRUG2>
<CLASS name="DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE" code="G02CB-001" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or of rapid elevation of blood pressure</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>498-INDIRECT-SYMPATHOMIMETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG1>
<DRUG2>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or of rapid elevation of blood pressure

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>498-INDIRECT-SYMPATHOMIMETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG1>
<DRUG2>
<CLASS name="HALOGENATED HYDROCARBON ANESTHETICS" code="N01AB0-001" /></DRUG2>
<DESCRIPTION>Perioperative hypertension</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In the case of scheduled surgery, it is preferable to stop the treatment several days before surgery.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>498-INDIRECT-SYMPATHOMIMETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>Paroxystic hypertension, hyperthermia that can be fatal. Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI has been stopped</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>498-INDIRECT-SYMPATHOMIMETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG1>
<DRUG2>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or rapid elevation of blood pressure</DESCRIPTION>
<SEVERITY>Contraindication:</SEVERITY>
<COMMENT>with bupropion</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>498-INDIRECT-SYMPATHOMIMETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG1>
<DRUG2>
<CLASS name="ALPHA-SYMPATHOMIMETICS (ORAL AND/OR NASAL)" code="R01AA" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or rapid elevation of blood pressure</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>499-TACROLIMUS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="AMINOGLYCOSIDES" code="J01GB-001" /></DRUG2>
<DESCRIPTION>Greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>499-TACROLIMUS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of tacrolimus due to inhibition of its metabolism by the amiodarone</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of tacrolimus, testing of the renal function, and adjustment of the dosage of tacrolimus during its administration with the amiodarone and when the amiodarone is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>499-TACROLIMUS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMPHOTERICIN B " rxcui="732">
<ATC code="A01AB04" />
<ATC code="A07AA07" />
<ATC code="G01AA03" />
<ATC code="J02AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the amphotericin B administered by IV route: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>499-TACROLIMUS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Risk of addition of the nephrotoxic effects, especially with older patients</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitor renal function at the beginning of treatment with the NSAI.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>499-TACROLIMUS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLINDAMYCIN" rxcui="2582">
<ATC code="D10AF01" />
<ATC code="G01AA10" />
<ATC code="J01FF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the blood concentrations of the immunosuppressant, with risk of loss of immunosuppressive activity. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforced testing of the blood dosages of tacrolimus and possible increase of its dosage. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>499-TACROLIMUS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of dabigatran</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>499-TACROLIMUS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DANAZOL" rxcui="3102">
<ATC code="G03XA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the tacrolimus due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the tacrolimus and adjustment of its dosage during the administration with the danazol and after it is stopped, with testing of the renal function.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>499-TACROLIMUS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)" code="C0E-004" /></DRUG2>
<DESCRIPTION>Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>499-TACROLIMUS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of tacrolimus and of the creatinemia, due to inhibition of the hepatic metabolism of the tacrolimus by the josamycin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>499-TACROLIMUS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LANSOPRAZOLE" rxcui="17128">
<ATC code="A02BC03" />
<ATC code="A02BD07" />
<ATC code="A02BD03" />
<ATC code="A02BD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the tacrolimus</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of the two substances together and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>499-TACROLIMUS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="OMEPRAZOLE" rxcui="7646">
<ATC code="A02BC01" />
<ATC code="A02BD05" />
<ATC code="A02BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the tacrolimus</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>499-TACROLIMUS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="POTASSIUM" rxcui="8588">
<ATC code="A12BA" />
</DRUG>
</DRUG2>
<DESCRIPTION>Essentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)</DESCRIPTION>
<SEVERITY>Not recommended </SEVERITY>
<COMMENT>Avoid administering these substances together unless there is preexisting hypokalemia.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>499-TACROLIMUS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the tacrolimus (decrease of its hepatic metabolism by the verapamil)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>49-CLASS-I-ANTIARRHYTHMICS-(EXCEPT-LIDOCAINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)" code="C01B-003" /></DRUG1>
<DRUG2>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)" code="C07AB-001" /></DRUG2>
<DESCRIPTION>Disorders of contractility, autoregulation, and electrical conduction (suppression of the compensatory sympathetic mechanisms)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>49-CLASS-I-ANTIARRHYTHMICS-(EXCEPT-LIDOCAINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)" code="C01B-003" /></DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>Negative inotropic effect with risk of acute decompensated heart failure 

</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>4-ACETOHYDROXAMIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETOHYDROXAMIC ACID" rxcui="16728">
<ATC code="G04BX03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of these two medications due to chelation of the iron</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>500-TAMOXIFEN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TAMOXIFEN" rxcui="10324">
<ATC code="L02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>500-TAMOXIFEN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TAMOXIFEN" rxcui="10324">
<ATC code="L02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine [sic] </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>500-TAMOXIFEN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TAMOXIFEN" rxcui="10324">
<ATC code="L02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the duloxetine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>500-TAMOXIFEN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TAMOXIFEN" rxcui="10324">
<ATC code="L02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the fluoxetine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>500-TAMOXIFEN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TAMOXIFEN" rxcui="10324">
<ATC code="L02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the paroxetine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>500-TAMOXIFEN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TAMOXIFEN" rxcui="10324">
<ATC code="L02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the quinidine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>500-TAMOXIFEN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TAMOXIFEN" rxcui="10324">
<ATC code="L02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TERBINAFINE" rxcui="37801">
<ATC code="D01AE15" />
<ATC code="D01BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>501-TAMSULOSIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TAMSULOSIN" rxcui="77492">
<ATC code="G04CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use </SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the tamsulosin during the treatment with the enzyme inhibitor and after it is stopped, if the situation requires. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>501-TAMSULOSIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TAMSULOSIN" rxcui="77492">
<ATC code="G04CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the tamsulosin during the treatment with the enzyme inhibitor and after it is stopped, if the situation requires.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>501-TAMSULOSIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TAMSULOSIN" rxcui="77492">
<ATC code="G04CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>501-TAMSULOSIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TAMSULOSIN" rxcui="77492">
<ATC code="G04CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the tamsulosin during the treatment with the enzyme inhibitor and after it is stopped, if the situation requires. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>502-TELAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>502-TELAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Risk of very large decrease of the concentrations of telaprevir.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>502-TELAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the atorvastatin)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>502-TELAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring, and adjustment, if needed, of the dosage of the digoxin during the treatment with the telaprevir and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>502-TELAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NON-CONTRACEPTIVE ESTROGENS" code="G03C-001" /></DRUG2>
<DESCRIPTION>Decrease of the effectiveness of the estrogen</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the telaprevir and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>502-TELAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the telaprevir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use a reliable contraceptive method, additional or alternative, during the administration of the substances together and two cycles after. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>502-TELAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the telaprevir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of its dosage during the administration of the substances together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>502-TELAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Decrease of the concentrations of the telaprevir and of the darunavir or of the fosamprenavir, with risk of therapeutic failure</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>502-TELAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of telaprevir and of the itraconazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. Avoid large doses of itraconaole (>200 mg per day).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>502-TELAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of very large decrease of the concentrations of telaprevir</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>502-TELAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
<ATC code="J04AM02" />
<ATC code="J04AM05" />
<ATC code="J04AM06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the concentrations of telaprevir</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>502-TELAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>502-TELAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the tenofovir alafenamide due to decrease of its intracellular activity by the telaprevir</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>503-TELBIVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELBIVUDINE" rxcui="474128">
<ATC code="J05AF11" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PEG-INTERFERON ALFA-2A" rxcui="120608">
<ATC code="L03AB11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of peripheral neuropathy</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>504-TELITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>504-TELITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>504-TELITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>504-TELITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the dogoxinemia during the treatment with the telithromycin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>504-TELITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>When these are taken together, strict testing of the renal function, blood concentration dosage of the immunosuppressant and possible adjustment of the dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>504-TELITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects, especially of the cardiac arrhythmia type</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
<COMMENT>with the patient having severe renal or hepatic insufficiency</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>504-TELITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of the hepatic metabolism of the telithromycin by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>504-TELITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MIZOLASTINE" rxcui="61455">
<ATC code="R06AX25" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmia, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>504-TELITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
<ATC code="J04AM02" />
<ATC code="J04AM05" />
<ATC code="J04AM06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of the hepatic metabolism of the telithromycin by the rifampicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>504-TELITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering drug). </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>504-TELITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VENLAFAXINE" rxcui="39786">
<ATC code="N06AX16" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of venlafaxine with risk of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>504-TELITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VINCA ALKALOIDS" code="L01CA" /></DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the telithromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical and biological monitoring. Possibly, use another antibiotic.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>505-TENOFOVIR-ALAFENAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of lower effectiveness of the tenofovir alafenamide due to decrease of its intracellular activity by the boceprevir</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>505-TENOFOVIR-ALAFENAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In case of co-administration with the ciclosporine, the dose of tenofovir alafenamide must be limited to 10 mg per day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>505-TENOFOVIR-ALAFENAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="VO3AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the atazanavir, the darunavir or the lopinavir boosted with cobicistat, increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In case of co-administration, the dose of tenofovir alafenamide must be limited to 10 mg per day. The administration with the other protease inhibitors of HIV has not been studied. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>505-TENOFOVIR-ALAFENAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYME INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the tenofovir alafenamide due to decrease of its absorption by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of these medications together cannot be avoided, clinical monitoring during the administration and 1 to2 weeks after the inducer is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>505-TENOFOVIR-ALAFENAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>With the atazanavir, the darunavir or the lopinavir, increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>If these are administered together, the dose of tenofovir alafenamide must be limited to 10 mg per day. Administration with the other protease inhibitors of HIV has not been studied.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>505-TENOFOVIR-ALAFENAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In case of co-administration with the itraconazole, the dose of tenofovir alafenamide must be limited to 10 mg per day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>505-TENOFOVIR-ALAFENAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In case of co-administration with the ketoconazole, the dose of tenofovir alafenamide must be limited to 10 mg per day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>505-TENOFOVIR-ALAFENAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of tenofovir alafenamide due to decrease of its absorption by the rifampicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together and 1 to 2 weeks after the rifampicin is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>505-TENOFOVIR-ALAFENAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the tenofovir alafenamide due to decrease of its intracellular activity by the telaprevir</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>505-TENOFOVIR-ALAFENAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In case of co-administration with the verapamil, the dose of tenofovir alafenamide must be limited to 10 mg per day</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>506-TENOFOVIR-DISOPROXIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR DISOPROXIL" rxcui="300195">
<ATC code="J05AF07" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Risk of increase of the nephrotoxicity of the tenofovir, especially with large doses of the anti-inflammatory or in the presence of factors of risk of renal insufficiency. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>When these are administered together, monitor renal function.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>506-TENOFOVIR-DISOPROXIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR DISOPROXIL" rxcui="300195">
<ATC code="J05AF07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same substances together</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>Do not administer the atazanavir with the tenofovir without ritonavir. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>506-TENOFOVIR-DISOPROXIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR DISOPROXIL" rxcui="300195">
<ATC code="J05AF07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIDANOSINE" rxcui="3364">
<ATC code="J05AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of failure of the antiretroviral treatment, even emergence of resistance. In addition, increase of the risk of the mitochondrial toxicity of the didanosine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>506-TENOFOVIR-DISOPROXIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TENOFOVIR DISOPROXIL" rxcui="300195">
<ATC code="J05AF07" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG2>
<DESCRIPTION>When co-administered with a protease inhibitor, increase of the plasma concentrations of the tenofovir by the ledipasvir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring, especially of the renal function.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>507-TERBINAFINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TERBINAFINE" rxcui="37801">
<ATC code="D01AE15" />
<ATC code="D01BA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the blood concentrations of ciclosporin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Testing of the blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with terbinafine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>507-TERBINAFINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TERBINAFINE" rxcui="37801">
<ATC code="D01AE15" />
<ATC code="D01BA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the terbinafine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the flecaidine during the treatment with the terbinafine. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>507-TERBINAFINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TERBINAFINE" rxcui="37801">
<ATC code="D01AE15" />
<ATC code="D01BA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MEQUITAZINE" rxcui="29528">
<ATC code="R06AD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>507-TERBINAFINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TERBINAFINE" rxcui="37801">
<ATC code="D01AE15" />
<ATC code="D01BA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>507-TERBINAFINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TERBINAFINE" rxcui="37801">
<ATC code="D01AE15" />
<ATC code="D01BA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the terbinafine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the terbinafine. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>507-TERBINAFINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TERBINAFINE" rxcui="37801">
<ATC code="D01AE15" />
<ATC code="D01BA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>507-TERBINAFINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TERBINAFINE" rxcui="37801">
<ATC code="D01AE15" />
<ATC code="D01BA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TAMOXIFEN" rxcui="10324">
<ATC code="L02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine. </DESCRIPTION>
<SEVERITY>Nor recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>507-TERBINAFINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TERBINAFINE" rxcui="37801">
<ATC code="D01AE15" />
<ATC code="D01BA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the terbinafine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>508-TERIFLUNOMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TERIFLUNOMIDE" rxcui="1310520">
<ATC code="L04AA31" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG2>
<DESCRIPTION>Risk of general vaccine disease, possibly fatal </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>509-TETRABENAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TETRABENAZINE" rxcui="10390">
<ATC code="N07XX06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="DOPAMINERGICS" code="N04B-002" /></DRUG2>
<DESCRIPTION>Reciprocal antagonism between the dopaminergic and the tetrabenazine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>509-TETRABENAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TETRABENAZINE" rxcui="10390">
<ATC code="N07XX06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>Risk of hypertensive crises. Because of the duration of the action of the MAOI, this interaction is still theoretically possible two weeks after the MAOI is stopped</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>509-TETRABENAZINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name=" TETRABENAZINE" rxcui="10390">
<ATC code="N07XX06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Reciprocal antagonism between the levodopa and the tetrabenazine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>50-CLASS-IA-ANTIARRHYTHMICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CLASS IA ANTIARRHYTHMICS" code="C01B-002" /></DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the antiarrhythmic, due to increase of its hepatic metabolism by the inducer

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and testing of the plasma concentrations; if needed, adjustment of the dosage of the antiarrhythmic during the treatment with the inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>50-CLASS-IA-ANTIARRHYTHMICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CLASS IA ANTIARRHYTHMICS" code="C01B-002" /></DRUG1>
<DRUG2>
<DRUG name="ESMOLOL" rxcui="49737">
<ATC code="C07AB09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of contractility, auto- regulation, and conduction (suppression of the compensatory sympathetic mechanisms)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>50-CLASS-IA-ANTIARRHYTHMICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CLASS IA ANTIARRHYTHMICS" code="C01B-002" /></DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the antiarrhythmic (increase of its hepatic metabolism). 

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the antiarrhythmic. If needed, adjustment of the dosage of the antiarrhythmic during the treatment with the rifampicin and after it is stopped (risk of overdose of the antiarrhythmic)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>510-THALIDOMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="THALIDOMIDE" rxcui="10432">
<ATC code="L04AX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIDANOSINE" rxcui="3364">
<ATC code="J05AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>510-THALIDOMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="THALIDOMIDE" rxcui="10432">
<ATC code="L04AX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="J05AF04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>510-THALIDOMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="THALIDOMIDE" rxcui="10432">
<ATC code="L04AX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>511-THEOPHYLLINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="THEOPHYLLINE " rxcui="10438">
<ATC code="R03DA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict monitoring of the the plasma concentrations of lithium and possible adjustment of the dosage of the lithium.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>511-THEOPHYLLINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="THEOPHYLLINE " rxcui="10438">
<ATC code="R03DA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the theophyllinemia due to decrease of its hepatic metabolism by the propafenone</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>511-THEOPHYLLINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="THEOPHYLLINE " rxcui="10438">
<ATC code="R03DA04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VEMURAFENIB" rxcui="1147220">
<ATC code="L01XE1" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large increase of the concentrations of theophylline, with risks of increase of its undesirable effects.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the theophylline during the treatment with vemurafenib and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the theophylline due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY> Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and, if needed, monitoring of the theophyllinemia. Possible adjustment of the dosage of the theophylline during the treatment with the inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia. If there is reason for it, adjustment of the theophylline during the treatment with the cimetidine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<DRUG name="CIPROFLOXACIN" rxcui="2551">
<ATC code="J01MA02" />
<ATC code="S01AE03" />
<ATC code="S02AA15" />
<ATC code="S03AA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the theophyllinemia, particularly with children</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<DRUG name="DIPYRIDAMOLE" rxcui="3521">
<ATC code="B01AC07" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the theophylline</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Interrupt a treatment with theophylline at least 5 days before myocardial perfusion imaging with the dipyridamole.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<DRUG name="ENOXACIN" rxcui="3925">
<ATC code="J01MA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Overdose of theophylline due to substantial decrease of its metabolism</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Overdose of theophylline due to decrease of its hepatic elimination, more particularly dangerous with children</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with risk of overdose (decrease of the clearance of the theophylline)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and, possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the fluconazole and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<DRUG name="FLUVOXAMINE" rxcui="42355">
<ATC code="N06AB08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with signs of overdose (decrease of the hepatic metabolism of the theophylline)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia; if needed, adjustment of the dosage of the theophylline during the treatment with the fluvoxamine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<DRUG name="HALOTHANE" rxcui="5095">
<ATC code="N01AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Serious ventricular arrhythmias due to increase of cardiac sensitization</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<CLASS name="XANTHINE OXYDASE INHIBITORS" code="M04AA0" /></DRUG2>
<DESCRIPTION>In case of large doses of the inhibitor, increase of the plasma concentrations of theophylline due to inhibition of its metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and testing of the theophyllinemia up to two or three weeks after the beginning of the treatment with the inhibitor; if there is reason for it, adjustment of the dosage during the treatment with these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the theophylline, due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the protease inhibitor and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the theophyllinemia, particularly with children</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<DRUG name="MEXILETINE" rxcui="6926">
<ATC code="C01BB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with risk of overdose (decrease of the hepatic metabolism of the theophylline)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the mexiletine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the theophylline, by reason of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (onset of an obstructive pulmonary syndrome)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
<COMMENT>In case of accidental use of the substances together, do not stop the St Johns wort abruptly but test the plasma concentrations (or the effectiveness) of the substance taken with it before and then after stopping the St Johns wort.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<DRUG name="NORFLOXACIN" rxcui="7517">
<ATC code="J01MA06" />
<ATC code="S01AE02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and possibly monitoring of the theophyllinemia. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<DRUG name="PEFLOXACIN" rxcui="7960">
<ATC code="J01MA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and, possibly monitoring of the theophyllinemia.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<DRUG name="PENTOXIFYLLINE" rxcui="8013">
<ATC code="C04AD03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with risk of overdose (competition at the level of the hepatic metabolism of the theophylline) </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the pentoxifylline and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the theophylline (increase of its metabolism by enzymatic induction) </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and, if needed, monitoring of the theophyllinemia. Adjust, if there is reason to, the dosage of the theophylline during the treatment with the rifampicin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<DRUG name="ROXITHROMYCIN" rxcui="9478">
<ATC code="J01FA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the theophyllinemia, particularly with children.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Possible increase of the theophyllinemia, with risk of overdose, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, plasma dosage, and possible adjustment of the dosage of theophylline. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<DRUG name="TIABENDAZOLE" rxcui="10450">
<ATC code="D01AC06" />
<ATC code="P02CA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with risk of overdose, due to decrease of the hepatic metabolism of the theophylline</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment (and after it is stopped, in the case where the anthelmintic is prescribed for a period exceeding 48 hours).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG1>
<DRUG2>
<DRUG name="TICLOPIDINE" rxcui="10594">
<ATC code="B01AC05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with risk of overdose (decrease of the plasma clearance of the theophylline)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the ticlopidine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>513-THROMBOLYTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THROMBOLYTICS" code="B01AD" /></DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>513-THROMBOLYTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THROMBOLYTICS" code="B01AD" /></DRUG1>
<DRUG2>
<CLASS name="PLATELET AGGREGATION INHIBITORS" code="B01AC-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>513-THROMBOLYTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THROMBOLYTICS" code="B01AD" /></DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>513-THROMBOLYTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THROMBOLYTICS" code="B01AD" /></DRUG1>
<DRUG2>
<DRUG name="DEFIBROTIDE" rxcui="1311089">
<ATC code="B01AX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Accrued risk of hemorrhage</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>513-THROMBOLYTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THROMBOLYTICS" code="B01AD" /></DRUG1>
<DRUG2>
<CLASS name="LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)" code="B01AB-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>513-THROMBOLYTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THROMBOLYTICS" code="B01AD" /></DRUG1>
<DRUG2>
<CLASS name="UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)" code="B01AB-003" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>514-TIABENDAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TIABENDAZOLE" rxcui="10450">
<ATC code="D01AC06" />
<ATC code="P02CA02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with risk of overdose, due to decrease of the hepatic metabolism of the theophylline</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment (and after it is stopped, in the case where the anthelmintic is prescribed for a period exceeding 48 hours).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>515-TIAGABINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TIAGABINE" rxcui="31914">
<ATC code="N03AG06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>An increase of the dosage of the tiagabine can prove necessary in cases when it is administered with an anticonvulsant enzyme inducer.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>515-TIAGABINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TIAGABINE" rxcui="31914">
<ATC code="N03AG06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>An increase of the dosage of the tiagabine can prove necessary in cases when it is administered with the rifampicin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>516-TIANEPTINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TIANEPTINE" rxcui="38252">
<ATC code="N06AX14" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>Risk of drop in blood pressure, paroxystic hypertension, hyperthermia, convulsions, death</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>517-TIBOLONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TIBOLONE" rxcui="38260">
<ATC code="G03CX01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tibolone and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>518-TICAGRELOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage due to addition of the platelet aggregation activities</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>--except for validated indications for this combination in acute coronary syndromes.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>518-TICAGRELOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the anticonvulsant enzyme inducer, with risk of decrease of the therapeutic effect</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>518-TICAGRELOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DABIGATRAN" rxcui="">
<ATC code="1037042" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>518-TICAGRELOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>518-TICAGRELOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>518-TICAGRELOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the St Johns wort, with decrease of its therapeutic effect.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>518-TICAGRELOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPRVIR" code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the ticagrelor due to decrease of its hepatic metabolism by the therapy with ombitasvir+paritaprevir</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>518-TICAGRELOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT (JUICE AND FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Doubling of the plasma concentrations of the antiagregant, with risk of increase of its undesirable effects, especially hemorrhagic ones</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>518-TICAGRELOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the rifampicin, with risk of decrease of the therapeutic effect.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>518-TICAGRELOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>519-TICLOPIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICLOPIDINE" rxcui="10594">
<ATC code="B01AC05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage due to addition of the platelet antiagregation action</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of the substances together cannot be avoided, strict clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>519-TICLOPIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICLOPIDINE" rxcui="10594">
<ATC code="B01AC05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the blood concentrations of ciclosporin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increase of the dosage of the ciclosporin according to testing of the blood concentrations. Reduction of the dosage if the ticlopidine is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>519-TICLOPIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICLOPIDINE" rxcui="10594">
<ATC code="B01AC05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and testing of the plasma concentrations of phenytoin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>519-TICLOPIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICLOPIDINE" rxcui="10594">
<ATC code="B01AC05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with risk of overdose (decrease of the plasma clearance of the theophylline). </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the ticlopidine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>51-ACETYLCHOLINESTERASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ACETYL-CHOLINESTERASE INHIBITORS" code="ACETCHO" /></DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>Risk of excessive bradycardia (addition of the bradycardia inducing effects)

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring, especially at the beginning of the administration of the substances together </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>51-ACETYLCHOLINESTERASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ACETYL-CHOLINESTERASE INHIBITORS" code="ACETCHO" /></DRUG1>
<DRUG2>
<DRUG name="PILOCARPINE" rxcui="8328">
<ATC code="N07AX01" />
<ATC code="S01EB01" />
<ATC code="S01EB51" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of addition of the undesirable cholinergic effects, especially digestive ones</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>51-ACETYLCHOLINESTERASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ACETYL-CHOLINESTERASE INHIBITORS" code="ACETCHO" /></DRUG1>
<DRUG2>
<DRUG name="SUXAMETHONIUM" rxcui="10154">
<ATC code="M03AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of lengthening of the motor block, increased in the case of partial deficit of pseudocholinesterase</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>520-GASTROINTESTINAL-TARGETED-MEDICATIONS,-ANTACIDS,-AND-ABSORBANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS" code="A07BC-A02AD" /></DRUG1>
<DRUG2>
<DRUG name="MEDICATIONS ADMINISTERED BY ORAL ROUTE" >
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the absorption of certain other medications ingested simultaneously</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>As a precaution, it is preferable to take these gastrointestinal targeted medications, antacids, and absorbent medications at a different time from any other medication (more than 2 hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>520-GASTROINTESTINAL-TARGETED-MEDICATIONS,-ANTACIDS,-AND-ABSORBANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS" code="A07BC-A02AD" /></DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES WITH ABSORPTION REDUCED BY GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS " code="RBGI" /></DRUG2>
<DESCRIPTION>Decrease of the absorption of these substances</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the medications, antacids, or absorbants at a different time from these substances (more than 2 hours apart, if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>521-TOPIRAMATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TOPIRAMATE" rxcui="38404">
<ATC code="N03AX11" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the carbamazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and if needed, adjustment of the dosage of the toprimate during the treatment with the carbamazepine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>521-TOPIRAMATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TOPIRAMATE" rxcui="38404">
<ATC code="N03AX11" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>For doses of topiramate &gt;= 200 mg/day: Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of estrogen</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Another method of contraception, in particular a barrier type, should be used. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>521-TOPIRAMATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TOPIRAMATE" rxcui="38404">
<ATC code="N03AX11" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>For doses of topiramate &gt;=200mg/day: increase of the the plasma concentrations of lithium that can reach toxic levels, with signs of overdose of lithium</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring. Adjustment of the dosage of lithium. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>521-TOPIRAMATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TOPIRAMATE" rxcui="38404">
<ATC code="N03AX11" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="OXCARBAZEPINE" rxcui="32624">
<ATC code="N03AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and if needed, adjustment of the dosage of the topiramate during the treatment with the oxcarbazepine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>521-TOPIRAMATE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TOPIRAMATE" rxcui="38404">
<ATC code="N03AX11" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG2>
<DESCRIPTION>Increase of the hyperammonemia, with increased risk of encephalopathy </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>522-TORSADES-DE-POINTES-INDUCING-MEDICATIONS-(EXCEPT-ANTIPARASITICS,-NEUROLEPTICS,-METHADONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TORSADES DE POINTES INDUCING MEDICATIONS (EXCEPT ANTIPARASITICS, NEUROLEPTICS, METHADONE)" code="C01B" /></DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--for erythromycin and vincamine, only the forms administered by IV route are affected by this interaction. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>523-TRABECTEDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRABECTEDINE" rxcui="397736">
<ATC code="L01CX0" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of the trabectedine by the itraconazole</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together is necessary, clinical monitoring and possible adjustment of the dosage of the trabectedine during the length of the treatment with the itraconazole</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>524-NICOTINE-SUBSTITUTION-TREATMENT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NICOTINE SUBSTITUION TREATMENT" code="N07BA" /></DRUG1>
<DRUG2>
<CLASS name="MEDICATIONS AT RISK WHEN WITHDRAWING FROM TOBACCO" code="N0-R0-002" /></DRUG2>
<DESCRIPTION>Risk of overdose when replacing tobacco by the substitution treatment</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>525-TRAMADOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRAMADOL" rxcui="10689">
<ATC code="N02AX02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tramadol and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>525-TRAMADOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRAMADOL" rxcui="10689">
<ATC code="N02AX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the tramadol due to decrease of its hepatic metabolism by the bupropion. In addition, risk of convulsions due to addition of the effects of the two medications</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>525-TRAMADOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRAMADOL" rxcui="10689">
<ATC code="N02AX02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome: diarrhea, sweats, trembling, confusion, even coma</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>525-TRAMADOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRAMADOL" rxcui="10689">
<ATC code="N02AX02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>525-TRAMADOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRAMADOL" rxcui="10689">
<ATC code="N02AX02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="MAOI-B " code="N04BD0-001" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>525-TRAMADOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRAMADOL" rxcui="10689">
<ATC code="N02AX02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)" code="N06AB" /></DRUG2>
<DESCRIPTION>Risk of appearance of convulsions and/or a serotonin syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>525-TRAMADOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRAMADOL" rxcui="10689">
<ATC code="N02AX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ONDANSETRON" rxcui="26225">
<ATC code="A04AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the intensity and of the duration of the analgesic effect of the tramadol and risk of decrease of the antiemitic effect of the ondansetron</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>525-TRAMADOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRAMADOL" rxcui="10689">
<ATC code="N02AX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VENLAFAXINE" rxcui="39786">
<ATC code="N06AX16" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of appearance of convulsions and/or of a serotonin syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>526-TRASTUZUMAB-EMTANSINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRASTUZUMAB EMTANSINE" rxcui="1371041">
<ATC code="L01XC14" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the DM1, a component of the trastuzumab emtansine, due to inhibition of its metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>527-TRICLABENDAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRICLABENDAZOLE" rxcui="38608">
<ATC code="P02BX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIHYDROERGOTAMINE" rxcui="3418">
<ATC code="N02CA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Wait 24 hours between stopping the triclabendazole and the dose of the medication derived from ergot of rye, and the reverse.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>527-TRICLABENDAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRICLABENDAZOLE" rxcui="38608">
<ATC code="P02BX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Wait 24 hours between stopping the thiclabendazole and the ergotamine, and the reverse.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>527-TRICLABENDAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRICLABENDAZOLE" rxcui="38608">
<ATC code="P02BX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Wait 24 hours between stopping the triclabendazole and the dose of the torsade inducing medication, and the reverse. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>527-TRICLABENDAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRICLABENDAZOLE" rxcui="38608">
<ATC code="P02BX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Wait 24 hours between stopping the triclabendazole and the dose of the torsade inducing medication, and the reverse.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>528-TRIMETHOPRIM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRIMETHOPRIM" rxcui="10829">
<ATC code="J01EA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporin

With trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>528-TRIMETHOPRIM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRIMETHOPRIM" rxcui="10829">
<ATC code="J01EA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>528-TRIMETHOPRIM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRIMETHOPRIM" rxcui="10829">
<ATC code="J01EA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PYRIMETHAMINE" rxcui="9010">
<ATC code="P01BD01" />
<ATC code="P01BF04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Megaloblastic anemia, more particularly with strong doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular CBC and addition of a treatment with folic acid (regular IM injections). </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>528-TRIMETHOPRIM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRIMETHOPRIM" rxcui="10829">
<ATC code="J01EA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, strict clinical and biological monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>529-TRIPTANS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRIPTANS" code="N02CC-001" /></DRUG1>
<DRUG2>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG2>
<DESCRIPTION>Risk of arterial hypertension, of constriction of coronary arteries

</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Wait 6 to 24 hours, depending on the triptan, between taking it and the ergot alkaloid.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>529-TRIPTANS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRIPTANS" code="N02CC-001" /></DRUG1>
<DRUG2>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)" code="N06AB" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>52-ORAL-ANTICOAGULANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG1>
<DRUG2>
<CLASS name="OTHER ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG2>
<DESCRIPTION>Risk of increase of hemorrhagic events when one oral anticoagulant is replaced with another.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>Take into account the half-life of the oral anticoagulant and observe, if the situation requires, a delay for clearance before the start of treatment with another. Be sure to inform the patient. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>52-ORAL-ANTICOAGULANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage, especially in cases with a previous gastroduodenal ulcer

</DESCRIPTION>
<SEVERITY>Contraindication with:</SEVERITY>
<COMMENT>- anti--inflammatory does of acetylsalicylic acid (>=1g per dose and/or >=3g per day)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>52-ORAL-ANTICOAGULANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG1>
<DRUG2>
<CLASS name="PLATELET AGGREGATION INHIBITORS" code="B01AC-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage

</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>52-ORAL-ANTICOAGULANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Increase of the oral anticoagulant&#39;s risk of hemorrhage (irritation of the gastroduodenal mucosa by the non-steroidal anti-inflammatories)

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, strict clinical monitoring, possibly biological monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>52-ORAL-ANTICOAGULANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG1>
<DRUG2>
<DRUG name="DEFIBROTIDE" rxcui="1311089">
<ATC code="B01AX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of hemorrhage</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>52-ORAL-ANTICOAGULANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG1>
<DRUG2>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG2>
<DESCRIPTION>Glucocorticoids (general and rectal routes): possible impact of the corticotherapy on the metabolism of the vitamin K antagonist and on that of the factors of coagulation. Risk of hemorrhage specific to the corticotherapy (digestive mucosa, vascular fragility) with large doses or in treatment prolonged beyond 10 days. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>When administering substances from these groups together is justified, strengthen monitoring: if the situation requires, with the vitamin K antagonists, biological monitoring on the 8th day, then every two weeks after that during the corticotherapy and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>52-ORAL-ANTICOAGULANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG1>
<DRUG2>
<CLASS name="LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)" code="B01AB-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>If administering these together cannot be avoided, reinforce clinical monitoring and, if the situation requires, biological monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>52-ORAL-ANTICOAGULANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG1>
<DRUG2>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)" code="N06AB" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and, if the situation requires, more frequent testing of the INR. Possible adjustment of the dosage of the oral anticoagulant during the administration with the SSRI and when it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>52-ORAL-ANTICOAGULANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG1>
<DRUG2>
<DRUG name="IPILIMUMAB " rxcui="1094833">
<ATC code="L01XC11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of digestive system hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>52-ORAL-ANTICOAGULANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG1>
<DRUG2>
<CLASS name="MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS" code="N06A" /></DRUG2>
<DESCRIPTION>Increase of the risk of hermorrhage.</DESCRIPTION>
<SEVERITY>Precaution for use </SEVERITY>
<COMMENT>Clinical monitoring and, if the situation requires, more frequent testing of the INR. Possible adjustment of the dosage of the oral anticoagulant during the administration of these medications together and when it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>530-TRIPTANS-METABOLIZED-BY-THE-MAO.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRIPTANS METABOLIZED BY THE MAO" code="N02CC-002" /></DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>Risk of arterial hypertension, of constriction of the coronary arteries </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>530-TRIPTANS-METABOLIZED-BY-THE-MAO.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRIPTANS METABOLIZED BY THE MAO" code="N02CC-002" /></DRUG1>
<DRUG2>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG2>
<DESCRIPTION>Risk of arterial hypertension, of constriction of the coronary arteries </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>530-TRIPTANS-METABOLIZED-BY-THE-MAO.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRIPTANS METABOLIZED BY THE MAO" code="N02CC-002" /></DRUG1>
<DRUG2>
<CLASS name="MAOI-B " code="N04BD0-001" /></DRUG2>
<DESCRIPTION>Risk of arterial hypertension, of constriction of the coronary arteries</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>531-TRIPTANS-NOT-METABOLIZED-BY-THE-MAO.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRIPTANS NOT METABOLIZED BY THE MAO" code="NO2CC-003" /></DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>Risk of arterial hypertension, of constriction of the coronary arteries</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>531-TRIPTANS-NOT-METABOLIZED-BY-THE-MAO.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRIPTANS NOT METABOLIZED BY THE MAO" code="NO2CC-003" /></DRUG1>
<DRUG2>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG2>
<DESCRIPTION>Risk of arterial hypertension, of constriction of the coronary arteries</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>531-TRIPTANS-NOT-METABOLIZED-BY-THE-MAO.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRIPTANS NOT METABOLIZED BY THE MAO" code="NO2CC-003" /></DRUG1>
<DRUG2>
<CLASS name="MAOI-B " code="N04BD0-001" /></DRUG2>
<DESCRIPTION>Risk of arterial hypertension, of constriction of the coronary arteries</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>532-ULIPRISTAL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Choose a therapeutic alternative that is little or not at all metabolized. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>532-ULIPRISTAL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="H2 RECEPTOR ANTAGONISTS" code="A02BA-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the ulipristal, due to decrease of its absorption</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>532-ULIPRISTAL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the ulipristal, due to decrease of its absorption</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>532-ULIPRISTAL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HA01" />
<ATC code="G03HB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of antagonism of the effects of the progestin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Do not take a progestin treatment fewer than 12 hours after stopping the ulipristal.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>532-ULIPRISTAL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>Risk of antagonism of the effects of the estrogen-progestin contraceptive</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Use an additional contraceptive method of the barrier type for several days after the ulipristal is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>532-ULIPRISTAL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the ritonavir</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Choose a therapeutic alternative that is little or not at all metabolised. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>532-ULIPRISTAL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Choose a therapeutic alternative that is little or not at all metabolized. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>532-ULIPRISTAL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG2>
<DESCRIPTION>Risk of antagonism of the effects of the progestin contraceptive</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Use an additional contraceptive method of the barrier type for several days after the ulipristal is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>532-ULIPRISTAL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT" code="G03-003" /></DRUG2>
<DESCRIPTION>Risk of antagonism of the effects of the progestin contraceptive</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Use an additional contraceptive method of the barrier type for several days after the ulipristal is stopped </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>532-ULIPRISTAL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Chose a therapeutic alternative that is little or not at all metabolized.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<DRUG name="ABATACEPT " rxcui="614391">
<ATC code="L04AA24" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of general vaccine disease, possibly fatal</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>as well as during the 3 months following the end of the treatment</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<CLASS name="MONOCLONAL ANTIBODIES (EXCEPT ANTI-TNF ALPHA)" code="MONANT" /></DRUG2>
<DESCRIPTION>Risk of general vaccine disease, possibly fatal. </DESCRIPTION>
<SEVERITY>Not recommended with</SEVERITY>
<COMMENT>-- belimumab, blinatumomab, canakinumab, obinutuzumab,ofatumumab, rituximab, tocilizumab, ustekinumab</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTI-TNF ALPHA" code="LO4AB" /></DRUG2>
<DESCRIPTION>Risk of possibly fatal general vaccine disease </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>And during the 3 months following the end of the treatment</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<DRUG name="BELATACEPT" rxcui="1112973">
<ATC code="L04AA28" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of general vaccine disease, possibly fatal</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<CLASS name="CYTOTOXICS" code="L01" /></DRUG2>
<DESCRIPTION>Risk of possibly fatal general vaccine disease</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>--And during the 6 months following the end of the chemotherapy</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<DRUG name="DIMETHYL (FUMERATE OF)" rxcui="1373478">
<ATC code="N07XX09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Possible increase of the risk of infection</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTI-LYMPHOCYTE GLOBULINS" code="L04AA0-001" /></DRUG2>
<DESCRIPTION>Risk of possibly fatal general vaccine disease. This risk is increased in older patients already immunodepressed by the underlying disease.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>In particular, use an inactive vaccine when one exists (poliomyelitis).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG2>
<DESCRIPTION>With the exception of inhaled and local routes and for dosages greater than 10mg/day of prednisone equivalent (or &gt;2mg/kg/day with children or &gt;20 mg/day for children weighing more than 10 kg) for more than two weeks and for administration in &quot;bolus&quot; of the corticoids:

risk of possibly fatal general vaccine disease.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>And during the 3 months following the end of the corticotherapy</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<DRUG name="HYDROXYCARBAMIDE " rxcui="5552">
<ATC code="L01XX05" />
</DRUG>
</DRUG2>
<DESCRIPTION>In its indication for the patient with drepanocytosis, theoretic risk of general fatal vaccine disease.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Administering these medications together should only be considered if the benefits are estimated to be superior to this risk.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Risk of possibly fatal general vaccine disease.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>And during the 3 months following the treatment</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<DRUG name="MYCOPHENOLATE MOFETIL" >
<ATC code="MYCOPHEN" />
<ATC code="OLIC" />
<ATC code="ACID" />
<ATC code="MYCOPHEN" />
<ATC code="OLATE" />
<ATC code="MOFETIL" />
<ATC code="MYCOPHEN" />
<ATC code="OLIC" />
<ATC code="ACID" />
<ATC code="MYCOPHEN" />
<ATC code="OLIC" />
<ATC code="ACID" />
<ATC code="7145" />
<ATC code="L04AA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of possibly fatal general vaccine disease.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>And during the 3 months following the end of the treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<DRUG name="MYCOPHENOLATE SODIUM " rxcui="408142">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of possibly fatal general vaccine disease </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>And during the 3 months after the end of the treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>533-ATTENUATED-LIVE-VIRUS-VACCINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG1>
<DRUG2>
<DRUG name="TERIFLUNOMIDE" rxcui="1310520">
<ATC code="L04AA31" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of general vaccine disease, possibly fatal</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="ACETAZOLAMIDE" rxcui="167">
<ATC code="S01EC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hyperammonemia, with accrued risk of encephalopathy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="AZTREONAM" rxcui="1272">
<ATC code="J01DF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of onset of convulsive crises, due to decrease of the plasma concentrations of the valproic acid</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, plasma dosages, and possible adjustment of the dosage of the anticonvulsant during the treatment with the antibiotic and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the active metabolite of the carbamazepine with signs of overdose. In addition, decrease of the plasma concentrations of valproic acid due to increase of its hepatic metabolism by the carbamazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, plasma dosages and adjustment of the dosage of the two anticonvulsants.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="FELBAMATE" rxcui="24812">
<ATC code="N03AX10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the valproic acid, with risk of overdose. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring, and possible adjustment of the dosage of the valproic acid or of the valpromide during the treatment with the felbamate and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="LAMOTRIGINE" rxcui="28439">
<ATC code="N03AX09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of serious cutaneous reactions (Lyell&#39;s syndorme). In addition, increase of the plasma concentrations of lamotrigine (decrease of its hepatic metabolism by the sodium valproate)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If this combination of medications is judged necessary, strict clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="NIMODIPINE" rxcui="7426">
<ATC code="C08CA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the nimodipine by oral route, and by extrapolation, by injection: risk of increase of the hypotensive effect of the nimodipine due to increase of its plasma concentrations (decrease of its metabolism by the valproic acid)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<CLASS name="PENEMS" code="J01DH" /></DRUG2>
<DESCRIPTION>Risk of onset of convulsive crises, due to rapid decrease of the plasma concentrations of the valproic acid, that can become undetectable</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG2>
<DESCRIPTION>Increase of the hyperammonemia, with accrued risk of encephalopathy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Increase of the hyperammonemia, with accrued risk of encephalopathy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of onset of convulsive crises, due to increase of the hepatic metabolism of the valproate by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring and possible adjustment of the dosage of the anticonvulsant during the treatment with the rifampicin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="RUFINAMIDE" rxcui="69036">
<ATC code="N03AF03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Possible increase of the concentrations of rufinamide, especially with children who weigh less than 30 kg</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>With children weighing less than 30kg: do not exceed the total dose of 600 mg/day after the period of titration.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="TOPIRAMATE" rxcui="38404">
<ATC code="38404" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hyperammonemia with accrued risk of encephalopathy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="ZIDOVUDINE (AZT)" rxcui="11413">
<ATC code="J05AF01" />
<ATC code="J05AR01" />
<ATC code="J05AR04" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects, especially hematological ones, of the zidovudine due to decrease of its metabolism by the valproic acid.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring. A CBC checking for anemia should be done during the course of the first two months of the administration of these substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG1>
<DRUG2>
<DRUG name="ZONISAMIDE " rxcui="39998">
<ATC code="N03AX15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hyperammonemia, with accrued risk of encephalopathy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>535-VARDENAFIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VARDENAFIL" rxcui="306674">
<ATC code="G04BE0" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT (JUICE AND FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the vardenafil, with risk of hypotension.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>536-VEMURAFENIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VEMURAFENIB" rxcui="1147220">
<ATC code="L01XE15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the bupropion, with increase of its active metabolite and increased toxicity</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>536-VEMURAFENIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VEMURAFENIB" rxcui="1147220">
<ATC code="L01XE15" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the combined estrogen-progestin contraceptive with the consequence of a risk of ineffectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>536-VEMURAFENIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VEMURAFENIB" rxcui="1147220">
<ATC code="L01XE15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IFOSFAMIDE" rxcui="5657">
<ATC code="L01AA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the ifosfamide, with increase of its active metabolite and increased toxicity</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>536-VEMURAFENIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VEMURAFENIB" rxcui="1147220">
<ATC code="L01XE15" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the immunosuppressants, with the consequence of a risk of ineffectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>536-VEMURAFENIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VEMURAFENIB" rxcui="1147220">
<ATC code="L01XE15" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYME INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the vemurafenib, with lower effectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>536-VEMURAFENIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VEMURAFENIB" rxcui="1147220">
<ATC code="L01XE15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="THEOPHYLLINE " rxcui="10438">
<ATC code="R03DA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large increase of the concentrations of theophylline, with risks of increase of its undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the theophylline during the treatment with vemurafenib and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>537-VENLAFAXINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VENLAFAXINE" rxcui="39786">
<ATC code="N06AX16" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of venlafaxine with risk of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>537-VENLAFAXINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VENLAFAXINE" rxcui="39786">
<ATC code="N06AX16" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of venlafaxine with risk of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>537-VENLAFAXINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VENLAFAXINE" rxcui="39786">
<ATC code="N06AX16" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Increase of the concentrations of venlafaxine with risk of overdose. </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>537-VENLAFAXINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VENLAFAXINE" rxcui="39786">
<ATC code="N06AX16" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of venlafaxine with risk of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>537-VENLAFAXINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VENLAFAXINE" rxcui="39786">
<ATC code="N06AX16" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of venlafaxine with risk of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>537-VENLAFAXINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VENLAFAXINE" rxcui="39786">
<ATC code="N06AX16" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of venlafaxine with risk of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>537-VENLAFAXINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VENLAFAXINE" rxcui="39786">
<ATC code="N06AX16" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TRAMADOL" rxcui="10689">
<ATC code="N02AX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of appearance of convulsions and/or of a serotonin syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>537-VENLAFAXINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VENLAFAXINE" rxcui="39786">
<ATC code="N06AX16" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of venlafaxine with risk of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of afatinib due to increase of its absorption by the verapamil</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommended that the verapamil be administered as far as possible from the afatinib, preferably at an interval of 6 to 12 hours distant from the dose of afatinib.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09XA02" />
<ATC code="C09DX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>For verapamil by injection:

--risk of bradycardia or of atrioventricular block

For verapamil by mouth:

--risk of bradycardia or of atrioventricular block, especially with older persons</DESCRIPTION>
<SEVERITY>Not recommended with</SEVERITY>
<COMMENT>--the verapamil via IV</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering medication</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of the cholesterol lowering medication. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG2>
<DESCRIPTION>Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>The administration of these medications together should only be undertaken under strict clinical monitoring and EKG, in particular with older patients or at the beginning of treatment. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest) and disorders of sinoatrial and atrioventricular conduction</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUSPIRONE" rxcui="1827">
<ATC code="N05BE01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the verapamil, with increase of its undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the buspirone if necessary.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the ciclosporin (decrease of its hepatic metabolism), and increase of the risk of gum disorders. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLONIDINE" rxcui="2599">
<ATC code="C02AC01" />
<ATC code="N02CX02" />
<ATC code="S01EA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the colchicine, due to increase of its plasma concentrations by the verapamil</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DABIGATRAN" rxcui="">
<ATC code="1037042" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150 mg/day in one dose, or even 75 mg/day in case of moderate renal insufficiency</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DANTROLENE" rxcui="3105">
<ATC code="M03CA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Excessive bradycardia and atrioventricular block due to increase of the effects of the digoxin on autoregulation and conduction and due to decrease of the renal and extrarenal elimination of the digoxin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG and, possibly, testing of the digoxinemia. If there is reason for it, adjustment of the dosage of the digoxin during the treatment with the verapamil and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DOXORUBICIN" rxcui="3639">
<ATC code="L01DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the doxorubicin due to increase of its plasma concentrations</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Start the treatment by the calcium channel blocker with the lowest recommended dosages, and adjust the doses according to the EKG.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERIBULINE" rxcui="1045453">
<ATC code="L01XX41" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of eribuline by the verapamil.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG, if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ESMOLOL" rxcui="49737">
<ATC code="C07AB09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-in case of alteration of the left ventricular function.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EVEROLIMUS" rxcui="141704">
<ATC code="L01XE10" />
<ATC code="L04AA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the everolimus due to decrease of its hepatic metabolism by the verapamil</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function and adjustment of the dosage during the administration of the two medications together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FIDAXOMICIN" rxcui="1111103">
<ATC code="A07AA12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the fidaxomicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IBRUTINIB" rxcui="1442981">
<ATC code="L01XE27" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the verapamil</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg per day during the length of the administration of the two medications together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the inhibitor</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the verapamil during the treatment with the inhibitor, and after it is stopped, as the situation requires.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the verapamil), that add to the bradycardia inducing effects of these molecules.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of midazolam (decrease of its hepatic metabolism with increase of sedation). </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of midazolam during the treatment with the verapamil.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Large reduction of the concentrations of verapamil, with risk of loss of its therapeutic effect.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="L01XE31" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the nintedanib due to increase of it absorption by the verapamil</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="OLAPARIB" rxcui="1597582">
<ATC code="L01XX46" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of olaparib by the verapamil</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these together cannot be avoided, limit the dose of olaparib to 200 mg twice a day. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT (JUICE AND FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of verapamil, with risk of the appearance of undesirable effects</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIROLIMUS" rxcui="35302">
<ATC code="L04AA10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the sirolimus (decrease of its hepatic metabolism by the verapamil).</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the tacrolimus (decrease of its hepatic metabolism by the verapamil)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TAMSULOSIN" rxcui="77492">
<ATC code="G04CA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the tamsulosin during the treatment with the enzyme inhibitor and after it is stopped, if the situation requires. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TENOFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In case of co-administration with the verapamil, the dose of tenofovir alafenamide must be limited to 10mg per day.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>538-VERAPAMIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>539-VIDARABINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VIDARABINE" rxcui="11194">
<ATC code="J05AB03" />
<ATC code="S01AD06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ALLOPURINOL" rxcui="519">
<ATC code="M04AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of neurological disorders (trembling, confusion) due to partial inhibition of the metabolism of the antiviral</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="ABIRATERONE" rxcui="1100072">
<ATC code="L02BX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Significant decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of afatinib due to increase of its metabolism by these substances</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these substances together and 1 to 2 weeks after they are stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="ALBENDAZOLE" rxcui="430">
<ATC code="P02CA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of reduction of its effectiveness. 

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzyme inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<CLASS name="CALCIUM CHANNEL BLOCKERS" code="CO8CA-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism 

</DESCRIPTION>
<SEVERITY>Not recommended </SEVERITY>
<COMMENT>with the nimodipine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<CLASS name="CLASS IA ANTIARRHYTHMICS" code="C01B-002" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the antiarrhythmic, due to increase of its hepatic metabolism by the inducer. 

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and testing of the plasma concentrations; if needed, adjustment of the dosage of the antiarrhythmic during the treatment with the inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Decrease (or, infrequently, increase with the phenytoin) of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the anticonvulsant inducer

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the anticonvulsant inducer and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="APIXABAN" rxcui="1364430">
<ATC code="B01AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decreased of the plasma concentrations of the apixaban by the anticonvulsant enzyme inducer, with risk of lower therapeutic effect.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of very large decrease of the concentrations of aprepitant</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of boceprevir

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these substances together cannot be avoided, regular clinical and biological monitoring, especially at the beginning of the administration of the substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of bosentan</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="VO3AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of deferasirox

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitor the ferritinemia during and after the treatment with the enzyme inducer. If needed, adjustment of the dosage of deferasirox.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="DELAMANID" rxcui="1344662">
<ATC code="J04AK06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentratioins of delamanid due to increase of its hepatic metabolism by the inducer. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="DOXYCYCLINE" rxcui="3640">
<ATC code="A01AB22" />
<ATC code="J01AA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the doxycycline due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the doxycycline</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the concentrations of dronedarone due to increase of its metabolism, without notable modification of the active metabolite</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<CLASS name="NON-CONTRACEPTIVE ESTROGENS" code="G03C-001" /></DRUG2>
<DESCRIPTION>Decrease of the effectiveness of the estrogen 

.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the anticonvulsant inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="FENTANYL" rxcui="4337">
<ATC code="N01AH01" />
<ATC code="N02AB03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the anticonvulsant</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Choose another opioid.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great with patients who have Addisons disease treated with hydrocortisone and in cases of organ transplants</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="HALOPERIDOL" rxcui="5093">
<ATC code="N05AD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Clinical monitoring and, if needed, dosage adjustment during the treatment with carbamazepine and after it is stopped. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and, if needed, dosage adjustment during the treatment with the carbamazepine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG2>
<DESCRIPTION>Risk of clinically low thyroid in patients with hypothyroidism, due to increase of the metabolism of the T3 and of the T4

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of the serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with the inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="IDELALISIB" rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the anticonvulsant enzyme inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the protease inhibitor due to increase of its hepatic metabolism by the inducer

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<CLASS name="METABOLIZED TYROSINE-KINASE INHIBITORS" code="L01XE" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the inducer

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of these substances together and after the inducer is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the anticonvulsant enzyme inducer.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="METRONIDAZOLE" rxcui="6922">
<ATC code="A01AB17" />
<ATC code="D06BX01" />
<ATC code="G01AF01" />
<ATC code="J01XD01" />
<ATC code="P01AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentration of the midazolam by the anticonvulsant</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<CLASS name="MINERALOCORTICOIDS" code="H02AA0" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great in patients with Addisons disease treated with the hydrocortisone and in the case of transplants.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="MONTELUKAST" rxcui="88249">
<ATC code="R03DC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the montelukast due to increase of its hepatic metabolism by the inducer

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="NIMODIPINE" rxcui="7426">
<ATC code="C08CA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="PERAMPANEL" rxcui="1356552">
<ATC code="N03AX22" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease (up to two thirds) of the concentrations of perampanel</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the posaconazole

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. If possible, plasma dosages of the posaconazole and possible adjustment of its dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="PRAZIQUANTEL" rxcui="8628">
<ATC code="P02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="PROCARBAZINE" rxcui="8702">
<ATC code="L01XB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hypersensitivity reactions (hypereosinophilia, rash), due to increase of the metabolism of the procarbazine by the inducer</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Precaution of use</SEVERITY>
<COMMENT>Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during its administration with the inducer and after the inducer is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="QUETIAPINE" rxcui="51272">
<ATC code="N05AH04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="QUININE" rxcui="9071">
<ATC code="P01BC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and adjustment of the dosage of the quinine during the treatment with the inducer and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="RANOLAZINE" rxcui="35829">
<ATC code="C01EB18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large decrease of the concentrations of ranolazine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="RIVAROXABAN" rxcui="1114195">
<ATC code="B01AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the anticonvulsant, with risk of overdose, due to inhibition of its hepatic metabolism by the stiripentol.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol and possible adjustment of its dosage. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of very large decrease of the concentrations of telaprevir</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the theophylline due to increase of its hepatic metabolism by the inducer

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and, if needed, monitoring of the theophyllinemia. Possible adjustment of the dosage of the theophylline during the treatment with the inducer and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="TIAGABINE" rxcui="31914">
<ATC code="N03AG06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>An increase of the dosage of tiagabine can prove necessary when it is administered with an anticonvulsant enzyme inducer</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolsim by the anticonvulsant enzyme inducer, with risk of decrease of the therapeutic effect.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03XB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Choose a therapeutic alternative that is little or not at all metabolized. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<CLASS name="VITAMIN D" code="A11CC" /></DRUG2>
<DESCRIPTION>Decrease of the concentrations of vitamin D more marked than in the absence of the inducer.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Concentration dosage of vitamin D and supplementation if necessary</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>53-ANTICONVULSANT-ENZYME-INDUCERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>-for carbamazipine, phenobarbital, primidone: Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the inducer

For phenytoin, fosphenytoin: 

Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the phenytoin, for one thing; and increase of the plasma concentrations of the phenytoin due to decrease of its hepatic metabolism by the voriconazole for another thing</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT> -for carbamazepine, phenobarbital, primidone</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>540-VINCA-ALKALOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VINCA ALKALOIDS" code="L01CA" /></DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
<ATC code="A02BD04" />
<ATC code="A02BD05" />
<ATC code="A02BD06" />
<ATC code="A02BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the clarithromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical and biological monitoring. Possibly, use another antibiotic. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>540-VINCA-ALKALOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VINCA ALKALOIDS" code="L01CA" /></DRUG1>
<DRUG2>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="V03AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the neurotoxicity of the antimitotic due to decrease of its hepatic metabolism by the cobicistat</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring and possible adjustment of the dosage of the antimitotic. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>540-VINCA-ALKALOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VINCA ALKALOIDS" code="L01CA" /></DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the erythromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical and biological monitoring. Possibly, use another antibiotic.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>540-VINCA-ALKALOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VINCA ALKALOIDS" code="L01CA" /></DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Increase of the toxicity of the antimitotic, due to decrease of its hepatic metabolism by the protease inhibitor. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring and possible adjustment of the dosage of the antimitotic.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>540-VINCA-ALKALOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VINCA ALKALOIDS" code="L01CA" /></DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the itraconazole</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>540-VINCA-ALKALOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VINCA ALKALOIDS" code="L01CA" /></DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the ketoconazole</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>540-VINCA-ALKALOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VINCA ALKALOIDS" code="L01CA" /></DRUG1>
<DRUG2>
<DRUG name="MITOMYCIN C" rxcui="632">
<ATC code="L01DC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the pulmonary toxicity of the mitomycin and of the vinca alkaloids</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>540-VINCA-ALKALOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VINCA ALKALOIDS" code="L01CA" /></DRUG1>
<DRUG2>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the posaconazole</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>540-VINCA-ALKALOIDS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VINCA ALKALOIDS" code="L01CA" /></DRUG1>
<DRUG2>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the telithromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical and biological monitoring. Possibly, use another antibiotic. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>541-VISMODEGIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VISMODEGIB" rxcui="1242987">
<ATC code="L01XX43" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYME INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of vismodegib due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>541-VISMODEGIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VISMODEGIB" rxcui="1242987">
<ATC code="L01XX43" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of vismodegib</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>542-VITAMIN-A.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VITAMIN A" rxcui="11246">
<ATC code="A11C" />
<ATC code="A11CA" />
<ATC code="A11CA01" />
<ATC code="A11CA02" />
<ATC code="A11CB" />
<ATC code="V04CB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="TETRACYCLINE ANTIBIOTICS" code="J01AA" /></DRUG2>
<DESCRIPTION>In case of intake of 10,000 IU/day and more: risk of intracranial hypertension</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>542-VITAMIN-A.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VITAMIN A" rxcui="11246">
<ATC code="A11C" />
<ATC code="A11CA" />
<ATC code="A11CA01" />
<ATC code="A11CA02" />
<ATC code="A11CB" />
<ATC code="V04CB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RETINOIDS" code="D05-D10" /></DRUG2>
<DESCRIPTION>Risk of symptoms evocative of hypervitaminosis A</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>543-VITAMIN-D.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN D" code="A11CC" /></DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the concentrations of vitamin D more noticeable than in the absence of the inducer</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Concentration dosage of vitamin D and supplementation if necessary.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>543-VITAMIN-D.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN D" code="A11CC" /></DRUG1>
<DRUG2>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the absorption of the vitamin D</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>543-VITAMIN-D.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN D" code="A11CC" /></DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of vitamin D more noticeable than in the absence of treatment with the rifampacin </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Concentration dosage of vitamin D and supplementation if necessary.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>544-VORICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes, due to possible decrease of the metabolism of the amiodarone. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG, and possible adjustment of the dosage of the amiodarone. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>544-VORICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>--for carbamazepine, phenobarbital, primidone: 

Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the inducer

--for phenytoin, fosphenytoin: 

Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the phenytoin, for one thing; and increase of the plasma concentrations of the phenytoin due to decrease of its hepatic metabolism by the voriconazole, for another. </DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--for carbamazepine, phenobarbital, primidone</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>544-VORICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with voriconazole and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>544-VORICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OTHER CORTICOIDES, ESPECIALLY INHALED ONES " code="D07AC-001" /></DRUG2>
<DESCRIPTION>In case of prolonged use by oral or inhaled route:

increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the voriconazole, with risk of appearance of Cushings syndrome even of adrenal insufficiency</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>544-VORICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamthasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>544-VORICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIHYDROERGOTAMINE" rxcui="3418">
<ATC code="N02CA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>544-VORICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AR06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the efavirenz</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these substances together cannot be avoided, strict clinical monitoring and adjustment of the dosage of the voriconazole and of the efavirenz during the administration of the two together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>544-VORICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GLIPIZIDE" rxcui="4821">
<ATC code="A10BB07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of the glipizide at the origin of potentially severe hypoglycemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during and after the treatment with voriconazole.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>544-VORICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the voriconazole. </DESCRIPTION>
<SEVERITY>Not recommended </SEVERITY>
<COMMENT>--with the everolimus, the sirolimus, and the temsirolimus</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>544-VORICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Very large reduction of the concentrations of the antifungal due to increase of its metabolism by the ritonavir, with risk of failure of the treatment</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>544-VORICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Significant reduction of the concentrations of voriconazole, with risk of loss of its therapeutic effect</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>544-VORICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NEVIRAPINE" rxcui="53654">
<ATC code="J05AG01" />
<ATC code="J05AR07" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the nevirapine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of the substances together cannot be avoided, strict clinical monitoring and possible adjustment of the dosage of the voriconazole during the administration of the substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>544-VORICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>544-VORICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifabutin for one thing, and risk of increase of the undesirable effects (uveitis) of the rifabutin for another. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of the substances together is judged necessary, clinical monitoring and adjustment of the dosage of the voriconazole (generally doubled) during the treatment with the rifabutin. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>544-VORICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>544-VORICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type due to decrease of the hepatic metabolism of the simvastatin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>544-VORICONAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VENLAFAXINE" rxcui="39786">
<ATC code="N06AX16" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of venlafaxine with risk of overdose. </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>545-VORTIOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CINACALCET" rxcui="407990">
<ATC code="H05BX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with cinacalcet and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>545-VORTIOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the vortioxetine by decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the fluoxetine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>545-VORTIOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Reduction of the plasma concentrations of the vortioxetine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the administration with the inducer and 1 to 2 weeks after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>545-VORTIOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PAROXETINE" rxcui="32937">
<ATC code="N06AB05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the viortioxetine during the treatment with the paroxetine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>545-VORTIOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the quinidine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>545-VORTIOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TERBINAFINE" rxcui="37801">
<ATC code="D01AE15" />
<ATC code="D01BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the terbinafine and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>546-YOHIMBINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="YOHIMBINE" rxcui="220982">
<ATC code="G04BE04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLONIDINE" rxcui="2599">
<ATC code="C02AC01" />
<ATC code="N02CX02" />
<ATC code="S01EA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Possible inhibition of the antihypertensive activity due to antagonism at the level of the receptors</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>547-ZALCITABINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIDANOSINE" rxcui="3364">
<ATC code="J05AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of pancreatitis and of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring and monitoring of the amylasemia. Do not administer these substances together if the amylasemia is at the high range of normal. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>547-ZALCITABINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GANCICLOVIR" rxcui="4678">
<ATC code="J05AB06" />
<ATC code="S01AD09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the two medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>547-ZALCITABINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LAMIVUDINE" rxcui="68244">
<ATC code="J05AF05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>547-ZALCITABINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PENTAMIDINE" rxcui="7994">
<ATC code="P01CX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>547-ZALCITABINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="J05AF04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of each antiviral, due to inhibition of the phosphorylation reaction at the origin of the active metabolites </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>547-ZALCITABINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="THALIDOMIDE" rxcui="10432">
<ATC code="L04AX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>548-ZIDOVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMPHOTERICIN B " rxcui="732">
<ATC code="A01AB04" />
<ATC code="A07AA07" />
<ATC code="G01AA03" />
<ATC code="J02AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the amphotericin B administered intravenously:

increase of the hematological toxicity (addition of effects of bone marrow toxicity)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent CBC.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>548-ZIDOVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DAPSONE" rxcui="3108">
<ATC code="D10AX05" />
<ATC code="J04BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hematological toxicity (addition of effects of bone marrow toxicity)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent CBC</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>548-ZIDOVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCYTOSINE" rxcui="4451">
<ATC code="D01AE21" />
<ATC code="J02AX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hematological toxicity (addition of effects of bone marrow toxicity)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent CBC</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>548-ZIDOVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GANCICLOVIR" rxcui="4678">
<ATC code="J05AB06" />
<ATC code="S01AD09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hematological toxicity (addition of effects of bone marrow toxicity)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Stop the zidovudine temporarily; CBC, and reintroduce, if possible, the zidovudine in weak doses.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>548-ZIDOVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIBAVIRIN" rxcui="9344">
<ATC code="J05AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>548-ZIDOVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="J05AF04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>548-ZIDOVUDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZIDOVUDINE " rxcui="11413">
<ATC code="J05AF01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects, especially hematological ones, of the zidovudine due to decrease of its metabolism by the valproic acid</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring. A CBC checking for anemia should be done during the course of the first two months of the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>549-ZINC.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZINC" rxcui="11416">
<ATC code="A12CB" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CALCIUM" rxcui="1895">
<ATC code="A12AA" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the zinc by the calcium </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the calcium salts at a different time from the zinc (more than 2 hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>549-ZINC.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZINC" rxcui="11416">
<ATC code="A12CB" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="TETRACYCLINE ANTIBIOTICS" code="J01AA" /></DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the tetracycline antibiotics</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the zinc salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>549-ZINC.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZINC" rxcui="11416">
<ATC code="A12CB" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the zinc by the iron</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the iron salts at a different time from the zinc (more than 2 hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>549-ZINC.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZINC" rxcui="11416">
<ATC code="A12CB" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="FLUOROQUINOLONES" code="J01MA-001" /></DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the fluoroquinolones</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the zinc salts at a different time from the fluoroquinlones (more than 2 hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>549-ZINC.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZINC" rxcui="11416">
<ATC code="A12CB" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STRONTIUM" rxcui="81638">
<ATC code="M05BX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decease of the digestive absorption of the strontium</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the strontium at a different time from the zinc salts (more than two hours apart if possible).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>54-METABOLIZED-ANTICONVULSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="METABOLIZED ANTICONVULSANTS" code="N03A-002" /></DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" >
<ATC code="258326" />
<ATC code="258326" />
<ATC code="258326" />
<ATC code="258326" />
<ATC code="258326" />
<ATC code="258326" />
<ATC code="258326" />
<ATC code="258326" />
<ATC code="258326" />
<ATC code="258326" />
<ATC code="258326" />
<ATC code="258326" />
<ATC code="258326" />
<ATC code="258326" />
<ATC code="258326" />
<ATC code="258326" />
<ATC code="258326" />
<ATC code="258326" />
<ATC code="258326" />
<ATC code="258326" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations and of the effectiveness of the anticonvulsant

.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>550-ZOLPIDEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZOLPIDEM" rxcui="39993">
<ATC code="N05CF02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Slight increase of the sedative effect of the zolpidem</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>550-ZOLPIDEM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZOLPIDEM" rxcui="39993">
<ATC code="N05CF02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the zolpidem due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring. Possibly use another hypnotic.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>551-ZONISAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZONISAMIDE" rxcui="39998">
<ATC code="N03AX15" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG2>
<DESCRIPTION>Increase of the hyperammonemia, with increased risk of encephalopathy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>552-ZOPICLONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZOPICLONE" rxcui="40001">
<ATC code="N05CF01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Slight increase of the sedative effect of the zopiclone</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>552-ZOPICLONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ZOPICLONE" rxcui="40001">
<ATC code="N05CF01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the zopiclone due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring.Possibly use another hypnotic.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>55-MONOCLONAL-ANTIBODIES-(EXCEPT-ANTI-TNF-ALPHA).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MONOCLONAL ANTIBODIES (EXCEPT ANTI-TNF ALPHA)" code="MONANT" /></DRUG1>
<DRUG2>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG2>
<DESCRIPTION>Risk of general vaccine disease, possibly fatal. </DESCRIPTION>
<SEVERITY>Not recommended with:</SEVERITY>
<COMMENT>--belimumab, blinatumomab, canakinumab, obinutuzumab, ofatumumab, rituximab, tocilizumab, ustekinumab</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>56-TRICYCLIC-ANTIDEPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG1>
<DRUG2>
<CLASS name="ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)" code="A01AD" /></DRUG2>
<DESCRIPTION>Serious ventricular arrhythmias due to increased cardiac sensitization

.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Limit the amount of adrenaline, for example: less than 0.1 mg of adrenalin in 10 minutes or 0.3 mg in an hour for an adult </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>56-TRICYCLIC-ANTIDEPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG1>
<DRUG2>
<DRUG name="BACLOFEN" rxcui="1292">
<ATC code="M03BX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the muscular hypotonia. </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>56-TRICYCLIC-ANTIDEPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>Vasodilator effect and risk of hypotension, especially orthostatic (additive effect)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>56-TRICYCLIC-ANTIDEPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG1>
<DRUG2>
<DRUG name="CLONIDINE" rxcui="2599">
<ATC code="C02AC01" />
<ATC code="N02CX02" />
<ATC code="S01EA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Described for desipramine, imipramine:

inhibition of the antihypertensive effect of the clonidine (antagonism at the level of the adrenergic receptors)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>56-TRICYCLIC-ANTIDEPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG1>
<DRUG2>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)" code="N06AB" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the tricyclic antidepressant with risk of convulsions and increase of the undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring and, if necessary, adjustment of the dosage</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>56-TRICYCLIC-ANTIDEPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG1>
<DRUG2>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of therapeutic failure in cases of concomitant treatment with orlistat</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>56-TRICYCLIC-ANTIDEPRESSANTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG1>
<DRUG2>
<CLASS name="ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)" code="C01CA" /></DRUG2>
<DESCRIPTION>Paroxysmal hypertension with the possibility of arrhythmia (inhibition of the entry of the sympathomimetic into the sympathic fiber)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>57-ANTIHYPERTENSIVE-ALPHA-BLOCKERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIHYPERTENSIVE ALPHA BLOCKERS" code="C02CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="ALPHA BLOCKERS FOR UROLOGICAL USE" code="G04CA-001" /></DRUG2>
<DESCRIPTION>Increase of the hypotensive effect. Risk of severe orthostatic hypotension

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>57-ANTIHYPERTENSIVE-ALPHA-BLOCKERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIHYPERTENSIVE ALPHA BLOCKERS" code="C02CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS" code="C0-001" /></DRUG2>
<DESCRIPTION>Increase of the hypotensive effect. Greater risk of orthostatic hypotension. 

</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>57-ANTIHYPERTENSIVE-ALPHA-BLOCKERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIHYPERTENSIVE ALPHA BLOCKERS" code="C02CA0-001" /></DRUG1>
<DRUG2>
<CLASS name="TYPE 5 PHOSPHODIESTERASE INHIBITORS" code="G04BE" /></DRUG2>
<DESCRIPTION>Risk of orthostatic hypotension, especially with older patients</DESCRIPTION>
<SEVERITY>Not recommended </SEVERITY>
<COMMENT>-with the doxazosine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>58-CENTRAL-ANTIHYPERTENSIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CENTRAL ANTIHYPERTENSIVES" code="C02AC-001" /></DRUG1>
<DRUG2>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG2>
<DESCRIPTION>Large increase of blood pressure in cases of sudden termination of the treatment with the central antihypertensive</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Avoid ending treatment with the central antihypertensive abruptly. Clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>58-CENTRAL-ANTIHYPERTENSIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CENTRAL ANTIHYPERTENSIVES" code="C02AC-001" /></DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>Central decrease of the sympathetic tone and vasodilator effect of the central antihypertensives, dangerous in case of heart failure treated with a beta-blocking agent and vasodilator</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>59-ANTIHYPERTENSIVES-EXCEPT-ALPHA-BLOCKERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS" code="C0-001" /></DRUG1>
<DRUG2>
<CLASS name="ALPHA BLOCKERS FOR UROLOGICAL USE" code="G04CA-001" /></DRUG2>
<DESCRIPTION>Increase of the hypotensive effect. Greater risk of orthostatic hypotension</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>59-ANTIHYPERTENSIVES-EXCEPT-ALPHA-BLOCKERS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS" code="C0-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTIHYPERTENSIVE ALPHA BLOCKERS" code="C02CA0-001" /></DRUG2>
<DESCRIPTION>Increase of the hypotensive effect. Greater risk of orthostatic hypotension</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ACETAZOLAMIDE" rxcui="167">
<ATC code="S01EC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the undesirable effects, and especially of metabolic acidosis, of the acetylsalicylic acid in large doses and of the acetazolamide, due to decrease of the elimination of the acetylsalicylic acid by the acetazolamide</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ANAGRELIDE" rxcui="596724">
<ATC code="L01XX35" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of hemorrhagic events 

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG2>
<DESCRIPTION>For anti-inflammatory dosages of acetylsalicylic acid (&gt;=1g per dose and/or &gt;=3g per day) or for analgesic or antipyretic doses (&gt;=500mg by dose and/or &lt;3g per day):

Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Hydrate the patient and monitor renal function at the beginning of treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ORAL ANTICOAGULANTS " code="B01A-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage, especially in cases with a previous gastro duodenal ulcer. 

</DESCRIPTION>
<SEVERITY>Contraindication with:</SEVERITY>
<COMMENT>- anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >= 3g per day)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Increase of the risk of digestive system ulceration and hemorrhage.</DESCRIPTION>
<SEVERITY>Not recommended </SEVERITY>
<COMMENT>-with anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3g per day)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLOPIDOGREL" rxcui="32968">
<ATC code="B01AC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage due to addition of the platelet aggregation activities. 

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-except in validated indications for this combination of drugs in acute coronary syndromes. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>With anti-inflammatory doses of acetylsalicylic acid (&gt;=1g per dose and/or &gt;=3g per day) or for analgesic or antipyretic doses (&gt;=500 mg per dose and/or &lt;3 g per day):

increase of the risk of digestive ulceration and hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="DIURETICS" code="C0E-001" /></DRUG2>
<DESCRIPTION>For anti-inflammatory doses of acetylsalicylic acid (&gt;=1g per dose and/or &gt;=3g per day) or for analgesic or antipyretic doses (&gt;=500 mg per dose and/or &lt;3 g per day):

Acute renal insufficiency in dehydrated patients, due to decrease of the glomerular filtration as a result of a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Hydrate the patient and monitor renal function at the start of treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="GLUCOCORTICODS (EXCEPT FOR HYDROCORTISONE) " code="A0-H0-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-with anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >3 g per day)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)" code="B01AB-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastro duodenal mucosa by the acetylsalicylic acid)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-with anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3 g per day)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES) " code="B01AB-002" /></DRUG2>
<DESCRIPTION>The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding heparin in preventive doses to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)" rxcui="5224">
<ATC code="B01AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastro duodenal mucosa by the acetylsalicylic acid)</DESCRIPTION>
<SEVERITY>Not recommended </SEVERITY>
<COMMENT>-with anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3 g per day)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="UNFRACTIONATED HEPARIN (PREVENTIVE DOSES)" rxcui="">
</DRUG>
</DRUG2>
<DESCRIPTION>The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>For anti-inflammatory doses of acetylsalicylic acid (&gt;=1g per dose and/or &gt;=3g per day) or for analgesic or antipyretic doses (&gt;=500 mg per dose and/or &lt;3 g per day):

Acute renal insufficiency in dehydrated patients, due to decreased glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Hydrate the patient and monitor renal function at the start of treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)" code="N06AB" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage 

</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the toxicity, especially hematological, of the methotrexate (decrease of its renal clearance by the acetylsalicylic acid)</DESCRIPTION>
<SEVERITY>With doses of methotrexate > 20 mg/week</SEVERITY>
<COMMENT>-Contraindication </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PEMETREXED" rxcui="68446">
<ATC code="L01BA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).</DESCRIPTION>
<SEVERITY>Not Recommended</SEVERITY>
<COMMENT>-in case of weak to moderate renal function</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROBENECID" rxcui="8698">
<ATC code="M04AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the uricosuric effect due to competition of the elimination of the uric acid at the level of the renal tubules</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THROMBOLYTICS" code="B01AD" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage

</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage due to addition of the platelet antiagregation actions

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>--except for validated indications for this combination in acute coronary syndromes</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TICLOPIDINE" rxcui="10594">
<ATC code="B01AC05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage due to addition of the platelet antiagregation actions

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering the substances together cannot be avoided, strict clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<CLASS name="OTHER NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>With the other non steroidal anti-inflammatory drugs: increase of the risk of causing ulcers and digestive hemorrhage </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of digestive system ulceration and hemorrhage</DESCRIPTION>
<SEVERITY>Not recommended with</SEVERITY>
<COMMENT>-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG2>
<DESCRIPTION>Acute renal insufficiency with patients at risk (older patient, dehydration, treatment with diuretics, changes in renal function), due to decrease of the glomerular filtration (inhibition of the vasodilator prostaglandins due to the non-steroidal anti-inflammatories). These effects are generally reversible. In addition, reduction of the antihypertensive effect. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Hydrate the patient and monitor renal function at the beginning of treatment and regularly while these substances are administered together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG2>
<DESCRIPTION>Increase of the oral anticoagulants risk of hemorrhage (irritation of the gastroduodenal mucosa by the non-steroidal anti-inflammatories)

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of these substances together cannot be avoided, strict clinical monitoring and possibly biological monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG2>
<DESCRIPTION>Reduction of the antihypertensive effect (inhibition of the vasodilating prostaglandins by the non steroidal anti-inflammatories</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of addition of the nephrotoxic effects, especially with older patients.

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitor renal function at the beginning of the treatment with the NSAI</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of causing ulcers and digestive hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<CLASS name="DIURETICS" code="C0E-001" /></DRUG2>
<DESCRIPTION>Acute renal insufficiency with the patient at risk (older patient and/or dehydrated one) due to decrease of the glomerular filtration (inhibition of the vasodilator prostaglandins due to the NSAIs). Furthermore, reduction of the antihypertensive effect</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Hydrate the patient and monitor renal function at the start of treatment</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of ulceration and of gastrointestinal hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<CLASS name="LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)" code="B01AB-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering the substances together cannot be avoided, strict clinical monitoring</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<CLASS name="LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)" code="B01AB-002" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<CLASS name="UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)" code="B01AB-003" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering the substances together cannot be avoided, strict clinical monitoring</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<CLASS name="UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)" code="B01AB-004" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>Acute renal insufficiency with patients at risk (older patients, dehydrated ones, those taking diuretics, those with altered renal function) due to decrease of the glomerular filtration (inhibition of the vasodilating prostaglandins due to the NSAIs). These effects are generally reversible. Furthermore, reduction of the antihypertensive effect.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Hydrate the patient and monitor renal function at the beginning of treatment and regularly during the administration of the substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSR1s)" code="NO6AB" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of lithium that can reach toxic values (decrease of the renal excretion of the lithium)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering the substances together cannot be avoided, monitor the plasma concentrations of lithium strictly and adjust the dosage of the lithium during the treatment with the substances together and after the NSAI is stopped </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hematological toxicity of the methotrexate (decrease of the renal clearance of the methotrexate by the NSAIs).</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-for doses of methotrexate higher than 20 mg per week</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<DRUG name="PEMETREXED" rxcui="68446">
<ATC code="L01BA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the NSAIs)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-in case of weak to moderate renal function</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<DRUG name="PENTOXIFYLLINE" rxcui="8013">
<ATC code="C04AD03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of addition of the nephrotoxic effects, especially with older patients</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitor the renal function at the beginning of treatment with the NSAI</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG1>
<DRUG2>
<DRUG name="TENOFOVIR DISOPROXIL" rxcui="300195">
<ATC code="J05AF07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the nephrotoxicity of the tenofovir, especially with large doses of the anti-inflammatory or in the presence of factors of risk of renal insufficiency</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>When these are administered together, monitor renal function.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>61-ANTIPARASITICS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIPARASITICS THAT TEND TO INDUCE TORSADES DE POINTES" code="P01B-001" /></DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>with citalopram, domperidone, escitalopram, hydroxyzine and piperaquine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>62-ANTIPARKINSONIAN-ANTICHOLINERGICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIPARKINSONIAN ANTICHOLINERGICS" code="N04AA-001" /></DRUG1>
<DRUG2>
<CLASS name="DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE" code="G02CB-001" /></DRUG2>
<DESCRIPTION>Risk of increase of neuropsychological disorders.

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>63-ANTIPARKINSONIAN-DOPAMINERGICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIPARKINSONIAN DOPAMINERGICS" code="N04B-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)" code="N05A-001" /></DRUG2>
<DESCRIPTION>Reciprocal antagonism of the dopaminergic and the neuroleptics. The dopaminergic can cause or aggravate the psychotic disorders. When a treatment with neuroleptics is necessary for a Parkinsons patient treated with dopaminergics, these latter must be decreased progressively until they are stopped (their abrupt discontinuation exposes the patient to a risk of &quot;neuroleptic malignant syndrome&quot; (NMS)).</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>64-ANTIPURINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIPURINES" code="ANTIPUR" /></DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Decrease of the effect of the Vitamin K antagonist due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the Vitamin K antagonist at the beginning of the treatment with the immuno-inhibitor and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>64-ANTIPURINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIPURINES" code="ANTIPUR" /></DRUG1>
<DRUG2>
<CLASS name="DERIVATIVES OF AMINOSALICYLIC ACID (ASA)" code="A07EC-001" /></DRUG2>
<DESCRIPTION>Risk of increase of the myelotoxicity of the immunoinhibitor, by inhibition of its hepatic metabolism by the ASA derivative, especially with patients presenting a partial deficit of thiopurine methyltransferase (TPMT)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>64-ANTIPURINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIPURINES" code="ANTIPUR" /></DRUG1>
<DRUG2>
<CLASS name="XANTHINE OXYDASE INHIBITORS" code="M04AA0" /></DRUG2>
<DESCRIPTION>Possibly serious medullary insufficiency</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>64-ANTIPURINES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTIPURINES" code="ANTIPUR" /></DRUG1>
<DRUG2>
<DRUG name="RIBAVIRIN" rxcui="9344">
<ATC code="J05AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risks of serious undesirable effects, due to inhibition of the metabolism of the immunoinhibitor by the ribavirin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>65-H2-RECEPTOR-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="H2 RECEPTOR ANTAGONISTS" code="A02BA-001" /></DRUG1>
<DRUG2>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the atazanavir</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>65-H2-RECEPTOR-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="H2 RECEPTOR ANTAGONISTS" code="A02BA-001" /></DRUG1>
<DRUG2>
<DRUG name="CYANOCOBALAMIN" rxcui="11248">
<ATC code="B03BA01" />
<ATC code="B03BA02" />
<ATC code="B03BA51" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of vitamin B12</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>65-H2-RECEPTOR-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="H2 RECEPTOR ANTAGONISTS" code="A02BA-001" /></DRUG1>
<DRUG2>
<CLASS name="METABOLIZED TYROSINE-KINASE INHIBITORS " code="L01XE" /></DRUG2>
<DESCRIPTION>Risk of decrease of the bioavailabilty of the tyrosine kinase inhibitor, by reason of its pH-dependent absorption</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>-except with the vandetanib</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>65-H2-RECEPTOR-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="H2 RECEPTOR ANTAGONISTS" code="A02BA-001" /></DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>65-H2-RECEPTOR-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="H2 RECEPTOR ANTAGONISTS" code="A02BA-001" /></DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>65-H2-RECEPTOR-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="H2 RECEPTOR ANTAGONISTS" code="A02BA-001" /></DRUG1>
<DRUG2>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-only with the oral suspension form of posaconazole</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>65-H2-RECEPTOR-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="H2 RECEPTOR ANTAGONISTS" code="A02BA-001" /></DRUG1>
<DRUG2>
<DRUG name="RILPIVIRINE" rxcui="1102270">
<ATC code="J05AG05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the rilpivirine</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>If necessary, use an active H2 antihistmine in one dose per day, to be taken at least 12 hours before, or at least 4 hours after. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>65-H2-RECEPTOR-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="H2 RECEPTOR ANTAGONISTS" code="A02BA-001" /></DRUG1>
<DRUG2>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the ulipristal due to decrease of its absorption </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>66-PROTON-PUMP-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG1>
<DRUG2>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of the atazanavir, with risk of therapeutic failure</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>66-PROTON-PUMP-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG1>
<DRUG2>
<DRUG name="CYANOCOBALAMIN" rxcui="11248">
<ATC code="B03BA01" />
<ATC code="B03BA02" />
<ATC code="B03BA51" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>66-PROTON-PUMP-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG1>
<DRUG2>
<CLASS name="METABLOIZED TYROSINE-KINASE INHIBITORS" code="L01XE" /></DRUG2>
<DESCRIPTION>Risk of decrease of the bioavailability of the tyrosine kinase inhibitor, by reason of its pH-dependent absorption</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>-except with the imatinib and the vandetanib</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>66-PROTON-PUMP-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>66-PROTON-PUMP-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the absorption of the azole antifungal due to increase of the intragastric pH by the antisecretory </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>66-PROTON-PUMP-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG1>
<DRUG2>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of ledipasvir when the proton pump inhibitor is administered before the ledipasvir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommended that the proton pump inhibitor and the ledipasvir be taken simultaneously.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>66-PROTON-PUMP-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG1>
<DRUG2>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the methotrexate due to decrease of its elimination</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-with the methotrexate in doses > 20mg /week</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>66-PROTON-PUMP-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG1>
<DRUG2>
<DRUG name="ST JOHN'S WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of ineffectiveness of the treatment by the antisecretory due to increase of its metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>66-PROTON-PUMP-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG1>
<DRUG2>
<DRUG name="MYCOPHENOLATE MOFETIL" >
<ATC code="MYCOPHEN" />
<ATC code="OLIC" />
<ATC code="ACID" />
<ATC code="MYCOPHEN" />
<ATC code="OLATE" />
<ATC code="MOFETIL" />
<ATC code="MYCOPHEN" />
<ATC code="OLIC" />
<ATC code="ACID" />
<ATC code="MYCOPHEN" />
<ATC code="OLIC" />
<ATC code="ACID" />
<ATC code="7145" />
<ATC code="L04AA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>66-PROTON-PUMP-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG1>
<DRUG2>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the absorption of the azole antifungal, due to increase of the intragastric pH by the antisecretory </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Not recommended</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>66-PROTON-PUMP-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG1>
<DRUG2>
<DRUG name="RILPIVIRINE" rxcui="1102270">
<ATC code="J05AG05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of rilpivirine by the proton pump inhibitor (decreased absorption due to the increase of the gastric pH). </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>66-PROTON-PUMP-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG1>
<DRUG2>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the ulipristal, due to decrease of its absorption</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>67-MERCURIAL-ANTISEPTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MERCURIAL ANTISEPTICS" code="D08AK0" /></DRUG1>
<DRUG2>
<DRUG name="POVIDONE-IODINE" rxcui="8611">
<ATC code="D08AG02" />
<ATC code="D09AA09" />
<ATC code="D11AC06" />
<ATC code="G01AX11" />
<ATC code="R02AA15" />
<ATC code="S01AX18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Erythema, blisters, even necrosis of skin and mucosa (formation of a caustic complex in the case of concomitant use of mercurials and iodine antiseptics). The interaction depends on the stability of the organo-mercurial at the cutaneous level and on individual sensitivity.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>68-URINARY-ANTISPASMODICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="URINARY ANTISPASMODICS" code="DFST" /></DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of undesirable effects

</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>-with the darifenacin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>69-ANTI-TNF-ALPHA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTI-TNF ALPHA" code="LO4AB" /></DRUG1>
<DRUG2>
<DRUG name="ABATACEPT " rxcui="614391">
<ATC code="L04AA24" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the immunodepression </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>69-ANTI-TNF-ALPHA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTI-TNF ALPHA" code="LO4AB" /></DRUG1>
<DRUG2>
<DRUG name="ANAKINRA" rxcui="72435">
<ATC code="L04AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of serious infections and neutropenia</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>69-ANTI-TNF-ALPHA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTI-TNF ALPHA" code="LO4AB" /></DRUG1>
<DRUG2>
<DRUG name="CANAKINUMAB" rxcui="853491">
<ATC code="L04AC08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of serious infections</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>69-ANTI-TNF-ALPHA.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="ANTI-TNF ALPHA" code="LO4AB" /></DRUG1>
<DRUG2>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG2>
<DESCRIPTION>Risk of general vaccine disease possibly fatal</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>And during the 3 months following the end of the treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>6-ASCORBIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ASCORBIC ACID" rxcui="1151">
<ATC code="A11GA" />
<ATC code="11GA01" />
<ATC code="A11GA01" />
<ATC code="A11GB" />
<ATC code="A11GB01" />
<ATC code="G01AD03" />
<ATC code="S01XA15" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEFEROXAMINE" rxcui="3131">
<ATC code="V03AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With large doses of ascorbic acid and by intravenous route: 

cardiac function anomalies, even acute heart failure (generally reversible by ending the administration of the Vitamin C).</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In the case of hemochromatosis, only give Vitamin C after having started the treatment with the deferoxamine. Monitor cardiac function when these substances are administered together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>70-MORPHINE-LIKE-ANTITUSSIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MORPHINE LIKE ANTITUSSIVES" code="R05DA0-001" /></DRUG1>
<DRUG2>
<CLASS name="AGONIST OPIOID ANALGESICS" code="N01A-N02A" /></DRUG2>
<DESCRIPTION>Increased risk of respiratory depression, which can be fatal in cases of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>70-MORPHINE-LIKE-ANTITUSSIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="MORPHINE LIKE ANTITUSSIVES" code="R05DA0-001" /></DRUG1>
<DRUG2>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of respiratory depression, which can be fatal in cases of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>71-TRUE-MORPHINE-ANTITUSSIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRUE MORPHINE ANTITUSSIVES" code="R0GDA0-002" /></DRUG1>
<DRUG2>
<CLASS name="AGONIST OPIOID ANALGESICS" code="N01A-N02A" /></DRUG2>
<DESCRIPTION>Increased risk of respiratory depression which can be fatal in cases of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>71-TRUE-MORPHINE-ANTITUSSIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRUE MORPHINE ANTITUSSIVES" code="R0GDA0-002" /></DRUG1>
<DRUG2>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of respiratory depression which can be fatal in case of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>71-TRUE-MORPHINE-ANTITUSSIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRUE MORPHINE ANTITUSSIVES" code="R0GDA0-002" /></DRUG1>
<DRUG2>
<CLASS name="AGONIST-ANTAGONIST OPIOIDS " code="NO2A-001" /></DRUG2>
<DESCRIPTION>Decrease of the antalgic or antitussive effect of the opioid, due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="ALCOHOL (DRINK OR INGREDIENT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Possible variations of the anticoagulating effect, with increase in case of acute intoxication or decrease in case of chronic alcoholism (increased metabolism)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="ALLOPURINOL" rxcui="519">
<ATC code="M04AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the allopurinol and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="ALPHA-TOCOPHEROL" rxcui="11256">
<ATC code="A11HA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the vitamin E used in doses greater than or equal to 500 mg/day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with vitamin E and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="AMINOGLUTETHIMIDE" rxcui="677">
<ATC code="L02BG01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Described for warfarin and acenocoumarol.

Decrease of the effect of the vitamin K antagonist, due to increase of its hepatic metabolism by the aminoglutethimide</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with aminoglutethimide and two weeks after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the amiodorone and a week after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="ANDROGENS" code="A14AA0" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage due to direct effect on the coagulation and/or the fibrinolytic systems</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the androgen and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease (or, infrequently, increase with the phenytoin) of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the anticonvulsant inducer</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the anticonvulsant inducer and a week after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTIPURINES" code="ANTIPUR" /></DRUG2>
<DESCRIPTION>Decrease of the effect of the Vitamin K antagonist due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequesnt testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist at the beginning of the treatment by the immunomodulator and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the aprepitant</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during and after the administration of the medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use </SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="CEFAMANDOLE" rxcui="2178">
<ATC code="J01DC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="CEFOPERAZONE" rxcui="2184">
<ATC code="J01DD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during treatment with the cephalosporin and after it is stopped </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="CEFOTETAN" rxcui="2184">
<ATC code="J01DC05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution of use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="CEFTRIAXONE" rxcui="2193">
<ATC code="J01DD04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800mg/day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cimetidine and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="CLINDAMYCIN" rxcui="2582">
<ATC code="D10AF01" />
<ATC code="G01AA10" />
<ATC code="J01FF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin Kantagonist during the treatment with clindamycin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the colchicine and a week after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="TETRACYCLINE ANTIBIOTICS" code="D06AA-J01AA" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tetracycline antibiotic and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="CYTOTOXICS" code="L01" /></DRUG2>
<DESCRIPTION>Increase of the risk of thrombosis and hemorrhage accompanying tumors. In addition, possible interaction between the vitamin K antagonist and the chemotherapy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="DANAZOL" rxcui="3102">
<ATC code="G03XA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage due to direct effect on coagulation and/or the fibrinolytic systems.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the danazol and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of causing ulcers and digestive hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="DISULFIRAM" rxcui="3554">
<ATC code="N07BB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the disulfiram and a week after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the dronedarone and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="ECONAZOLE" rxcui="3743">
<ATC code="G01AF05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Regardless of the route of administration of the econazole:

increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with econazole and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AR06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="FIBRATES" code="C01AB-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fibrate and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluconazole and a week after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="FLUOROQUINOLONES" code="J01MA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)" code="L01BC-001" /></DRUG2>
<DESCRIPTION>Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If it is not possible to avoid administering these together, more frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the cytotoxic and a week after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="GLUCOSAMINE" rxcui="4845">
<ATC code="M01AX05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the Vitamin K antagonist</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="GRISEOFULVINE" rxcui="5021">
<ATC code="D01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the griseofulvine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the griseofulvine and a week after it is stopped </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENT)" code="B01AB-003" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>When the heparin alternates with the vitamin K antagonist, strengthen clinical monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="IMATINIB" rxcui="282388">
<ATC code="L01XE01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these together cannot be avoided, strict clinical monitoring and more frequent monitoring of the INR</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS)" code="C10AA" /></DRUG2>
<DESCRIPTION>Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the Vitamin K antagonist.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Variation of the effect of the vitamin K antagonist, most often by decreasing it</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the length of the treatment</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the itraconazole and a week after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="LEVOCARNITINE" rxcui="42955">
<ATC code="A16AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequenttesting of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with levocarnitine and a week after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="MACROLIDES (EXCEPT SPIRAMYCIN)" code="J01FA" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage the vitamin K antagonist during the treatment with the macrolide and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="METHYLPREDNISOLONE " rxcui="6902">
<ATC code="D07AA01" />
<ATC code="D10AA02" />
<ATC code="H02AB04" />
<ATC code="D07CA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>For doses of 0.5g to 1g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Testing of the INR 2 to 4 days after the bolus of mythylprednisolone or in the presence of any signs of hemorrhage</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="MICONAZOLE " rxcui="6932">
<ATC code="A01AB09" />
<ATC code="A07AC01" />
<ATC code="D01AC02" />
<ATC code="G01AF04" />
<ATC code="J02AB01" />
<ATC code="S02AA13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Unpredictable hemorrhage, possibly serious</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="ST JOHN'S WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the vitamin K antagonist, by reason of its enzyme inducer effect, with risk of reduction of effectiveness, even complete loss of the effect, which could have serious consequences (thrombolitic event)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>In case of an accidental use of the two substances together, do not stop the St Johns Wort suddenly, but test the INR before and then after the St Johns Wort is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="NEVIRAPINE " rxcui="53654">
<ATC code="J05AG01" />
<ATC code="J05AR07" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR Possible adjustment of the dosage of the vitamin K antagonist</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="NOSCAPINE" rxcui="7533">
<ATC code="R05DA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the orlistat and after it is stopped </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="PARACETAMOL" rxcui="161">
<ATC code="N02BE01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage when taking paracetamol in maximal doses (4g/day) for at least 4 days</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during treatment with the paracetamol and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="PENTOXIFYLLINE" rxcui="8013">
<ATC code="C04AD03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the pentoxifylline and a week after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="PRISTINAMYCIN" rxcui="66958">
<ATC code="J01FG01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the pristinamycin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="PROGUANIL" rxcui="2382">
<ATC code="P01BB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the proguanil and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the anticoagulant effect and of the risk of hemorrhage. Mecanism proposed: inhibition of the metabolism of the vitamin K antagonist</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the propafenone and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the rifampicin. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the rifampicin and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="ROPINIROLE" rxcui="72302">
<ATC code="N04BC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with ropinirole and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="SUCRALFATE" rxcui="10156">
<ATC code="A02BX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the vitamin K antagonist</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the sucralfate at a different time from the vitamin K antagonist (more than 2 hours apart, if possible)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="SULFAFURAZOLE" rxcui="10207">
<ATC code="S01AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the antibiotic and a week after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="SULFAMETHIZOLE" rxcui="10179">
<ATC code="B05CA04" />
<ATC code="D06BA04" />
<ATC code="J01EB02" />
<ATC code="S01AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the antibiotic treatment and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="SULFAMETHOXAZOLE" rxcui="10180">
<ATC code="J01EC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering the substances together cannot be avoided, more frequent testing of the INR and adjustment of the dosage of the vitamin K antagonist during the treatment with cotrimoxazole and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="TAMOXIFEN" rxcui="10324">
<ATC code="L02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="THROMBOLYTICS" code="B01AD" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="TIBOLONE" rxcui="38260">
<ATC code="G03CX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tibolone and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="TRAMADOL" rxcui="10689">
<ATC code="N02AX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tramadol and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with voriconazole and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>73-APIXABAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="APIXABAN" rxcui="1364430">
<ATC code="B01AF02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the apixaban by the anticonvulsant enzymatic inducer, with risk of decrease of the therapeutic effect.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>73-APIXABAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="APIXABAN" rxcui="1364430">
<ATC code="B01AF02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the apixiban by the fluconazole, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>73-APIXABAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="APIXABAN" rxcui="1364430">
<ATC code="B01AF02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the apixaban by the inhibitor, with increase of the risk of bleeding. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>73-APIXABAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="APIXABAN" rxcui="1364430">
<ATC code="B01AF02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the apixaban by the rifampicin, with risk of decrease of the therapeutic effect. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>74-APOMORPHINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="APOMORPHINE" rxcui="1043">
<ATC code="G04BE07" />
<ATC code="N04BC0" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ONDANSETRON" rxcui="26225">
<ATC code="A04AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Severe hypotension and loss of consciousness have been reported when ondansetron and apomorphine were taken together. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>75-APREPITANT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Risk of very large decrease of the concentrations of aprepitant</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>75-APREPITANT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the aprepitant</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during and after the administration of the medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>75-APREPITANT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HA01" />
<ATC code="G03HB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the cyproterone with risk of lower contraceptive effectiveness</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>--In its use as a hormonal contraceptive: </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>75-APREPITANT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>Decrease of the concentrations of the estrogen-progestin or of the progestin, with risk of lower contraceptive effectiveness. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Chose another contraceptive method, in particular a barrier type, during the time these medications are taken together and a cycle following. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>75-APREPITANT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IFOSFAMIDE" rxcui="5657">
<ATC code="L01AA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the neurotoxicity of the ifosfamide</DESCRIPTION>
<SEVERITY>Take into account </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>75-APREPITANT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of aprepitant due to decrease of its hepatic metabolism by the itraconazole. </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>75-APREPITANT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>75-APREPITANT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG2>
<DESCRIPTION>(Except for IUD), decrease of the concentrations of progestin, with risk of lower contraceptive effectiveness.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Choose another method of contraception, in particular a barrier type, during the administration of these medications together and a cycle after. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>75-APREPITANT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the concentrations of aprepitant</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>76-ARIPIPRAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ARIPIPRAZOLE" rxcui="89013">
<ATC code="N05AX12" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the aripiprazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the aripiprazole during the administration of these medications together and 1 to 2 weeks after the inducer is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>77-ATALUREN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATALUREN" rxcui="">
<ATC code="M09AX03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="AMINOGLYCOSIDES" code="J01GB-001" /></DRUG2>
<DESCRIPTION>Risk of increase of the renal toxicity of the aminoglycoside</DESCRIPTION>
<SEVERITY>CONTRAINDICATIOIN</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>78-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="H2 RECEPTOR ANTAGONISTS" code="A02BA-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the atazanavir</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>78-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of the atazanavir, with risk of therapeutic failure</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>78-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUPRENORPHINE" rxcui="1819">
<ATC code="N02AE01" />
<ATC code="N07BC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase or decrease of the effects of the buprenorphine, due to simultaneous inhibition and acceleration of its metabolism by the protease inhibitor</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>78-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of clarithromycin and inhibition of the formation of its active metabolite</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of these drugs together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>78-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the atazanavir due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of the two substances together proves necessary, adjustment of the dosage of the atazanavir with regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>78-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NEVIRAPINE " rxcui="53654">
<ATC code="J05AG01" />
<ATC code="J05AR07" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the atazanavir due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of these medications together proves necessary, adjustment of the dosage of the atazanavir with regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>78-ATAZANAVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TENOFOVIR DISOPROXIL" rxcui="300195">
<ATC code="J05AF07" />
<ATC code="J05AR06" />
<ATC code="J05AR08" />
<ATC code="J05AR09" />
<ATC code="J05AR03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same two substances together [sic]</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>Do not administer atazanavir with the tenofovir without ritonavir</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AZITHROMYCIN" rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol-lowering medication</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of the cholesterol-lowering medication or another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type, due to decrease of the hepatic metabolism of the atorvastatin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Do not exceed the dosage of 20 mg/day of atorvastatin. If the therapeutic objective is not attained with this dosage, use another statin not affected by this type of interaction.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the metabolism of the cholesterol-lowering medication)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Do not exceed the dosage of 10mg/day of atorvastatin. If the therapeutic objective is not reached at that dosage, use another statin not affected by this type of interaction.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering drug</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Administer weaker doses of cholesterol-lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering agent</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of cholesterol-lowering agent or another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering agent</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of cholesterol-lowering medication. If the therapeutic objective is not reached, use another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Use weaker doses of atorvastatin. If the therapeutic objective is not reached, use another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="">
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPRVIR" code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the atorvastatin due to decrease of its hepatic metabolism by the therapy with the two drug combination</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT (JUICE AND FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the hypokaliemiant, with risk of undesirable effects, especially muscular ones</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RANOLAZINE" rxcui="35829">
<ATC code="C01EB18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to inhibition of the metabolism of the atorvastatin by the ranolazine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of cholesterol-lowering agent or another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of atorvastastatin, due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ROXITHROMYCIN" rxcui="9478">
<ATC code="J01FA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of cholesterol lowering agent</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol-lowering medication)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the atorvastatin)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (dose-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol-lowering medication)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>79-ATORVASTATIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol-lowering medication</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of cholesterol-lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>7-CHOLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CHOLIC ACID" rxcui="1440856">
<ATC code="A05AA03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG2>
<DESCRIPTION>Antagonist effect of the barbiturate</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>80-ATOVAQUONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATOVAQUONE" rxcui="60212">
<ATC code="P01AX06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AR06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of atovaquone by the enzyme inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>80-ATOVAQUONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATOVAQUONE" rxcui="60212">
<ATC code="P01AX06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Decrease, possibly very large, of the plasma concentrations of the atovaquone due to increase of its metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>80-ATOVAQUONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATOVAQUONE" rxcui="60212">
<ATC code="P01AX06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Moderate decrease of the plasma concentrations of atovaquone by the enzyme inducer</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>80-ATOVAQUONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ATOVAQUONE" rxcui="60212">
<ATC code="P01AX06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of atovaquone by the enzyme inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>81-OTHER-CORTICOIDES,-ESPECIALLY-INHALED-ONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OTHER CORTICOIDES, ESPECIALLY INHALED ONES" code="D07AC-001" /></DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing&#39;s syndrome, even of adrenal insufficiency</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>81-OTHER-CORTICOIDES,-ESPECIALLY-INHALED-ONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OTHER CORTICOIDES, ESPECIALLY INHALED ONES" code="D07AC-001" /></DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the itraconazole, with risk of appearance of Cushing&#39;s syndrome, even of adrenal insufficiency</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>81-OTHER-CORTICOIDES,-ESPECIALLY-INHALED-ONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OTHER CORTICOIDES, ESPECIALLY INHALED ONES" code="D07AC-001" /></DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the ketoconazole, with risk of appearance of Cushing&#39;s syndrome, even of adrenal insufficiency</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>81-OTHER-CORTICOIDES,-ESPECIALLY-INHALED-ONES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OTHER CORTICOIDES, ESPECIALLY INHALED ONES" code="D07AC-001" /></DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the voriconazole, with risk of appearance of Cushing&#39;s syndrome, even of adrenal insufficiency</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>82-AVANAFIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AVANAFIL" rxcui="1291301">
<ATC code="G04BE10" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT (JUICE AND FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the avanafil, with risk of hypotension</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>83-AZITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AZITHROMYCIN " rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering medication</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of the cholesterol lowering medication or another statin not affected by this type of interaction.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>83-AZITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AZITHROMYCIN " rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the blood concentrations of ciclosporin and of the creatinemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the two substances together and after the macrolide is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>83-AZITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AZITHROMYCIN " rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia due to increase of its absorption</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the azithromycin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>83-AZITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AZITHROMYCIN " rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IVABRADINE" rxcui="1649480">
<ATC code="C01EB17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of problems with ventricular rhythm, especially of torsades de pointes. In addition, increase of the plasm concentrations of the ivabradine due to decrease of its metabolism by the azithromycin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>83-AZITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AZITHROMYCIN " rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolosis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of the cholesterol lowering agent or chose another statin not affected by this type of interaction.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>83-AZITHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AZITHROMYCIN " rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>84-AZTREONAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="AZTREONAM" rxcui="1272">
<ATC code="J01DF01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG2>
<DESCRIPTION>Risk of onset of convulsive crises, due to decrease of the plasma concentrations of the valproic acid</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, plasma dosages, and possible adjustment of the dosage of the anticonvulsant during the treatment with the antibiotic and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>85-BACLOFEN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BACLOFEN" rxcui="1292">
<ATC code="M03BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG2>
<DESCRIPTION>Risk of increase of hypotonia</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>85-BACLOFEN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BACLOFEN" rxcui="1292">
<ATC code="M03BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LEVODOPA" rxcui="6375">
<ATC code="N04BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of aggravation of the Parkinsons syndrome or of undesirable central effects (visual hallucinations, confusion, headaches)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>86-BARBITURATES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BARBITURATES" code="N05CA-001" /></DRUG1>
<DRUG2>
<CLASS name="BENZODIAZEPINES AND RELATED" code="N05-001" /></DRUG2>
<DESCRIPTION>Increased risk of respiratory depression, which can be fatal in case of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>86-BARBITURATES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BARBITURATES" code="N05CA-001" /></DRUG1>
<DRUG2>
<CLASS name="OPIOIDS" code="N0-R0" /></DRUG2>
<DESCRIPTION>Increased risk of respiratory depression, which can be fatal in case of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>87-BEDAQUILINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BEDAQUILINE" rxcui="1364504">
<ATC code="J04AK05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>87-BEDAQUILINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BEDAQUILINE" rxcui="1364504">
<ATC code="J04AK05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>87-BEDAQUILINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BEDAQUILINE" rxcui="1364504">
<ATC code="J04AK05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>88-BELATACEPT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BELATACEPT" rxcui="1112973">
<ATC code="L04AA28" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG2>
<DESCRIPTION>Risk of general vaccine disease, possibly fatal. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>89-BENZODIAZEPINES-AND-RELATED.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BENZODIAZEPINES AND RELATED" code="N05-001" /></DRUG1>
<DRUG2>
<CLASS name="BARBITURATES" code="N05CA-001" /></DRUG2>
<DESCRIPTION>Increased risk of respiratory depression, which can be fatal in case of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>89-BENZODIAZEPINES-AND-RELATED.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BENZODIAZEPINES AND RELATED" code="N05-001" /></DRUG1>
<DRUG2>
<DRUG name="BUPRENORPHINE" rxcui="1819">
<ATC code="N02AE01" />
<ATC code="N07BC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the buprenorphine used in replacement therapy: increased risk of respiratory depression, which can be fatal. </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
<COMMENT>Evaluate carefully the risk /benefit relationship of administering these substances together. Inform the patient of the necessity of adhering to the prescribed doses. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>89-BENZODIAZEPINES-AND-RELATED.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BENZODIAZEPINES AND RELATED" code="N05-001" /></DRUG1>
<DRUG2>
<DRUG name="CLOZAPINE" rxcui="2626">
<ATC code="N05AH02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Accrued risk of drop in blood pressure with respiratory and/or cardiac arrest.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>89-BENZODIAZEPINES-AND-RELATED.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BENZODIAZEPINES AND RELATED" code="N05-001" /></DRUG1>
<DRUG2>
<CLASS name="OPIOIDS" code="N0-R0" /></DRUG2>
<DESCRIPTION>Increased risk of respiratory depression, which can be fatal in case of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>8-CLODRONIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CLODRONIC ACID" rxcui="3350">
<ATC code="M05BA02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ESTRAMUSTINE" rxcui="4089">
<ATC code="L01XX11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of estrasmustine by the clodronate</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>90-BETA-2-MIMETICS-or-BETA2-ADRENERGIC-AGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS" code="R03C-001" /></DRUG1>
<DRUG2>
<DRUG name="HALOTHANE" rxcui="5095">
<ATC code="N01AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>In cases of obstetrical surgery, increased uterine inertia with risk of hemorrhage; furthermore serious ventricular arrhythmias, due to increase of the cardiac reactivity</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Interrupt treatment with the beta-2 agonist if the anesthesia must be done with halothane</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>90-BETA-2-MIMETICS-or-BETA2-ADRENERGIC-AGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS" code="R03C-001" /></DRUG1>
<DRUG2>
<DRUG name="INSULIN" rxcui="631657">
<ATC code="A10AC01" />
<ATC code="A10AC02" />
<ATC code="A10AC03" />
<ATC code="A10AC04" />
<ATC code="A10AD01" />
<ATC code="A10AD02" />
<ATC code="A10AD03" />
<ATC code="A10AD04" />
<ATC code="A10AD05" />
<ATC code="A10AE01" />
<ATC code="A10AE02" />
<ATC code="A10AE03" />
<ATC code="A10AE04" />
<ATC code="A10AE05" />
<ATC code="A10AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Elevation of the glycemia by the beta-2 mimetic</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforce blood and urine monitoring</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>90-BETA-2-MIMETICS-or-BETA2-ADRENERGIC-AGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS" code="R03C-001" /></DRUG1>
<DRUG2>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG2>
<DESCRIPTION>Elevation of the glycemia by the beta-2 mimetic</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Reinforce blood and urine monitoring. Possibly change to insulin, if the situation requires. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>91-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL-AND-SOTALOL).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)" code="C07AB-001" /></DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of autoregulation and conduction (suppression of the compensatory sympathetic mechanisms)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>91-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL-AND-SOTALOL).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)" code="C07AB-001" /></DRUG1>
<DRUG2>
<CLASS name="CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)" code="C01B-003" /></DRUG2>
<DESCRIPTION>Disorders of contractility, autoregulation, and electrical conduction (suppression of the compensatory sympathetic mechanisms)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG1>
<DRUG2>
<CLASS name="HALOGENATED HYDROCARBON ANESTHETICS" code="N01AB0-001" /></DRUG2>
<DESCRIPTION>Reduction of the compensatory cardiovascular reactions by the beta-blocking agents. The beta-adrenergic inhibition can be elevated during the surgical procedure by the beta-mimetics</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>As a general rule, do not stop the treatment with the beta-blocking agent and, in any case, avoid stopping it abruptly. Inform the anesthesiologist of this treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG1>
<DRUG2>
<CLASS name="CENTRAL ANTIHYPERTENSIVES" code="C02AC-001" /></DRUG2>
<DESCRIPTION>Large increase of blood pressure in cases of sudden discontinuation of the treatment with the central hypertensive</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Avoid stopping the treatment with the central antihypertensive abruptly. Clinical monitoring</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Reduction of the antihypertensive effect (inhibition of the vasodilator prostaglandins by the non steroidal anti-inflammatories)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG1>
<DRUG2>
<CLASS name="DIHYDROPYRIDINES" code="C08CA-002" /></DRUG2>
<DESCRIPTION>Hypotension, heart failure in patients with latent or uncontrolled cardiac insufficiency (addition of the negative inotropic effects). The beta-blocking agent can furthermore minimize the sympathetic reflex reaction brought into play in the case of excessive hemodynamic repercussion </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and heart failure</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>The administration of these medications together should only be done under clinical monitoring and strict EKG, in particular with older patients or at the beginning of treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG1>
<DRUG2>
<DRUG name="DIPYRIDAMOLE" rxcui="3521">
<ATC code="B01AC07" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dipyridamole by injection: increase of the antihypertensive effect

</DESCRIPTION>
<SEVERITY>Take into account </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG1>
<DRUG2>
<CLASS name="GLINIDES" code="A10BX-001" /></DRUG2>
<DESCRIPTION>All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG1>
<DRUG2>
<CLASS name="GLIPTINS" code="A10B-001" /></DRUG2>
<DESCRIPTION>All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG1>
<DRUG2>
<DRUG name="INSULIN " rxcui="5856">
<ATC code="A10AC01" />
<ATC code="A10AC02" />
<ATC code="A10AC03" />
<ATC code="A10AC04" />
<ATC code="A10AD01" />
<ATC code="A10AD02" />
<ATC code="A10AD03" />
<ATC code="A10AD04" />
<ATC code="A10AD05" />
<ATC code="A10AE01" />
<ATC code="A10AE02" />
<ATC code="A10AE03" />
<ATC code="A10AE04" />
<ATC code="A10AE05" />
<ATC code="A10AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG1>
<DRUG2>
<DRUG name="LIDOCAINE" rxcui="6387">
<ATC code="C01BB01" />
<ATC code="C05AD01" />
<ATC code="D04AB01" />
<ATC code="N01BB02" />
<ATC code="R02AD02" />
<ATC code="S01HA07" />
<ATC code="S02DA01" />
<ATC code="N01BB52" />
</DRUG>
</DRUG2>
<DESCRIPTION>With lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment, if needed, of the dosage of the lidocaine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG1>
<DRUG2>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG2>
<DESCRIPTION>All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient and reinforce self-monitoring of blood glucose, especially at the beginning of treatment. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and heart failure</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>The administration of these medications together should only be undertaken under strict clinical monitoring and EKG, in particular with older patients or at the beginning of treatment. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring and EKG</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<CLASS name="HALOGENATED HYDROCARBON ANESTHETICS" code="N01AB0-001" /></DRUG2>
<DESCRIPTION>Reduction of the compensatory cardiovascular reactions by the beta-blocking agents. The beta-adrenergic inhibition can be elevated by the beta-stimulants during the surgery </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>As a general rule, do not stop the treatment with the beta blocking agent and, in any case, avoid stopping it abruptly. Inform the anesthesiologist of this treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<CLASS name="CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)" code="C01B-003" /></DRUG2>
<DESCRIPTION>Negative inotropic effect with risk of acute decompensated heart failure</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<CLASS name="ACETYLCHOLINESTERASE INHIBITORS" code="ACETCHO" /></DRUG2>
<DESCRIPTION>Risk of excessive bradycardia (addition of the bradycardia inducing effects)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring, especially at the beginning of the administration of the substances together </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<CLASS name="TRICYCLIC ANTIDEPRESSANTS" code="N06AA-001" /></DRUG2>
<DESCRIPTION>Vasodilator effect and risk of hypotension, especially orthostatic (additive effect)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<CLASS name="CENTRAL ANTIHYPERTENSIVES" code="C02AC-001" /></DRUG2>
<DESCRIPTION>Central decrease of the sympathetic tone and vasodilator effect of the central antihypertensives, dangerous in cases of heart failure treated with a beta-blocking agent and vasodilator </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Difficulties of autoregulation (bradycardia, sinus arrest) and of sinoatrial and atrioventricular conduction </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<CLASS name="DIHYDROPYRIDINES" code="C08CA-002" /></DRUG2>
<DESCRIPTION>Hypotension, heart failure in patients with latent or uncontrolled cardiac insufficiency (negative iotropic effect of the dihydropyridines in vitro more or less marked and susceptible of adding to the negative inotropic effects of the beta-blocking agents). The presence of a beta-blocking treatment can furthermore minimize the sympathetic reflex reaction put into play in cases of excessive hemodynamic repercussion</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest), and disorders of sinoatrial and atrioventricular conduction</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<CLASS name="GLINIDES" code="A10BX-001" /></DRUG2>
<DESCRIPTION>All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient and, especially at the beginning of treatment, strengthen self-monitoring of blood glucose.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<DRUG name="INSULIN " rxcui="5856">
<ATC code="A10AC01" />
<ATC code="A10AC02" />
<ATC code="A10AC03" />
<ATC code="A10AC04" />
<ATC code="A10AD01" />
<ATC code="A10AD02" />
<ATC code="A10AD03" />
<ATC code="A10AD04" />
<ATC code="A10AD05" />
<ATC code="A10AE01" />
<ATC code="A10AE02" />
<ATC code="A10AE03" />
<ATC code="A10AE04" />
<ATC code="A10AE05" />
<ATC code="A10AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient and, especially at the start of treatment, reinforce self-monitoring of blood glucose</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<DRUG name="LIDOCAINE" rxcui="6387">
<ATC code="C01BB01" />
<ATC code="C05AD01" />
<ATC code="D04AB01" />
<ATC code="N01BB02" />
<ATC code="R02AD02" />
<ATC code="S01HA07" />
<ATC code="S02DA01" />
<ATC code="N01BB52" />
</DRUG>
</DRUG2>
<DESCRIPTION>Negative inotropic effect with risk of acute decompensated heart failure</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<CLASS name="NEUROLEPTICS" code="N05AA-003" /></DRUG2>
<DESCRIPTION>Vasodilator effect and risk of hypotension, especially orthostatic (additive effect)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<CLASS name="BLOOD GLUCOSE LOWERING SULFONAMIDES" code="A10BB" /></DRUG2>
<DESCRIPTION>All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient and reinforce self-monitoring of blood glucose, especially at the beginning of treatment. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest) and disorders of sinoatrial and atrioventricular conduction </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>94-BISPHOSPHONATES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BISPHOSPHONATES" code="M05B-001" /></DRUG1>
<DRUG2>
<DRUG name="CALCIUM" rxcui="1895">
<ATC code="A12AA" />
</DRUG>
</DRUG2>
<DESCRIPTION>For calcium salts administered via oral route: decrease of the digestive absorption of the bisphosphonates</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the calcium salts and antacids at a different time from the bisphosphonates (from 30 minutes minimum to more than 2 hours apart, if possible, depending on the bisphosphonate).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>94-BISPHOSPHONATES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BISPHOSPHONATES" code="M05B-001" /></DRUG1>
<DRUG2>
<DRUG name="IRON" rxcui="90176">
<ATC code="B03A" />
</DRUG>
</DRUG2>
<DESCRIPTION>For the iron salts administered via oral route: decrease of the digestive absorption of the bisphosphonates</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the iron salts at a different time from the bisphosphonates (from 30 minutes minimum to more than 2 hours apart, if possible, depending on the bisphosphonate).</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>95-BLEOMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BLEOMYCIN " rxcui="1622">
<ATC code="L01DC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BRENTUXIMAB " rxcui="1147320">
<ATC code="L01XC12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of pulmonary toxicity</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>96-BOCEPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of boceprevir</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these substances together cannot be avoided, regular clinical and biological monitoring, especially at the beginning of the administration of them together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>96-BOCEPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN " rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the atorvastatin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Do not exceed the dosage of 20mg/day of atorvastatin. If the therapeutic objective is not reached with this dosage, use another statin not affected by this type of interaction.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>96-BOCEPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DROSPIRENONE" rxcui="840781">
<ATC code="G03AA12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase by more than double of the concentrations of drosperinone when taken with the boceprevir</DESCRIPTION>
<SEVERITY>Nor recommended</SEVERITY>
<COMMENT>Choose a contraceptive with another progestin, especially in cases of hyperkalemia</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>96-BOCEPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NON-CONTRACEPTIVE ESTROGENS" code="G03C-001" /></DRUG2>
<DESCRIPTION>Decrease of the effectiveness of the estrogen.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration with the boceprevir.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>96-BOCEPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>Aside from the combination with ethinylestradiol (0.035mg)/noresthisterone (1mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the boceprevir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use a reliable contraceptive method, additional or alternative, during the time these medications are taken together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>96-BOCEPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the immunosuppressant (substantial for the ciclosporin, extremely large for the tacrolimus)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the immunosuppressant, testing of renal function, and adjustment of its dosage during the administration of the medications together and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>96-BOCEPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Decrease of the concentrations of the boceprevir and of the lopinavir (or darunavir or fosamprenavir), with risk of therapeutic failure</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>96-BOCEPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHADONE " rxcui="6813">
<ATC code="N07BC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of methadone, with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism by the boceprevir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical monitoring and possible adjustment of the dosage of methadone.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>96-BOCEPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG2>
<DESCRIPTION>Aside from the combination with ethinylestradiol (0.035mg)/noresthisterone (1mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the boceprevir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use a reliable contraceptive method, additional or alternative, during the time these medications are taken together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>96-BOCEPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of boceprevir</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these together cannot be avoided, regular clinical and biological monitoring, especially at the beginning of treatment with the two medications together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>96-BOCEPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type due to decrease of the metabolism of the simvastatin</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>96-BOCEPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOCEPREVIR" rxcui="1102129">
<ATC code="J05AE12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TENEFOVIR ALAFENAMIDE" rxcui="1721603">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the tenefovir alafenamide by decrease of its intracellular activity by the boceprevir</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>97-BORTEZOMIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BORTEZOMIB" rxcui="358258">
<ATC code="L01XX32" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>97-BORTEZOMIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BORTEZOMIB" rxcui="358258">
<ATC code="L01XX32" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects, especially neurological, of the bortezomib due to decrease of its metabolism.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the bortezomib during the length of the treatment with the enzymatic inhibitor.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>98-BOSENTAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of bosentan</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>98-BOSENTAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of INR. Possible adjustment of the dosage of the vitamin K antagonist. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>98-BOSENTAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the blood concentrations of the ciclosporin and increase of the plasma concentrations of bosentan</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>98-BOSENTAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HA01" />
<ATC code="G03HB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cyproterone</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In its indications such as anti-androgen, clinical monitoring and if possible adjustment of the dosage of the cyproterone during the administration with the bosentan and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>98-BOSENTAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use a reliable contraceptive method, additional or alternative, during the length of time the two substances are administered together and for a cycle after. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>98-BOSENTAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GLIBENCLAMIDE" rxcui="4815">
<ATC code="A10BB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduced effectiveness of the glibenclamide due to decrease of its plasma concentrations, because of the inducer effect of the bosentan. Furthermore, cases of hepotoxicity have been reported with these two substances administered together. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of the glycemia, adjustment of the treatment if needed, and monitoring of the hepatic biological constants. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>98-BOSENTAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increased risk of the undesirable effects of the bosantan, especially hepatic attacks, due to decrease of its metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring during the administration of these together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>98-BOSENTAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use an additional or alternative reliable method of contraception during the time these substances are administered together and one cycle following</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>98-BOSENTAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT" code="G03-003" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the progestogen</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the bosentan and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>98-BOSENTAN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease, large for the rifampicin, of the plasma concentrations of bosentan</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>99-BOTULINUM-TOXIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BOTULINUM TOXIN" rxcui="1716">
<ATC code="M03AX01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="AMINOGLYCOSIDES" code="J01GB-001" /></DRUG2>
<DESCRIPTION>Risk of increase of the effects of the botulinum toxin with the aminoglycosides (by extrapolation from the effects observed during the course of the botulism)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Use another antibiotic.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>9-FOLINIC-ACID.html</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FOLINIC ACID" rxcui="6313">
<ATC code="B03BB" />
<ATC code="B03BB01" />
<ATC code="B03BB51" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)" code="L01BC-001" /></DRUG2>
<DESCRIPTION>Strengthening of the effects, both cytostatic and undesirable, of the fluorouracil. </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
</INTERACTIONS>